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  Abstract 
i 
Abstract 
 
BACKGROUND. Breast cancer is the most common type of cancer in women in the UK and is 
often treated with chemotherapy. Psychosocial side effects (anxiety, depression and fatigue) and 
cognitive side effects (memory and concentration difficulties) are frequently reported by breast 
cancer patients. Following recent advances in screening and treatment technology for the 
disease, survivorship rates have increased. Therefore, women are able to continue or resume 
their daily tasks during and following treatment. The impact of chemotherapy-related 
psychological side effects on quality of life and work ability are documented, however the 
impact on safety outcomes has currently been overlooked in this patient population. Evidence 
from other research fields suggests that anxiety, depression, fatigue and cognitive difficulties 
are associated with increased risk of accidents and injuries. OBJECTIVES. This research 
provides longitudinal self-report data on psychosocial well-being, cognitive function, quality of 
life, work ability and accident frequency outcomes. METHOD. A mixed-methods, prospective, 
longitudinal approach was employed. Breast cancer patients about to undergo chemotherapy 
treatment (n = 60) completed questionnaires at pre-treatment baseline, and again four months 
(follow-up time 1), eight months (follow-up time 2), and twelve months (follow-up time 3) 
later. A treatment control group of breast cancer patients receiving radiotherapy (n = 56), and an 
age-matched healthy control group (n = 58) were assessed at comparable intervals. In addition, 
a subsample of participants from the chemotherapy group (n = 11), radiotherapy group (n = 6), 
and healthy control group (n = 15) kept personal solicited diaries for a four-month period to 
capture the lived experience of managing daily tasks. The diary data were examined using 
thematic analysis. The combination of the quantitative and qualitative approaches added breadth 
and depth to the study with the aim of obtaining a realistic and comprehensive understanding of 
the impact of chemotherapy for breast cancer on patients’ daily lives. RESULTS. 
Chemotherapy patients reported a subtle decline in psychosocial well-being, cognitive function 
and quality of life, and encountered more accidents, particularly at mid-chemotherapy. 
CONCLUSION. It is important that healthcare professionals, breast cancer patients, relatives 
and employers are aware of the temporal fluctuations associated with chemotherapy-related side 
effects, particularly potential safety outcomes. Interventions could be developed to help patients 
manage their daily tasks in the home and in the workplace safely. 
 
KEYWORDS. Breast cancer; chemotherapy; psychosocial well-being; cognitive function; 
safety; quality of life; work ability; self-report.
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Chapter One                Introduction 
1 
 
Chapter One 
Introduction 
1.1 The Research Problem 
Breast cancer is a disease in which cells in the breast tissue grow at an abnormal and 
uncontrollable rate. It is one of the most common types of cancer in the UK and is 
particularly prevalent in women, with approximately 46,100 diagnoses annually, but is 
rare in men, with only 400 diagnoses per year
1
 (Office for National Statistics, 2012). 
Following recent advancements in cancer screening technology and treatment regimens, 
the survival rate for breast cancer has increased. Subsequently, research has shifted 
from extending patients’ survival (quantity of life) to understanding and enhancing their 
quality of life during and following treatment (Bakitas, Lyons, Hegel, & Ahles, 2012; 
Reid-Arndt, Hsieh, & Perry, 2010).  
 
Chemotherapy is one of the main conventional treatments for breast cancer, yet it is 
associated with a number of adverse biological and psychological side effects. Over the 
past 30 years, research has examined the impact of chemotherapy on cognitive function. 
There have been reports of cognitive impairment in up to 90% of breast cancer patients 
undergoing chemotherapy (Pullens, De Vries, & Roukema, 2010). The types of 
cognitive difficulties that characterise chemotherapy-related cognitive impairment, or 
‘chemo brain’ as coined by breast cancer patients, include deficits in memory and 
concentration abilities. A number of studies have documented impairment enduring up 
to ten years post-treatment (Ahles et al., 2005). Since cognitive difficulties can have a 
profound impact on breast cancer patients’ quality of life (Ahles & Saykin, 2001; 
Tannock, Ahles, Ganz, & van Dam, 2004), it is important to recognise the implications 
of this side effect on daily functioning. In turn, this could facilitate the development of 
appropriate support to enable breast cancer patients to better manage their daily tasks in 
the home and in the workplace, and thereby improve their quality of life during and 
beyond treatment. 
                                            
1
 Male breast cancer patients were excluded from the current research due to this low incidence rate. 
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Despite increasing evidence supporting the existence of chemotherapy-related cognitive 
impairment in the breast cancer population, a handful of studies document otherwise 
(Donovan, Small, Andrykowski, Schmitt, Munster, & Jacobsen, 2005; Mehlsen, 
Pedersen, Jensen, & Zachariae, 2009; Tager et al., 2010). This discrepancy in findings 
may be linked to methodological differences across studies, such as the sample 
characteristics (variability in the type and dosage of chemotherapeutic agents 
administered), measures (objective neuropsychological tests and/or subjective self-
report measures), definition of cognitive impairment (pre-determined cut-off levels or 
comparisons with treatment controls and/or healthy controls), study design (cross-
sectional, longitudinal, retrospective, prospective), and timing of assessment(s) 
(baseline measure present/absent, weeks, months or years following chemotherapy 
administration). Further inconsistencies in the psycho-oncology literature include strong 
evidence for a disassociation between objective cognitive difficulties and subjective 
cognitive difficulties (Castellon, Ganz, Bower, Petersen, Abraham, & Greendale, 2004; 
Hermelink et al., 2007; Jansen, Dodd, Miaskowski, Dowling, & Kramer, 2008; Jenkins 
et al., 2006). These findings could be interpreted as evidence for a lack of ecological 
validity associated with neuropsychological tests. Moreover, since the vast majority of 
neuropsychological tests were designed for, and validated in, other clinical populations 
(e.g. patients with stroke and head injury), these measures may not be sufficiently 
sensitive to detect the types of subtle cognitive changes experienced by the breast 
cancer population (Jansen, Miaskowski, Dodd, Dowling, & Kramer, 2005). 
  
Consequently, there has been a call for research to examine breast cancer patients’ 
subjective accounts of their cognitive function. In particular, there have been 
recommendations for further research to adopt longitudinal designs (including pre-
treatment baseline) with both treatment control groups and healthy control groups in 
order to address the limitations associated with previous work, and to establish the 
severity and onset of cognitive change (Vardy et al., 2008). Since self-report measures 
are often significantly correlated with psychosocial factors (e.g. anxiety, depression and 
fatigue) (Hermelink et al., 2007), it is important that studies take into account the 
complexity of this when designing and analysing cognitive change. Furthermore, breast 
cancer patients’ descriptions of their lived experience of psychosocial well-being and 
cognitive function may provide rich data relating to the impact of chemotherapy-related 
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side effects on daily functioning and quality of life, an area which is currently 
understudied. 
 
In other research fields, anxiety, depression, fatigue and cognitive difficulties have been 
documented in a number of clinical and non-clinical populations, and evidence suggests 
that these have associated safety implications. For example, Lach and Chang (2007) 
found that 94.9% of caregivers reported difficulties regarding safety, such as motor 
vehicle crashes, falls and cooking difficulties, in individuals with dementia. 
Furthermore, research has found that employees who are fatigued are more likely to 
experience accidents in the workplace (Åkerstedt, Fredlund, Gillberg, & Jansson, 
2002). However, the potential safety outcome relating to cognitive and psychosocial 
difficulties has not currently been addressed in the breast cancer population. This is a 
particular concern since the survivorship rate is currently increasing and individuals aim 
to successfully continue or resume pre-diagnosis levels of daily functioning in the home 
and workplace (Steiner, Cavender, Main, & Bradley, 2004). Therefore, it is important 
that future research examines the accident proneness of this population. It is vital that 
breast cancer patients, their family members, health professionals, support groups and 
employers are provided with comprehensive information regarding the impact of 
chemotherapy treatment on daily functioning. This could facilitate the decision-making 
process for breast cancer patients regarding the most suitable treatment by considering 
the known potential benefits and side effects. In addition, support tailored to the 
individual could be provided in the home and in the workplace to improve the 
successful management of daily tasks, thereby enhancing quality of life and work 
ability. 
1.2 The Aims of this Research 
The current research addresses two main issues: (a) the need for further longitudinal 
research to examine chemotherapy-related cognitive impairment in an attempt to verify 
its onset and change over time (Vardy et al., 2008), and (b) the current gap in the 
psycho-oncology literature regarding potential safety implications associated with 
anxiety, depression, fatigue and subjective cognitive difficulties following 
chemotherapy for breast cancer. The specific objectives of the current study were to: 
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1. Examine the impact of chemotherapy for breast cancer on psychosocial well-
being and subjective cognitive function. 
2. Examine the impact of chemotherapy for breast cancer on safety outcomes in 
the home and workplace. 
3. Examine the impact of chemotherapy for breast cancer on quality of life and 
work ability. 
4. Explore the impact of chemotherapy for breast cancer on patients’ daily life 
during and shortly following treatment. 
 
In order to address these objectives, a patient-focussed, mixed-methods, longitudinal 
approach was adopted. In addition to a cohort of breast cancer patients undergoing 
chemotherapy, a treatment control group comprising breast cancer patients undergoing 
local therapy (radiotherapy pre- or post-surgery) was included in order to separate the 
potentially confounding psychosocial impact of breast cancer diagnosis from 
chemotherapy-related side effects (Aapro & Cull, 1999). Radiotherapy patients 
experience similar diagnostic procedures but fewer treatment-related side effects due to 
the localised nature of this treatment. A healthy control group, age-matched to the 
chemotherapy group, was included as an additional comparison group. These control 
groups have been included in other psycho-oncology research in an attempt to map out 
the impact of chemotherapy more clearly and accurately (e.g. Jenkins et al., 2006; 
Quesnel, Savard, & Ivers, 2009). 
 
The current research comprised two methods of data collection: questionnaires and 
diaries. The questionnaire consisted predominantly of self-report rating-style and 
closed-ended questions that measured the frequency and severity of psychosocial 
difficulties, cognitive failures and accidents, as well as perceptions of quality of life and 
work ability (for those in employment) that could be analysed quantitatively (see 
Appendix 12). In addition, several open-ended questions were included that requested 
contextual information that could be analysed qualitatively. The questionnaire was 
administered at baseline (pre-chemotherapy) and follow-up time-points at 4 months, 8 
months and 12 months to measure change over time. The questionnaire was either 
posted to participants or accessed online. A subgroup of participants from each 
participant group also kept a diary for a four-month period between follow-up time-
points (see Appendices 13 & 14). Diary data were analysed qualitatively to provide in-
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depth information about the lived experience of psychosocial functioning, cognitive 
difficulties and accidents during daily tasks. The diary was available in paper form 
(participants handwrote entries in four monthly booklets), electronic form (participants 
typed their entries into four monthly booklets that were emailed to them), or audio form 
(participants made verbal entries on a digital recorder). 
1.3 The Approaches Toward Breast Cancer 
The dominant approach to healthcare in Western countries is the biomedical model, 
which focuses on the biological account of illness with a limited emphasis on the 
psychosocial dimensions (Engel, 1977). This is a traditional paradigm based on a 
dualistic approach to the individual that conceptualises the mind and body as 
functioning independently from each other (Engel, 1977). The biomedical framework is 
often implemented within the UK National Health Service (NHS), as evidenced when 
breast cancer patients are offered a wealth of information on the biological side effects 
of breast cancer and its treatment, but relatively little on the psychological impact, 
despite increasing research addressing these concerns. Although the application of this 
reductionist model has been crucial in the progression of medical understanding and 
advancements in treatment technology leading to increased survivorship, it is not well-
suited to understanding the quality of life of breast cancer survivors, which is an 
important focus for current research. 
 
Engel (1977) is credited as one of the first to consider a more holistic approach to 
medicine. The biopsychosocial model adopts a holistic approach to disease and 
treatment in relation to the individual and values the interaction between the 
psychological, social and economic concerns as well as the biological symptoms. It 
takes into account the quality of the individual’s survival. Following greater awareness 
of the benefit of adopting a holistic view in a complementary approach, psycho-
oncology has emerged as a relatively new scientific discipline that combines the study 
of the biological and psychological aspects associated with cancer and its treatment 
(Kidman & Edelman, 1997). Such an approach towards breast cancer within the 
healthcare setting needs to be further established and research can facilitate this by 
examining the psychological impact of the disease and its associated treatment. 
Consequently, this thesis adopts a biopsychosocial approach to understanding the 
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experiences of breast cancer patients to ascertain a more comprehensive understanding 
of the impact of chemotherapy on daily life. 
  
In light of the advantages of this holistic biopsychosocial model of breast cancer, this 
research project employed a mixed-methods approach. This approach can be defined as 
“the collection or analysis of both quantitative and/or qualitative data in a single study 
in which the data are collected concurrently or sequentially” (Creswell, Clark, 
Gutmann, & Hanson, 2003, p. 212) and is considered valuable in applied health 
psychology research. The following section discusses the main research approaches 
within the applied health psychology research field. It considers the limitations of 
employing quantitative or qualitative methods in isolation and justifies the need for a 
holistic mixed-methods approach to the study of chemotherapy-related side effects in 
the breast cancer population. 
1.4 The Research Approach 
There are a range of ontological and epistemological positions that researchers can hold 
within Psychology, each with related research methods. The quantitative paradigm is 
based on positivism. This empirical approach involves measuring and quantifying 
phenomena that leads to deductive reasoning and the generalisation of findings that 
support or disprove hypotheses. Sample sizes tend to be large so that statistical analyses 
have adequate power to detect differences between groups and the strength of 
association between variables. Due to the ability to take precise measures and control 
for extraneous variables, advantages of this approach include high levels of internal 
validity and reliability, and data from the recruited sample can be generalised to the 
population as a whole. A weakness, however, is that it can oversimplify the complexity 
of human nature and decontextualise data (Janesick, 1994), thereby reducing external 
validity. 
 
In contrast, the qualitative paradigm is based on interpretivism and constructivism and 
focuses on meanings and context (Hayes, 1997). This approach is idiographic in nature, 
whereby analysis focuses on the in-depth lived experience of individuals in small, 
purposeful samples (Castro, Kellison, Boyd, & Kopak, 2010). Although traditional 
notions of validity, reliability and generalisability cannot always be applied to the data 
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(due to the typically small sample sizes and lack of experimental condition controlling 
variables) the qualitative approach can generate rich, detailed accounts of human 
experience (Castro et al., 2010). 
 
Traditionally, researchers adopt a particular ontological and epistemological position 
that stipulates whether quantitative or qualitative research methods are to be employed. 
Indeed, some researchers argue that quantitative and qualitative methods represent two 
different paradigms that make them incommensurate since fundamentally the two 
paradigms study different phenomena (Sale, Lohfeld, & Brazil, 2002). However, using 
a single research method can lead to a limited understanding of the phenomena of 
interest (Bowling, 1997). Furthermore, from a health research perspective, Casebeer 
and Verhoef (1997) argue that separating the research perspectives can lead to 
incomplete results and understanding about an illness. It has been noted that integrating 
quantitative and qualitative methods (known as methodological pluralism) can be useful 
for effectively capturing the complexities of human experience (Neumann, Kreps, & 
Visser, 2011), and thereby enabling a more comprehensive understanding of the issue 
under investigation. 
 
Adopting a mixed-methods research approach is a popular strategy within applied 
healthcare research (e.g. Casebeer & Verhoef, 1997). In addition, this approach 
supports the national service frameworks (NSFs). These are currently established across 
a number of NHS services with the aim of ensuring that care is delivered in a patient-
focussed manner and that effort is taken to listen to the ‘expert patient’ (Department of 
Health, 2009). The combination of quantitative and qualitative methods is a valid, 
complementary approach since both strive to acquire a better understanding of different 
aspects of the same phenomena: qualitative methods can facilitate the understanding of 
human experience while quantitative methods can facilitate the measuring of this 
experience (Sale, Lohfeld, & Brazil, 2002). Indeed, employing methodological 
pluralism in longitudinal research can facilitate understanding of the trajectory of 
patients’ experiences during treatment (Casebeer & Verhoef, 1997). 
 
Taking into consideration the benefits of methodological pluralism, the current research 
adopted a pragmatic, mixed-methods approach. A summary of the research process is 
shown in Figure 1.1. Questionnaires were administered to produce quantifiable data 
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from which statistical inferences could be generalised to the female breast cancer 
patient population receiving chemotherapy. In addition, a subsample of participants 
kept a diary to produce rich data with the aim of obtaining a detailed understanding of 
the nature and context surrounding the lived experience of psychosocial and cognitive 
difficulties as well as hazardous events. This exploration of personal accounts 
supplemented and complemented the examination of large group differences between 
breast cancer patients undergoing chemotherapy and two control groups.
Chapter One                Introduction 
9 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 1.1. An overview of the research process. 
1.5 The Structure of this Thesis  
This thesis is presented over ten chapters. The current chapter introduces the research 
programme. Subsequent chapters are arranged as follows: 
LITERATURE REVIEW 
A review of the relevant literature provided an understanding of the existing research and 
the identification of current methodological weaknesses and research gaps. The 
questionnaire and diary materials were developed. 
PARTICIPANTS THANKED AND THESIS COMPLETION 
ETHICAL APPROVAL 
Ethical approval was obtained from the Loughborough University Ethical Approval 
Committee, the NHS Research Ethics Committee, and Research and Development 
departments at two NHS recruitment sites. 
ANALYSES AND CONCLUSIONS 
Questionnaire data (from rating-style and closed-ended questions) were entered into 
PASW and analysed using descriptive and inferential statistics. 
Diary data and questionnaire data (from open-ended questions) were entered into an Excel 
Spreadsheet and analysed using thematic analysis. 
RECRUITMENT AND DATA COLLECTION 
Breast cancer patients about to receive chemotherapy (n = 67) and breast cancer patients 
about to receive radiotherapy (n = 61) were recruited from five local NHS cancer clinics 
and through support groups across the UK. 
Healthy controls (n = 122) were recruited from newspaper and radio advertisements 
following a press release. 
Questionnaires were administered at baseline (pre-treatment) and follow-up time-points at 
4 months, 8 months and 12 months. 
Diaries were kept for a four-month period between follow-up time-points by a subgroup 
of participants in the chemotherapy group (n = 11), radiotherapy group (n = 6), and 
healthy control group (n = 15). 
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Chapter Two introduces key facts regarding breast cancer including its incidence, 
diagnosis and treatment. This chapter also presents a review of the published research 
examining the biological side effects associated with the treatment of the disease. 
 
Chapter Three discusses the literature on the psychological side effects of 
chemotherapy treatment for breast cancer. In particular, studies examining psychosocial 
and cognitive side effects experienced by the breast cancer population are reviewed.  
 
Chapter Four consolidates research conducted in other fields that have considered the 
link between anxiety, depression, fatigue, cognitive impairment and safety outcomes. 
This final literature review chapter concludes with a clear argument for the need to 
address the association between these factors in the breast cancer population, and closes 
with the research aims and hypotheses examined in this thesis. 
 
Chapter Five presents details of the mixed-methods approach used in the current 
research and includes a description of the procedure involved in collecting the 
questionnaire data. Details are also provided about the measures, recruitment strategies, 
and ethical considerations relevant to the current study. 
 
Chapter Six reports the results from the quantitative analysis of the questionnaire data 
relating to Objective One. This chapter begins with a description of the sample 
characteristics and proceeds to examine the impact of chemotherapy for breast cancer 
on psychosocial well-being and subjective cognitive function. 
 
Chapter Seven reports the results from the quantitative analysis of the questionnaire 
data relating to Objective Two. This chapter examines the impact of chemotherapy for 
breast cancer on safety outcomes in the home and in the workplace. 
 
Chapter Eight reports the results from the quantitative analysis of the questionnaire 
data relating to Objective Three. This chapter examines the impact of chemotherapy for 
breast cancer on quality of life and work ability. 
 
Chapter Nine begins with a description of the procedures involved in collecting the 
diary data and presents the results from the qualitative analysis. This chapter explores 
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the context and temporal patterns of psychosocial difficulties, cognitive failures and 
accidents reported by breast cancer patients undergoing chemotherapy. 
 
Chapter Ten discusses the principal findings and acknowledges the strengths and 
limitations of this research. This chapter also considers the implications of the findings 
in the context of breast cancer care and identifies practical recommendations for future 
research. The chapter closes with consideration of the contributions to current 
knowledge that this thesis has to offer. 
1.6 Chapter Summary 
Following improved prognosis of breast cancer, survivors aim to continue or resume 
daily tasks during and following treatment. However, a number of breast cancer patients 
undergoing chemotherapy experience anxiety, depression, fatigue and cognitive 
difficulties that can impact upon daily functioning, and which can persist for several 
years post-treatment. Evidence suggests that these psychological side effects are 
associated with increased accident risk; however, this safety outcome has not currently 
been examined in the breast cancer population. This could have major implications for 
breast cancer patients, their families, employers, and society at large. Therefore, it is 
important that this current research gap is addressed and that further work on the 
biopsychosocial impact of chemotherapy is undertaken. This will enable more 
comprehensive information to be available to breast cancer patients regarding the 
impact of chemotherapy on daily functioning. A mixed-methods approach was 
considered valuable to provide a detailed understanding of breast cancer patients’ lived 
experiences and perceptions of managing chemotherapy-related side effects over a 12-
month period. Figure 1.2 summarises the hypothesised relationship between treatment-
related side effects and the outcomes being examined in the current study. This research 
is of clinical importance considering the increasing survival rate of breast cancer as well 
as the use of progressively more aggressive chemotherapy dosages in this population 
(Taillibert, Voillery, & Bernard-Marty, 2008).
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Figure 1.2. Theoretical model of chemotherapy-related side effects impacting upon breast cancer patients’ management of their daily tasks. 
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Chapter Two 
A Review of the Literature on Breast Cancer, its Treatment and 
Biological Side Effects 
2.1 Chapter Introduction 
The aim of this first review chapter is to provide relevant background information relating 
to breast cancer, its treatment and biological side effects. The chapter begins by 
highlighting the key statistics on the incidence and recent increase in the survival of breast 
cancer in the UK. In order to offer an insight into the general experiences of breast cancer 
patients, the conventional methods of diagnosis and treatment are considered. The chapter 
concludes with a description of the biological side effects associated with each treatment. 
2.2 Breast Cancer Incidence 
Cancer is a collective name for a heterogeneous group of diseases in which cells divide 
abnormally and uncontrollably. Worldwide, an estimated 1,643,000 women were 
diagnosed with cancer in 2010 (Forouzanfar et al., 2011). In the UK, there are 
approximately 315,200 new cases of cancer annually (Office for National Statistics, 2012). 
One in three individuals will develop cancer during their lifetime. Although over 200 
different types of cancer have been identified, breast, prostrate, lung and large bowel 
cancers account for approximately 42% of all new cases (Office for National Statistics, 
2011a). Table 2.1 illustrates the current incidence rates of these four common cancers in 
males and females in England. 
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Table 2.1 
Incidence of the Most Common Cancers in England (Office for National Statistics, 2011a) 
 Incidence rates in 2010 
Cancer type Males (n) Females (n) 
Proportion of total 
cancer population (%) 
Breast 375 46,075 13.20 
Prostate 34,892 N/A 9.92 
Lung 18,756 15,062 9.61 
Colorectal 18,590 14,628 9.44 
 
As shown in Table 2.1, breast cancer is currently the leading cause of malignancy in 
women in England. One in nine women will develop the disease in their lifetime (Steward 
& Thomas, 2006). Historically, breast cancer was often terminal. However, following 
recent advances in medical technology and increased public awareness surrounding the 
disease (e.g. self-examination of the breasts), there have been improvements in the 
detection and treatment of breast cancer. Subsequently, survival rates have increased 
dramatically due to earlier detection and improved prognosis for these patients (Skeel, 
2003). For example, between 1971 and 2007, the incidence rate of breast cancer increased 
by approximately 84% while the mortality rate fell by 35% (Office for National Statistics, 
2011a). Recently published figures estimate that the five-year survival rate of breast cancer 
is now 85.1% (Office for National Statistics, 2011a). As a result of the rise in survival of 
this disease, female breast cancer patients represent one of the largest and growing groups 
of cancer survivors. Many of these women look to continue or resume pre-diagnosis levels 
of daily functioning (e.g. employment, domestic, social and academic) during and 
following treatment, which can provide a sense of ‘normality’ for patients (Steiner, 
Cavender, Main, & Bradley, 2004). In response to this, the outcome of treatment has 
shifted from survival to quality of life (Bakitas, Lyons, Hegel, & Ahles, 2012; Reid-Arndt, 
Hsieh, & Perry, 2010). Subsequently, understanding the lived experiences of breast cancer 
patients during and beyond treatment is now an important research area. Although 
advances in treatment have greatly improved survival rates, some treatment regimens are 
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associated with a number of adverse side effects, which can endure several years following 
treatment completion (see section 2.7).  
 
Figure 2.1 shows that breast cancer incidence generally increases with age, with 
approximately 55% of new cases being of working age (18 to 65 years). In response to the 
anticipated increase in life expectancy in the future, the UK Government has announced an 
increase in State Pension to 67 years between 2026 and 2028, with further increases to 
State Pension aimed to reflect increases in life expectancy (Directgov, 2012). Accordingly, 
there may be more breast cancer diagnoses in the working population in the near future. It 
is therefore important to understand the impact of breast cancer treatment and the 
associated side effects on return to work and work ability issues so that appropriate support 
can be provided to those in the workplace, as stipulated by the Equality Act 2010. This 
legislation supersedes the Disability Discrimination Act and includes an amendment to 
protect individuals who have, or who have had, cancer from discrimination at the 
workplace. It also states that employers should make reasonable adjustments for employees 
diagnosed with cancer. A number of studies have examined the impact of breast cancer and 
its treatment on return to work and work ability issues. These are discussed in more detail 
in Chapter Three, section 3.7. 
 
Although this thesis is concerned with the psychological aspects of breast cancer and its 
treatment, it is first necessary to provide some background information on what breast 
cancer is and how it can manifest. This is provided in the following section and will 
facilitate understanding of how treatment for this disease works and how biological side 
effects can develop, details of which are presented later in this chapter (sections 2.6 and 
2.7). 
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Figure 2.1. Number of new female breast cancer cases in the UK (Cancer Research UK, 
2011). 
2.3 A Brief Biological Account of Breast Cancer 
Cells contain genetic material (deoxyribonucleic acid [DNA]) that instructs the cell how to 
behave, including when to reproduce, by dividing, and when to die (Blows, 2005). 
Mutations can occur in the cell DNA, sometimes causing the cell to behave differently, 
such as dividing abnormally and uncontrollably. Since successive cell divisions contain the 
same cell DNA, abnormal cell division can result in the development of a tumour over 
time. There are two main types of tumours: benign and malignant. Benign tumours are non-
cancerous and tend not to invade or cause damage to neighbouring tissues. These may be 
fluid-filled sacs (cysts) or fibrous glandular tissue (fibroadenoma), which are not usually 
harmful to the body. However, malignant tumours are cancerous and can be detrimental to 
the body due to their ability to metastasise (spread to other parts of the body) through the 
bloodstream and lymphatic system, thus causing secondary cancer (Pelengaris & Khan, 
2006). Since the body’s immune system does not detect cancerous cells as foreign, there is 
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no natural defence from within the body. Consequently, a number of treatments have been 
developed to target and destroy the cancerous cells (see section 2.6). 
 
The development of breast cancer is complex but can be simplified into four main phases:  
(a) hyperplasia (occurs when normal cells multiply excessively causing the tissue to 
thicken and develop into a mass); 
(b) dysplasia (occurs when hyperplasic cells undergo further genetic mutation, further 
increasing the rate of cell division as well as abnormal cell appearance); 
(c) carcinoma in situ (occurs when dysplastic cells continue to divide abnormally and 
develop into a tumour that stops responding to the body’s growth hormones), and 
(d) invasive carcinoma (occurs when the malignant tumour metastasises and enters the 
blood and lymph vessels, causing secondary tumours elsewhere in the body) 
(Blows, 2005). 
At diagnosis, the phase of the tumour’s development is an important prognostic factor and 
is considered when determining the best course of treatment (see section 2.5). 
 
The human body is composed of millions of cells (Pelengaris & Khan, 2006), which can be 
grouped into approximately 200 types. Cancer can originate in any type of cell, giving rise 
to just as many different types of cancer. Thus, cancer has great heterogeneity with a range 
of diagnoses, treatment regimens and prognoses. These different cancer types can be 
broadly classified by their biological origin and include: 
(a) carcinoma that originate in epithelial cells in the skin or in tissues that line or cover 
internal organs (e.g. the breast); 
(b) sarcoma that originate in bone, cartilage, fat, muscle, blood vessels, or other 
connective tissue;  
(c) leukemias that originate in bone marrow and blood cells, and 
(d) lymphomas that originate in the lymphatic system (Pelengaris & Khan, 2006).  
 
Since there are different cells within the breast, there are also different types of breast 
cancer, depending upon the location of the tumour. The breast is primarily composed of 
fatty tissue, as shown in Figure 2.2. A tumour often originates in the lobes (lobular 
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carcinoma), which contain milk glands in females, or in the ducts (ductal carcinoma), 
which transport milk from the lobes to the nipple. Non-invasive (in situ) breast cancer 
includes lobular carcinoma in situ (LCIS) or ductal carcinoma in situ (DCIS). If these 
tumours spread then this is known as invasive (metastatic) breast cancer and includes 
invasive lobular carcinoma and invasive ductal carcinoma. Metastatic breast cancer 
typically involves more complex treatment regimens and consequently patients may 
experience a greater number of side effects. The exclusion of metastatic breast cancer 
patients with a secondary tumour is common within the literature examining treatment-
related side effects due to the interaction between the side effects associated with multiple 
treatment courses (e.g. Schagen, Muller, Boogerd, & van Dam, 2002a). 
 
Figure 2.2. The biology of a female breast. 
 
The breast is also composed of blood vessels that transport blood to the cells, providing 
nourishment, and lymph vessels that connect to the lymph nodes, helping the body to 
combat contagion by draining waste products into the veins and eventually out of the body 
(lymphatic system). Cells are immersed in tissue fluid that drains into the lymphatic 
system. Although vital to keep the body alive, this cyclical process allows metastasised 
tumours to travel via the tissue fluid to the lymph glands. Consequently, the lymph glands 
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in the armpit may be examined during diagnosis to determine whether the cancer has 
metastasised. Although biologists have an understanding of how breast cancer develops, 
the precise mechanisms involved in women developing breast cancer are largely unknown. 
However, researchers have identified a number of potential contributory factors involved in 
the development of breast cancer and these are identified in the following section (section 
2.4). 
2.4 Risk Factors for Breast Cancer 
The risk factors for developing breast cancer are thought to involve a combination of 
lifestyle, geographic and genetic factors. Since a detailed account of the evidence and 
reasoning for these factors is out of the scope of this thesis, only the key risk factors are 
listed in this section.  
 
One of the main risk factors for breast cancer is older age (as illustrated in Figure 2.1). 
Geographical location can also be influential, as evidenced by a higher incidence of breast 
cancer reported in Western countries compared to Eastern countries (McPherson, Steel, & 
Dixon, 2000). A previous history of the disease can also increase the risk of its 
development. Lifestyle factors such as obesity, high alcohol consumption, the use of 
hormone replacement therapy (HRT) and hormonal contraceptives have been shown to 
increase the risk (Murray, 2010). More full-term pregnancies, young age at first childbirth, 
breastfeeding, late menarche, and early menopause have all been shown to decrease the 
risk of developing breast cancer (McPherson, Steel, & Dixon, 2000; Murray, 2010).  
 
A family history of breast cancer can increase the lifetime risk of developing the disease 
(Murray, 2010). This is because breast cancer susceptibility can be inherited through the 
Breast Cancer 1 (BRCA1) and Breast Cancer 2 (BRCA2) genes, which are located on the 
long arms of chromosomes 17 and 13, respectively. These genes may be transmitted by 
either parent and account for approximately 2% of all breast cancers (Murray, 2010). 
However, possessing one of these genes does not necessarily lead to the development of 
the disease, which suggests that both genetics and lifestyle are influential. Research has 
also shown that women are three or more times likely to develop breast cancer if they: 
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(a) have one first degree relative (e.g. mother, sister or daughter) with bilateral breast 
cancer or breast and ovarian cancer; 
(b) have one first degree relative with breast cancer diagnosed under the age of 40 
years or one first degree male relative with breast cancer diagnosed at any age; 
(c) have two first or second degree relatives (e.g. grandmother, granddaughter, aunt or 
niece) with breast cancer diagnosed under the age of 60 years or ovarian cancer at 
any age on the same side of the family, or  
(d)  have three first or second degree relatives with breast and ovarian cancer on the 
same side of the family (McPherson, Steel, & Dixon, 2000).  
 
It is clear that breast cancer can develop as a result of a complex interaction between a 
number of factors, which makes establishing the aetiology of the disease difficult. Research 
in this area is active with frequent reports in the media of newly identified potential risk 
factors; however, the validation of results is likely to take some time. Meanwhile, it is 
important to understand the experiences of those with the disease, and the next section 
(section 2.5) describes the processes involved in diagnosing breast cancer. These processes 
enable the breast cancer patient’s general practitioner (GP) to determine the prognosis of 
the disease and the most suitable treatment regime for the patient. 
2.5 Diagnosing Breast Cancer 
Since cancer can metastasise, it is important that the disease is detected at the earliest stage 
to increase the likelihood of a successful prognosis for the patient (Pelengaris & Khan, 
2006). Breast cancer can be detected symptomatically via self-examination or following a 
mammography through the NHS breast cancer screening programme. One of the main 
biological symptoms that may be identified during self-examination includes an isolated, 
painless lump in the breast (Skeel, 2003). However, as outlined in section 2.3, there are 
several stages in cancer development, thus it can take some time before cancerous cells 
develop into a tumour that can be physically detected by hand. Further developments can 
lead to the tumour becoming attached to the skin or chest wall, ulcerated, painful or 
inflamed and there may be discharge or bleeding from the nipple (Skeel, 2003). Typically, 
upon recognition of these symptoms, a woman may seek medical advice from her GP and 
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be invited to undergo a mammography (an x-ray of the breasts). However, not all women 
are aware of, or choose not to perform, self-examination of the breasts. If left undetected, 
the tumour will become more advanced and could metastasise and lead to the development 
of a secondary tumour elsewhere in the body. 
 
Alternatively, breast cancer may be detected following attendance at the NHS breast 
screening programme. The programme was established in 1988 with the aim of reducing 
the number of breast cancer-related deaths by detecting breast cancer at an earlier stage 
(when the tumour is too small to be detected by hand) and thus improving prognosis 
(Cheung, Greenway, Lagord, Williams, Kearins, & Lawrence, 2009). It involves inviting 
asymptomatic women aged 50 to 70 years for a mammography every three years. More 
than 1,500,000 women aged 50 to 70 years are screened annually through the programme 
and the Government is currently extending the range of women eligible for breast cancer 
screening to those aged 47 to 73 years (Cheung et al., 2009). Consequently, it is expected 
that there will soon be more diagnoses of breast cancer at an earlier stage with favourable 
prognoses, enabling survivors to continue or resume daily activities, such as within 
employment, academic and domestic settings, during and/or following cancer treatment. 
However, there are a number of side effects associated with cancer treatments, and these 
could have implications for patients’ daily functioning and quality of life (see Chapter 
Three, section 3.6). 
 
Treatment for breast cancer is tailored to the individual. Typically, a biopsy of the cancer 
cells is examined under a microscope by a pathologist, who evaluates how much the cells 
resemble normal cells in terms of the size and shape of the nucleus. The grade of the cancer 
refers to the appearance of the cancer cells and provides information about the potential for 
the cancer cells to metastasise. When the biopsied cells appear similar to healthy cells, the 
grade of the cancer is deemed relatively low, whereas the more abnormal the cells appear, 
the higher the grade of the cancer. Breast cancer can be graded as I (low grade), II 
(intermediate grade) or III (high grade). This information informs treatment decisions, for 
instance tumours with a higher grade are faster-growing and metastasise more quickly and 
may require more complex invasive treatment. The stage of the cancer refers to how 
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advanced the cancer is and can be used to estimate a patient’s prognosis. Staging can range 
from Stage 0 (an early in situ cancer) to Stage IV (a tumour that has metastasised). 
Pathologists also detect the presence of receptors on the breast cancer cells that enable 
endogenous oestrogen or protein to attach to them, which activates growth signals to 
increase the development of the tumour. Cancerous tumours with these proteins are called 
oestrogen-receptor positive (or ER positive) and hormone therapy is typically administered 
in these cases. In contrast, cancerous cells with many progesterone receptors (PGR 
positive) do not respond well to hormone treatment (Cancer Research UK, 2009). 
 
To summarise, the prognosis of breast cancer is a vital factor in determining the most 
appropriate course of treatment. In turn, this can have a significant impact on the 
experiences of the breast cancer patient as some types of treatment, particularly 
chemotherapy, are associated with a number of adverse biological side effects (see section 
2.7) and psychological side effects (see Chapter Three). An overview of the conventional 
treatments available to breast cancer patients (with curative intent) is presented in the next 
section (section 2.6). 
2.6 Treatments for Breast Cancer 
Following a diagnosis of breast cancer, most patients undergo treatment, usually within a 
month following diagnosis. Conventional treatment can be complex and include any one of 
a combination of the following treatments: 
(a) local therapy, which targets specific areas of the body (e.g. the breast), such as 
surgery and radiotherapy, 
(b) systemic therapy, which affects the whole body, such as chemotherapy and 
hormone therapy, and/or 
(c) biological therapy, which uses naturally occurring substances in the body.  
The stage and grade of the tumour, as well as other prognostic factors (outlined in section 
2.5), determine the most favourable treatment course. For example, to treat carcinoma in 
situ (localised to the breast region) the purpose of treatment is to remove the tumour and 
prevent recurrence. However, for those with metastatic cancer that is often incurable, the 
purpose of treatment is palliative.  
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Chemotherapy, radiotherapy and hormone therapy can be administered pre-surgery (known 
as neo-adjuvant therapy) with the aim of shrinking the tumour thus making surgery more 
effective. Alternatively, and more commonly, these therapies can be administered post-
surgery (known as adjuvant therapy) as a preventative measure with the aim of targeting 
potential remaining cancerous cells. Some breast cancer patients may also choose to 
receive complementary medicine - defined as therapies that tend to lie beyond the official 
health sector (British Medical Association, 1993). Complementary medicine includes 
herbal medicine, acupuncture, massage, aromatherapy, relaxation and meditation (Rees, 
Feigel, Vickers, Zollman, McGurk, & Smith, 2000). The prevalence of complementary 
medicine usage amongst breast cancer patients has been reported in only a handful of 
studies with estimates of 16% and 36% (e.g. Downer et al., 1994; Molassiotis et al., 2005). 
Due to the scarce research on complimentary medicine and the relatively limited usage by 
breast cancer patients, this type of treatment is considered out of the scope of this thesis. A 
summary of the main conventional medical treatments for breast cancer follows in the next 
sections (see sections 2.6.1 to 2.6.5). 
 
2.6.1 Surgery 
The purpose of surgery is to remove the tumour. There are different types of surgery 
depending on the prognosis. For example, breast conserving surgery is offered to patients 
with a lower stage of breast cancer (Stage II or lower) and includes lumpectomy (removal 
of the tumour and a small portion of healthy breast tissue), partial mastectomy (removal of 
the tumour and a larger portion of healthy breast tissue), and quadrantectomy (removal of 
the tumour and a quarter of the breast). Following advances in treatment technology, breast 
conserving surgery can target the cancerous cells and leave healthy tissue intact. This may 
help to reduce some of the adverse biological and psychological impacts of treatment. 
Reconstructive surgery can be offered to some breast cancer patients during or following 
the removal of the tumour, with the aim of helping to restore the appearance of the breast, 
thus improving quality of life, for example in terms of body image (White, 2000). A 
mastectomy is offered to patients with a higher stage of breast cancer, for example when 
the tumour is advanced and located in different parts of the breast. This procedure can be 
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further classified as a total mastectomy (removal of the entire breast tissue) or a radical 
mastectomy (removal of the entire breast tissue, lymph nodes and muscle behind the breast 
tissue). Statistics from an NHS report of surgically treated breast cancer patients in England 
in 2006 showed that the majority of operations (68%) were undertaken on invasive ductal 
carcinomas, while far fewer were on DCIS (10%) and LCIS (10%) (Cheung et al., 2009). 
The report also highlighted that of all surgically treated breast cancer patients, 43% of 
patients with invasive breast cancer and 35% of non-invasive breast cancer had a 
mastectomy. Breast conserving surgery was more prevalent in younger patients (aged less 
than 50 years) (Cheung et al., 2009). Only 27% of older patients (over 70 years old) did not 
have surgery and those who did were more likely to undergo a mastectomy (Cheung et al., 
2009). Breast cancer patients who underwent a mastectomy were more likely to have 
chemotherapy than radiotherapy, compared to patients treated with breast conserving 
surgery (Cheung et al., 2009). 
 
2.6.2 Radiotherapy 
Radiotherapy uses ionising radiation to penetrate tissue and change the DNA of the cell, 
which affects the growth and reproduction of the cell. Although healthy cells can recover 
following this damage, cancerous cells cannot. Since large radiation doses can be harmful, 
it is used to destroy in situ tumours so that the radiation damage is localised to a small area 
to minimise the damage to healthy cells. Radiotherapy treatment varies depending on the 
type of cancer, its location, stage and grade. It can be administered pre-surgery to reduce 
the tumour’s size, thus increasing the effectiveness of surgery. Typically, a dose (known as 
a fraction) is given each day or on alternate days over several weeks. Patients can receive 
radiotherapy to reduce the risk of cancerous cells returning following a lumpectomy or to 
target potential remaining cancerous cells following a mastectomy. 
 
2.6.3 Hormone Therapy 
Some breast cancer cells are oestrogen-sensitive, which means that oestrogen, a female 
hormone naturally produced by the ovaries prior to the menopause, facilitates their growth. 
Following the menopause, the adrenal glands (situated above the kidneys) produce smaller 
levels of oestrogen. Hormone therapy (also known as endocrine therapy) works by 
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reducing the levels of oestrogen and progesterone and blocking their effects (Cancer 
Research UK, 2009). This type of treatment targets breast cancer cells that have oestrogen 
receptors (ER) (Schilder, Schagen, & van Dam, 2008). There are three types of hormone 
therapy and they each work differently:  
(a) anti-oestrgoens, for example tamoxifen (Nolvadex), bind to ER+ cells to block the 
attachment of endogenous oestrogen thus stunting cell growth, 
(b) aromatase inhibitors, such as anastrozole (Arimidex), exemestane (Aromasin) and 
letrozole (Femara), prevent the production of oestrogen in post-menopausal women, 
and  
(c) luteinising hormone releasing hormone (LHRH) blockers, such as goserelin 
(Zoladex), block a hormone in the pituitary gland which stimulates the release of 
oestrogen (Cancer Research UK, 2009).  
 
Hormone therapy can be administered pre-surgery to shrink tumours with ER+ cells. 
However, it is more commonly administered up to five years post-surgery to help prevent 
the risk of the cancer returning. Statistics from an NHS report showed that, in 2006, 
younger breast cancer patients (less than 70 years) were more likely to be diagnosed with 
node positive tumours and thus less likely to have hormone therapy (Cheung et al., 2009). 
 
2.6.4 Monoclonal Antibody Therapy (Biological Therapy) 
Monoclonal antibody therapy is a type of biological therapy that involves the use of 
naturally occurring substances in the body to inhibit tumour growth. Trastuzumab 
(Herceptin) is the most common type of biological therapy and is successful in 20% to 25% 
of early-stage breast cancer patients. It works by binding to the Human Epidermal growth 
factor Receptor-2 (HER2), present in excessive quantities on cancerous cells, which 
subsequently prevents cell growth. Herceptin activates the immune system and destroys 
only the cancerous cells. It is administered intravenously once a week or once every three 
weeks for 12 months. 
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2.6.5 Chemotherapy 
Chemotherapy is a drug treatment involving chemicals that are poisonous (cytotoxic) to 
cancerous cells. The chemotherapeutic agents disrupt the cell division process by damaging 
the control centre of the cell, such as proteins or DNA. There are several methods of 
delivering chemotherapy and include injection into a vein (intravenous bolus) or through a 
drip (intravenous infusion), infusion pumps or orally in tablet form. These 
chemotherapeutic agents then circulate around the body in the bloodstream and target fast-
dividing cells, destroying them or prohibiting them from spreading. The systemic nature of 
this therapy means that it is effective at targeting cancerous located cells anywhere in the 
body, including potential metastases. However, healthy fast-dividing cells are also targeted. 
These include bone marrow cells, immune cells and hair follicle cells and subsequently this 
can lead to a number of adverse side effects. Chemotherapy is often administered in cycles 
where one cycle can last between one and five days, followed by a break of three to four 
weeks. In total, chemotherapy can last for up to eight cycles. Chemotherapy can be 
administered pre-surgery to shrink a tumour or post-surgery to destroy any remaining cells. 
In 2006, approximately 72% of younger patients (less than 50 years) received 
chemotherapy, which is partly due to the greater proportion of Grade 3, node positive 
cancers in this age group, whereas only 16% of older patients (over 70 years) received 
chemotherapy in England in 2006 (Cheung et al., 2009). 
 
There are more than 50 different types of chemotherapy drugs (also known as anti-cancer 
drugs or antineoplastics) and there are several factors that determine the type of 
chemotherapy administered to the patient, such as the type of cancer, its stage and grade. A 
chemotherapy drug may be administered in isolation, but more frequently in various 
combinations (called combination chemotherapy) in order to maximise the effectiveness of 
the treatment, as each drug works in a different way. Some of the most commonly 
administered regimes include: 
(a) FEC (fluorouracil, epirubicin and cyclophosphamide); 
(b) FEC-T (FEC followed by taxotere); 
(c) CMF (cyclophosphamide, methotrexate and fluorouracil); 
(d) E-CMF (epirubicin followed by CMF); 
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(e) AC (doxorubicin and cyclophosphamide); 
(f) MMM (methotrexate, mitozantron and mitomycin), and 
(g) CTC (cyclophosphamide, thiotepa and carboplatin). 
Currently, there is no consensus regarding the most effective chemotherapy regime and 
further clinical trials are required to address this. Clinical trials endeavour to find the most 
effective combination of chemotherapeutic agents that destroy cancerous cells while 
minimising the damage to healthy cells. Blood tests are taken prior to each chemotherapy 
cycle to provide information about liver and kidney function as well as an indication of the 
number of red cells, white cells and platelets in the blood. This is important since 
chemotherapy can affect bone marrow, which is involved in the production of these cells. 
Chemotherapy treatment can be delayed if the blood count has not resumed to normal 
levels following the previous chemotherapy cycle. 
 
Establishing the best treatment course for breast cancer is a complex task. It requires the 
oncologist to consider a range of prognostic factors to select a treatment regime that will 
remove the cancerous cells from the body, to prevent metastasis and potential reoccurrence. 
In short, survival is an important endpoint. However, survival rates have increased 
following recent advances in treatment technology, and so attention has turned to the 
patient’s experience of the side effects related to breast cancer treatment. The common 
biological side effects associated with breast cancer treatment are reviewed in the following 
section (see section 2.7). 
2.7 The Biological Side Effects of Breast Cancer Treatment 
Although conventional treatments for breast cancer are frequently effective in their curative 
intent, patients have reported a number of adverse biological and psychological side 
effects. Although the biological side effects of breast cancer treatments are well-
documented (e.g. see meta-analysis by Tsai, Dennis, Lynch, Snetselaar, Zamba, & Scott-
Conner, 2009), research has recently focussed on the psychological side effects. These can 
be divided into psychosocial side effects (such as anxiety, depression and fatigue) as well 
as cognitive side effects (such memory and concentration impairment). This thesis is 
concerned with the psychological impact of treatment and Chapter Three discusses the 
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relevant literature in detail. However, in order to understand the complete experience of 
breast cancer patients, particularly since biological side effects can have an impact on 
psychological well-being, the key biological side effects are reviewed in this section.  
 
It is important to note that since an individual’s genetic material is unique, breast cancer 
can originate and develop in many ways. Therefore, treatment is tailored to the individual 
in response to the tumour’s particular characteristics (e.g. grade and stage) as well as the 
individual’s characteristics (e.g. age). In turn, this means that the impact of treatment can 
vary between individuals due to differences in the body’s capacity to tolerate side effects 
and so there is great heterogeneity in the range and severity of side effects experienced 
within the breast cancer population. Furthermore, a breast cancer patient may experience 
different side effects following each chemotherapy cycle, which may result from the 
cytotoxic accumulation of several cycles of chemotherapy leading to cumulative or 
synergistic side effects (Guill & Raynor, 2008). In addition, these side effects are often 
experienced in combination rather than in isolation and may interact negatively with each 
other (Meyers & Perry, 2008). For example, a patient may experience concentration 
difficulties that require greater mental effort to complete tasks, which in turn may increase 
fatigue, and subsequently may contribute to cognitive decline. It is clear that understanding 
the impact of treatment can be a difficult task; however, it is important that research does 
so in order to inform health professionals and future breast cancer patients so that 
appropriate support can be implemented. 
 
Surgery. There are relatively few biological side effects associated with surgery compared 
to other breast cancer treatments. Short-term pain and tenderness in the localised area is 
often experienced, which can be relieved by opioid analgesics. During surgery, breast 
cancer patients may be anaesthetised to prevent feeling pain during the operation. 
However, breast cancer patients who undergo a mastectomy may experience long-term 
pain (post-operative pain syndrome). Fatigue and sleep disturbance can be induced by 
opioids (Kehlet & Wilmore, 2002; Rubin & Hotopf, 2002). Lymphoedema (the chronic 
swelling caused by an accumulation of fluid) can occur when the lymph nodes have been 
damaged or removed and the lymph ducts are unable to drain waste products into the veins. 
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Approximately 1 in 5 breast cancer patients will develop lymphoedema of the arm (Cancer 
Research UK, 2009). 
 
Radiotherapy. Although radiotherapy is painless during the treatment itself, cumulative 
doses can produce side effects, such as short-term pain and tenderness in the localised area. 
Some breast cancer patients may develop anaemia, which can result in fatigue. Breast 
cancer patients may also experience a change in skin colour (red or darker in colour), 
swallowing difficulties, sickness, weight loss and breathlessness. 
 
Hormone therapy. The biological side effects of hormone therapy depend on the type of 
therapy administered. However, breast cancer patients commonly report digestive 
difficulties, nausea, diarrhoea, increased or decreased appetite, hair thinning, headaches 
and joint pain. Hormone therapy can also induce temporary or permanent menopause 
(including in post-menopausal patients) resulting in hot flushes, sweating and vaginal 
dryness. 
 
Biological therapy. Similarly, the biological side effects of biological therapy depend on 
the type of monoclonal antibodies administered. The most common side effect is associated 
with an allergic reaction, which may induce chills, fever, an itchy rash, nausea, 
breathlessness, headaches, flushes, faintness, and changes in blood pressure. 
 
Chemotherapy. As previously described, chemotherapeutic agents target all rapidly 
proliferating cells in the body, which includes cancerous cells as well as healthy cells (e.g. 
situated in the skin, hair, mouth, lining of the digestive system, bone marrow, and red blood 
cells). This can produce a number of adverse side effects, such as alopecia, nail loss, 
stomatitis (inflammation of the mucous tissue of the mouth), changes in taste, mucositis 
(inflammation of the digestive tract tissue lining), diarrhoea, constipation and nausea 
(Boehmke & Dickerson, 2005). The range of side effects experienced is dependent upon 
the agents administered, the dose and format of administration (e.g. intravenously or 
orally). Side effects tend to commence two to three weeks following the start of 
chemotherapy administration. Antiemetic drugs can be administered before or after 
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chemotherapy to help manage nausea and vomiting (Hesketh, 2009). The reduction in bone 
marrow can leave breast cancer patients highly susceptible to infection and so antibiotics 
are often prescribed. The reduction in red blood cells can induce anaemia and subsequent 
breathlessness and fatigue (O’Shaughnessy, 2003; Kayl, Wefel, & Meyers, 2006). In the 
psycho-oncology literature, fatigue is generally considered to be a psychosocial side effect 
due to its impact upon daily functioning and quality of life (Curt et al., 2000), and so is 
addressed separately in Chapter Three. Chemotherapy may also damage the visual system 
(Raffa & Tallarida, 2010), affect fertility by inducing premature menopause, and reduce the 
production of platelets in the blood (thrombocytopenia). Since the role of platelets is to 
help the blood to clot, breast cancer patients may develop a tendency to bruise and bleed 
more easily and experience nosebleeds following treatment. Breast cancer patients may 
also experience numbness and weakness in the muscles of the hands and feet as well as loss 
of proprioception due to nerve damage (peripheral neuropathy), which can lead to 
accidents and falls (Tofthagen, Overcash, & Kip, 2012) (see Chapter Four for further 
details). Furthermore, chemotherapy can cause or worsen osteoporosis due to the negative 
effect on bone mineral density (Mincey, Moraghan, & Perez, 2000). It is clear that there are 
a number of potential biological side effects of chemotherapy, which can have a profound 
detrimental impact on daily life. 
2.8 Chapter Summary 
This section has presented a biological background of breast cancer, the conventional 
treatments for this disease, and the associated biological side effects. The incidence and 
survival rate of breast cancer is high, as well as the prevalence of treatment-related side 
effects. Therefore, it is important that appropriate information and support are available to 
breast cancer patients so that the impact on daily tasks and quality of life is minimal. The 
biological side effects are part of the traditional biomedical approach (see Chapter One). 
Since there is a current trend to adopt the holistic biopsychosocial model in medicine and 
health research, it is also important to consider the psychological impact of breast cancer 
and its treatment upon daily functioning and quality of life. Psycho-oncology researchers 
have documented numerous psychological side effects associated with chemotherapy for 
breast cancer and this literature is discussed in the following chapter (see Chapter Three). 
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Chapter Three 
A Review of the Literature on Psychosocial Well-Being and 
Cognitive Function in Breast Cancer Patients 
3.1 Chapter Introduction 
In addition to the biological side effects described in Chapter Two (see section 2.7), 
breast cancer and its treatment are associated with a number of adverse psychological 
side effects. Increasing evidence suggests that some breast cancer patients experience 
anxiety, depression, fatigue and cognitive difficulties, particularly following 
chemotherapy treatment. The current chapter begins by defining these psychological 
domains. This is followed by a critical evaluation of the relevant key studies that have 
examined psychosocial and cognitive side effects in breast cancer patients undergoing 
chemotherapy. The postulated causes of chemotherapy-related cognitive impairment are 
then summarised, followed by the impact of this side effect on quality of life and work 
ability. The chapter concludes with a summary of the current gaps in this research area. 
3.2 Psychosocial Side Effects 
Historically, cancer care has focussed on the biomedical approach to treating the 
disease, such as improving the effectiveness of treatment and addressing the associated 
biological side effects. Psychosocial side effects, such as anxiety, depression and 
fatigue, associated with cancer and its treatment are often overlooked (Artherholt & 
Fann, 2012). These psychosocial side effects can have a negative impact upon the 
effectiveness of healthcare and subsequently the health of the cancer patient (Adler & 
Page, 2008). For example, psychosocial difficulties can “cause additional suffering, 
weaken adherence to prescribed treatments, and threaten patients’ return to health” 
(Adler & Page, 2008, p. 1). Following improvements in the prognosis and survival of 
breast cancer, many women are now able to resume their daily tasks following 
treatment while some continue their daily tasks during treatment (Steiner, Cavender, 
Main, & Bradley, 2004). Therefore, it is important that the psychosocial impact of 
breast cancer and its treatment is understood so that this can be appropriately managed. 
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This need has recently been acknowledged by a number of organisations, including the 
Institute of Medicine (Adler & Page, 2008) and the International Psychosocial 
Oncology Society (Holland, Watson, & Dunn, 2011), which have recommended further 
research into the psychosocial impact of cancer on the individual. The commonly 
reported psychosocial difficulties reported by breast cancer patients are described 
below. 
 
3.2.1 Anxiety 
Anxiety is “a state of uneasiness, accompanied by dysphoria and somatic signs and 
symptoms of tension, focused on apprehension of possible failure, misfortune, or 
danger” (Colman, 2009, p. 46). The prevalence of anxiety in the general adult 
population is estimated at 12.6% (Crawford, Henry, Crombie, & Taylor, 2001). In 
breast cancer patients undergoing chemotherapy, the prevalence is estimated much 
higher at 35% (Maly, Umezawa, Leake, & Silliman, 2005). 
 
Anxiety can develop in the breast cancer population for several reasons. Firstly, the 
diagnosis of a life-threatening disease can be a stressful event and influence the 
emotional well-being of the individual (Vardy & Tannock, 2007; Minisini, Atalay, 
Bottomley, Piccart, & Biganzoli, 2004). Secondly, treatment for breast cancer may be 
related to anxiety and studies have shown increased levels of anxiety in breast cancer 
patients undergoing chemotherapy compared to other treatments (Schreier & Williams, 
2007). Thirdly, following successful treatment for the disease, the transition in identity 
from cancer patient to cancer survivor can be challenging and can create psychosocial 
adjustment disturbances (Dolbeault et al., 2009). For example, anxiety may result from 
attending follow-up medical examinations as well as coping with physical and 
psychological changes (Stanton et al., 2005). This might include a change in body 
image and fears regarding recurrence of the disease. Anxiety may exist for several years 
following diagnosis and treatment completion (Spiegel, 1997). 
 
Schreier and Williams (2007) examined anxiety in breast cancer patients receiving 
chemotherapy (n = 31) or radiotherapy (n = 17). A self-report measure of anxiety 
(Speilberger’s State-Trait Anxiety Inventor; STAI) was administered at the start of 
treatment and at 4 and 12 weeks later. Results suggested that trait anxiety was 
significantly higher in breast patients undergoing chemotherapy and state anxiety was 
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significantly higher at all three time-points for this treatment group. Schreier and 
Williams also reported that higher anxiety at the start of treatment was associated with 
decreased quality of life at the start of treatment and post-diagnosis. Although the 
relatively small sample size makes it difficult to generalise these findings, the study’s 
longitudinal design provides evidence for temporal changes in anxiety over the course 
of chemotherapy. 
 
Anxiety can have a negative impact on quality of life and is related to reduced 
compliance to treatment (Buccheri, 1998). Furthermore, strong evidence suggests an 
interaction between anxiety and/or depression and perceived cognitive impairment (van 
Dam et al., 1998; Castellon et al., 2004). Prolonged feelings of anxiety can also lead to 
fatigue (Bower et al., 2006). 
 
3.2.2 Depression 
Depression can be described as feelings of sadness, fear, anger and grief (Aapro & Cull, 
1999). The prevalence of depression in the general adult population is estimated at 
3.6% (Crawford, Henry, Crombie, & Taylor, 2001). Burgess, Cornelius, Love, Graham, 
Richards, and Ramirez (2005) reported the prevalence of depression among early-stage 
breast cancer patients (n = 222) to be approximately 50% in the first year after 
diagnosis, but with a decline to 15% in the fifth year post-diagnosis. This finding 
suggests that psychosocial support for breast cancer patients is necessary, particularly in 
the first year following diagnosis. 
 
Brennan (2001, p. 3) describes “the diagnosis, treatment and aftermath of cancer 
involves a long process of adaptation to multiple threats and novel experiences”. 
Furthermore, research findings suggest that the duration of time since diagnosis predicts 
adjustment to cancer (Deshields, Tibbs, Fan, & Taylor, 2006). Symptoms of depression 
include fatigue, sleep difficulties, and appetite loss (Artherholt & Fann, 2012). 
However, these may not be reliable indicators of depression in breast cancer patients 
due to the overlap with cancer treatment-related side effects (Artherholt & Fann, 2012). 
A number of studies have found that breast cancer patients receiving chemotherapy 
report higher levels of depression compared to breast cancer patients who receive local 
therapy (e.g. Schagen et al., 1999). Furthermore, depression can have an adverse impact 
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on quality of life in breast cancer patients (Badger, Braden, Mishel, & Longman 2004; 
Deshields, Tibbs, Fan, & Taylor, 2006). 
 
3.2.3 Fatigue 
Fatigue can be described as “a subjective and multidimensional concept with several 
modes of expression: physical (e.g. diminished energy, need to rest), cognitive (e.g. 
diminished concentration or attention), and affective (e.g. decreased motivation or 
interest)” (Servaes, Verhagen, & Bleijenberg, 2002b, p. 27). It is prevalent in the 
general population with approximately 20% of men and 30% of women reporting 
feelings of fatigue (Hjermstad, Fayers, Bjordal, & Kaasa, 1998). It can act as a response 
to physical or psychological stress and help to maintain a balance between rest and 
activity (Servaes, Verhagen, & Bleijenberg, 2002b). In healthy individuals, fatigue 
typically diminishes following adequate sleep (Servaes, Verhagen, & Bleijenberg, 
2002b). However, researchers have suggested that there is a difference in the aetiology 
of fatigue experienced by cancer patients compared to the general population in terms 
of severity (Cella, Lai, Chang, Peterman, & Slavin, 2002). For example, cancer-related 
fatigue can be a distressing symptom, is not relieved by increased rest or sleep, and can 
limit daily activity (Iop, Manfredi, & Bonura, 2004). As a result of this disparity, 
cancer-related fatigue has been accepted as a diagnosis in the International 
Classification of Diseases 10th Revision-Clinical Modification (Portenoy & Itri, 1999). 
 
Cancer-related fatigue is one of the most extensively researched psychosocial side 
effects and has been reported to affect up to 91% of breast cancer patients undergoing 
chemotherapy (Gaston-Johansson, Fall-Dickson, Bakos, & Kennedy, 1999; Jacobsen, 
Hann, Azzarello, Horton, Balducci, & Hyman, 1999). Furthermore, cancer-related 
fatigue may persist for up to 10 years post-radiotherapy and/or chemotherapy in an 
estimated 34% of breast cancer survivors (Bower et al., 2006). Fatigue has complex and 
interactive underlying aetiologies - such as sleep, mood and cognitive disturbance, 
depression, anxiety, pain, anaemia, weight loss, and impaired nutritional status – which 
are not currently fully understood (Yellen, Cella, Webster, Blenowski, & Kaplan, 
1997). Fatigue can impair daily functioning and reduce quality of life in cancer patients 
(Cella, Peterman, Passik, Jacobsen, & Breitbart, 1998).  
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Servaes, Verhagen, and Bleijenberg (2002a) found that in disease-free breast cancer 
survivors, those who reported severe fatigue experienced more cognitive difficulties, 
such as memory and concentration impairment, than breast cancer patients without 
severe fatigue and non-cancer participants. The persistence of fatigue post-treatment in 
breast cancer patients is currently debated. A systematic review by Minton and Stone 
(2008) identified 18 studies that measured fatigue in cancer patients between four 
months and 10 years following treatment. Fourteen of these studies documented fatigue 
and/or a difference in levels of fatigue in cancer patients compared to a control group 
up to five years post-treatment (Minton & Stone, 2008).  
 
Curt et al. (2000) found that 76% of cancer patients experienced fatigue for several days 
each month during chemotherapy and 30% experienced fatigue daily. Ninety-one 
percent of cancer patients who experienced fatigue reported that it prevented a ‘normal’ 
life (e.g. difficulty participating in social activities and performing cognitive tasks) and 
changed their daily routine (88%). In relation to employment, 75% of employed cancer 
patients altered their employment status due to fatigue. Interestingly, a study by 
Vogelzang et al. (1997) found that 74% of cancer patients considered that fatigue 
should be tolerated as a side effect and only 50% of cancer patients discussed this side 
effect with a health professional (Bower, 2008). It is important to note that fatigue may 
have psychological or biological causes and may be linked to other symptoms such as 
depression and insomnia (Curt, 2001; Respini, Jacobsen, Thors, Tralongo, & Balducci, 
2003).  
 
Some of the predisposing factors of cancer-related fatigue include: underlying disease; 
treatment; inter-current systemic disorders (e.g. anaemia, infection, dehydration); sleep 
disorders; chronic pain; use of opioids; anxiety disorders, and depressive disorders 
(Portenoy & Itri, 1999). Treatment for cancer-related fatigue include: changing the 
treatment regime; correcting metabolic disorders; addressing depression and insomnia, 
and engaging in exercise (Iop, Manfredi, & Bonura, 2004). Dimeo, Schwartz, Wesel, 
Voigt, and Thiel (2008) report that cancer patients experiencing fatigue may be advised 
to rest and reduce activity levels; however, extended rest can perpetuate fatigue as 
inactivity can induce muscular catabolism. This contradiction in alleviators for fatigue 
highlights the complexity surrounding cancer-related psychological side effects. 
Chapter Three              Literature Review: Cognitive Side Effects 
 
36 
3.3 An Overview of Cognitive Function and Cognitive Failures 
Cognition is a generic term that refers to brain-based or mental processes, including 
memory, concentration, communication, reasoning and decision-making, which are 
necessary for daily functioning. A wealth of research has been conducted on the 
processes involved in cognitive function. Table 3.1 provides an overview of the 
commonly studied cognitive domains in psycho-oncology research. Cognitive 
impairment, or cognitive failure, occurs when an error is present in one or more of these 
cognitive domains. This is also referred to as human error (see Chapter Four, section 
4.3). Incidences of cognitive failure are common in the general population and are part 
of everyday life, for example going from one room to the other and forgetting why, and 
typically the impact is merely an inconvenience. Shallice, Burgess, Schon, and Baxter 
(1989) proposed the model of action, which suggests that during routine tasks when 
little cognitive effort is required, a contention scheduling system is used, similar to 
auto-pilot (or skill-based performances – see Chapter Four, section 4.3). This has the 
advantage of using few cognitive resources and is therefore an efficient method. 
However, when task demands or goals are altered, distraction, boredom and cognitive 
failures can occur (Broadbent, Cooper, FitzGerald, & Parkes, 1982). 
 
Increasing evidence suggests that breast cancer patients undergoing chemotherapy 
experience cognitive impairment more frequently and more severely compared to the 
general population, particularly in the domains of memory, attention, executive function 
and psychomotor function (Mar Fan et al., 2005; Tannock, Ahles, Gazna, & van Dam, 
2004). The prevalence of cognitive impairment in breast cancer patients undergoing 
chemotherapy has been reported to be up to 75% (Wieneke & Dienst, 1995), and can 
endure several years post-treatment in 17% to 34% of patients (Ahles & Saykin, 2007). 
The term chemotherapy-related cognitive impairment refers to changes in cognitive 
ability associated with the onset of chemotherapy treatment (Cull, Hay, Love, Mackie, 
Smets, & Stewart, 1996). It is important to recognise that cognitive impairment in this 
population is not as severe and as long-lasting as found in other patient populations, 
such as in individuals with dementia (Jenkins et al., 2006). However, subtle cognitive 
difficulties can still have a profound impact on daily functioning and quality of life 
(Steiner, Cavender, Main, & Bradley, 2004). This includes employment, academic and 
social activities (Wefel, Lenzi, Theriault, Buzdar, Cruickshank, & Meyers, 2004a). 
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Although the existence of chemotherapy-related cognitive impairment has become 
almost universally accepted (Shilling, Jenkins, & Trapala, 2006), there are 
inconsistencies in the literature. For example, reports relating to the prevalence and 
severity of chemotherapy-related cognitive impairment vary widely, resulting from 
methodological variations across studies, such as study design, timing of assessment 
and the definition impairment (Shilling et al., 2006). Furthermore, the mechanism(s) 
involved in chemotherapy-related cognitive impairment are currently unclear (see 
section 3.5 for a discussion). Consequently, further research examining chemotherapy-
related cognitive impairment in the breast cancer population is required. A review of the 
research is included in this chapter. 
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Table 3.1 
Cognitive and Motor Domains Commonly Assessed in Neuropsychological Testing (adapted from Rich & Troyer, 2008)
Domain Definition 
Cognitive domain  
Attention/concentration 
and processing speed 
The ability to focus on incoming information. Includes a) selective attention: the ability to focus on information 
relevant to the current task and filter out irrelevant information; b) sustained attention: the ability to maintain 
focus on a task over a prolonged period of time; c) divided attention: the ability to focus on several tasks 
simultaneously; d) alternating attention: the ability to shift focus between several sources of information; e) 
working memory: the ability to manipulate information held in memory for a short period; f) processing speed: 
the ability to rapidly process and respond to information. 
 
Visual ability Includes a) object perception: the ability to recognise items; b) spatial perception: the ability to understand the 
physical location of objects; c) visual constriction: the ability to merge individual parts to make a clear whole. 
 
Language 
 
Includes a) receptive language: the ability to comprehend orally or visually presented verbal information, and b) 
expressive language: the ability to produce words or sentences. 
Memory The ability to encode, store and retrieve information. Includes a) short-term memory: the ability to remember 
information presented seconds ago; b) long-term memory: the ability to remember information presented hours 
ago; c) remote memory: the ability to remember events from years ago; d) prospective memory: the ability to 
remember to carry out intentions at a future time-point; e) episodic memory: the ability to remember novel 
information; f) semantic memory: the ability to remember known general facts; g) verbal memory: the ability to 
remember lists of words; h) non-verbal memory: the ability to remember geometric information or new faces. 
 
Executive function Includes higher order cognitive abilities, such as a) planning: the ability to formulate and consider different 
approaches to a task and to conduct an effective approach to achieve a goal; b) abstract thinking: the ability to 
create generalised concepts from discrete instances; c) response inhibition: the ability to produce an uncommon 
response instead of an automatic response; d) switching: the ability to alternate between different types of 
information or different response categories. 
Motor domain  
Sensorimotor ability Includes a) sensory ability: the ability to detect visual, auditory or tactile stimuli, and b) motor ability: the ability 
to produce movement. 
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3.4 Measuring Chemotherapy-Related Cognitive Impairment 
Over the past 30 years, there have been many developments in the approach to 
examining chemotherapy-related cognitive impairment, including neuropsychological 
assessment, neuroimaging and self-report. This section is structured to reflect these 
developments. First, the use of neuropsychological tests is introduced in section 3.4.1. 
These are commonly used in psycho-oncology research and involve the administration 
of standardised tests to obtain an objective behavioural measure of cognitive domains, 
such as memory, attention, language, and psychomotor speed, and visuospatial skills. 
Until recently they were regarded as the gold standard tool for measuring cognitive 
changes in the breast cancer population. Next, the pivotal cross-sectional studies are 
discussed in section 3.4.2. Although these early studies provided evidence on the 
existence of a subgroup of cognitively-impaired breast cancer patients, the inherent 
shortcoming of this between-group design prevented researchers from identifying the 
onset of cognitive impairment or temporal fluctuations in cognitive change. 
Longitudinal studies were later conducted in response to the limitations of previous 
research and generally provided further support for the existence of cognitive 
impairment in breast cancer patients undergoing chemotherapy. The seminal 
longitudinal studies are discussed in section 3.4.3. More recently, the value of 
subjective measures has become widely recognised and contemporary research has 
focussed on findings from self-report measures. The relevant studies are described in 
more detail in section 3.4.4. Neuroimaging techniques, such as magnetic resonance 
imaging (MRI), functional MRI (fMRI) and positron emission tomography (PET), have 
revealed differences in the structure and function of the brain, such as neural activity, 
between cancer patients who have received chemotherapy and those who have not 
(Saykin, Ahles, & McDonald, 2003; Silverman et al., 2007). A comprehensive 
summary of the published research examining cognitive impairment following 
chemotherapy for breast cancer is presented in Table 3.2 (see p. 47; a note explaining 
the acronyms used in the table is on p. 54). 
 
3.4.1 Neuropsychological Measures 
The majority of studies that have examined the cognitive impact of chemotherapy in 
breast cancer patients have done so using objective neuropsychological measures 
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(Pullens, De Vries, & Roukema, 2010). These measures provide scores of cognitive 
performance relating to specific cognitive domains, such as those described in Table 
3.1. Typically, several neuropsychological measures are included in a battery of tests 
that the patient is asked to work through, often using a laptop and lasting several hours 
(Freeman & Broshek, 2002). Neuropsychological tests are useful because of the 
standardised administration and scoring of data, such as comparing scores against 
normative data adjusted for factors including age and education (Smith & Wefel, 2008). 
 
However, a limitation of neuropsychological tests is their lengthy administration, which 
may contribute to fatigue and thus provide unreliable cognitive function scores (Jansen, 
Dodd, Miaskowski, Dowling, & Kramer, 2008; Mehnert et al., 2007). More than 50 
neuropsychological tests have been used in psycho-oncology research (Jansen, 
Miaskowski, Dodd, Dowling, & Kramer, 2005), and so it can be difficult to compare 
findings across studies and ascertain a clear understanding of the impact of 
chemotherapy on different cognitive domains. Furthermore, neuropsychological tests 
can sometimes map on to a range of cognitive domains, and two tests that measure the 
same cognitive domain may yield different levels of cognitive impairment due to 
variation in the specified cut-off levels. This may be a contributing factor to the 
inconsistent findings relating to the prevalence, severity and onset of cognitive decline 
in breast cancer patients undergoing chemotherapy. 
 
As shown in Table 3.2, studies often include both an objective and subjective measure 
of cognitive function. Interestingly, only a handful of studies have found a significant 
correlation between these measures in the breast cancer population (e.g. Castellon, 
Ganz, Bower, Petersen, Abraham, & Greendale, 2004). The majority of studies report 
no association between objective and self-report measures (e.g. Cull, Hay, Love, 
Mackie, Smets, & Stewart, 1996; Klepstad, Hilton, Moen, Fougner, Borchgrevink, & 
Kaasa, 2002). Instead, subjective cognitive function is often related to anxiety and 
depression (Iconomou, Mega, Koutras, Iconomou, & Kalofonos, 2004; Jenkins, 
Shilling, Fallowfield, Howell, & Hutton, 2004; Jenkins et al., 2006; Schagen, van Dam, 
Muller, Boogerd, Lindeboom, & Bruning, 1999; van Dam et al., 1998). Subsequently, 
self-report measures of cognitive function have been criticised and neuropsychological 
tests are seen as the gold standard (Wagner, Sweet, Butt, Lai, & Cella, 2009). It may be 
that subjective cognitive function is indicative of psychosocial functioning. The 
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following section discusses the pivotal cross-sectional studies that have focused on 
findings from neuropsychological measures as well as self-report measures to assess 
cognitive ability in breast cancer patients undergoing chemotherapy. 
 
3.4.2 Cross-Sectional Design: The Key Studies 
The first studies investigating cognitive side effects in breast cancer patients were cross-
sectional in design and consistently found greater cognitive impairments in women who 
had received chemotherapy compared to controls (Schagen, van Dam, Muller, Boogerd, 
Lindeboom & Bruning, 1999; van Dam et al., 1998; Wieneke & Dienst, 1995). As 
shown in Table 3.2, studies have included a range of control group types, for example a 
treatment control group (i.e. breast cancer patients with a comparable diagnosis and 
thus exposed to similar associated psychosocial impact, but undergoing different 
treatment), a healthy control group, or normative data from published norms. The 
pivotal cross-sectional studies are discussed below. 
 
Wieneke and Dienst (1995) conducted one of the first cross-sectional studies using 
comprehensive neuropsychological tests to measure objective cognitive ability in breast 
cancer patients (n = 28). The participants were female, aged 28 to 54 years, diagnosed 
with Stage I or II breast cancer, and received standard-dose adjuvant chemotherapy 
(mainly cyclophosphamide, methotrexate and fluorouracil; CMF). Hormonal therapy 
with tamoxifen was also administered to some participants. Neuropsychological tests 
were administered between 5 to 12 months following the receipt chemotherapy. 
Findings suggested that 75% of breast cancer patients experienced moderate cognitive 
impairment in at least one measure compared to published normative data. Cognitive 
deficits were discovered in concentration, mental flexibility and processing speed, 
verbal and visual memory, visuospatial ability and motor function, suggesting a 
generalised pattern of cognitive impairment. Wieneke and Dienst found that the 
duration of chemotherapy (range 3 to 18 months) was significantly associated with 
cognitive impairment (p < .01). However, no significant association was found between 
cognitive decline and chemotherapy type, time since last treatment, or depression. 
 
Although Wieneke and Dienst’s (1995) study has been criticised for its relatively small 
sample size, retrospective design and lenient definition of impairment (cut off set at two 
standard deviations required on only one test), this research has provided some of the 
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first scientific evidence for chemotherapy-related cognitive changes in a cohort of 
breast cancer patients. Later studies employed more stringent definitions of cognitive 
impairment and have generally not replicated this high prevalence of cognitive 
impairment (Vardy & Tannock, 2007).  
 
van Dam et al. (1998) conducted the first randomised study comparing breast cancer 
patients treated with standard-dose chemotherapy (FEC; n = 36) or high-dose 
chemotherapy (FEC-CTC with peripheral blood stem cell transplant; n = 34), followed 
by radiotherapy and tamoxifen. A control group of Stage I breast cancer patients treated 
with local therapy (surgery plus local radiotherapy; n = 34) was also included. 
Neuropsychological tests plus self-report measures of anxiety, depression and quality of 
life were administered on average two years post-treatment. In addition, semi-structured 
interviews were conducted to ascertain cognitive difficulties encountered in daily life. 
Cognitive impairment was defined as at least two standard deviations below the control 
group mean for individual tests and below the fifth percentile of controls overall. 
Results showed that 32% of breast cancer patients assigned to high-dose chemotherapy 
were cognitively impaired, compared to 17% of breast cancer patients assigned 
standard-dose chemotherapy, and 9% of breast cancer patients in the control group (p = 
.043). In comparison with controls, breast cancer patients treated with high-dose 
chemotherapy were at 8.2 times higher risk of cognitive impairment, while breast 
cancer patients treated with standard-dose chemotherapy were at 3.5 times higher risk. 
No significant association between objective cognitive measures and subjective 
cognitive measures was found. Breast cancer patients in the high-dose chemotherapy 
group scored higher on self-report measures of fatigue and depression. This study was 
one of the first to identify a potential dose-dependent link between adjuvant 
chemotherapy and cognitive difficulties, suggesting greater central nervous system 
toxicity in the higher dose group, as well as to report the enduring cognitive side effects 
associated with chemotherapy (van Dam et al., 1998).  
 
A year later, the same research group as above (Schagen, van Dam, Muller, Boogerd, 
Lindeboom, & Bruning, 1999) compared lymph node positive breast cancer patients 
who had received standard-dose adjuvant chemotherapy (CMF; n = 39) with an age-
matched control group of lymph node negative breast cancer patients (n = 34) who had 
received surgery and radiotherapy. Twenty of the chemotherapy patients had completed 
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six courses of CMF followed by three years of hormonal therapy with tamoxifen, while 
19 participants did not receive hormonal therapy. The same neuropsychological tests as 
before were employed at an average of 1.9 years following chemotherapy or 2.4 years 
following local therapy in the control group. Across all domains, results suggested that 
breast cancer patients who received chemotherapy showed higher cognitive impairment 
compared to the control group (28% vs. 12%), suggesting late effects of chemotherapy. 
There was no significant difference between those who did and did not receive 
tamoxifen. Age, time since treatment, anxiety, depression and fatigue were not found to 
be significant predictors of cognitive ability. Multivariate analyses showed that only IQ 
and adjuvant chemotherapy significantly impacted test scores. Breast cancer patients 
who received chemotherapy self-reported significantly more memory difficulties 
compared to controls (21% vs. 3%) and concentration difficulties (31% vs. 6%) during 
daily life (p < .05) when interviewed about the extent of cognitive complaints. Those in 
the chemotherapy group also scored significantly lower on the self-report EORTC-
QLQ-C30 in relation to physical function (p < .035) and cognitive function (p < .01). 
No correlation was found between self-report and objective cognitive function; 
however, self-report cognitive function was significantly associated with anxiety, 
depression and quality of life. This study demonstrated that although both participant 
groups had received a diagnosis of breast cancer and experienced the psychosocial 
impact of this (although a difference in the staging of breast cancer was noted), there 
were significant differences in the prevalence of cognitive impairment between the 
treatment groups. The study also suggested late effects of chemotherapy, approximately 
two years post-treatment, which impacted upon quality of life. 
  
In one of the largest studies conducted to date, Tchen et al. (2003) found moderate to 
severe cognitive impairment in 16% of breast cancer patients currently receiving 
adjuvant chemotherapy (mainly anthracycline-based; n = 100) compared to 4% in age-
matched healthy controls (n = 100) (p = .008). The High Sensitivity Cognitive Screen 
(HSCS) was used to measure cognitive ability. Highly significant differences were also 
found in fatigue and menopausal status between the participant groups. There was a 
strong correlation between these factors and quality of life, but no significant 
association was found with cognitive decline.  
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In a recent study, Von Ah et al. (2009) examined cognitive function in breast cancer 
survivors (n = 52) and age- and education-matched healthy controls (n = 52). Breast 
cancer survivors were found to be significantly impaired in one or more 
neuropsychological tests (36%), particularly related to learning and delayed recall 
abilities. 
 
In contrast to these reported findings, several studies have found no evidence of 
cognitive impairment following chemotherapy in breast cancer patients (e.g. Donovan, 
Small, Andrykowski, Schmitt, Munster, & Jacobsen, 2005; Scherwath et al., 2006). For 
example, a cross-sectional study conducted by Donovan et al. (2005) found no 
significant differences in objective cognitive function in breast cancer patients treated 
with standard-dose adjuvant chemotherapy plus radiotherapy (n = 60) and radiotherapy 
treatment alone (n = 83) in relation to episodic memory, attention, motor performance 
and language. However, this study has been criticised for the lack of control between 
patient groups as breast cancer patients in the radiotherapy group were significantly 
older compared to those in the chemotherapy group and so may have experienced age-
related cognitive decline (Charlton et al., 2006). This may have masked the impact of 
chemotherapy-related cognitive impairment in the chemotherapy group. Inconsistencies 
in findings may be attributed to variations in methodological approach across studies, 
such as definition in cognitive impairment, sensitivity of neuropsychological measures, 
type of chemotherapy regimen, timing of assessment, study design, small sample sizes, 
and type of comparison control group. 
 
Despite these inconsistencies, the findings from published cross-sectional studies 
generally suggest that breast cancer patients undergoing chemotherapy experience 
cognitive impairment during and following treatment. However, these studies are 
characterised by several methodological shortcomings inherent to their cross-sectional 
design. In particular, the lack of opportunity to measure cognitive ability over time 
offers a limited insight into cognitive impairment, such as its onset. Furthermore, a pre-
treatment baseline would be advantageous in order to account for pre-existing or pre-
treatment cognitive differences between participant groups (Donovan, Small, 
Andrykowski, Schmitt, Munster, & Jacobsen, 2005). Following recognition of these 
limitations, a wave of prospective longitudinal studies was conducted. In general, these 
studies found cognitive impairment in breast cancer patients undergoing chemotherapy, 
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although to a lesser extent than found in cross-sectional research. The key longitudinal 
studies are discussed in the following section. 
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Table 3.2 
Summary of Research Examining Chemotherapy-Related Cognitive Impairment in Breast Cancer Patients 
 
Author (year) 
Design 
(Timing of assessment) 
Sample 
Objective 
measures 
Subjective measures Summary of findings 
 
Ahles et al. (2008) 
 
Cross-sectional 
(Post-surgery; pre-CT, RT or 
HT) 
 
Invasive BC (n = 110); 
non-invasive BC (n = 
22); matched HC 
controls (n = 45) 
 
Neuropsychological 
test battery 
 
Cognitive function 
(MASQ); anxiety 
(STAI); depression 
(CES-D); fatigue 
(FSI) 
 
OCD scores within normal range. Lower 
overall cognitive performance in invasive 
BC (22%) compared to non-invasive BC 
patients (0%) and healthy controls (4%). 
 
Ahles et al. (2010) 
 
Longitudinal 
(Pre-treatment; 1, 6 & 18 
months post-treatment) 
 
CT (n = 60); non-CT 
(n = 72); HC (n = 45) 
 
Neuropsychological 
test battery 
 
Cognitive function 
(MASQ); anxiety 
(STAI); depression 
(CES-D); fatigue 
(FSI) 
 
Age and pre-treatment cognitive reserve 
associated with post-treatment decline in 
processing speed. CT had a short-term 
impact on verbal ability. 
 
Ahles & Saykin 
(2002a) 
 
Cross-sectional 
(5 years post-diagnosis) 
 
CT (BC, n = 35; 
lymphoma, n = 36); LT 
(BC, n = 35; 
lymphoma, n = 22) 
 
Neuropsychological 
test battery 
 
Cognitive function 
(SSRQ); anxiety 
(STAI); depression 
(CES-D); fatigue 
(FSI) 
 
Survivors treated with CT had 
significantly poorer performance, 
particularly relating to verbal memory and 
psychomotor functioning, as well self-
reporting more SCD. 
 
Bender et al. (2006) 
 
Longitudinal 
(0, 6 & 18 months) 
 
 
 
CT (n = 19); CT plus 
tamoxifen (n = 15); 
controls (DCIS no CT 
or tamoxifen, n = 12) 
 
Neuropsychological 
test battery 
 
Cognitive function 
(PAOF); anxiety 
(POMS); depression 
(BDI-II) 
 
CT plus tamoxifen patients had lower 
performance on visual memory and verbal 
working memory measures and reported 
more SCD. No association between OCD 
and SCD. 
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Author (year) 
Design 
(Timing of assessment) 
Sample 
Objective 
measures 
Subjective measures Summary of findings 
 
Bender et al. (2008) 
 
Cross-sectional 
(2 years post-treatment) 
 
CT (n = 30); CT with 
tamoxifen (n = 50);  
DCIS no-
CT/tamoxifen (n = 48) 
 
Neuropsychological 
test battery 
 
Cognitive function 
(PAOF); anxiety & 
fatigue (POMS); 
depression (BDI-II) 
 
CT patients reported significantly more 
memory deficits (25%) than HC (6%). No 
differences in memory difficulties between 
patients receiving tamoxifen (28%) and 
exemestane (24%). SCD correlated with 
anxiety, depression, fatigue and 
menopausal symptoms, but not with OCD. 
 
Brezden et al. (2000) 
 
Cross-sectional 
(2 years post-treatment) 
 
 
Receiving adjuvant CT 
(n = 31); completed 
adjuvant CT (n = 40); 
HC (n = 36) 
 
HSCS 
 
Anxiety & depression 
(POMS) 
 
Cognitive impairment in 48% of patients 
receiving adjuvant CT, 50% completed 
adjuvant CT, and 11% HC.  
 
Castellon et al. 
(2004) 
 
Cross-sectional 
(2 - 5 years post-diagnosis) 
 
CT (sometimes with 
HT, n = 36); local 
therapy (n = 17); HC 
(n = 19) 
 
Neuropsychological 
test battery 
 
Cognitive function 
(CFQ); anxiety 
(STAI); depression 
(BDI-II) 
 
CT patients had poorer cognitive function. 
No relationship between objective and 
self-report measures. Self-report measures 
associated with depression, anxiety and 
fatigue. 
 
Collins et al. (2009) 
 
Longitudinal 
(Pre-treatment baseline; 1 
month post-CT; 12 months 
later) 
 
 
CT (n = 53); HT (n = 
40) 
 
Neuropsychological 
test battery 
 
 
Anxiety, depression 
& fatigue (POMS) 
 
At 1 month post-treatment, more cognitive 
decline in CT patients than HT patients; 
after 12 months, cognitive decline was the 
same in both groups (11% and 10%, 
respectively).  
 
Debess et al. (2010) 
 
Longitudinal 
(Pre-CT; 6 months later) 
 
CT (n = 120); age-
matched HC (n = 208) 
 
Neuropsychological 
test battery 
 
Cognitive function 
(ISPOCD); anxiety; 
depression & fatigue 
(POMS); QOL 
(EORTC-QLQ-C30); 
self-efficacy (GPS) 
 
No significant difference in OCD between 
BC patients post-CT and HC. Significant 
correlation between OCD and SCD. 
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Author (year) 
Design 
(Timing of assessment) 
Sample 
Objective 
measures 
Subjective measures Summary of findings 
 
Donovan et al. 
(2005) 
 
Cross-sectional 
(6 months post-treatment) 
 
CT plus RT (n = 60);  
RT (n = 83) 
 
Neuropsychological 
battery 
 
Cognitive function 
(MASQ) 
 
No significant differences in OCD or SCD 
between CT plus RT patients and RT 
patients. The sample as a whole reported 
SCD occurring ‘frequently’. 
 
Downie et al. (2006) 
 
Cross-sectional 
(2 - 6 weeks post-CT) 
 
CT (n = 21) 
 
Neuropsychological 
test battery 
 
Semi-structured 
interview; fatigue 
(FACT-F); QOL 
(FACT-G) 
 
Fatigue was common in all patients. 
Majority of patients experienced 
concentration difficulties that impacted on 
daily functioning. 
 
Hermelink et al. 
(2007) 
 
Longitudinal 
(Baseline pre-neoadjuvant 
CT, toward the end of 
neoadjuvant CT) 
 
Neoadjuvant CT (n = 
101) 
 
Neuropsychological 
test battery 
 
Cognitive function 
(FEDA & EORTC-
QLQ-C30); anxiety 
& depression 
(HADS) 
 
OCD in 27% of BC patients at end of 
neoadjuvant CT. No correlation between 
OCD and SCD, anxiety, depression, and 
menopausal state. SCD was significantly 
correlated with anxiety and depression. 
Significant increase in SCD at the end of 
CT compared to baseline. 
 
Hurria et al. (2006) 
 
Longitudinal 
(Baseline; 6 months post-CT) 
 
CT patients aged ≥ 65  
years (n = 45; 76% 
HT) 
 
None 
 
Cognitive function 
(SSRQ) 
 
BC patients who self-report more memory 
difficulties at baseline reported further 
memory difficulties post-CT (63%). 
Ability to learn new information was the 
most affected cognitive domain (49%). 
 
Iconomou et al. 
(2004) 
 
Longitudinal 
(Baseline; post-CT) 
 
CT (n = 102) 
 
MMSE 
 
Cognitive function 
(EORTC-QLQ-C30) 
 
Significant correlation between OCD and 
SCD. 
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Author (year) 
Design 
(Timing of assessment) 
Sample 
Objective 
measures 
Subjective measures Summary of findings 
 
Jansen et al. (2008) 
 
Longitudinal 
(Pre-treatment baseline; 1 
week after completion of four 
CT cycles) 
 
CT (n = 30; treated 
with AC only) 
 
Neuropsychological 
test battery 
 
Cognitive function 
(AFI); anxiety 
(STAI); depression 
(CES-D); fatigue 
(LFS) 
 
Cognitive impairment found in 13% of BC 
patients at pre-chemotherapy baseline. 
Significant decrease in visuospatial ability, 
but a significant improvement in executive 
function. SCD (attention) significantly 
decreased over time. No significant 
correlations between SCD and OCD. 
Significant correlation between SCD and 
depression. 
 
Jenkins et al. (2004) 
 
Cross-sectional 
 
 
HT (n = 94; 67% 
combined with RT); 
CEF (n = 36; 53% 
combined with HT); 
HC (n = 35) 
 
Neuropsychological 
test battery 
 
Cognitive function 
(CFQ); depression 
(BDI); general health 
(GHQ-12) 
 
High depression scores significantly 
associated with SCD, although no 
correlation between SCD and OCD. 
 
Jenkins et al. (2006) 
 
Longitudinal 
(Baseline; post-treatment; 12-
months post-treatment) 
 
CT (n = 85); HT and/or 
RT (n = 43); HC (n = 
49) 
 
Neuropsychological 
test battery 
 
Cognitive function 
(CFQ); fatigue 
(FACT-F); QOL 
(FACT-B); general 
health (GHQ-12) 
 
 
No correlation between OCD and SCD. 
QOL and SCD significantly correlated. No 
differences in SCD between patients and 
HC. CT patients reported significantly 
more SCD post-treatment compared to the 
baseline. 
 
Mar Fan et al. (2005) 
 
Longitudinal 
(Post-CT; 1 year post-CT; 2 
years post-CT) 
 
CT (n = 104); HC (n = 
102) 
 
Neuropsychological 
test battery 
 
Fatigue (FACT-F); 
QOL (FACT-G); 
menopausal 
symptoms (FACT-
ES) 
 
Moderate-severe cognitive impairment 
decreased in CT patients from 16.0% to 
4.4% and 3.8%, and in HC from 5.0% to 
3.6% and 0%.  
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Author (year) 
Design 
(Timing of assessment) 
Sample 
Objective 
measures 
Subjective measures Summary of findings 
 
Mehlsen et al. (2009) 
 
Longitudinal  
(CT group: baseline; 2 - 4 
weeks post-CT; 24 weeks 
post-T1; cardiac group: 
baseline; 3 months post-T1; 
HC: interval 12 - 16 weeks) 
 
CEF (n = 34; 53% 
combined with HT); 
cardiac patients (n = 
12); HC (n = 12) 
 
Neuropsychological 
test battery 
 
Cognitive function 
(interview; rated on 
5-point Likert scale); 
stress (PSS); 
depression (BDI); 
fatigue (POMS); 
social support 
(SSQT); life 
satisfaction (SLS) 
 
No significant differences in cognitive 
ability over time between CT group, 
cardiac group and healthy control group. 
Results suggest no impact of CT on 
cognitive function. 
 
Mehnert et al. (2007) 
 
Cross-sectional 
(5 years post-treatment) 
 
High-dose CT (n = 24); 
standard-dose CT (n = 
23); RT (n = 29) 
 
Neuropsychological 
test battery 
 
Cognitive function 
EORTC-QLQ-C30; 
attention (FEDA); 
fatigue (MFI-20) 
 
No association between OCD and SCD.  
 
Mulrooney (2007) 
 
Longitudinal 
(Median 39 months post-CT; 
4 – 8 weeks later) 
 
Post-CT (n = 10) 
 
None 
 
Cognitive function 
(interview) 
 
Three themes were identified: ‘I just don’t 
feel like me’, ‘trying my best to live with 
it’, and ‘I am alive’ to describe BC 
patients’ lived experience of cognitive 
difficulties. 
 
Myers (2010) 
 
Cross-sectional 
(Within 6 – 12 months of 
completing CT) 
 
CT (n = 18) 
 
None 
 
Cognitive function 
(interview) 
 
SCD relating to short-term memory, word 
finding ability, reading, and driving, for 
which coping strategies were employed. 
BC patients wanted more information 
about SCD. 
 
Prokasheva et al. 
(2011) 
 
Cross-sectional 
(18 months post-CT) 
 
CT (n = 20); 
Tamoxifen only (n = 
20) 
 
Neuropsychological 
test battery 
 
 
Dutch cognitive 
problems in daily life 
checklist 
 
OCD in 40% of patients. SCD in 69% of 
patients. No correlation between OCD and 
SCD. 
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Author (year) 
Design 
(Timing of assessment) 
Sample 
Objective 
measures 
Subjective measures Summary of findings 
 
Quesnel et al. (2009) 
 
Longitudinal 
(Baseline, post-treatment, 3 
months post-treatment) 
 
CT (n = 41); RT (n = 
40); matched controls 
(n = 45) 
 
Neuropsychological 
test battery 
 
Cognitive function 
(CFQ; EORTC-QLQ-
C30) 
 
CT patients reported more SCD than RT 
patients at post-treatment. At the 3-month 
follow-up assessment, SCD returned to 
baseline levels. CT patients reported less 
SCD compared to matched healthy 
controls. 
 
Reid-Arndt et al. 
(2010) 
 
Longitudinal 
(6 months & 12 months post-
CT) 
 
CT (n = 33) 
 
Neuropsychological 
test battery 
 
Confusion (POMS-
SF) 
 
OCD correlated with scores on the POMS.  
 
Schagen et al. (1999) 
 
Cross-sectional 
(2 years post-CT) 
 
 
CT (n = 39; 51% CT 
plus HT); age-matched 
local therapy (RT & S; 
n = 34) 
 
Neuropsychological 
test battery 
 
Cognitive function 
(semi-structured 
interview; 5-point 
Likert scale, EORTC-
QLQ-C30; HSCL-25) 
 
CT patients reported significantly more 
memory difficulties (21% vs. 3%) and 
concentration difficulties (31% vs. 6%) 
compared to controls. No relationship 
between OCD and SCD. SCD was 
associated with anxiety and depression. 
 
Schagen et al. 
(2002b) 
 
Cross-sectional 
(3.5 years post-CT) 
 
CMF (n = 31); CTC (n 
= 22); FEC (n = 23); 
RT & S (n = 27) 
 
Neuropsychological 
test battery 
 
Cognitive function 
(semi-structured 
interview & EORTC-
QLQ-C30) 
 
OCD in 14% high-dose, 9% - 13% 
standard-dose, and 11% HC. Overall OCD 
scores significantly correlated with SCD 
interview. 
 
Schagen et al. (2006) 
 
Longitudinal 
(Pre-treatment & 6 months 
post-treatment) 
 
High-dose CT (n = 28); 
standard-dose CT (n = 
39); no CT (n = 57); 
HC (n = 60) 
 
Neuropsychological 
test battery 
 
None 
 
No significant between-groups differences 
at the first assessment. High-dose CT 
experienced greater cognitive impairment 
over time. 
 
Scherwath et al. 
(2006) 
 
Cross-sectional 
(5 years post-treatment) 
 
High-dose CT (n = 24); 
standard-dose (n = 23); 
early-stage BC (n = 29) 
 
Neuropsychological 
test battery 
 
None 
 
Slightly, but not significantly, more OCD 
in standard-dose CT group than high-dose 
CT group. 
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Author (year) 
Design 
(Timing of assessment) 
Sample 
Objective 
measures 
Subjective measures Summary of findings 
 
Schilder et al. (2009) 
 
 
Cross-sectional 
(2 years post-CT) 
 
 
BC patients post-
menopausal CT plus 
HT (n = 80) 
 
Neuropsychological 
test battery 
 
Cognitive function 
(CFQ) 
 
OCD in 3% of tamoxifen users and 6% of 
exemestane users. SCD in 25% of patients. 
Significant correlation between OCD and 
SCD. 
 
Shilling et al. (2005) 
 
Longitudinal 
(Baseline; 6 months post-CT) 
 
Early stage BC CT (n 
= 50); HC (n = 43) 
 
Neuropsychological 
test battery 
 
Cognitive function 
(CFQ); fatigue 
(FACT-F); QOL 
(FACT-B); general 
health (GHQ-12) 
 
Decline in 34% CT group compared to 
19% HC. 
 
Shilling et al. 
(2007) 
 
Longitudinal 
(Baseline, 1 month, 12 
months) 
 
CT (sometimes with 
HT and/or RT; n = 93); 
no CT (n = 49) 
 
Neuropsychological 
test battery 
 
Structured interview 
 
78% to 83% reported SCD at 1 month; 
45% to 60% at 12 months. 
 
Stewart et al. (2008) 
 
Longitudinal 
(Baseline; 2 months post-CT) 
 
CT (n = 61); HT (n = 
51) 
 
Neuropsychological 
test battery 
 
Anxiety, depression 
& fatigue (POMS) 
 
CT patients 3.3 times more likely than HT 
patients to show reliable cognitive change 
(31% and 12% respectively). 
 
Tchen et al. (2003) 
 
Cross-sectional 
(2 - 6 weeks post CT 
administration) 
 
 
Adjuvant CT (n = 
100); HC (n = 100) 
 
Neuropsychological 
test battery 
 
Fatigue (FACT-F); 
QOL (FACT-G); 
menopausal 
symptoms (FACT-
ES) 
 
Significant correlations between 
subjective measures. No significant 
association between subjective measures 
and OCD. 
 
van Dam et al. 
(1998) 
 
Cross-sectional 
(≥ 6 months post-CT) 
 
High-dose CT (n = 34); 
standard-dose CT (n = 
36); LT (n = 34) 
 
Neuropsychological 
test battery 
 
Cognitive function 
(semi-structured 
interview; cognitive 
problems in daily life 
checklist; EORTC-
QLQ-C30) 
 
OCD in 32% high-dose CT, 17% 
standard-dose CT, and 9% LT. SCD in 
12% - 38% of high-dose CT, 11% - 31% 
of standard-dose CT, and 6% LT. No 
significant relationship between overall 
OCD score and SCD from interview.  
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Author (year) 
Design 
(Timing of assessment) 
Sample 
Objective 
measures 
Subjective measures Summary of findings 
 
Vardy et al. (2006) 
 
Longitudinal 
(3 assessments, 7 – 90 days 
apart) 
 
BC (n = 27) and 
colorectal cancer (n = 
2) reporting SCD 
 
Neuropsychological 
test battery 
 
Cognitive function 
(FACT-COG) 
 
Significant correlation between OCD and 
SCD. 
 
 
Von Ah et al. (2009) 
 
Cross-sectional 
(Between 1.2 & 15.8 years 
post-treatment) 
 
BC (n = 52); HC (n = 
52) 
 
Neuropsychological 
test battery 
 
Memory (SRS); 
depression (CES-D) 
 
BC group reported more SCD and scored 
worse on learning and delayed recall 
measures than healthy controls. 
 
Wefel et al. (2004b) 
 
Randomised longitudinal trial 
(Baseline; 6 months post-CT; 
18 months post-CT) 
 
BC (n = 18) 
 
Neuropsychological 
test battery 
 
Anxiety & depression 
(MMPI); QOL 
(FACT-B) 
 
33% of BC patients exhibited OCD at pre-
treatment. The first longitudinal study to 
report an association between CT and 
cognitive impairment in the BC 
population. 
 
Weis et al. (2009) 
 
Longitudinal 
(9 months post-treatment) 
 
CT (sometimes with 
RT or HT, n = 90) 
 
Neuropsychological 
test battery 
 
Attention (FEDA); 
anxiety & depression 
(HADS); fatigue 
(MFI-20); QOL 
(EORTC-QLQ-C30) 
 
OCD in 21% of patients. SCD in 36% of 
patients. 
 
 
 
 
Wieneke & Dienst 
(1995) 
 
Cross-sectional 
(5 – 12 months post-CT) 
 
CT (n = 28) 
 
Neuropsychological 
test battery 
 
Depression (BDI) 
 
OCD in 75% of patients. 
 
Key. AC: doxorubicin and cyclophosphamide; AFI: Attentional Function Index; BDI: Beck Depression Inventory; CEF: cyclophosphamide, epirubicin, fluorouracil; CES-D: Center for Epidemiological 
Study-Depression scale; CFQ: Cognitive Failures Questionnaire; CMF: cyclophosphamide, methotrexate, fluorouracil; CT: chemotherapy; CTC: cyclophosphamide, thiotepa, carboplatin; DCIS: ductal 
carcinoma in situ; EORTC-QLQ-C30: European Organization for Research and Treatment of Cancer – quality of life core questionnaire; FACT-B/COG/ES/F/G: Functional Assessment of Cancer 
Therapy-Breast(QOL)/Cognitive Function/Endocrine Symptoms/Fatigue/General (QOL); FEC: fluorouracil, epirubicin and cyclophosphamide; FEDA: Questionnaire of Experienced Attention Deficits; 
FSI: Fatigue Symptom Inventory; GHQ: General Health Questionnaire; GPS: General Perceived Self-Efficacy; HADS: Hospital Anxiety and Depression Scale; HC: healthy controls; HSCL: Hopkins 
Symptom Checklist; HSCS: High Sensitivity Cognitive Screen; HT: hormone therapy; ISPOCD: International Study of Postoperative Cognitive Dysfunction; LFS: Lee Fatigue Scale; LT: local therapy; 
MASQ: Multiple Ability Self-Report Questionnaire; MFI: Multidimensional Fatigue Inventory; MMPI: Minnesota Multiphasic Personality Inventory; OCD: objective cognitive difficulties; PAOF: 
Patient’s Assessment of Own Functioning; POMS: Profile of Mood States; PSI: Pittenburgh Sleep Inventory; PSS: Perceived Stress Scale; QOL: quality of life; RT: radiotherapy; S: surgery; SCD: 
subjective cognitive difficulties; SLS: Satisfaction with Life Scale; SRS: Squire Self-Report Scale; SSQT: Social Support Questionnaire of Transactions; SSRQ: Squire Memory Self-Rating 
Questionnaire; STAI: Spielberger State Anxiety Inventory.
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3.4.3 Longitudinal Design: The Key Studies 
The longitudinal design enables researchers to collect data at several time-points and to 
identify temporal changes. This is important in psycho-oncology research so that the 
onset of cognitive change can be identified, thus adding evidence regarding potential 
causes of impairment. This section discusses the key published research that has 
adopted a longitudinal design. 
 
The first prospective study examining chemotherapy-related cognitive impairment in 
breast cancer patient (n = 18) was conducted by Wefel et al. (2004b), with measures 
taken prior to the administration of chemotherapy, 6 months later (3 weeks post-
chemotherapy), and 18 months later. An important finding was that 33% of breast 
cancer patients demonstrated cognitive impairment prior to starting treatment. 
Cognitive deficits increased to 61% at the 6-month assessment, and by 18 months 50% 
of breast cancer patients who experienced cognitive decline showed improvement 
whereas 50% remained stable. Although this study is limited by its relatively small 
sample size and lack of comparison groups, findings from this ignited the debate 
relating to co-morbid factors impacting upon cognitive function, the onset of cognitive 
impairment, and the extent to which chemotherapy was responsible for changes to 
cognition. In addition, this finding highlighted the limited insight gained from cross-
sectional research, as well as the importance of including a pre-chemotherapy baseline 
measure in longitudinal research. 
 
Bender et al. (2005) compared the cognitive ability of breast cancer patients undergoing 
chemotherapy (n = 19), breast cancer patients undergoing chemotherapy plus tamoxifen 
(n = 15), and DCIS patients undergoing no systemic therapy (n = 12). Measurements 
were taken at baseline (post-surgery; pre-chemotherapy), 6 months and 18 months later. 
They found that breast cancer patients receiving chemotherapy only showed impairment 
on verbal working memory, whereas breast cancer patients receiving chemotherapy 
plus tamoxifen experienced a decline in verbal and visual working memory. DCIS 
patients showed improvement in cognitive scores, suggesting practice effects. 
 
Jenkins et al. (2006) examined the cognitive function of breast cancer patients receiving 
chemotherapy (n = 35; mainly FEC) with breast cancer patients receiving hormone 
therapy and/or radiotherapy (n = 43) and healthy controls (n = 49) at baseline, post-
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chemotherapy (or at 6 months) and at 18 months. After controlling for age and 
intelligence, no significant interactions or main effects were found, suggesting that age 
and education can have independent effects on cognitive functioning. Only a non-
significant minority of breast cancer patients experienced cognitive deficits following 
chemotherapy. Individual declines in cognitive ability were found in 20% of breast 
cancer patients treated with chemotherapy, 26% of breast cancer patients treated with 
hormone therapy, and 18% of healthy controls at 6 months. By 18 months, cognitive 
impairment decreased to 18%, 14% and 11%, respectively. Jenkins and colleagues 
reported no correlation between objective and self-report measures of cognitive ability. 
There was an association between quality of life, psychological distress and self-report 
cognitive ability. 
 
Currently, the evidence relating to the prevalence and severity of chemotherapy-related 
cognitive impairment is inconsistent. Indeed, the justification for the association 
between chemotherapy treatment and cognitive impairment is not without question 
since some evidence suggests that cognitive difficulties are present prior to the 
commencement of chemotherapy in 13% to 64% of breast cancer patients (Jansen, 
Dodd, Miaskowski, Dowling, & Kramer, 2008; Wefel et al., 2004b; Hurria et al., 2006). 
It could be that the diagnosis of breast cancer impacts upon cognitive function or that 
the subgroup of breast cancer patients scoring lower on cognitive measures simply 
represents heterogeneity of cognitive function that may also be present in the general 
population. Furthermore, the cognitive decline in breast cancer patients who may have 
scored to a high level above a defined normal range at pre-treatment and then scored 
lower but within the normal range at post-treatment is not captured for this subgroup, 
and neither for those who scored below the norm at pre-treatment and who were not 
affected by chemotherapy (Ahles et al., 2002c; Vardy & Tannock, 2007). Consequently, 
these studies should be interpreted with caution. 
 
As Table 3.2 shows, not all longitudinal studies include a pre-treatment baseline 
assessment. The interval between assessments also varies, ranging from months to 
years. Generally, a shorter interval between assessments enables the onset of cognitive 
change to be identified more accurately. This lack of consensus highlights the current 
ambiguity in what constitutes a clinically meaningful cognitive impairment (Chaytor & 
Schmitter-Edgecombe, 2003). Furthermore, inconsistencies in findings may be due to 
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the definition of cognitive impairment, as previously described in this chapter. In 
contrast, there are standardised diagnostic criteria for cognitive impairment in other 
patient groups such as dementia. Therefore, there is a need for an agreed standardised 
definition of cognitive impairment to diagnose clinically meaningful changes in 
cognitive functioning in breast cancer patients (Hess & Insel, 2007). Meta-analyses by 
Anderson-Hanley, Sherman, Riggs, Agocha, and Compas (2003), and Jansen, 
Miaskowksi, Dodd, Dowling, and Kramer (2005) found that the number of 
neuropsychological measures included in the reviewed literature ranged from three to 
ten (with a mean of six measures) and some studies used the same test as a measure of 
different cognitive domains. For example, the Rey Auditory Verbal Learning Test has 
been used to assess the ability to learn and remember new verbal information (Paraska 
& Bender, 2003) and also to assess immediate memory span (van Dam et al., 1998). 
 
Neuropsychological tests are typically seen as the gold standard measurement of 
cognitive ability, and subjective accounts of cognitive impairment are often overlooked 
due to their disassociation with objective measures (Cull, Hay, Love, Mackie, Smets, & 
Stewart, 1996; Schagen, Hamburger, Muller, Boogerd, & van Dam, 2001; Schagen, van 
Dam, Muller, Boogerd, & Lindeboom, 1999; Tannock, Ahles, Ganz, & van Dam, 2004; 
van Dam et al., 1998). Instead, subjective measures of cognitive ability are associated 
with anxiety, depression and fatigue. Several plausible explanations for this have been 
proposed. Firstly, it may be that breast cancer patients overestimate their perceptions of 
cognitive difficulties. Secondly, neuropsychological tests and self-report measures may 
not assess the same cognitive constructs (Calvio, Peugeot, Bruns, Todd, & Feuerstein, 
2010; Downie, Mar Fan, Houede-Tchen, Yi, & Tannock, 2006). For example, 
neuropsychological tests may lack ecological validity and may not accurately reflect the 
types of cognitive tasks experienced in daily life (Hermelink et al., 2010). Typically, 
neurocognitive testing occurs in a formal or laboratory setting that have little reference 
to everyday experience (Schagen, Muller, Boogerd, & van Dam, 2002a) Thirdly, 
neuropsychological tests may not be sufficiently sensitive to subtle changes in cognitive 
ability (Boykoff, Moieni, & Subramanian, 2009). Since these neuropsychological tests 
were initially designed and validated in other patient populations, such as individuals 
with dementia, they may not be appropriate to be used for assessing breast cancer 
patients. However, significant associations between objective cognitive difficulties and 
subjective cognitive difficulties have been documented in other patient populations such 
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as in people with chronic fatigue syndrome (Capuron et al., 2006) and mild multiple 
sclerosis (Matotek, Saling, Gates, & Sedal, 2001). This suggests that objective measures 
are sensitive to detect cognitive difficulties in these groups.  
  
Currently, considerable work is required to develop neuropsychological tests that map 
on to real-life situations and that are sensitive to detect subtle cognitive difficulties 
experienced in the breast cancer population (Ahles & Saykin, 2007). In the meantime, 
researchers are recognising the value of self-report measures of cognitive functioning 
with the aim of better understanding the lived experiences of breast cancer patients 
undergoing treatment while they manage their daily tasks. The following section 
reviews the literature that has focused on subjective accounts of cognitive ability in 
breast cancer patients undergoing chemotherapy. 
 
3.4.4 Self-Report Measures 
Subjective measures of cognitive functioning, such as questionnaires, diaries and 
interviews, enable the reporting of perceived experiences of cognitive difficulties 
during daily tasks (Hess & Insel, 2007). Subjective accounts suggest a much higher 
prevalence of cognitive impairment than confirmed by objective measures (Hutchinson, 
Hosking, Kichenadasse, Mattiske, & Wilson, 2012), which may reflect their sensitivity 
to detect subtle cognitive deficits (Schagen, Muller, Boogerd, & van Dam, 2002a). In a 
recent systematic review of research examining subjective cognitive difficulties in 
breast cancer patients, Pullens, De Vries, and Roukema (2010) identified 27 studies, 
with findings describing a prevalence of cognitive difficulties ranging from 21% to 
90%. Similar to the reasons for a large prevalence range reported using 
neuropsychological measures, methodological inconsistencies can contribute to this 
vast range in prevalence. For example, sample sizes are often small and study designs 
include cross-sectional, longitudinal and a randomised control trial (Pullens et al., 
2010).  
 
Subjective measures can provide valuable insight into the meaningful impact upon daily 
functioning and quality of life, and for this reason they have clinical relevance (Downie, 
Mar Fan, Houede-Tchen, Yi, & Tannock, 2006). Researchers recognise that perceived 
cognitive function is an important outcome due to the profound impact on quality of life 
(Ferguson, McDonald, Saykin, & Ahles, 2007; Scherwath et al., 2006; Wagner, Sweet, 
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Butt, Lai, & Cella, 2009). For example, Wefel, Lenzi, Theriault, Davis, and Meyers 
(2004b) outlined that individuals who are well-educated with high baseline cognitive 
function may perform well on neuropsychological tests throughout treatment, however 
they may perceive cognitive changes that impact upon their daily functioning and 
quality of life. Therefore, subjective measures, particularly breast cancer patients’ 
qualitative description of their lived experience, can be useful in accurately defining the 
types of cognitive difficulties experienced during chemotherapy. Pullens, De Vries, and 
Roukema (2010) suggested that there is a need for further research to use self-report 
measures to enable valid conclusions about subjective cognitive decline in breast cancer 
patients due to the current unclear prevalence of, and factors involved in contributing 
to, cognitive impairment. However, there are obvious limitations associated with 
reporting cognitive failures, as described by the Metamemory Paradox (Rabbitt, 
Maylor, McInnes, Bent, & Moore, 1995). In particular, not all incidences of cognitive 
failures may be recalled and subsequently reported. Consequently, the accuracy of 
absolute frequencies of cognitive failures may be inaccurate. However, under more 
controlled settings with the researcher present may not provide a realistic portrayal of 
the problems experienced during daily life. Despite these limitations, patient-reported 
outcomes can provide a unique understanding of the lived experiences of breast cancer 
patients throughout treatment and are considered to be more indicative of real-world 
cognitive difficulties than neuropsychological tests. 
 
In a focus group study examining chemotherapy-related cognitive change in multi-
ethnic Asian breast cancer patients (n = 43), memory impairment, difficulty in decision 
making and speech problems were common in participants (Cheung, Shwe, Tan, Fan, 
Ng, & Chan, 2012). An interesting finding was that participants were averse to the term 
‘chemobrain’. Instead, Cheung et al. reported that participants viewed their cognitive 
difficulties holistically, as a by-product of the physical effects (ageing and fatigue) and 
psychosocial effects (anxiety and mood changes) related to chemotherapy. Participants 
who were married expressed frustration associated with the impact of cognitive 
difficulties on their ability to manage daily tasks in the home.  
 
Support for the usefulness of self-report measures comes from a study by Ferguson, 
McDonald, Saykin, and Ahles (2007) who examined the cognitive function of 
monozygotic twins using self-report measures, neuropsychological tests and structural 
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and functional magnetic resonance imaging (MRI). One twin had breast cancer and 
underwent chemotherapy while the other had no breast cancer diagnosis. Ferguson and 
colleagues found small differences between the cognitive function of the twins on 
neuropsychological test performance; however, striking differences were reported in 
self-report measures and structural and functional MRI. This finding suggests that 
physiologic mechanisms may underlie long-term cognitive complaints in breast cancer 
survivors who have received chemotherapy when neuropsychological performance is 
scored as normal. 
 
In sum, the literature regarding chemotherapy-related cognitive impairment report 
inconsistent findings. Variation in study design, such as the type and timing of objective 
and subjective measures of cognitive function, measurement of potentially confounding 
factors (e.g. anxiety, depression and fatigue) make comparisons across studies difficult. 
Furthermore, studies are often limited by small sample sizes and significant attrition 
over time. Therefore, it is difficult to identify the onset and duration of cognitive 
impairment. 
3.5 Potential Factors Involved in Chemotherapy-Related Cognitive 
Impairment 
Although the majority of the work described above suggests that cognitive change 
coincides with the onset of chemotherapy treatment, the specific mechanisms involved 
are not currently well understood. A number of factors have been associated with 
cognitive impairment and are thought to contribute. Myers (2010) developed a 
conceptual model of chemotherapy-related cognitive change in cancer patients (see 
Figure 3.1, p. 65).  
 
Chemotherapeutic agents. A number of neurophysiological studies propose that some 
chemotherapeutic agents cross the blood-brain barrier and enter the cerebrospinal fluid 
resulting in central neurotoxic effects (Abraham, Haut, Moran, Filburn, Lemiuex, & 
Kuwabara, 2008; Troy et al., 2000; Verstappen, Heimans, Hoekman, & Postma, 2003). 
Researchers have documented structural cerebral damage, in particular damage to the 
white matter (Brown et al., 1998; Inagaki et al., 2007) in cancer patients compared to 
control groups. This has been identified through computed tomographic scanning and 
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MRI techniques (e.g. Asato et al., 1992; Brown et al., 1998). In addition, Saykin, Ahles, 
and McDonald (2003) compared MRI of long-term (at least five years post-treatment) 
breast cancer survivors (n = 12) with long-term lymphoma survivors (n = 12) and age-
matched healthy controls (n = 12). Significant abnormalities were present in the grey 
and white matter of the brain, consistent with the pattern of cognitive deficiencies 
identified in the majority of previous research. 
 
In a recent fMRI study, Kesler, Bennett, Mahaffey, and Spiegel (2009) found that breast 
cancer patients had significantly reduced prefrontal cortex activation during memory 
tasks compared with age- and education-matched healthy controls. In addition, these 
patients displayed significantly more neural recruitment to recall information, which 
Kesler and colleagues suggest could have resulted in increased cognitive fatigue and 
frustration. They argue that this could impact upon a negative subjective evaluation of 
patients’ cognitive ability, which may explain the often reported association between 
subjective cognitive difficulties and fatigue (e.g. Bender et al., 2006; Castellon, Ganz, 
Bower, Petersen, Abraham, & Greendale, 2004; Jenkins et al., 2006; Tchen et al., 
2003). The presence of the apolipoprotein E ε4 (APOE ε4) allele has been suggested to 
predispose breast cancer patients to cognitive impairment (Ahles et al., 2003). Other 
aetiologies of chemotherapy-related cognitive impairment include cytokine-induced 
inflammatory response (Ahles & Saykin, 2007), DNA damage and oxidative stress 
(Ahles & Saykin, 2007; Chen, Jungsuwadee, Vore, Butterfield, & St. Claire, 2007). In 
addition, chemotherapy-induced menopause (Jansen, Miaskowski, Dodd, Dowling, & 
Kramer, 2005) and chemotherapy-induced anaemia (Mancuso, Migliorino, De Santis, 
Saponiero, & De Marinis 2006) may contribute to cognitive impairment. 
 
Pre-treatment cognitive ability. Some studies suggest that a subset of breast cancer 
patients have poorer cognitive ability prior to adjuvant therapy (e.g. Ahles et al., 2008; 
Bender et al., 2006; Hermelink et al., 2007; Hurria et al., 2006; Mar Fan et al., 2005; 
Paraska & Bender, 2003; Quesnel, Savard, & Ivers, 2009; Wefel et al., 2004a). 
However, Jenkins et al. (2006), Schagen, Muller, Boogerd, Mellenbergh, and van Dam 
(2006) and Stewart, Collins, Mackenzie, Tomiak, Verma, and Bielajew (2008) did not 
find that a subgroup of breast cancer patients had lower cognitive ability prior to 
adjuvant therapy. Patients may experience adverse effects of surgery and anaesthesia 
(Newman, Stygall, Hirani, Shaefi, & Maze, 2007), fatigue, anxiety or depression 
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following cancer diagnosis, which may impact upon cognitive ability at pre-
chemotherapy.  
 
Age and education. Research findings have shown that younger age is associated with 
an increased perception of  cognitive change (Cimprich, So, Ronis, & Trask, 2005). In 
addition, having more years in education is associated with higher cognitive functioning 
(Cimprich, So, Ronis, & Trask, 2005). 
 
Anxiety, depression and fatigue. The diagnosis of breast cancer may cause anxiety, 
depression and fatigue (see section 3.2). These psychosocial factors are thought to 
contribute to cognitive decline. For example, a number of studies have documented an 
association between both mild and severe forms of depression with cognitive decline, 
motor, perceptual and communication tasks (Murphy, Sahakian, & O’Carroll, 1998). 
Evidence also suggests an association between fatigue and subjective cognitive 
difficulties (e.g. Bender et al., 2006; Castellon, Ganz, Bower, Petersen, Abraham, & 
Greendale, 2004; Jenkins et al., 2006; Schagen, van Dam, Muller, Boogerd, 
Lindeboom, & Bruning, 1999; Tchen et al., 2003; van Dam et al., 1998). 
 
Menopause. There is also evidence that chemotherapy can damage the ovaries, which 
subsequently may lead to changes in oestrogen levels. It is thought that oestrogen helps 
to maintain normal memory function (Genazzani, Pluchino, Luisi, & Luisi, 2007) due to 
its role in neural plasticity and protection (Bender, Paraska, Sereika, Ryan, & Berga, 
2001). Therefore, any impact on oestrogen levels may change cognitive ability. It is 
thought that cognitive difficulties are reported by post-menopausal women in the 
general population (Halbreich, Rojansky, Palter, Tworek, Hissin, & Wang, 1995). 
Chemotherapy-induced menopause has been shown to affect 20% to 100% of female 
cancer patients and is dependent upon the patient’s age, the chemotherapy dosage and 
regime, and previous or concurrent use of radiotherapy (Molina, Barton, & Loprinzi, 
2005). There is therefore a need for further research to provide a clearer picture of the 
pathophysiology of cognitive deficits. 
 
Dosage and duration of chemotherapy. There are inconsistent findings relating to the 
influence of chemotherapy dosage and duration (in terms of cycles administered) on 
cognitive impairment. For example, van Dam et al. (1998) found that cognitive 
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impairment was observed in 32% of breast cancer patients who received high-dose 
chemotherapy (with peripheral blood stem cell transplant), 17% who received standard-
dose chemotherapy (plus tamoxifen) and 9% of a local treatment control group. The 
randomised cross-sectional design of this study was important in ascertaining a 
potential chemotherapy dosage link. In contrast, Scherwath et al. (2006) found that 
standard-dose breast cancer patients showed greater cognitive impairment compared to 
high-dose patients at five years post-treatment, although this did not reach statistical 
significance. 
 
An association has also been reported between cognitive impairment and treatment 
duration (e.g. Ahles & Saykin, 2002; Rugo & Ahles, 2003). Ahles and colleagues found 
that more cycles of chemotherapy was associated with poorer cognitive scores; 
however, the correlation was significant but low (r = -.31). Wieneke and Dienst (1995) 
found an association between cognitive impairment and increased duration of 
chemotherapy (p < .01). They used neuropsychological tests to compare cognitive 
impairment in breast cancer patients (3 to 18 months post-chemotherapy) receiving 
standard dose chemotherapy to published normative data. Seventy-five percent of breast 
cancer patients were reported to have cognitive impairment. They found no association 
between cognitive impairment and type of chemotherapy, time since last treatment, or 
depression. However, the use of normative data as the only means of a comparison 
group has its limitations. 
 
Other treatments. In addition to chemotherapy, other cancer treatments (e.g. surgery, 
radiotherapy, and hormone therapy) can destroy or change tumour cells. In turn, this 
may release harmful chemicals or produce an overactive response (e.g. anti-
inflammatory, immunological). For example, many breast cancer patients treated with 
chemotherapy also receive hormone therapy and there is increasing research on the 
influence of chemotherapy and hormone therapy on cognitive functioning in breast 
cancer patients and long-term survivors. Hormone therapy can affect the level and 
activity of reproductive hormones, which may in turn impact upon cognitive ability 
(Schilder, Schagen, & van Dam, 2008). Oestrogen can have beneficial effects on 
cognitive function, as identified by a number of observational studies and clinical trials. 
As outlined in Chapter Two section 2.6, hormone therapy (e.g. tamoxifen) works by 
binding to the oestrogen receptors in the breast tissue. Several studies suggest that 
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tamoxifen may produce additional cognitive changes from chemotherapy alone (Bender 
et al., 2006; Castellon, Ganz, Bower, Petersen, Abraham, & Greendale, 2004; van Dam 
et al., 1998), increasing the chances of cognitive decline. Several studies have shown 
that cancer patients who received chemotherapy plus tamoxifen demonstrated more 
widespread cognitive deficits compared to patients who received chemotherapy alone 
(e.g. Bender et al., 2006; Castellon et al., 2004). However, other studies reported no 
differences in cognitive ability in these two treatment groups (e.g. Brezden, Phillips, 
Abdolell, Bunston, & Tannock, 2000; Jenkins, Shilling, Fallowfield, Howell, & Hutton, 
2004; Schagen, van Dam, Muller, Boogerd, Lindeboom, & Bruning, 1999; Tchen et al., 
2003; van Dam et al., 1998). There is a need for further investigation into the role of 
hormone treatment on cognitive ability in breast cancer patients. 
Chapter Three       Literature Review: Cognitive Side Effects 
64 
Figure 3.1. Conceptual model of chemotherapy-related cognitive changes (Myers, 2010).
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3.6 The Impact of Cognitive Side Effects on Quality of Life 
Quality of life is a multidimensional concept that considers “competence and health, 
perceived quality of existence, and psychological well-being” (Robb et al., 2007, p. 85). 
Traditionally, following the biomedical approach to disease, health outcomes have been 
assessed using laboratory or clinical tests, such as blood pressure and pulse (Higginson 
& Carr, 2001). While these measures provide valuable disease-related information, the 
personal and social context of patients are often excluded. Following recognition of the 
value of the biopsychosocial approach to healthcare, quality of life measures are now 
considered important outcome measures in clinical research (Higginson & Carr, 2001). 
These measures often provide an overall score of quality of life as well as scores for 
each dimension. Physical well-being may be influenced by disease or treatment side 
effects (e.g. pain). Functional well-being refers to the patient’s ability to perform typical 
daily tasks. Emotional well-being can include states of distress to being happy and 
social well-being refers to relationships. A number of studies have shown that cancer 
patients report lower levels of quality of life compared to the general population (e.g. 
Robb et al., 2007). Chemotherapy-related cognitive difficulties can adversely impact on 
physical, functional, social and emotional well-being (Ahles & Saykin, 2002b). 
 
The biological and psychosocial side effects experienced by breast cancer patients as a 
result of the tumour, diagnosis and treatment can have a profound impact on breast 
cancer patients’ daily functioning. These can include difficulty returning to work as 
well as managing social activities and household chores. In turn, this can result in 
reduced quality of life (Ferguson & Ahles, 2003; Spelten, Sprangers, & Verbeek, 2002). 
Breast cancer patients may question why psychological side effects persist following 
the completion of treatment and why they cannot function at the same capacity of pre-
diagnosis levels after being effectively cured of the cancer (Guill & Raynor, 2008). 
Evidence suggests that cognitive difficulties can last up to ten years post-treatment 
(Ahles et al., 2005). This can lead to increased psychological distress as many breast 
cancer patients see the end of successful treatment (i.e. the removal of cancerous cells) 
as being the benchmark for the transition from patient identity to survivor (Dolbeault et 
al., 2009). Subsequently, quality of life is an important treatment-related consideration 
as returning to pre-diagnosis levels of academic, employment, social and domestic 
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activities are thought to be a benchmark of recovery and provide a sense of ‘normality’ 
for breast cancer patients (Amir, Neary, & Luker, 2008; Steiner, Cavender, Main, & 
Bradley, 2004). It is important that research continues to provide a comprehensive 
understanding of the range of side effects experienced by breast cancer patients during 
and following treatment. 
 
A number of intervention studies to improve quality of life in cancer patients have been 
conducted, although relatively few have addressed cognitive side effects. In fact, many 
studies exclude cancer patients with cognitive difficulties (Locke, Cerhan, & Malec, 
2008). In contrast, cognitive rehabilitation interventions are widely applied in patients 
with acquired brain injury. However, it is important to recognise that breast cancer 
patients report relatively subtle cognitive difficulties, although their impact on daily 
functioning can still be profound. For some breast cancer patients, greater mental effort 
is required to perform routine tasks, which contributes to the often co-existing symptom 
of fatigue (Meyers & Perry, 2008). For example, an individual working in a high-
demanding job may experience a greater impact (and thus require more adjustment to 
work) than an individual with fewer demands (Meyers & Perry, 2008). For the majority 
of breast cancer patients, these cognitive side effects diminish post-treatment; however, 
a subset of patients report long-term effects (Ahles et al., 2002c; Tannock, Ahles, Ganz, 
& van Dam, 2004). Furthermore, Bower (2008) suggested that cognitive impairment 
may be under-reported and under-treated because it is portrayed as an expected 
consequence of cancer treatment. Further research is warranted to provide a 
comprehensive understanding of the mechanisms involved in contributing to cognitive 
decline in these patients so that the short- and long-term difficulties can be predicted in 
individual patients (Ahles et al., 2002c). Evidence suggests that chemotherapy-related 
side effects can also impact upon working life and a review of the key literature is 
presented in the following section (section 3.7). 
3.7 The Impact of Cognitive Side Effects on Work Ability 
As previously stated in Chapter Two (section 2.2), approximately 55% of new cases of 
breast cancer are of working age and this proportion is likely to increase following the 
UK Government’s plans to increase in the State Pension to 67 and above years to reflect 
the anticipated increase in life expectancy (Directgov, 2012). Furthermore, 
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improvements in the prognosis of breast cancer and subsequent increase in the survival 
rate has meant that the impact of breast cancer and its treatment on the workplace has 
become an important issue. In particular, following the introduction of the Equality Act 
2010, which protects individuals who have, or have had, cancer from discrimination at 
the workplace, employers are expected to make reasonable adjustments for workers 
who have been diagnosed with cancer (Morrell & Pryce, 2005). The Equality Act 
covers the recruitment process, terms, conditions and benefits, as well as promotion and 
training opportunities, dismissal and harassment. It is therefore important that 
organisations are aware of the issues surrounding the work ability of cancer survivors 
and that appropriate policies and evidence-based guidelines are in place to support the 
successful transition back into the workplace (Peteet, 2000). 
 
Returning to work following treatment is now a realistic outcome for a growing number 
of breast cancer survivors (Rowland, Aziz, Tesauro, & Feuer, 2001). Indeed, the ability 
to do so is thought to be important for quality of life. However, for some breast cancer 
patients, resuming employment and performing work tasks can be challenging due to 
treatment-related side effects. For the large proportion of breast cancer patients who are 
in employment, maintaining working life can be an important issue for financial (Amir, 
Neary, & Luker, 2008), social and psychological reasons. The return to work process 
may also act as a benchmark for recovery and the transition in identity from cancer 
patient to cancer survivor as a sense of normality resumes (Amir et al., 2008; Steiner, 
Cavender, Main, & Bradley, 2004). To date, the literature surrounding cancer survivors 
and employment has tended to focus on the return to work process. While this is an 
important area of research, little has been done to explore the experiences of survivors 
once they have returned to work. Since this research is concerned with the safety 
outcome that breast cancer patients may experience during their daily life, this thesis 
focuses on work ability issues. 
 
In addition to experiencing absence from work (absenteeism), cancer patients may also 
encounter difficulties whilst at work (presenteeism) (Boles, Pelletier, & Lynch, 2004). 
Absenteeism and presenteeism are indicators of worker productivity (Escorpizo et al., 
2007). Presenteeism is an important issue for employers as more lost productivity costs 
are attributed to people at work as opposed to those absent from work, for example 
taking sickness absence (Stewart, Ricci, & Leotta, 2004). Thomas-MacLean et al. 
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(2009) interviewed breast cancer patients and found that some patients were able to 
continue working but only with the support of co-workers, for example when 
performing more physical tasks such as heavy lifting. A measure of presenteeism can 
help to gain a better understanding of the effect of breast cancer and its treatment on the 
employee. Studies have found that cancer survivors with higher work ability scores are 
more likely to be working during or following treatment compared to those with lower 
scores (de Boer et al., 2008; Taskila, Martikainen, Hietanen, & Lindbohm, 2007). 
 
Taskila and Lindbohm (2007) conducted a review of the research on the impact of 
cancer on employment and work ability. Work ability can be defined as how able a 
worker is to do his or her job with respect to the work demands, health and mental 
resources (Ilmarinen, Tuomi, & Seitsamo, 2005). The review revealed that a large 
proportion of cancer survivors experience a decreased ability to work and this is an 
important issue that employers need to address.  
 
There are some interesting discrepancies in recent research on cancer and work ability. 
For example, some studies have found differences between cancer groups and healthy 
comparison groups in relation to reported impaired physical and mental work capacity 
(Bradley, Neumark, Luo, & Schenk, 2007; Gudbergsson, Fossa, Borgerass, & Dahl, 
2006; Maunsell et al., 2004), whereas others have found no differences between work 
ability among these groups (Taskila, Martikainen, Hietanen, & Lindbohm, 2007). These 
differences may be due to the prognosis, severity and treatment course. Therefore, it is 
important to note that cancer survivors should be judged idiosyncratically as there may 
be some issues with generalisability. In another comparison study, Bradley et al. (2007) 
reported that female breast cancer survivors experienced impairments in mentally and 
physically demanding work whereas male prostate cancer survivors predominantly 
experienced impairments in physically demanding work. This may be due to the types 
of treatment received for these different cancer types. 
 
Munir, Burrows, Yarker, Kalawsky, and Bains (2010) conducted a qualitative 
exploratory study to examine the awareness of chemotherapy-related cognitive change 
in breast cancer patients on working life. Findings from two focus groups (n = 6; n = 7) 
revealed that breast cancer patients experienced cognitive decline that they attributed to 
chemotherapy, and which negatively impacted upon their work ability as well as their 
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confidence. As work plays an important role in an individual’s economic, social and 
psychological health (Waddell & Burton, 2006),  it is important that the impact of 
cognitive side effects on work ability is clear.  
3.8 Chapter Summary  
This chapter has demonstrated that anxiety, depression, fatigue, and cognitive 
difficulties are prevalent in breast cancer patients undergoing chemotherapy. However, 
the mechanisms involved in chemotherapy-related cognitive impairment are currently 
unclear. Despite a focus on findings from neuropsychological measures in the psycho-
oncology literature, these measures have been criticised for their lack of sensitivity and 
limited ecological validity. Self-report measures are becoming more favourable and can 
provide an in-depth account of the lived experiences of breast cancer patients. These 
measures can be used to identify the subtle cognitive changes specific to the breast 
cancer population. In turn, findings from self-report measures can inform future breast 
cancer patients of what it is like to live with the side effects associated with 
chemotherapy. In addition, findings can help to develop neuropsychological tests that 
are better suited to this population.
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Chapter Four 
A Review of the Literature on Safety Outcomes associated 
with Anxiety, Depression, Fatigue and Cognitive Difficulties 
4.1 Chapter Introduction 
Psycho-oncology researchers have considered the impact of chemotherapy-related side 
effects (e.g. anxiety, depression, fatigue, and subjective cognitive difficulties) on 
important outcomes such as quality of life and work ability in breast cancer patients 
(see Chapter Three). Researchers examining the experiences of other patient 
populations, as well as the general population, have shown that psychosocial and 
cognitive difficulties are associated with safety outcomes, such as accidents and 
unintentional injury. To date, the impact of chemotherapy-related psychological side 
effects on safety outcomes has not been considered in the breast cancer population. 
Since the survival rate of breast cancer is increasing, many breast cancer patients aim to 
continue or resume pre-diagnosis levels of daily functioning during and following 
chemotherapy. Therefore, investigation of the safety outcomes associated with breast 
cancer treatment is an important research area that warrants consideration. 
 
This chapter begins by describing the chief accident and injury statistics in the home 
and workplace in the UK. Since the literature on accident and injury investigation is 
vast and diverse, with links in industrial psychology, medicine, ergonomics and human 
factors engineering, safety engineering, organisation theory, environmental sciences, 
and law (Khanzode, Maiti, & Ray, 2012), a comprehensive review of this literature is 
out of the scope of this thesis. Instead, a summary of the most influential accident 
theories is presented. This is followed by recent evidence of an association between 
psychological difficulties (anxiety, depression, fatigue and cognitive failure) and safety 
outcomes that has been identified in various clinical and non-clinical populations. The 
next section reviews the literature on safety-related outcomes in the cancer population. 
Finally, this chapter concludes with the objectives, hypotheses and aims of the current 
study. 
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4.2 The Definition of Accidents and Key Statistics 
The terms ‘injury’ and ‘accident’ are often used interchangeably in the safety-related 
literature. However, in a recent comprehensive review of occupational injury and 
accident research, Khanzode, Maiti, and Ray (2012) highlighted that these terms are not 
synonymous: “Every accident need not necessarily result in human injury, but every 
injury is a result of an incident that can be termed as accident” (p. 1356). Accidents and 
injuries occur when hazard is present, which can be described as a source of danger that 
has the potential to cause harm (Khanzode et al., 2012). Injury can be categorised as 
intentional or unintentional. 
 
A recent report by National Statistics (2010) provides informative statistics on the 
number of unintentional injuries in the UK. This is a common cause for emergency 
hospital admissions and is one of the main causes of death in the UK. However, the 
report described an annual decrease in the number of unintentional injuries for both 
emergency hospital admissions and deaths. In 1999/2000, the number of emergency 
hospital admissions was 66,087, which decreased to 61,997 in 2009/2010 (National 
Statistics, 2010). Furthermore, from 2000 to 2009 the number of deaths resulting from 
unintentional injury decreased from 1,367 to 1,347. Unintentional injuries accounted for 
1 in 9 emergency hospital admissions for adults and 1 in 40 deaths in adults in 
2009/2010. The report identified falls as being the most common cause of emergency 
admission to hospital as well as the most common cause of death. Road traffic 
accidents, burns and scalds were also frequently reported. However, it is difficult to 
establish the true incidence of unintentional injuries in the UK since the majority are 
treated by General Practitioners (GPs) or in the outpatient unit in Accident and 
Emergency departments (National Statistics, 2010), which is not included in the 
previously reported statistics. 
 
It is clear that accidents and unintentional injuries impact upon a number of lives, and 
so injury prevention and control is an important issue. Traditionally, unintentional 
injuries have been regarded as unavoidable accidents (WHO, 2000). However, 
following increased research over the last few decades, unintentional injuries are now 
regarded as mostly preventable events (WHO, 2000). Consequently, the health 
implications of unintentional injuries have been given much consideration by decision-
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makers worldwide and injury prevention strategies have shown to reduce fatalities 
(WHO, 2000). 
 
4.2.1 Accidents in the Home 
In the UK, unintentional injuries occurring in the home account for more than 25% of 
all emergency hospital admissions in adults aged over 15 years. People aged over 75 
years accounted for 50% of these admissions (National Statistics, 2010). The most 
common type of injury resulting in emergency hospital admission is fracture of the 
femur, followed by fracture of the shoulder and upper arm, other and unspecified head 
injuries, and open head wound injury (National Statistics, 2010).  
 
4.2.2 Accidents in the Workplace 
There are two main sources of workplace injury data in the UK. These include injury 
reports made under the Reporting of Injury, Diseases and Dangerous Occurrences 
Regulations (RIDDOR) and the results of questions included in the Labour Force 
Survey. In 2010/2011, there were approximately 115,000 injuries reported under 
RIDDOR and 171 deaths in the workplace (Health and Safety Executive, n.d.). The 
incidence of these events is a cause for concern as workplace injuries accounted for an 
estimated 4.4 million working days lost in 2010/2011 (Health and Safety Executive, 
n.d.). It is estimated that the cost to society of work-related injuries and ill health 
(excluding cancer) in 2009/2010 was £14 billion (Health and Safety Executive, n.d.). 
The consequences of work-related injury can also include lost income for the employee, 
resulting health difficulties and burden on relatives (Wilkins & Mackenzie, 2007). 
Therefore, the impact of work-related injury for employees, employers, the health 
sector and society is substantial. However, over the past 30 years, there has been a 
decrease in the number of deaths and unintentional injuries in the workplace (Health 
and Safety Executive, 2009). Research in accident causation (see section 4.4) and injury 
prevention strategies, particularly in industry, have contributed to establishing safer 
work practices (such as risk assessment) and safety legislation at the workplace. 
 
4.3 The Psychology of Human Error 
As previously stated in Chapter Three (see section 3.3), human error is a generic term 
that encompasses cognitive, perception and action errors. These errors refer to 
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incidences when a planned sequence of mental or physical activities does not achieve 
the intended result and produces an undesirable outcome, which cannot be attributed to 
some change agency (Health and Safety Executive, 1999; Reason, 1990; Whittingham, 
2003). Human errors are often trivial and inconsequential, posing as a mere 
inconvenience to the individual, for example going from one room to the other and 
forgetting why. However, others result in more serious and tragic outcomes, for 
example the Chernobyl and Challenger disasters (Reason, 1990; Robertson, 2003). 
Consequently, human error has been widely studied and a number of human error 
theories have been proposed. These theories offer scope to develop preventative 
measures to improve safety (Reason, 1990; van Dyck, Frese, Baer, & Sonnentag, 2005). 
One of the most influential psychological theories of human error is Rasmussen’s 
(1983) skill-rule-knowledge model of behaviour (see Figure 4.1). In this model, 
Rasmussen describes three levels of cognitive processing (skill-based, rule-based, and 
knowledge-based) that are utilised when performing a task. The nature of the task, as 
well as the individual’s degree of experience with the task, determine what level of 
cognitive processing is employed. The levels can be described as follows: 
(a) Skill-based behaviours occur when a task is highly familiar to the individual so 
that the cognitive processing required to perform the task is habitual and 
automatic. An individual extremely experienced at a particular task can process 
at this skill-based level, for example an experienced car driver changing gears in 
response to the environment while maintaining a conversation with a passenger. 
These types of behaviour require minimal conscious effort, allowing attentional 
resources to be applied elsewhere. However, this automisation can produce 
incidences of absent-mindedness due to the sensitivity to distraction. Errors in 
skill-based performances usually occur during the execution of a behaviour, 
whereby an individual performs an automatic behaviour that is typically 
associated with another cue (e.g. driving past a turning). 
(b) Rule-based performances are more advanced than skill-based performances. The 
individual may be somewhat familiar with the task, but greater conscious effort 
due to a lack of experience with the task is required. In order successfully 
complete the task, the individual applies a rule, for example: If [problem X] then 
[apply solution Y]. Such rules are formulated through experience and training, 
and are stored in memory, leading to expertise. However, rule-based errors can 
occur when an incorrect rule is applied to an unfamiliar situation (e.g. 
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misreading the problem), or when the essential information to perform the task 
is not available. 
(c) Knowledge-based performance is the highest level of performance and occurs 
when an individual applies previously learned information to solve novel 
problems. This requires a high degree of conscious effort where the individual 
has to ‘think on his/her feet’. Although this conscious cognitive control is 
flexible, it can be effortful, tiring, and subsequently prone to error. In order to 
successfully complete a knowledge-based performance, the individual is 
required to assign meaning to the novel task, which requires working memory, 
and an action plan is devised. Since working memory processes information 
serially, the individual may wrongly focus on relatively unimportant aspects of 
the task. Attention is subsequently diverted and there is a failure to monitor the 
actions being performed, resulting in an error in completing the task. 
 
Figure 4.1. Rasmussen’s (1983) skill-rule-knowledge (SRK) model of human 
performance. 
 
Reason (1990) further developed the psychological taxonomy of human error through 
his research on organisational accidents. He proposed the Generic Error Modelling 
System (GEMS), which is based on Rasmussen’s three main categories of human 
performance (see Figure 4.2). In the GEMS conceptual model, Reason identified three 
basic error types: skill-based slips (and lapses), rule-based mistakes, and knowledge-
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based mistakes. This model focuses on cognitive factors in human error rather than on 
environment or context-related factors. During familiar routine tasks, where little 
conscious effort is required to perform skill-based tasks, slips and lapses can occur. 
These result from failure in the execution of an action sequence. Slips are considered as 
actions-not-as-planned, for example slips of the tongue. Lapses are more covert in 
nature, such as lapses of memory, and may only be noticeable by the individual. 
Mistakes are failures in the formation of a correct plan of action to achieve a goal. 
Reason also acknowledged intentional deviations from practice and classified these as 
violations. 
 
 
Figure 4.2. Reason’s (1990) Generic Error Modelling System (GEMS) 
4.4 Accident Causation Theories 
A recent review of the occupational injury and accident research by Khanzode, Maiti, 
and Ray (2012) illustrates that a considerable body of knowledge exists on accident 
causation theories. Despite researchers from various fields working to help identify, 
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isolate and ultimately eliminate the factors that influence accidents, no theory has been 
universally accepted as yet (Issever, Ozdilli, Onen, Tan, Disci, & Yardimci, 2008). One 
of the most widely accepted conceptual models of accident causation is Reason’s (1990, 
1997) Swiss cheese model, which was developed following his work on organisational 
accidents and extensive evidence from diary studies. This model proposes that 
organisations have consecutive layers of defensive barriers and safeguards (e.g. 
policies, fire alarms) that aim to provide protection from hazards. However, there are 
holes in each layer of the defence (which Reason compared to those found in Swiss 
cheese) that are created by active failures and latent conditions. Active failures are 
unsafe acts performed by individuals at the ‘sharp end’, such as those in direct contact 
with a patient or system. These types of failures are inevitable and unpredictable, and 
include slips, lapses, mistakes, and violations. Latent conditions are identifiable and 
may lie dormant for some time before an accident occurs. They include organisational 
weaknesses, such as lack of training or resources, or decisions made by management. 
When these active failures and latent conditions line up they can create windows of 
opportunity for an accident (Reason, 1997). Although the Swiss cheese model has been 
praised for its advancement of our understanding of human error and accident 
causation, particularly in the aviation domain, it has been criticised for being too 
theoretical and descriptive and lacking real-world application (Shappell & Wiegmann, 
2000). Due to the absence of specification regarding the nature of the holes causing the 
accident and their inter-relationships, the model cannot easily be applied as an 
investigation tool. Furthermore, Dekker (2002) argues that the layers of the defence are 
neither static, constant, nor independent, as the model suggests.  
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Fire 4.3. Reason’s (1990) Swiss cheese model of accident causation 
 
A summary of the main theories of accident causation is presented below in Table 4.1. 
Despite early work focusing on the person-related factors causes of accidents, the 
literature has developed a strong interest in the influence of situation-related factors, 
such as supervisor support and work pressures (Clarke, 2012).  
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Table 4.1 
Summary of Accident Theories (Khanzode, Maiti, & Ray, 2012) 
Theory Summary 
 
Accident proneness theory 
 
The person (unsafe acts) is the cause of the accident, 
in particular personality traits and unsafe behaviour 
(Greenwood & Woods, 1919). Individual-related 
factors for accident causation are examined. 
 
Domino theories The system (unsafe conditions) and the person (unsafe 
acts) are the causes of the accident. A chain of 
sequential events (dominoes) leads to an accident  
(Heinrich, 1932). Used widely in industry. Individual- 
and job-related factors for accident causation are 
examined. 
 
Injury epidemiology theory The sequence between system and person is the cause 
of the accident, in particular uncontrolled energy 
transfer (Haddon et al., 1964). Job-related factors 
(leading to energy interactions) for accident causation 
are examined. 
 
System theory 
 
A holistic approach: the system (unsafe conditions) 
and sequence between system and person (energy 
interaction) are the causes of accident. Organisation-, 
job- and individual-related factors for accident 
causation are examined. 
 
Sociotechnical system (STS) theory 
 
Interacting social and technical subsystems, job 
design based on STS principles. 
 
Macroergonomic theory Holistic approach like system models, organisation-
centred approach. 
 
 
After consideration of the main accident causation theories, it is the person-related 
factors that are highly applicable to this thesis. In particular, the accident proneness 
theory offers a psychological approach to accident investigation and is therefore 
discussed further in the following section. 
 
4.4.1 Accident Proneness Theory 
The accident proneness theory was developed to explain why some individuals 
experience more accidents than others (or that would be expected by chance). The 
theory originated following a study by Greenwood and Woods (1919) where accidents 
amongst workers in a British munitions factory were found to be unevenly distributed 
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amongst the sample. In light of these findings, Greenwood and Woods proposed that 
some individuals have a greater accident propensity than others. Since the accident 
proneness theory was published, accident causation theories have tended to focus on the 
design of the work environment as potentially hazardous factors (Day, Brasher, & 
Bridger, 2012). As the majority of accident and injury research is conducted in 
industrial settings, particular interest lies in task-related and organisation-related 
factors, as opposed to individual-related factors. Subsequently, the popularity of the 
psychological approach to accident causation dwindled due to the idea that person-as-
cause theme associated with this theory lays the blame of accident liability with certain 
individuals (Khanzode, Maiti, & Ray, 2012), rather than on safety regulations in the 
workplace (Green, 1991).  
 
Following a recent meta-analysis of 79 studies examining accident proneness, Visser, 
Pijl, Stolk, Neeleman, and Rosmalen, (2007) concluded that although there is lack of 
consensus regarding definitions of accident and operationalisations of accident 
proneness, evidence was discovered providing support for the existence of accident 
proneness. Studies often examine accidents in specific contexts such as traffic, work 
and sports, or specific populations, such as children, students, or patients (Visser et al., 
2007). Originally, accident proneness was described as a non-modifiable characteristic. 
However, more recently, research has identified transient factors to explain the theory, 
such as stress (Khanzode, Maiti, & Ray, 2012). 
 
A number of studies have shown that the Cognitive Failures Questionnaire (CFQ; 
Broadbent, Cooper, FitzGerald, & Parkes, 1982) is able to predict safety behaviour in 
the workplace (e.g. Wallace & Vodanovich, 2003) and increased driving accidents (e.g. 
Larson, Alderton, Neideffer, & Underhill, 1997; Larson & Merritt, 1991). Furthermore, 
several other psychological factors have been shown to be associated with accidents, 
such as anxiety (e.g. Murata et al., 2000) and fatigue (e.g. Åkerstedt, Fredlund, Gillberg, 
& Jansson, 2002; Simpson et al., 2005). Salminen and Heiskanen (1997) suggested that 
individuals who are prone to accidents in the workplace are also at risk of accidents in 
the home and during leisure activities. The value of the accident proneness theory is 
that once factors associated with the accident-prone individual are identified, preventive 
strategies can be tailored to reduce future accidents (Visser, Pijl, Stolk, Neeleman, & 
Rosmalen, 2007). 
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4.5 Psychological Factors Associated with Accidents 
A variety of psychological factors have been associated with accident propensity. Since 
this thesis is concerned with developing an understanding of the impact of 
chemotherapy-related side effects on breast cancer patients’ daily life, the evidence on 
the association between accident frequency and anxiety, depression, fatigue and 
cognitive difficulties is reviewed below. The literature discussed in Chapter Three 
suggests that these psychological factors are present following chemotherapy treatment. 
 
4.5.1 Anxiety, Depression and Fatigue 
A number of studies have identified a relationship between anxiety and an increased 
risk of accidents (e.g. Murata, Kawakami, & Amari, 2000). For example, in response to 
the increased prevalence of anxiety and depression among the UK population (HSC, 
2004), and subsequent use of medications for these conditions, several studies have 
examined the effects of anxiety and depression on safety outcomes in the workplace. 
Haslam, Atkinson, Brown, and Haslam (2005) found that that the physical and 
psychological symptoms of anxiety and depression and the associated prescribed 
medication impaired work performance. Participants attributed a range of near-misses 
and accidents, including industrial injuries and falls, to their medical condition or 
medication. In particular, employees with responsibilities for others where their actions 
could endanger lives, such as doctors, teachers, managers, electricians and mechanics, 
were reported to repeatedly check their work. This group were also identified as being 
at a greater risk of experiencing hazardous events (Haslam et al., 2005). More recent 
work by Kim, Park, Min, and Yoon (2009) also found that workers who reported 
depressive symptoms were more likely to self-report occupational injury. 
 
The potential mechanisms of how anxiety and depression impact on accident proneness 
are currently unclear. Studies that are cross-sectional in design are limited as it is not 
possible to establish the direction of causality (e.g. Nordstrom, Zwerling, Stromquist, 
Burmeister, & Merchant, 2001). Researchers have proposed direct effects (e.g. the 
symptoms related to anxiety and depression) as well as indirect effects mediated by 
adverse health behaviours (Bhattacherjee et al., 2003; Simpson, Wadsworth, Moss & 
Smith, 2005; Wadsworth, Simpson, Moss, & Smith, 2005). There is strong evidence for 
the association between depression and cognitive impairment, in particular in the 
Chapter Four              Literature Review: Safety Outcomes 
81 
 
domains of executive function, memory, concentration, and psychomotor speed 
(Castaneda et al., 2008). Consequently, research efforts have focussed on accident risk 
in individuals experiencing depression, particularly in contexts with high cognitive 
demands. For example, Bulmash, Moller, Kayumov, Shen, Wang, and Shapiro (2006) 
examined the association between Major Depressive Disorder (MDD) and driving 
ability using a simulated driving paradigm. In this study, MDD outpatients (n = 18) and 
controls (n = 29) completed four 30-minute simulated driving trials throughout the day. 
Scores on the Beck Depression Inventory (BDI) and the Epworth Sleepiness Scale 
(ESS) were recorded. Results showed that after controlling for age and sleepiness, 
participants with MDD exhibited impaired driving performance, such as slower steering 
reaction times and increased crash rate compared to the control group.  
 
A number of studies have identified a link between fatigue and increased rates of 
accidents and injuries. Indeed, the role of fatigue in road traffic accidents is thought to 
contribute to up to 20% of accidents occurring on major roads and motorways (Horne & 
Reyner, 1995). Fatigue and disturbed sleep have also been implicated in workplace 
accidents (Åkerstedt, Fredlund, Gillberg, & Jansson, 2002; Melamed & Oksenberg, 
2002; Simpson, Wadsworth, Moss, & Smith, 2005; Wadsworth, Simpson, Moss, & 
Smith, 2003).  
 
4.5.2 Cognitive Difficulties 
Larson, Alderton, Neideffer, and Underhill (1997) found a strong association between 
cognitive difficulties (as measured on the CFQ) and accidents, which suggests that 
accidents may result from perception, action and memory lapses. Further evidence from 
Wallace and Vodanovich (2003) demonstrated that high scores on the CFQ (suggesting 
impaired cognitive function) predicted safety behaviour as well as accidents in the 
workplace. 
 
A series of studies examining the frequency of cognitive failures and unintentional 
injuries has been conducted by researchers from Cardiff University. Wadsworth, 
Simpson, Moss, and Smith (2003) conducted a postal questionnaire study (n = 4,673) 
measuring the prevalence and associations of cognitive failures, minor injuries and 
accidents in the workplace. Participants were asked to rate how often they experienced 
problems with memory, attention, or action had been experienced in the workplace over 
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the past 12 months, using a 5-point scale (not at all, rarely, occasionally, quite 
frequently, very frequently). Similarly, a rating scale was used to measure minor 
injuries, such as cuts and bruises that did not require medical attention. Accidents were 
defined as incidents that required medical attention. Wadsworth et al. found that 
accidents were reported by 4% of participants, 8% reported experiencing minor injuries 
quite frequently or very frequently, and 13% experienced cognitive failures quite 
frequently or very frequently. Findings suggested that all three outcomes were 
associated with each other. Cognitive difficulties were also related to anxiety, work 
stress and sleeping problems in the previous 14 days. In a similar study, the same 
research group (Simpson, Wadsworth, Moss, & Smith, 2005) found evidence from 
7,980 questionnaire responses that supported earlier findings. Accidents were 
associated with minor injuries, and minor injuries were associated with cognitive 
difficulties. They suggested that the context may contribute to the result of an accident 
following minor injury or cognitive failure. They found that accidents when lifting or 
carrying were the most common, with slips, trips and falls also being frequent. Despite 
low response rates, which may have contributed to response bias, these studies 
documented new factors that are associated with accidents. 
4.6 Evidence of Accident Risk in Clinical Populations 
Researchers have examined the impact that illness, disease and treatment-related side 
effects can have on daily functioning in a number of clinical populations. Several 
studies have identified elevated accident risk in clinical populations, and are reviewed 
in this section. 
 
4.6.1 Evidence from Dementia Patients 
Dementia, a generic term used to describe a chronically progressive brain disease, is 
characterised by cognitive and perceptual impairments. Research has examined 
everyday safety implications within this patient group. For example, it has been found 
that some individuals with dementia find it difficult to navigate the home environment 
safely and that caregivers are often required to make changes in the home environment 
or during activities to reduce the potential risk for injury (Lach & Chang, 2007). Lach 
and Chang conducted a focus group study with caregivers who cared for people with 
dementia and results revealed a high proportion of caregivers highlighting safety issues. 
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This included people with dementia experiencing driving difficulties, such as getting 
lost and being involved in road traffic crashes (69.2%), falls (41.0%), and difficulties 
related to cooking (30.8%). Another study specifically examining the safety of drivers 
with dementia found that one-fifth of dementia patients attending a Memory Clinic (n = 
329) continued to drive following diagnosis (O’Neill et al., 1992). Two-thirds of those 
who continued to drive had impaired driving ability and drove unsafely, such as driving 
the wrong way around a roundabout and up the wrong lane of a dual carriage-way. 
Furthermore, 29% of dementia patients were involved in road traffic crashes, which 
carers rated as being caused by impaired driving ability. There is particular concern 
regarding the safety of dementia patients as some may be limited by a lack of insight of 
their condition and limited awareness of the implications of their cognitive difficulties. 
Similarly, due to the lack of research relating to the safety implications of safety 
behaviour amongst breast cancer patients experiencing cognitive side effects, these 
patients may also lack awareness of the limitations of their cognitive ability and thus 
put themselves into situations that may prove hazardous. However, it is important to 
note that the type of cognitive difficulties experienced by breast cancer patients tend to 
be more subtle and temporary compared to those experienced amongst people with 
dementia. 
 
4.6.2 Evidence from Cancer Patients 
A review of the literature on safety outcomes associated with any cancer treatment was 
conducted and a summary of the identified papers is presented in Table 4.2. Many 
studies were conducted in the hospital setting (e.g. Alcee, 2000; Capone, Albert, Bena, 
& Morrison, 2010; Capone, Albert, Bena, & Tang, 2013; Fischer et al., 2005; Hendrich, 
Nyhuis, Kippenbrock, & Soja, 1995; Hitcho et al., 2004; Lakatos et al., 2009; 
O’Connell, Baker, Gaskin, & Hawkins, 2007; Stone, Lawlor, Nolan, & Kenny, 2011) 
with a heterogeneous patient sample (e.g. included oncology, neurology, orthopaedics, 
psychiatry and cardiology department). Evidence suggests that having a cancer 
diagnosis is associated with safety concerns, particularly fall risk (e.g. Chen et al., 2009; 
Hendrich, Nyhuis, Kippenbrock, & Soja, 1995), although one study did not support this 
finding (Spoelstra, Given, von Eye, & Given, 2010). 
 
A handful of studies have considered the safety implications of cognitive impairment on 
driving ability in head and neck cancer patients (Yuen, Gillespie, Day, Morgan, & 
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Burik, 2007; Yuen, Logan, Boyd, Day, & Brooks, 2009). Chemotherapy for head and 
neck cancer can cause central neurotoxicity and peripheral neurotoxicity (Verstappen, 
Heimans, Hoekman, & Postma, 2003; Vihinen, Katka, Johansson, Vihinen, & 
Salminen, 2003) while radiotherapy to the central nervous system can result in 
neurocognitive difficulties (Meyers, Geara, Wong, & Morrison, 2000). As a result, 
impairment in cognitive, psychomotor and visuoperceptual-motor abilities have been 
documented. Importantly, these abilities are necessary for successful driving ability. 
Yuen et al. (2007) were the first to explore the driving behaviours of head and neck 
cancer patients during and after cancer treatment. They employed a cross-sectional 
survey design and found that self-report cognitive impairment affecting driving ability 
was among the reasons for why 67.5% of head and neck cancer patients chose to drive 
less frequently or ceased driving during treatment while 26.5% continued to drive less 
frequently or ceased driving post-treatment. Yuen and colleagues argued that this 
significant reduction in driving can impact upon quality of life, in particular relating to 
access to social and leisure activities. They also found that six head and neck cancer 
patients reported traffic violations or crashes following cancer treatment and when 
compared to pre-diagnosis data, more crashes were reported post-treatment. Further 
research is required in order to understand causality relating to road traffic accidents 
amongst this cancer patient population. Nonetheless, these findings raise important 
issues for the implications of cognitive side effects experienced by breast cancer 
patients
2
, although it is important to note that there are differences between the 
experiences of head and neck cancer patients and breast cancer patients. These include 
specific side effects relating to the origin of the cancer and treatment-related side 
effects, such as neck mobility restriction among head and neck cancer patients (Hunter-
Zaworski, 1990), which breast cancer patients would not normally experience. 
 
                                            
2
 In the UK, the Driver and Vehicle Licensing Agency (DVLA) maintains registers of drivers and 
vehicles and aims to facilitate road safety. Currently, ‘cancer’ is listed under the conditions that require 
notification to the DVLA if disease- or treatment-related side effects impact upon driving ability, and 
specifically, ‘cognitive problems’ is listed. Affected drivers are required to complete a medical 
questionnaire so that the DVLA can assess the potential safety implications of these conditions. 
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Table 4.2 
Summary of Literature on Safety and Accident Issues associated with Cancer Treatment 
 
Author 
(year) 
Design 
(Timing of 
assessment) 
Sample Measures Summary of findings Critical appraisal 
Relevance to 
research question 
 
Alcee (2000) 
 
Retrospective 
review 
 
Acute-care community 
hospitalised patients who 
had experienced a fall (n 
= 209). The following 
departments were 
included: surgical; 
emergency; 
oncology/medical; 
paediatrics/medical; 
orthopaedic/medical; 
ICU/CCU; telemetry; 
adolescent psychiatry; 
adult psychiatry. 
 
SAFE; number of falls and 
repeat falls; severity of falls; 
description of measures that 
were applied to reduce falls 
by the hospital; frequency 
of falls related to bathroom 
use; time of fall; medication 
use. 
 
Out of 9 nursing units, 
falls most often 
occurred on the 
oncology/medical unit 
(26%). 57% of patients 
fell during the night 
shift. 68% of patients 
experienced no injury 
following a fall. 
Medication use 
(sedatives, hypnotics, 
pain relief) did not 
correlate with falls. 
 
 
Strengths: large sample size; 
in-depth review of falls 
included. 
 
Weaknesses: retrospective 
design; no oncology-specific 
fall details provided; lack of 
demographic information for 
sample. 
 
It is not stated if this 
study included BC 
patients undergoing 
CT. There was no 
longitudinal data and 
psychological risk 
factors for falls were 
not considered. 
Bylow et al. 
(2008) 
Longitudinal 
(Baseline; 3 
months) 
Male prostate cancer 
patients receiving ADT 
aged >70 years (n = 50). 
Functional and physical 
ability (ADLs; IADLs; 
VES-13, SPPB); history of 
falls within the previous 3 
months; cognitive screen 
(Short Portable Mental 
Status Questionnaire); 
Charlson Comorbidity 
Index; medication history; 
social support; Mini-
Nutritional Assessment; 
fatigue (Medical Outcomes 
Study Short Form 36-item 
Health Survey). 
 
22% of participants 
reported falls within the 
previous 3 months. 
ADL deficits, use of an 
assistive device, and 
abnormal functional 
screen findings were 
associated with an 
increased risk of falls. 
24% of patients had an 
underlying cognitive 
impairment. All patients 
who fell reported 
fatigue. 
Strengths: homogeneous 
cancer sample but many 
received treatments other 
than ADT; detailed 
demographic data reported; 
standardised measures. 
 
Weaknesses: relatively small 
convenience sample; limited 
generalisability due to single 
recruitment site; 20% 
attrition rate; short follow-
up. 
 
This study did not 
include BC patients 
undergoing CT. The 
study captured some 
longitudinal data and 
psychological factors 
(cognitive ability 
and fatigue) were 
included. 
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Author 
(year) 
Design 
(Timing of 
assessment) 
Sample Measures Summary of findings Critical appraisal 
Relevance to 
research question 
 
Bylow et al. 
(2011) 
 
Cross-sectional, 
case-control 
 
Males aged  >60 years 
with BCR of prostate 
cancer on ADT (n = 63); 
prostate cancer survivors 
without recurrence (n = 
71). 
 
 
Frailty prevalence; obese 
frailty; objective physical 
ability (SPPB); grip strength 
(Jamar hydraulic hand 
dynamometer); walking 
speed (timed 15-foot walk); 
self-reported frequency of 
falls in the last 6 months; 
self-reported comorbidities 
(OARS); fatigue (CES-D); 
testosterone levels; fasting 
glucose levels. 
 
 
Males with BCR of 
prostate cancer on  
ADT experienced more 
falls than controls 
(14.3% vs. 2.8%; p = 
0.02). Comorbidity 
significantly increased 
the likelihood of falls 
(OR 2.02, p = .01). 
 
Strengths: inclusion of a 
homogeneous treatment 
group and a well-matched 
control group; recruited 
from several clinics; 
considered impact of 
confounders. 
 
Weaknesses: cross-sectional 
design; possible recruitment 
bias. 
 
This study did not 
include BC patients 
undergoing CT. No 
longitudinal data 
was collected and 
psychological risk 
factors for falls were 
not considered 
 
 
Capone et al. 
(2010) 
Prospective and 
retrospective 
medical record 
review 
Hospitalised cancer 
patients who had 
experienced a fall (n = 
158). 
Patient characteristics (e.g. 
age, comorbid conditions; 
use of walking aide; 
medical treatments or 
effects of treatments such as 
pain, pain treatment; 
weight, gait, fall risk); fall 
location; fall injury 
(National Database of 
Nursing Quality Indicators 
injury scale); fall severity. 
The majority of falls 
occurred in the patients’ 
room (80.4%), followed 
by the bathroom 
(17.1%). Most falls 
resulted in no injury 
(70.9) or a minor injury 
(25.9%). More falls 
occurred during the 
night shift (37%) than 
on evening shifts (32%) 
or day shift (30%). Of 
those who fell, 15% had 
depression and 8% had 
dementia. 
Strengths: mixed-methods; 
large sample size; quality 
assurance monitoring of data 
collection. 
 
Weaknesses: heterogeneous 
cancer and treatment 
sample; no comparison 
group; limited 
generalisability due to single 
recruitment site. 
This study reported 
on a heterogeneous 
cancer sample; some 
completed CT. This 
was a record review 
study and so the 
patients’ perspective 
was not considered. 
No longitudinal data 
was collected. Some 
psychological factors 
were measured (e.g. 
depression and 
dementia), but only 
reported 
descriptively. 
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Author 
(year) 
Design 
(Timing of 
assessment) 
Sample Measures Summary of findings Critical appraisal 
Relevance to 
research question 
 
Capone et al. 
(2013) 
 
Retrospective 
medical record 
review 
 
Hospitalised patients 
who had experienced a 
fall and sustained a 
serious injury and had 
cancer (n = 16); did not 
have cancer (n = 41). 
 
Cancer type; cancer 
treatment; fall event details; 
injury type (National 
Database of Nursing 
Quality Indicators injury 
scale); injury severity level 
(observation, review of 
radiographs, CAT scans, 
healthcare provider 
assessments, and other post-
fall medical record details); 
comorbid conditions; 
medication; gait (Morse 
Falls Scale). 
 
No significant 
differences in serious 
injury level patient 
groups. Cancer patients 
who had received 
corticosteroids were 
more likely to have a 
serious injury. 
Depression and 
dementia (measured 
comorbid conditions) 
did not differ based on 
cancer hospitalisation. 
 
Strengths: quality assurance 
monitoring of data 
collection. 
 
Weaknesses: small, single-
centre sample, limiting 
generalisability; 
retrospective data collection 
may have led to bias; limited 
data on cancer diagnosis and 
cancer treatment; data on 
medication was not 
recorded; possible recording 
bias (falls not witnessed may 
not have been recorded). 
 
This study reported 
on a heterogeneous 
hospitalized cancer 
sample (did not 
analyse BC patients 
separately). This was 
a record review 
study and so the 
patients’ perspective 
was not considered. 
No longitudinal data 
was collected. Some 
psychological factors 
were measured (e.g. 
depression and 
dementia). 
 
Chen et al. 
(2005) 
Longitudinal 
(Baseline; annually 
up to 5.1 years) 
Female breast cancer 
survivors (n = 5,298); 
female non-cancer (n = 
80,848). 
Fracture occurrence (annual 
self-reports). Hip fractures 
(medical records); patient 
characteristics (e.g. age. 
Age at menopause, 
ethnicity, smoking, fracture 
history, fall history, 
hysterectomy, walking, 
medication uses); physical 
function (Medical 
Outcomes Study Scale); 
depression (CES-D); dietary 
intake; alcohol 
consumption; BMI. 
 
Fracture rates were 
higher in the BC 
survivor group (expect 
for hip fractures). BC 
survivors were more 
likely to experience 
fractures if they had an 
indication of 
depression. Post-
menopausal BC 
survivors are at an 
increased risk for 
sustaining clinical 
fractures. 
Strengths: large sample size; 
control group; assessed 
covariates. 
 
Weaknesses: lack of cancer-
specific data (e.g. age at 
diagnosis; tumour stage; 
treatment regimens; bone 
metastasis); control group 
not well-matched on 
demographic variables. 
This study included 
a homogenous 
sample of BC 
survivors and a non-
cancer control group, 
although treatment-
related information 
was not recorded. 
Longitudinal data 
was collected and 
psychological factors 
were considered. 
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Author 
(year) 
Design 
(Timing of 
assessment) 
Sample Measures Summary of findings Critical appraisal 
Relevance to 
research question 
 
Chen et al. 
(2009) 
 
Longitudinal 
(Baseline; annually 
in the observational 
group and 
biannually in the 
clinical trials group 
up to 9 years) 
 
At baseline: healthy post-
menopausal females at 
baseline (n = 146,959) 
At follow-up: no cancer 
diagnosis (n = 132,840); 
invasive BC (n = 4,804); 
non-invasive BC (n = 1, 
073); other cancer type 
(n = 8,242). 
 
Self-administered 
questionnaires: medical 
history; health status; 
reproductive history; 
medication; physical 
activity; dietary intake; 
fracture history; other 
lifestyle factors; height; 
weight. Physician medical 
review: cancer incident; BC 
treatment; fractures 
incident.  
 
Fall risk and fracture 
risk are significantly 
increased following a 
BC diagnosis or other 
cancer diagnosis in 
postmenopausal 
women. 
 
Strengths: longitudinal 
design; large sample size 
recruited from a wide 
geographical area; detailed 
treatment-related 
information recorded; 
controlled for potential 
confounders. 
 
Weaknesses: pathological 
fractures could not be 
distinguished from other 
fractures. 
 
This study included 
invasive BC patients, 
non-invasive BC 
patients, other cancer 
patients, all 
undergoing various 
treatments, and 
healthy women. This 
was a prospective 
study that used self-
report measures to 
obtain fall-related 
data; however, 
psychological factors 
were not considered. 
 
Fischer et al. 
(2005) 
Retrospective, 
observational 
Hospitalised patients 
who had experienced a 
fall (n = 1,082). The 
following departments 
were included: 
women/infants; surgery; 
cardiology; 
neurology/orthopaedics; 
oncology; medicine; 
psychiatry. 
Mental status prior to fall; 
date and time of fall; 
reporting department; fall 
location; mechanism of the 
fall/activity at the time of 
the fall; bed position; 
severity of injury; 
description of the fall. 
Oncology service had 
highest number of falls 
and second highest 
injury rate (40%) and 
third highest number of 
falls resulting in injury 
(33%). Older age ( >75 
years), sedated or 
unconscious mental 
status, and residence on 
the geriatric psychiatry 
floor were significant 
predictors of serious 
fall-related injury. 
 
Strengths: large sample size; 
detailed fall-related 
information obtained. 
 
Weaknesses: retrospective 
design; heterogeneous 
patient sample; limited 
generalisability due to single 
recruitment site; lack of 
standardised assessment 
(e.g. mental status of 
participants prior to the fall 
assessed subjectively by 
staff); multicollinearity. 
This study reported 
on a heterogeneous 
hospitalised patient 
group, and did not 
comment 
specifically on BC 
patients or CT. No 
longitudinal data 
was collected. Some 
psychological factors 
were considered. 
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Author 
(year) 
Design 
(Timing of 
assessment) 
Sample Measures Summary of findings Critical appraisal 
Relevance to 
research question 
 
Hendrich et 
al. (1995) 
 
Retrospective chart 
review 
 
Charts of patients who 
had experienced a fall (n 
= 102); charts of patients 
who had not experienced 
a fall (n = 236). 
 
Medication use; presence of 
known risk factors (recent 
surgery; diagnosis of 
cancer, cardiovascular 
disease, depression, or 
orthopaedic disease; 
confusion; decreased 
mobility; dizziness/vertigo; 
generalised weakness; 
history of falls; impaired 
speech/hearing or vision; 
incontinence; level of 
consciousness; 
sleeplessness; walking 
aids/devices). 
 
 
Significant risk factors 
for falls included recent 
history of falls, altered 
elimination; depression, 
dizziness or vertigo, 
primary cancer 
diagnosis, confusion, 
and altered mobility.  
 
Strengths: large sample size; 
assessed an extensive list of 
documented risk factors. 
 
Weaknesses: retrospective 
design; heterogeneous 
patient sample. 
 
This study included 
a heterogeneous 
hospitalised patient 
population. No 
longitudinal data 
was collected. Some 
psychological risk 
factors for falls were 
examined (e.g. 
depression, 
sleeplessness, and 
confusion). 
Hitcho et al. 
(2004) 
Prospective, 
descriptive 
Hospitalised patients 
who fell (n = 183). The 
following departments 
were included: medicine; 
neurology; oncology; 
cardiology; surgery; 
orthopaedics; women 
and infants. 
Interviews with patients 
and/or nurses, review of 
adverse event reports and 
medical records: patient 
characteristics (e.g. 
demographics, mental 
condition at time of fall); 
fall circumstances (e.g. date, 
time, location, discovery 
type, activity trying to 
perform at time of fall, 
reason for activity, 
mechanism of fall); other 
factors (e.g. footwear and 
clothing, visibility); result 
of fall (e.g. injury severity). 
The oncology service 
had the highest rate of 
injury: 74% of first falls 
resulted in injury, with 
11% resulting in 
moderate or severe 
injury. Lost balance was 
the most common 
mechanism of falls 
(12%). 
Strengths: large sample size; 
included characteristics of 
those who fell (e.g. age, 
sex); triangulation of data 
sources. 
 
Weaknesses: limited 
generalisability due to single 
recruitment site; cancer 
patients had the highest 
average length of stay, 
which may have confounded 
results; lack of data 
describing the types of 
injuries; lack of a control 
group. 
This study included 
a heterogeneous 
hospitalised patient 
population. No 
longitudinal data 
was collected. Some 
psychological factors 
were considered 
(e.g. mental 
condition at time of 
fall). 
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Author 
(year) 
Design 
(Timing of 
assessment) 
Sample Measures Summary of findings Critical appraisal 
Relevance to 
research question 
 
Hussain et al. 
(2010) 
 
Longitudinal 
(Baseline; 3 
months, 6 months; 
12 months) 
 
PC patients receiving 
ADT (n = 88); PC 
patients not receiving 
ADT (n = 86); HC (n = 
86). 
 
Participant characteristics 
(e.g. Charlson score, current 
smoker; bone mineral 
density; previous 
treatment); ability to 
perform ADL (Barthel 
Index; Lawton and Brody 
Scale); physical function 
(Timed Up and Go; 6MWT; 
grip strength); balance 
difficulties. 
 
Independent predictors 
of falls included prior 
history of falls, being 
unmarried and arthritis. 
ADT use was 
borderline (p = .08).  
 
Strengths: well-matched 
control groups on age and 
education; prospective 
longitudinal design; assessed 
extensive list of documented 
risk factors for falls. 
 
Weaknesses: participant 
attrition; lack of data on 
participants’ physical 
activity; limited 
generalisability due to single 
recruitment site. 
 
 
This study reported 
on a homogeneous 
PC sample 
undergoing ADT, 
with two control 
groups. Longitudinal 
data was reported, 
but no psychological 
risk factors for falls 
were considered.  
Lakatos et al. 
(2009) 
Retrospective chart 
review 
Hospitalised patients 
who experienced a fall (n 
= 252). The following 
departments were 
included: oncology; 
medicine; surgery; 
neurology; neurosurgery; 
orthopaedics; cardiology; 
psychiatry; other. 
Medical records: 
demographic data; delirium 
diagnosis (DSM-IV); data 
and location of fall; fall 
severity. 
Cancer patients 
experienced the third 
highest number of 
hospital falls (approx.. 
16%). Falls were 
associated with 
delirium, advanced age, 
and specific surgical 
procedures. 96% of 
patients who fell 
showed signs of 
delirium. 
 
 
 
 
Strengths: large sample size. 
 
Weaknesses: heterogeneous 
patient group; limited 
description of falls; limited 
generalisability due to single 
recruitment site. 
This study reported 
on a heterogeneous 
hospitalised patient 
sample undergoing 
various treatments. 
No longitudinal or 
patient-perspective 
data obtained. Some 
psychological factors 
considered 
(delirium). 
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Author 
(year) 
Design 
(Timing of 
assessment) 
Sample Measures Summary of findings Critical appraisal 
Relevance to 
research question 
 
O’Connell et 
al. (2007) 
 
Retrospective and 
prospective 
 
Hospitalised patients 
from oncology and 
palliative care units (n = 
377). 
 
FRAT: demographics (e.g. 
age, patient type); history of 
falls; continence issues; 
physical functioning 
(ECOG); bedside confusion 
(MMSE); orientation in 
person, year, month and 
place (MMSE); muscle 
strength; fatigue. 
 
Patients who did not 
experience a fall were 
more likely to have 
stronger leg muscles 
than patients who did 
experience a fall. No 
differences between 
fallers and non-fallers 
on fatigue score. 
 
Strengths: mixed-methods 
design; many variables were 
measured. 
 
Weaknesses: heterogeneous 
patient group; limited data 
on diagnosis; recall bias 
(recall falls in the previous 
12 months). 
 
 
This study examined 
falls in a 
heterogeneous 
hospitalised patient 
group. No 
longitudinal data. 
Psychological 
factors considered. 
 
Overcash et 
al. (2008) 
Prospective Aged <70 years: cancer 
patients receiving CT (n 
= 86; 38.4% BC); cancer 
patients not receiving CT 
(n = 211; 55.5% BC); 
healthy controls (n = 55). 
Interviews: demographics; 
diagnosis; medical history; 
comorbid conditions; 
Comprehensive Geriatric 
Assessment: functional 
ability (ADLS); depression 
(Geriatric Depression 
Scale); cognitive ability 
(MMSE); falls (American 
Geriatrics Society). 
ADL scores 
significantly predicted 
falls in the CT group 
and non-CT BC groups. 
None of the variables 
significantly predicted 
falls in the HC group. 
Strengths: large sample 
sizes; inclusion of two 
control groups. 
 
Weaknesses: unequal sample 
sizes; limited 
generalisability due to single 
recruitment site. 
This study included 
a heterogeneous 
cancer group, all 
received CT, plus 
two control groups. 
No longitudinal data 
was collected. 
Psychological risk 
factors for falls were 
examined. 
 
Overcash et 
al. (2010) 
Prospective, 
exploratory 
Cancer patients aged >70 
years who had 
experienced a fall within 
3 months (n = 20). 
Structured interview: 
demographic details; cancer 
site; cancer treatment; 
information about falls 
(location of falls, fear of 
falls). 
75% of falls occurred in 
the home. Physical 
problems, general 
weakness and difficulty 
walking were thought to 
cause falls. Themes 
“being more careful” 
and “using an assistive 
device” were employed 
by participants to 
reduce fall risk. 
Strengths: good sample size; 
detailed contextual 
information obtained about 
fall encounters. 
 
Weaknesses: heterogeneous 
cancer population; limited 
generalisability due to single 
recruitment site. 
This study reported 
on a heterogeneous 
cancer group, with 
some receiving CT. 
No longitudinal data 
was included. 
Qualitative design: 
self-report data 
about falls 
examined. 
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Author 
(year) 
Design 
(Timing of 
assessment) 
Sample Measures Summary of findings Critical appraisal 
Relevance to 
research question 
 
Puts et al. 
(2013) 
 
Longitudinal, pilot, 
secondary data 
analysis 
(Pre-treatment 
baseline; 3 months; 
6 months) 
 
Cancer patients aged >65 
years 6 months after 
diagnosis (n = 112; 
39.3% BC). 
 
Interviews: demographic 
details; experience of falls 
in previous 3 months; frailty 
markers: mobility 
impairment (4-m timed gait 
speed test, cognitive 
impairment (MMSE), mood 
disturbance (HADS), 
fatigue (EORTC-QLQ-
C30), low grip strength 
(Fried’s norms); physical 
inactivity (Canadian Health 
and Aging Study 
Questionnaire), poor 
nutritional status; 
comorbidity (Functional 
Comorbidity Index); 
functional status (IADL; 
OARS). Patient chart: 
diagnosis, stage, treatment. 
 
 
17 participants (18.6%) 
experienced 1 or more 
falls within 6 months 
post-diagnosis. No 
significant differences 
between fallers and 
non-fallers on health 
and functioning. No 
significant association 
between 
sociodemographic and 
health characteristics 
and falls. 
 
Strengths: large sample size; 
prospective longitudinal 
design; short timeframe 
between interviews (reduce 
recall bias); physical and 
psychological fall risk 
factors examined. 
 
Weaknesses: heterogeneous 
cancer and treatment 
sample; attrition; context of 
falls not considered. 
 
This study examined 
prospectively the 
risk of falls in a 
newly-diagnosed 
heterogeneous 
cancer group 
(including BC and 
CT-treated). 
Longitudinal data 
was collated and 
psychological risk 
factors for falls were 
considered. 
Spoelstra et 
al. (2010) 
Retrospective, 
cross-sectional; 
secondary data 
analysis 
Community-dwelling 
adults aged >65 years (n 
= 7,448). 
Number of falls; age; sex; 
ethnicity; cancer diagnosis; 
ADLs; IADLs; cognitive 
ability; vision; 
incontinence; pain; 
depression. 
Cancer diagnosis was 
not a predictor of falls. 
Ethnicity, sex, ADLs, 
incontinence, 
depression and pain 
were significant 
predictors of falls. 
Strengths: large sample size. 
 
Weaknesses: heterogeneous 
cancer and treatment 
sample; cross-sectional 
design; lack of control of 
comorbidities. 
Community-
dwelling cancer 
patients, but 
unknown diagnosis 
and treatment. No 
longitudinal data 
collected. Some 
psychological factors 
considered 
(cognitive ability 
and depression). 
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Author 
(year) 
Design 
(Timing of 
assessment) 
Sample Measures Summary of findings Critical appraisal 
Relevance to 
research question 
 
Stone et al. 
(2011) 
 
Prospective 
(Weekly for up to 6 
months) 
 
Advanced cancer 
patients admitted to 
palliative care services (n 
= 119). 
 
Patient interview and 
routine record review: 
demographic details. 
Performance status 
(Palliative Performance 
Scale). Weekly telephone or 
face-to-face contact: fall-
related information. 
 
62 patients (52.1%) fell 
during follow-up. Falls 
occurred in the 
community (55%) and 
in hospital or hospice 
inpatient settings 
(45%). 
 
Strengths: large sample size; 
longitudinal design; 
recruited consecutive 
admissions.  
 
Weaknesses: heterogeneous 
cancer sample; limited 
generalisability due to single 
recruitment site; possible 
selection bias (>50% of 
eligible patients declined 
participation). 
 
 
This study reported 
on patients receiving 
palliative care. 
Longitudinal self-
report data was 
obtained, although 
psychological fall 
risk factors were not 
considered. 
Tofthagen et 
al. (2012) 
Prospective, 
descriptive 
Cancer patients 
experiencing 
chemotherapy-induced 
peripheral neuropathy (n 
= 109; 22% BC). 
Questionnaire: demographic 
information; cancer- and 
treatment-related data. 
Neuropathic symptoms, 
functional status and 
incidence of falls 
(CIPNAT). 
Loss of balance and 
number of CT cycles 
were independently 
associated with falling. 
Patients who received 
taxanes were more 
likely to encounter a fall 
than those who received 
platinum-based CT. 
Strengths: large sample size; 
prospective design; several 
recruitment sites 
(generalisability). 
 
Weaknesses: no longitudinal 
data; heterogeneous cancer 
group; lack of control group. 
This study examined 
risk factors for falls 
in a heterogeneous 
cancer sample 
experiencing 
chemotherapy-
induced peripheral 
neuropathy. No 
longitudinal data 
was collected and 
psychological risk 
factors for falls were 
not considered. 
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Author 
(year) 
Design 
(Timing of 
assessment) 
Sample Measures Summary of findings Critical appraisal 
Relevance to 
research question 
 
Winters-Stone 
et al. (2009) 
 
Cross-sectional, 
prospective 
(Baseline; 12 
months) 
 
BC survivors with CT-
induced amenorrhea (n = 
35; 1 year post-CT); HC 
(n = 26). 
 
Demographic details (e,g. 
menopausal status); cancer-
related information (e.g. BC 
stage, type of treatment); 
fall and fracture incidence; 
leg strength; bone mineral 
density; body composition; 
bone turnover; habitual 
calcium intake (Block Food 
Frequency Questionnaire); 
habitual physical activity 
(Kaiser Physical Activity 
Survey). 
 
 
Significantly more BC 
survivors (75%) 
experienced >1 fall 
compared to HC (46%). 
BC survivors who fell 
had lower leg strength 
and calcium intakes 
than BC non-fallers. 
 
Strengths: homogenous 
cancer group; inclusion of a 
control group; controlled for 
potential confounders. 
 
Weaknesses: small sample 
size; heterogeneous 
treatment group; limited 
generalisability due to single 
recruitment site. 
 
This study examined 
BC survivors who 
had received CT 12 
months prior and 
compared falls in a 
HC group. No 
psychological risk 
factors for falls were 
considered. 
Winters-Stone 
et al. (2011) 
Case-control and 
prospective 
observation 
(Previous 12 
months; monthly up 
to 6 months) 
BC survivors <2 years 
CT completion and/or on 
adjuvant endocrine 
therapy (n = 59). 
Demographic and clinical 
data (e.g. BC stage, 
treatment type); balance 
difficulties (computerised 
dynamic posturography; 
sensory organisation test); 
gait speed (4m walk); 
neuromuscular function (leg 
press, chair raises, 
functional stair climb 
ability); muscle mass 
(DXA); vision (visual 
acuity; spatial contrast 
sensitivity); self-reported 
falls in previous 12 months 
and monthly for 6 months. 
 
58% of BC survivors 
experienced falls in the 
previous 12 months. 
Balance disturbances 
and delays in detecting 
low contrast visual 
stimuli were associated 
with falls. 
Strengths: homogeneous 
cancer group; retrospective 
and prospective data 
collection. 
 
Weaknesses: lack of control 
group. 
This study reported 
on the experience of 
falls in 
postmenopausal BC 
survivors; some had 
received CT. 
Longitudinal data 
was recorded, 
although no 
psychological risk 
factors for falls were 
measured. 
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Author 
(year) 
Design 
(Timing of 
assessment) 
Sample Measures Summary of findings Critical appraisal 
Relevance to 
research question 
 
Yuen et al. 
(2007) 
 
Nonrandomized 
controlled trial; 
pilot 
 
Head and neck cancer 
patients (n = 10); HC (n 
= 50). 
 
Laboratory driving 
simulator: average speed, 
mean brake reaction time, 
steering variability, total 
number of collisions during 
the 12-min driving 
simulator course; Simulator 
Driving Performance Scale. 
 
 
Brake reaction time was 
significantly longer and 
steering variability was 
significantly larger in 
the head and neck 
cancer group than HC 
group. 
 
Strengths: inclusion of a 
control group; driving 
simulators can be an 
ecologically valid method 
for assessing driving 
behaviour. 
 
Weaknesses: heterogeneous 
treatment group; control 
group not well-matched; 
small sample size; limited 
generalisability due to single 
recruitment site. 
 
 
This study reported 
on safety-related 
driving behaviour in 
head and neck 
cancer patients, with 
heterogeneous 
treatment. No 
longitudinal data or 
psychological risk 
factors for safety 
behaviour were 
considered. 
 
 
Yuen et al. 
(2009) 
 
Pilot 
 
Head and neck cancer 
patients (n = 8) 
 
 
Laboratory driving 
simulator: brake reaction 
time. Questionnaire on 
driving behaviour; amount 
of driving pre- and post-
treatment; anxiety and 
depression (HADS). 
 
 
The amount of driving 
post-treatment was 
negatively correlated 
with the mean brake 
reaction time and with 
the anxiety subscale and 
depression scale on the 
HADS. 
 
 
Strengths: driving simulators 
can be an ecologically valid 
method for assessing driving 
behaviour. 
 
Weaknesses: small sample 
size; lack of control group. 
 
This study reported 
on driving behaviour 
in head and neck 
cancer patients, with 
heterogeneous 
treatment. No 
longitudinal data 
collected. 
Psychological 
factors considered 
(anxiety and 
depression). 
Key. ADLs: Activities of Daily Living; ADT: androgen deprivation therapy; BC: breast cancer; BCR: biochemical recurrence; CAM: Confusion Assessment Method; CAT: 
computerised axial tomographic; CCU: Cardiac Care Unit; CIPNAT: Chemotherapy-Induced Peripheral Neuropathy Assessment Tool; CT: chemotherapy; CES-D: Center for 
Epidemiological Studies depression scale; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; ECOG: Eastern Cooperative Oncology Group; EORTC-
QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life core questionnaire 30 items; FRAT: falls risk-assessment tool; HC: healthy controls; 
IADLs: Instrumental Activities of Daily Living; ICU: Intensive Care Unit; MMSE: mini mental state examination; OARS: Older Americans Resources and Service; PC: prostate 
cancer; SAFE: Staff Against Falls Everywhere; SPPB: Short Physical Performance Battery; VES-13: Vulnerable Elder’s Survey-13.  
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4.6.3 Section Summary 
This review chapter has demonstrated clear evidence for the association between 
anxiety, depression, fatigue, subjective cognitive difficulties and safety outcomes, such 
as increased risk of accidents and injuries. As shown in Table 4.2, there is currently a 
lack of literature investigating the impact of chemotherapy-related psychological side 
effects on safety outcomes particularly in the breast cancer population. Since survival 
rates in this population are increasing (Skeel, 2003), many breast cancer patients now 
look to continue or resume pre-diagnosis levels of daily functioning (Steiner, Cavender, 
Main, & Bradley, 2004). Therefore, it is important that further research examines the 
potential safety risks in this cancer population. Figure 4.4  below has been developed 
from the literature review presented in this chapter and provides a general model of 
accident risks identified in the cancer population. This model will be revised in Chapter 
Ten following a review of the findings from the current study. 
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Figure 4.4. Accident theory model illustrating risk factors as reported in the relevant literature cited in Chapter Four (Lawrence Model 1)
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4.7 Research Aims 
This section outlines the aims, objectives, and hypotheses addressed in this work. As 
documented in Chapter Two, breast cancer survival rates are rising in the UK. 
Following improved prognosis and increased survivorship, more women are now 
looking to resume or return to pre-diagnosis levels of daily functioning during or 
following treatment. However, there are a number of adverse psychological side effects 
associated with chemotherapy, which is one of the main treatments for breast cancer. 
Despite a wealth of research on the cognitive impact of chemotherapy (as discussed in 
Chapter Three), many studies have been criticised for their methodological limitations. 
More recently, the value of measuring self-report cognitive changes in this population 
has been recognised and there is a current need for further longitudinal work to examine 
cognitive changes in patients during chemotherapy treatment. This thesis reports the 
subjective experiences of a cohort of breast cancer patients undergoing chemotherapy 
treatment and offers a comparison of their psychosocial well-being, cognitive function 
and frequency of accidents over a 12-month period against two control groups. Self-
completion questionnaires and diaries were used to collect data. The first objective of 
the current study was to: 
 
Objective One: Examine the impact of chemotherapy for breast cancer on 
psychosocial well-being and subjective cognitive function. 
 
Hypothesis I: There will be differences in levels of anxiety, depression and fatigue 
between the chemotherapy group, radiotherapy group and healthy control group, and 
over time. 
 
Hypothesis II: There will be differences in subjective cognitive function scores 
between the chemotherapy group, radiotherapy group and healthy control group, and 
over time. 
 
Hypothesis III (a): Anxiety, depression and fatigue scores will be significantly 
associated with each other and with subjective cognitive function scores in the 
chemotherapy group at each time-point. 
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Hypothesis III (b): Anxiety, depression and fatigue scores will predict subjective 
cognitive function scores in the chemotherapy group at each time-point. 
 
Based on a review of the literature presented earlier in this chapter (see sections 4.5 and 
4.6), evidence suggests that anxiety, depression, fatigue and subjective cognitive 
difficulties are associated with an increased risk of accident reporting. This relationship 
between factors has not currently been addressed in the breast cancer population. Breast 
cancer patients undergoing chemotherapy frequently reported anxiety, depression, 
fatigue and subjective cognitive difficulties. Therefore, it is important that research 
considers the safety outcome of chemotherapy-related side effects in the breast cancer 
population. This could have important implications for breast cancer patients and health 
professionals when making treatment decisions. Since breast cancer prevalence and 
survival is increasing and disease and treatment side effects have been shown to persist 
several years following successful treatment, the potential safety risks may be a concern 
for a considerable number of women and impact upon home and work environments. 
This research could help to support patients and practitioners to develop interventions 
and strategies to assist patients, relatives and employers if, and when, necessary. The 
impact of safety concerns may also have important implications for managing daily 
activities in the home and workplace. Knowledge of this would form the development 
of compensatory and preventative strategies in future intervention studies should safety 
risks be a concern within this population. The second objective provides a novel insight 
into the experiences of breast cancer patients managing their daily tasks. Since some 
breast cancer patients report experiencing chemotherapy-related side effects up to ten 
years post-treatment (Ahles et al., 2005), it is important to clarify the potential safety 
implications of these side effects. The second objective of the current study was to: 
 
Objective Two: Examine the impact of chemotherapy for breast cancer on safety 
outcomes in the home and workplace. 
 
Hypothesis IV: Breast cancer patients undergoing chemotherapy will report more 
incidences of accidents at all follow-up time-points compared to treatment and healthy 
controls.  
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Hypothesis V (a): Demographic, psychosocial, and cognitive function variables will be 
significantly associated with accident frequency in the chemotherapy group at each 
time-point. 
 
Hypothesis V (b): Demographic, psychosocial, and cognitive function variables will 
predict accident frequency in the chemotherapy group at each time-point. 
 
Following improvement in the prognosis of this cancer population, the focus for 
psycho-oncology research relates to understanding and enhancing patients’ daily 
functioning, such as quality of life (Ahles et al., 2005; Reid-Arndt, Hsieh & Perry, 
2010), which is an important outcome for breast cancer patients (Montazeri, 2008). 
Based on the literature review in Chapter Three, treatment-related side effects have 
been shown to impact upon quality of life (Montazeri, 2008) and work ability. 
Returning to, or staying at, work during and following treatment is now a realistic 
outcome for many cancer patients following improved prognosis (Rowland, Aziz, 
Tesauro, & Feuer, 2001). The Equality Act 2010 states that employers are expected to 
make reasonable adjustments for employees with cancer to support them in their return 
to work and to maintain successful work ability (Morrell & Pryce, 2005). Since 
approximately 55% of new breast cancer cases are of working age, research into the 
impact of chemotherapy in the workplace is an important focus, particularly as there 
may be more cancer diagnoses in the working population in the near future following 
the predicted extension of working life in the UK (Department for Work and Pensions, 
2006). However, the potential impact of chemotherapy-related safety outcomes on 
quality of life and work ability has not yet been investigated in the breast cancer 
population.  
 
Although psycho-oncology research has considered return to work and work ability 
issues pertaining to breast cancer patients (e.g. Amir, Neary, & Luker, 2008; de Boer et 
al., 2008; Steiner, Cavender, Main, & Bradley, 2004; Taskila, Martikainen, Hietanen, & 
Lindbohm, 2007), there has been a considerable lack of focus on the impact of 
treatment side effects on daily life within the home. Taking into account that a large 
proportion of breast cancer patients take sickness absence during and for some time 
following chemotherapy (Munir, Kalawsky, Lawrence, Yarker, Haslam, & Ahmed, 
2011), it is surprising that the home environment has been overlooked. Therefore, there 
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is a current need for research to incorporate breast cancer patients’ daily experiences 
within the home. The third objective of the current study was to: 
 
Objective Three: Examine the impact of chemotherapy for breast cancer on 
quality of life and work ability. 
 
Hypothesis VI: There will be differences in quality of life scores between the 
chemotherapy group, radiotherapy group and healthy control group, and over time. 
  
Hypothesis VII (a): Anxiety, depression, fatigue, cognitive function and frequency of 
accidents will be significantly associated with quality of life in the chemotherapy group 
at each time-point. 
 
Hypothesis VII (b): Anxiety, depression, fatigue, cognitive function and frequency of 
accidents will predict quality of life scores in the chemotherapy group at each time-
point. 
 
Hypothesis VIII: There will be significant differences in work ability scores between 
the chemotherapy group, radiotherapy group and healthy control group, and over time. 
 
Hypothesis IX (a): Demographic, psychosocial, cognitive function and accident 
frequency variables will be significantly correlated with work ability scores in the 
chemotherapy group at each time-point. 
 
Hypothesis IX (b): Demographic, psychosocial, cognitive function and accident 
frequency variables will predict work ability scores in the chemotherapy group at each 
time-point. 
 
There is now a considerable body of literature addressing the impact of chemotherapy 
for breast cancer with findings from neuropsychological tests. However, research 
describing the lived experiences of breast cancer patients is sparse (Boykoff, Moieni, & 
Subramanian, 2009; Pullens, De Vries, & Roukema, 2010; Rey, Bouhnik, Mancini, 
Bendiane, Seror, & Viens, 2012; Wagner, Sweet, Butt, Lai, & Cella, 2009). In 
particular, the use of qualitative methods has often been overlooked. This approach can 
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provide rich data and was employed in the current study to capture an in-depth insight 
into the experiences of breast cancer patients undergoing chemotherapy, as well as to 
provide subtle temporal fluctuations not captured by the questionnaires. The fourth 
objective and its research aim were to: 
 
Objective Four: Explore the impact of chemotherapy for breast cancer on 
patients’ daily life during and shortly following treatment 
 
Describe the experience of cognitive failures, psychosocial difficulties and accidents 
in breast cancer patients undergoing chemotherapy patients in the home and in the 
workplace. 
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Chapter Five  
Methods: Questionnaire Survey 
5.1 Chapter Introduction 
Following a review of the documented literature in Chapters Two, Three and Four, it is 
clear that there is a need for further longitudinal research to examine the lived 
experiences of breast cancer patients undergoing chemotherapy. In particular, it is 
important to address the current research gap within psycho-oncology research 
regarding the risk of accidents in this population. The current chapter describes the 
overall research design, recruitment strategy, procedure (specific to the questionnaire 
phase) and ethical considerations related to the study. Due to some procedural 
variations relating to the qualitative phase, specific information about this phase is 
presented separately in Chapter Nine. 
5.2 Ethical Approval 
Ethical approval for this research was obtained from the Loughborough University 
Ethical Advisory Committee and the NHS Research Ethics Committee at Nottingham 
(see Appendices 1 & 2 for approval letters). Research and Development departments at 
University Hospitals of Leicester and Nottingham University Hospitals provided 
permission for the study to be conducted at Leicester Royal Infirmary and Nottingham 
City Hospital, respectively. The process of obtaining ethical approval took 
approximately six months. 
5.3 Research Design 
This research employed a prospective, longitudinal, mixed-methods, between-within 
participants design with four time-points.  The methodological limitations of previous 
research were addressed as follows:  
(a) the prospective nature of the study provided the opportunity to measure changes 
as they occurred, thereby reducing retrospection bias; 
(b) the longitudinal design facilitated the mapping of data in a temporal sequence; 
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(c) the pre-treatment baseline enabled any impact of chemotherapy on patients’ 
experiences to be recorded, and 
(d) the inclusion of a treatment control group enabled any psychosocial impact of a 
cancer diagnosis to be controlled for, while a healthy control group acted as a 
comparison group from which any differences could be considered as deviations 
from the general population. 
 
A combination of quantitative and qualitative approaches to data collection and analysis 
was applied to this research. The quantitative component involved the use of 
questionnaires that enabled the collection of quantifiable data that were analysed using 
statistical tests in order to detect the severity of and temporal changes in psychosocial 
factors, cognitive function, work ability and accident frequency over a twelve-month 
period. During this phase, all participants were assessed using questionnaires on four 
occasions: at baseline (pre-chemotherapy) and follow-up time-points at 4 months, 8 
months and 12 months. These data collection time-points synchronised approximately 
with important timings within the chemotherapy treatment course and were feasible 
within the research timeframe. Chemotherapeutic drugs are often administered for 
between one and five days followed by a break of three to four weeks. This constitutes 
one chemotherapy cycle and a complete treatment course may last up to eight treatment 
cycles. Therefore, a complete course of chemotherapy can take up to eight months and 
so follow-up time-points mapped onto chemotherapy treatment as follows:  
(a) follow-up time 1 captured breast cancer patients’ experiences at approximately 
the middle of the chemotherapy treatment course, 
(b) follow-up time 2 captured breast cancer patients’ experiences at approximately 
the end of the chemotherapy treatment course, and 
(c) follow-up time 3 captured breast cancer patients’ experiences at approximately 
four months post-chemotherapy treatment cessation. 
In addition, a four-month interval between assessments was considered not too great so 
that uncontrollable factors could have greatly influenced the data, which is an important 
concept acknowledged by Budischewski, Fuschbeck, and Mose (2008).  
 
The qualitative component of the current study involved several questions from the 
questionnaire and the use of diaries (from a sub-sample of participants) that provided 
rich in-depth data about the individual lived experiences of participants that were 
Chapter Five           Methods: Questionnaire Survey 
 105 
analysed using thematic analysis (as described by Braun & Clarke, 2006). This 
approach focussed on the context of cognitive difficulties, psychosocial well-being and 
accident frequency and captured subtle temporal fluctuations experienced by 
participants. The qualitative component expanded on subtle contextual differences not 
captured by the quantitative data collection (see Chapter Nine for further details). 
 
This mixed-methods approach provided a valuable, synergistic strategy as it 
compensated for the limitations of utilising either quantitative or qualitative methods in 
isolation, as discussed in Chapter One. In addition, this approach can strengthen 
research findings by increasing the validity of a study’s argument when similar findings 
across different approaches are found and to increase the probability that the findings 
are credible by increasing the reliability of the data and the method of collating it 
(Gifford, 1996). 
5.4 Participants and Recruitment Strategy 
5.4.1 Participants 
Three participant groups were recruited: breast cancer patients undergoing adjuvant or 
neoadjuvant chemotherapy treatment (n = 67), a treatment control group of breast 
cancer patients undergoing radiotherapy (n = 61) and a healthy control group (n = 122). 
All participants were recruited from July 2009 to December 2010.  
 
The inclusion criteria for breast cancer patients were to: 
(a) be female, due to the relatively small incidence of breast cancer in males (as 
previously outlined in Chapter Two section 2.2); 
(b) be older than 18 years, as the incidence of breast cancer in younger individuals 
is relatively rare, and no upper age limit was set to enable the experiences of 
older breast cancer patients to be captured (a subsample often overlooked within 
this type of research); 
(c) have breast cancer as the primary diagnosis, as other cancers and the various 
treatments for them may add confounding factors thus making it difficult to 
definitively attribute side effects to chemotherapy;  
(d) have been diagnosed with stage 0, I, II or III breast cancer, to exclude metastatic 
cancer that would require a more complex treatment regime, and  
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(e) be expecting to undergo chemotherapy and/or radiotherapy treatment.  
 
Healthy female controls were matched to breast cancer patients undergoing 
chemotherapy on age (± 2.5 years) to control for any effect that age might have on the 
ability to manage daily tasks, such as age-related cognitive decline (Charlton et al., 
2006). Healthy controls were absent from a history of cancer. All participants were 
required to be fluent in English.  
 
5.4.2 Recruitment Strategy 
The following section provides a detailed account of the strategies employed to recruit 
participants from a range of sources and is divided accordingly: the recruitment of 
breast cancer patients from NHS clinics, the recruitment of breast cancer patients from 
cancer support groups, and the recruitment of healthy controls. Table 5.1 provides a 
summary of these recruitment methods. 
 
Breast cancer patients: NHS cancer clinics 
Several consultant oncologists from local NHS hospitals were contacted with the aim of 
establishing collaboration and access to breast cancer patients. Following meetings 
involving the consideration of recruitment feasibility, the support and collaboration of 
five consultant oncologists from cancer clinics across two counties were obtained 
(Leicestershire and Nottinghamshire). This type of multi-centre research is valuable as 
it offers the opportunity to obtain relatively large sample sizes over a shorter period of 
time and broadens the generalisability of the findings by extending the geographic area 
of recruited participants. The researcher was granted permission to recruit breast cancer 
patients by approaching them in the waiting area of the cancer clinic before or after 
their appointment with the consultant oncologist. A consecutive, convenience sampling 
strategy was employed to recruit breast cancer patients so that the researcher could 
approach as many breast cancer patients as possible during the recruitment period. The 
majority of breast cancer patients were recruited via NHS cancer clinics (Leicester 
Royal Infirmary, n = 75; Nottingham City Hospital, n = 52).  
 
Breast cancer patients: cancer support groups 
Since on-site recruitment at the NHS cancer clinics was a time-demanding activity for 
the researcher, an additional strategy for recruiting breast cancer patients was 
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considered with the aim of increasing the sample size. Cancer support groups provided 
the opportunity for a viable and convenient method to achieve this aim. An online 
search engine was used to identify breast cancer support groups in the UK. The 
researcher sent details regarding the nature and purpose of the study to numerous 
contact persons. Those who expressed an interest in the study were sent recruitment 
posters to be displayed at support group centres (see Appendix 3) or permission was 
requested to advertise the study on online support group forums. Only two breast cancer 
patients were recruited from cancer support groups. This may have been due to 
relatively few breast cancer patients utilising cancer support groups at the pre-treatment 
stage. 
 
Healthy controls 
Healthy controls were recruited opportunistically. A press release through 
Loughborough University was issued that included a summary of the study and invited 
those interested in participating to contact the researcher. This raised awareness about 
the study, resulting in an article in a local newspaper and the University alumni 
newsletter as well as an advertisement on a local radio station. Furthermore, posters 
advertising the study were placed in libraries, leisure centres, community centres and 
churches in the local area (see Appendix 4). A snowballing technique was also used 
whereby recruited healthy controls were invited to raise awareness about the study to 
female relatives, friends and colleagues. Since breast cancer can be a personal and 
sensitive topic for some women, snowballing was considered a useful technique to help 
identify others with no history of cancer in a non-invasive manner. The healthy control 
group within this research represented a convenience sample. 
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Table 5.1. 
Recruitment Strategies for the Chemotherapy Group, Radiotherapy Group and Healthy Control Group 
 
Participant group Source Recruitment strategy 
Breast cancer patients 
NHS cancer clinics 
Researcher emailed consultant oncologists to obtain access to breast cancer patients. On-site 
recruitment: researcher approached potential participants in the clinic waiting area and verbally 
explained the study and provided to those interested with an information sheet. 
Cancer support group 
centres 
Researcher contacted cancer support group centre representatives and provided details about the study. 
Posters were displayed at cancer support group centres. 
Online cancer support 
forums 
Researcher emailed the cancer support group representative with details about the study. 
Advertisements were written on online forums. 
Press release through 
Loughborough University 
Newspaper advertisement invited interested readers to contact the researcher. Snowballing technique. 
   
Healthy controls 
Local amenities 
Researcher obtained permission from representatives at local amenities to display posters on notice 
boards. 
Press release through 
Loughborough University 
Newspaper and radio advertisements invited interested persons to contact the researcher. Snowballing 
technique. 
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5.5 Sample Size 
A power calculation was performed to ensure that the sample size for the quantitative 
analyses was large enough to be able to detect any differences between the participant 
groups. An a-prior power calculation was performed for each statistical analyses, as 
detailed below. 
 
One-way between-groups ANOVA 
Using Cohen’s (1992) tables, a sample size of 26 per participant group was required to 
detect a large effect size (f = 0.40) where α = 0.05 and power = 0.80. A sample size of 
76 per participant group was required to detect a medium effect size (f = 0.64) where α 
= 0.05 and power = 0.80. 
 
3 x 3 mixed ANOVA 
Using G*Power Version 3.1.3 (Faul, Erdfelder, Lang, & Buchner, 2007), a sample size 
of 78 per participant group was required to detect a large effect size (f = 0.40) where α = 
0.05 and power = 0.80 (with three participant groups and three follow-up time-points). 
A sample size of 65 per participant group was required to detect a medium effect size (f 
= 0.25) where α = 0.05 and power = 0.80 (with three participant groups and three 
follow-up time-points). 
 
Correlations 
Using Cohen’s (1992) tables, a sample size of 28 was required to detect a large effect 
size (f
2
 = 0.35) where α = 0.05 and power = 0.80. A sample size of 85 was required to 
detect a medium effect size (f
2
 = 0.15) where α = 0.05 and power = 0.80. 
 
Multiple regression 
Using Cohen’s (1992) tables, a sample size of 42 was required to detect a large effect 
size (f
2
 = 0.35) where α = 0.05 and power = 0.80 with five independent variables (this is 
the maximum number of variables included in the regression analyses). A sample size 
of 91 was required to detect a medium effect size (f
2
 = 0.15) where α = 0.05 and power 
= 0.80 with five independent variables. 
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5.6 Measures 
This research included measures of cognitive function, psychosocial well-being, quality 
of life, work ability and accident frequency. The following criteria were considered 
when selecting measures for the questionnaire booklet: 
(a)  applicability of the measure to both a cancer patient group and a healthy control 
group, 
(b) favourable reliability and validity reported in previous studies (reported in 
section 5.6.4 where available), and  
(c)  accessibility of measures. 
 
The content of the Recruitment Questionnaire and questionnaire survey, which was 
developed following feedback from the collaborating consultant oncologists, are 
described below. Importantly, the questionnaire survey was designed not to be unduly 
time-consuming in an attempt to minimise fatigue, maintain participant motivation and 
increase response rate. Measures were available in paper format and online, hosted by 
Survey Monkey. 
 
5.6.1 Recruitment Questionnaire 
The Recruitment Questionnaire requested the following demographic information from 
participants: age, marital status, education, ethnicity, menopausal status and co-
morbidity. Three versions of the Recruitment Questionnaire were developed with 
wording tailored to the site of recruitment and participant group: breast cancer patients 
recruited from NHS cancer clinics, breast cancer patients recruited from cancer support 
groups (with additional questions relating to treatment) and healthy controls (with 
diagnosis- and treatment-related questions omitted) (shown in Appendices 8 to 10). 
This information was used for describing the sample characteristics and for including in 
quantitative analyses (see Chapter Six). 
 
5.6.2 Treatment Questionnaire 
The Treatment Questionnaire was completed by the collaborating consultant 
oncologists at the NHS cancer clinics and requested details about the breast cancer 
patient’s diagnosis and treatment course (shown in Appendix 11). 
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5.6.3 Questionnaire Booklet 
A description of the validated measures included in the questionnaire survey is 
presented below and summarised in Table 5.3. The questionnaire took approximately 
30 minutes to complete. See Appendix 12 for the questionnaire booklet designed for 
breast cancer patients, only minor amendments were made to the version completed by 
healthy controls (e.g. removal of reference to ‘illness’). 
 
Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983). This is a 
measure of anxiety (seven items) and depression (seven items). Participants are asked 
to reflect upon the past week and to rate 14 items on a 4-point Likert scale. An example 
of an item from the anxiety subscale is: ‘Worrying thoughts go through my mind’, 
which is rated on the scale 0 = ‘only occasionally’ to 3 = ‘a great deal of the time’, and 
the following item is from the depression subscale: ‘I feel cheerful’, which is rated on 
the scale 0 = ‘most of the time’ to 3 = ‘not at all’. Scores are summed giving maximum 
scores of 21 for each subscale. When interpreting the scores, on each subscale, scores 
from 11 to 21 indicate probable clinical disorder, scores from 8 to 10 represent possible 
clinical disorder and scores from 0 to 7 are considered normal. This measure usually 
takes no more than five minutes to complete and has been widely used in research with 
breast cancer patients (e.g. Hermelink et al., 2007; Weis, Poppelreuter, & Bartsch, 
2009). An exploratory factor analysis of this measure carried out in 568 cancer patients 
demonstrated excellent internal consistency (anxiety subscale, α = 0.93; depression 
subscale, α = 0.90) (Moorey et al., 1991). For the current research, the anxiety subscale 
had an internal consistency of α = 0.88 at baseline; α = 0.87 at follow-up time 1; α = 
0.90 at follow-up time 2, and α = 0.89 at follow-up time 3 (in the chemotherapy group). 
The depression subscale had an internal consistency of α = 0.83 at baseline; α = 0.88 at 
follow-up time 1; α = 0.90 at follow-up time 2, and α = 0.90 at follow-up time 3 (in the 
chemotherapy group). 
 
Functional Assessment of Cancer Therapy-Fatigue (FACIT-F; Yellen, Cella, 
Webster, Blendowski, & Kaplan, 1997). This is a commonly used measure of cancer-
related fatigue (e.g. Downie, Mar Fan, Houede-Tchen, Yi, & Tannock, 2006; Jenkins et 
al., 2006; Mar Fan et al., 2005; Shilling, Jenkins, Morris, Deutsch, & Bloomfield, 2005; 
Tchen et al., 2003). Participants are asked to rate 13 items on a 5-point Likert scale 
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ranging from 0 = ‘not at all’ to 4 = ‘very much’ in reference to fatigue experienced in 
the past week. This measure usually takes no more than 5 minutes to complete. This 
measure has demonstrated excellent internal consistency in a study of 1,011 cancer 
patients (α = 0.93) (Lai, Cella, Chang, Bode, & Heinemann, 2003). For the current 
research, this measure had an internal consistency of α = 0.73 at baseline; α = 0.83 at 
follow-up time 1; α = 0.86 at follow-up time 2, and α = 0.86 at follow-up time 3 (in the 
chemotherapy group). 
 
Functional Assessment of Cancer Therapy-General Population (FACT-GP; Cella, 
Lai, Chang, Peterman, & Slavin, 2002). This is a measure of quality of life designed for 
the general population. Four dimensions of quality of life are assessed: physical well-
being; social well-being; emotional well-being, and functional well-being. Participants 
are asked to rate 21 items on a 5-point Likert scale ranging from 0 = ‘not at all’ 4 = to 
‘very much’ in reference to quality of life in the past week. This measure usually takes 
no more than five minutes to complete. A review of the literature examining quality of 
life in breast cancer patients described this measure as one of the most common and 
well-developed measures of quality of life (Downie, Mar Fan, Houede-Tchen, Yi, & 
Tannock, 2006; Mar Fan et al., 2005; Montazeri, 2008; Tchen et al., 2003). 
 
Cognitive Failures Questionnaire (CFQ; Broadbent, Cooper, FitzGerald, & Parkes, 
1982). This is a self-report measure of error proneness in perception, memory and 
motor function during everyday tasks. The CFQ measures the behavioural 
consequences of cognitive impairment (Stuss, Winocur, & Robertson, 1999). 
Participants are asked to rate 25 items on a 5-point Likert scale ranging from 0 = 
‘never’ to 4 = ‘very often’. Scores can range from 0 to 100 with higher scores 
representing a higher frequency of cognitive failures. In the general population, typical 
scores range from 25 to 35 (Wagle, Berrios, & Ho, 1999). The timescale was changed 
from ‘in the past 6 months’ to ‘in the past week’ to maintain consistency with the other 
measures within the questionnaire and to fit in with the four questionnaires 
administered over a 12-month period. This measure usually takes no more than five 
minutes to complete. The CFQ is typically used as a unitary measure of cognitive 
function and has been extensively used in research with breast cancer patients 
(Castellon, Ganz, Bower, Petersen, Abraham, & Greendale, 2004; Jenkins, Shilling, 
Fallowfield, Howell, & Hutton, 2004; Jenkins et al., 2006; Munir, Kalawsky, Lawrence, 
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Yarker, Haslam, & Ahmed, 2011; Quesnel, Savard, & Ivers, 2009; Schilder et al., 2009; 
Schilder et al., 2012; Shilling, Jenkins, Morris, Deutsch, & Bloomfield, 2005). 
Evidence suggests that the CFQ has good discriminant validity and has demonstrated 
differences in the reporting of frequency of cognitive failures in participant groups with 
depression (Wagle, Berrios, & Ho, 1999), stress (Broadbent, Cooper, FitzGerald, & 
Parkes, 1982) and multiple sclerosis (Phillips et al., 2009) compared to healthy controls. 
Therefore, it was anticipated that the CFQ would be sufficiently sensitive to detect 
differences in cognitive function in the breast cancer patient group and healthy controls. 
Research suggests that the CFQ has considerable ecological validity and a high internal 
consistency of 0.91 in a sample of 335 healthy participants (Wallace, Kass, & Stanny, 
2002) and 0.90 in a sample of 235 cancer survivors (Spelten et al., 2003). For the 
current research, this measure had an internal consistency of α = 0.91 at baseline; α = 
0.94 at follow-up time 1; α = 0.94 at follow-up time 2, and α = 0.96 at follow-up time 3 
(in the chemotherapy group). 
 
Accident frequency. A question was developed by the researcher to obtain further 
information about participants’ everyday experiences of accident frequency in the 
home and in the workplace. Participants were asked to choose from a 5-point rating 
scale from 5 = ‘all the time’ to 0 = ‘never’ about ‘How often have accidents occurred, 
while you were at home, during the past week?’ Participants were then asked to list the 
types of accidents that had occurred during the past week. This question was also asked 
in relation to work for those who were employed at the time. The use of a single-item 
question to measure incidences of human error has been used within health and 
occupational research (e.g. Simpson, Wadsworth, Moss, & Smith, 2005; Wadsworth, 
Simpson, Moss, & Smith, 2003). As demonstrated in Chapter Four, the accident and 
injury research often use the terms accident and injury synonymously, although they are 
not synonyms (Khanzode, Maiti, & Ray, 2012). However, only the term ‘accident’ was 
used in the questionnaire in the current study as this was considered a useful generic 
and simple term to describe unsafe events that may or may not involve injury. 
Furthermore, this term is frequently used in psychological research that is closely 
related to the current study (e.g. Simpson, 2005). 
 
Work Ability Index (WAI; Tuomi, Ilmarinen, Jahkola, Katajarinne, & Tulki, 1998). 
This is a measure of work ability. Three items were taken from the WAI to measure 
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work ability – an approach employed by other researchers examining cancer patients 
(e.g. Bains, Munir, Yarker, Thomas, Armitage, & Steward, 2012; de Boer, Verbeek, 
Spelten, Uitterhoeve, Ansink, & Reijke, 2008). This is beneficial in terms of simplicity 
and interpretation (Bowling, 2005), as well as reduced time demands for participants as 
it takes less than five minutes to complete. Participants are asked to rate their current 
work ability with their lifetime best a scale from 0 = ‘completely unable to work’ to 10 
= ‘work ability at its best’. They are then asked to rate their work ability with respect to 
the physical demands of their job and the mental demands, both on a scale from 1 = 
‘very poor’ to 5 = ‘very good’. Ahlstrom, Grimby-Ekman, Hagberg, and Dellve (2010) 
found a strong association (r = 0.87) between the WAI and the first item on the 
measure. The internal consistency for the full scale has been demonstrated to be good (α 
= 0.79) in a sample of 40,000 healthy participants (Radkiewicz & Widerszal-Bazyl, 
2005). For the current research, this measure had an internal consistency of α = 0.84 at 
baseline; α = 0.76 at follow-up time 1; α = 0.69 at follow-up time 2, and α = 0.82 at 
follow-up time 3 (in the chemotherapy group). 
 
Additional questions. The questionnaires concluded with a blank page and invited 
participants to share additional information about their experiences of managing daily 
activities. Chapter Nine presents the findings of this data that were analysed 
qualitatively. 
5.7 Procedure 
This section describes the data collection procedures involved in the current study. 
Procedures relating to breast cancer patients recruited from NHS cancer clinics are 
presented first, followed by breast cancer patients recruited from cancer support groups, 
and finally the collection of data from healthy controls. Informed written consent was 
obtained from all participants. To maximise response rate, participants were contacted 
by telephone, email or post if the questionnaire had not been returned within two weeks. 
Data collection occurred from July 2009 to December 2011. 
 
5.7.1 Breast Cancer Patients Recruited from NHS Cancer Clinics 
The researcher contacted the clinic co-ordinators on a weekly basis to establish whether 
any new breast cancer patients eligible for the research would be attending the clinic 
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during the week. The clinic co-ordinators were able to identify eligible breast cancer 
patients from their medical records. The researcher approached these potential 
participants individually in a quiet area of the clinic waiting room to explain the 
purpose and nature of the research. The opportunity to ask any questions about the 
study was provided. An information pack containing the Participant Information Sheet, 
Consent Form, Recruitment Questionnaire, Questionnaire Booklet, and a pre-paid 
envelope was given to those who expressed an interest in the research and their 
telephone or email contact details were obtained. These details were entered into a 
Microsoft Excel® spreadsheet on a password-protected computer, along with the dates 
to send out follow-up questionnaires. These breast cancer patients were contacted 
approximately seven days later, as this had been considered sufficient time by the NHS 
ethics committee for careful evaluation of the details provided in the information pack 
and for the patient to come to an informed decision about taking part in the research. 
The researcher answered any questions the breast cancer patient had and confirmed 
their interest in the research. A number of breast cancer patients (33.51%) declined to 
take part in the research at this stage. Common reasons for refusal included having too 
much to deal with in their personal lives such as coping with treatment, feeling too 
emotional and general lack of interest in the research. These breast cancer patients were 
thanked for their time and their contact details were subsequently destroyed. Those who 
wished to take part in the research were asked to complete and return the Consent Form, 
Recruitment Questionnaire and Questionnaire Booklet to the researcher in the pre-paid 
envelope prior to the start of chemotherapy or radiotherapy (usually within seven days). 
Participants were also given the option to complete the questionnaire online (hosted by 
Survey Monkey). 
 
The researcher signed and dated returned Consent Forms and copies were sent to the 
breast cancer patients and to the clinic co-ordinators to be filed in the patients’ medical 
records. The questionnaires were assigned an anonymising identifier and this 
information was entered into the Microsoft Excel® spreadsheet. The researcher 
obtained the contact details for recruited participants’ General Practitioners from the 
clinical co-ordinators and a letter was sent informing them that their patients were 
involved in the study and a Participant Information Sheet was included. 
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Subsequent questionnaire booklets were posted to patients 4 months, 8 months and 12 
months later. At each follow-up time-point, a covering letter providing an update of 
participant recruitment developments (in an attempt to maintain participant interest), 
questionnaire booklet, and stamped addressed envelope were posted to participants. The 
covering letter asked participants to complete and return the questionnaire to the 
researcher within seven days and they were reminded that they were free to withdraw 
from the research at any time with no reason necessary. The researcher acknowledged 
returned completed questionnaires by a letter thanking participants for their time. The 
researcher asked the consultant oncologists to complete the Treatment Questionnaire for 
their respective breast cancer patients after follow-up time 3 so that complete treatment 
information during the study period could be obtained. A letter summarising the 
findings was disseminated to all participants following complete data analyses. 
 
5.7.2 Breast Cancer Patients Recruited from Cancer Support Groups 
Cancer support group members who responded to the study advertisements and 
expressed an interest in taking part in the research were given the option to be sent the 
Participant Information Sheet, Consent Form and questionnaire booklet by post or 
online. The online version asked participants to provide their email address, and a 
hyperlink directing the participant to the online questionnaire was sent to this email 
address. The online database was checked on a regular basis for newly completed 
questionnaires. For those who wished to complete a paper version of the questionnaire, 
a contact postal address was obtained and similar methods as described above were 
performed. Participants were thanked by email or post for their time and for sharing 
their experiences after completion of each questionnaire.  
 
5.7.3 Healthy Control Group 
Healthy control participants who responded to the study advertisements and expressed 
an interest in taking part in the research were given the option to complete either a 
paper or an online version. Similar procedures previously described were undertaken.  
5.8 Ethical Considerations 
This research was conducted in accordance with the guidelines stipulated by the ethical 
committees at Loughborough University and the NHS. This section describes the 
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ethical considerations involved in the study relating to the research design, recruitment 
strategy, data collection and analysis. 
 
Due to the applied setting of this study, the researcher discussed feasible methods of 
approaching breast cancer patients with the consultant oncologists (who agreed to 
collaborate and offered access to their patients at the NHS) and with the staff at the 
hospitals involved in the day-to-day running of the clinics. It was important that the 
study design and recruitment methods caused minimal distress to the breast cancer 
patients (e.g. not being time-consuming, inconvenient or overly burdensome) as well as 
minimal disruption to the appointment schedule at the cancer clinics. Short versions of 
validated measures were included in the questionnaire survey, where available, in an 
attempt to reduce fatigue and the time-demands placed on the participants. The majority 
of the breast cancer patients recruited for this study had recently received their 
diagnosis of the disease and were awaiting confirmation of their treatment course, while 
others had recently undergone surgery, and so this was an anxious time for many 
patients. Therefore, breast cancer patients were approached in a sensitive manner, 
provided with a clear summary of the study verbally, and offered the opportunity to ask 
any questions about the study. All participants were also given detailed written 
information about the study and had approximately seven days to consider their 
decision to participate. All participants provided informed consent to take part in the 
study and were made aware that they were free to withdraw at any time with no reason 
necessary, without their decision affecting their treatment or standard of care that they 
received. Due to the longitudinal nature of the current research, participants were 
reminded at each time-point that they could withdraw from the study at any time, with 
no reason necessary, so that they did not feel pressured into participating. In addition, 
breast cancer patients were informed that the researcher was not a healthcare 
professional and that they should contact their GP, breast cancer nurse, consultant or 
local cancer support group should they experience distress at any time. As stipulated by 
the NHS Nottingham Research Ethics Committee, the researcher informed the GPs of 
breast cancer patients recruited from NHS cancer clinics that their patients were 
involved in the study.  
 
The procedure for handling, processing, storage and destruction of data were compliant 
with the Data Protection Act 1998 and the Loughborough University data protection 
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policy. A unique identification number was allocated to each participant to protect their 
identity and was written on the questionnaires and diaries. This meant that all measures 
were anonymised and data was confidential – only the researcher could identify 
participants. This identification number was used to link data between questionnaires 
and diaries. Documents containing personal details, such as Consent Forms and an 
electronic spreadsheet containing personal data, were stored separately from 
questionnaires and diaries. All paper documents were stored securely in a locked filing 
cabinet at Loughborough University. All electronic data were stored securely on a 
password-protected computer at Loughborough University, and an electronic password-
protected spreadsheet included the participants’ contact details. The results report 
anonymous data to ensure that participants cannot be identified. 
5.9 Data Analysis 
The demographic data, treatment data and quantitative data from the questionnaire 
booklets were entered into the quantitative software package Predictive Analytics 
SoftWare (PASW) Version 18.0 and were screened for potential inputting errors as part 
of data cleaning procedures. Totals for each variable were calculated according to 
standard scoring rules for the questionnaire. Missing data for questionnaire items 
remained as blank values if the questionnaire scoring rules specified this; otherwise, 
missing values were substituted with the mean value for that variable, as recommended 
by Loewenthal (2001). This approach was considered appropriate for the current study 
since participants may have missed questionnaire items due impaired psychosocial 
and/or cognitive function (e.g. poor concentration) (Smith & Wefel, 2008). Since the 
aim of this study was to examine the psychosocial and cognitive experiences of 
participants, it was important not to exclude incomplete data unnecessarily since this 
may have distorted findings and their subsequent interpretation. 
 
Exploratory data analysis was conducted to check the suitability of data in relation to 
the assumptions associated with the specific tests used for the hypotheses. While it is 
often advised that parametric tests tend to be robust to moderate violations of 
assumptions in relatively large samples (over 30) (e.g. Field, 2009; Tabachnick & 
Fidell, 2007), a number of steps were taken to check the normality of data for all 
dependent variables (DVs). Firstly, the significance of the Shapiro-Wilk test was 
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considered. A number of DVs were not normally distributed, however this is common 
in larger samples since small deviations from normality can produce significant results 
and does not necessarily mean that the data could bias statistical analyses (Field, 2009; 
Pallant, 2007). Secondly, distributions were visually inspected using histograms with 
normality curves and Q-Q plots. These also showed that several variables were skewed. 
Therefore, the data were transformed using square root or reflect and square 
transformations to normalise the data. During hypothesis-testing, both the original 
variables and transformed variables were used in the analyses, and the results were 
compared. Since no differences in the results were found (i.e. no difference in level of 
significance or interpretation of findings), the original data are reported here. This 
allows for comparisons to be made easily with other studies and avoids potential 
confusion in interpreting transformed data values. Boxplots revealed several outliers, 
but none were considered sufficiently extreme to warrant exclusion from analysis. 
Details of specific statistical analyses conducted to test the hypotheses in Objectives 
One, Two and Three are described in Chapters Six, Seven and Eight, respectively. 
5.10 Chapter Summary 
This chapter has described the design, recruitment strategies and ethical issues involved 
in this research, as well as the measures and procedures specific to the questionnaire 
phase. The results of the questionnaire phase are presented in the following chapters. 
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Chapter Six 
The Impact of Chemotherapy for Breast Cancer on 
Psychosocial Well-Being and Subjective Cognitive Function 
6.1 Chapter Introduction 
This chapter presents the results of the questionnaire data in relation to Objective One. 
This considered the impact of chemotherapy for breast cancer on self-reported 
psychosocial well-being and cognitive function during and after treatment. Increasing 
evidence suggests that breast cancer patients undergoing chemotherapy report higher 
levels of anxiety, depression, fatigue and cognitive difficulties compared to controls 
(see Chapter Three for a review of the literature). However, many of these studies are 
criticised due to their cross-sectional design, lack of appropriate control groups, and 
their focus on objective measures, which often lack ecological validity and have 
insufficient sensitivity to detect subtle cognitive changes in the breast cancer population 
(Vardy et al., 2008). The purpose of the current study was partly to address these 
limitations. The following hypotheses are examined in this chapter: 
 
Hypothesis I: There will be differences in levels of anxiety, depression and fatigue 
between the chemotherapy group, radiotherapy group and healthy control group, and 
over time. 
 
Hypothesis II: There will be differences in subjective cognitive function scores 
between the chemotherapy group, radiotherapy group and healthy control group, and 
over time. 
 
Hypothesis III (a): Anxiety, depression and fatigue scores will be significantly 
associated with each other and with subjective cognitive function scores in the 
chemotherapy group at each time-point. 
 
Hypothesis III (b): Anxiety, depression and fatigue scores will predict subjective 
cognitive function scores in the chemotherapy group at each time-point. 
Chapter Six  Quantitative Results: Objective One 
121 
6.2 Sample Accrual 
The recruitment phase for all participants took place from July 2009 to December 2010. 
During this time, breast cancer patients about to undergo chemotherapy (n = 108) or 
radiotherapy (n = 86) were approached by the researcher at cancer clinics in Leicester 
Royal Infirmary and Nottingham City Hospital and provided with an information pack. 
In total, 67 breast cancer patients about to undergo chemotherapy and 61 breast cancer 
patients about to undergo radiotherapy met the inclusion criteria for the study, 
consented to take part and completed the recruitment questionnaire and baseline 
questionnaire (recruitment rate of 61.1% and 70.9%, respectively). Concurrently, three 
breast cancer patients were recruited via advertisements at support group centres and on 
online forums across the UK (including one chemotherapy patient; treatment data 
missing from the other two breast cancer patients who later withdrew from the study). 
Healthy controls were recruited via advertisements in the local community and using a 
snowballing technique (see Chapter Five, section 5.4.2 for further details). Due to the 
indirect nature of recruitment strategies employed for support group users and healthy 
controls (i.e. without direct presence of the researcher), it was not possible to ascertain 
sample accrual estimates. In total, 122 healthy controls met the inclusion criteria, 
consented to take part in the study and completed the recruitment questionnaire and 
baseline questionnaire. 
6.3 Sample Attrition 
Sample attrition is inevitable in longitudinal research due to time demands and 
commitment required from participants over multiple assessments, and is particularly 
present in applied research involving patient groups (see Chapter Ten for a discussion). 
Therefore, in order to minimise sample attrition and its impact on the current study, 
short versions of questionnaires were included and the researcher maintained rapport 
with participants throughout the data collection period (see Chapter Five for further 
details). Participants who failed to return the questionnaire within a week of its 
reception were contacted by telephone or email and asked if they required more time to 
complete the questionnaire or if they wished to withdraw from the study. The attrition 
associated with each participant group at follow-up time-points is described in Table 
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6.1. The fluctuation in sample size is the result of some participants not completing all 
questionnaires (typically due to feeling unwell). 
 
The final sample size included 60 chemotherapy patients, 56 radiotherapy patients, and 
58 healthy controls. For the chemotherapy group and radiotherapy group, the final 
sample was determined by excluding participant data where insufficient data was 
available to conduct repeated measures analyses. For the healthy control group, the final 
sample was determined firstly by excluding participants with any missing follow-up 
questionnaire data, and secondly if participants were not well-matched to the 
chemotherapy group in relation to age (± 2.5 years).
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Table 6.1  
Attrition at Baseline and Follow-Up Time-Points in the Chemotherapy Group, Radiotherapy Group and Healthy Control Group 
Assessment 
Chemotherapy group 
 
Radiotherapy group 
 
Healthy control group 
Completed 
questionnaires (n) 
Attrition rate 
(%) 
Completed 
questionnaires (n) 
Attrition rate 
(%) 
Completed 
questionnaires (n) 
Attrition rate 
(%) 
Baseline 67 - 
 
61 - 
 
122 - 
Follow-up time 1 55 17.91 
 
52 14.75 
 
109 10.66 
Follow-up time 2 59 10.45 
 
51 16.39 
 
104 14.75 
Follow-up time 3 57 14.93 
 
48 21.31 
 
83 31.97 
Note. Attrition rates calculated from baseline value. 
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6.4 Statistical Analyses 
This section briefly describes the statistical analyses employed in this chapter relevant 
to Objective One. 
 
Sociodemographic characteristics 
Differences in sociodemographic characteristics between participant groups were 
analysed using univariate analysis of variance (ANOVA) for continuous variables and 
Chi-square tests for independence for categorical variables.  
 
Preliminary baseline data analysis 
Preliminary analyses compared baseline scores of anxiety, depression, fatigue, and 
subjective cognitive function across the three participant groups. A series of one-way 
between-groups ANOVAs were conducted with participant group (chemotherapy, 
radiotherapy, healthy control) as the between-subjects factor and anxiety, depression, 
fatigue, and subjective cognitive function as separate DVs. Pearson’s product moment 
correlation and Spearman’s rank order correlation analyses were performed to examine 
the association between age and education with the DVs. Education (none, high school, 
university) significantly correlated with some DVs. Upon further inspection of the data, 
this variable was found to violate the assumption of regression slopes, which meant that 
it could not be included as a covariate, and instead was entered as an additional 
between-subjects factor so that its effect could be filtered out. Therefore, a series of 
two-way between-groups ANOVAs were also conducted where appropriate. 
 
Hypothesis I 
To examine any differences in levels of anxiety, depression and fatigue between the 
chemotherapy group, radiotherapy group and healthy control group over time, a series 
of 3 x 3 mixed ANOVAs were conducted with participant group as the between-
subjects factor and time (follow-up time 1, follow-up time 2, follow-up time 3) as the 
within-subjects factor. A series of 3 x 3 mixed ANCOVAs were also performed with 
the DV baseline measure as a covariate to control for differences in pre-treatment 
levels. Further analyses were conducted with a series of 3 x 3 x 3 mixed ANCOVAs 
with education as a second between-subjects factor, where relevant.  
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Hypothesis II 
To examine any differences in cognitive function between the chemotherapy group, 
radiotherapy group and healthy control group over time, a 3 x 3 mixed ANOVA was 
conducted with participant group as the between-subjects factor and time as the within-
subjects factor. Pearson’s product moment correlations were conducted between 
potential covariates (baseline measures of anxiety, depression and fatigue) and 
cognitive function. A 3 x 3 mixed ANCOVA was then conducted to control for the 
effect of covariates. 
 
Hypothesis III (a) and (b) 
For Hypothesis III (a), Pearson’s product moment correlations and Spearman’s rank 
order correlations were conducted to examine the associations between age, education, 
anxiety, depression, fatigue and cognitive function at each time-point.  
 
For Hypothesis III (b), standard multiple regressions were conducted to examine the 
ability of anxiety, depression and fatigue to predict cognitive function. Where 
demographic variables were significantly correlated with cognitive function, 
hierarchical multiple regressions were conducted with covariates entered at Step 1. 
 
Preliminary analyses were conducted to check that the assumptions underlying each of 
the statistical tests mentioned above were met. This included assumptions of normality, 
linearity, multicollinearity and homoscedasticity. An alpha level of .05 was used for all 
analyses, unless otherwise stated. Effect size statistics (e.g. phi [φ], eta squared [η2] and 
partial eta squared [ηp
2
]) are reported, where relevant, and determined using Cohen’s 
(1992) criteria: 0.10 to 0.29 is considered small, 0.30 to 0.49 is considered medium, and 
0.50 to 1.00 is considered large. 
6.5 Demographics 
Table 6.2 summarises the demographic characteristics for the three participant groups. 
Significant group differences were found for age, F(2, 171) = 11.07, p < 0.001, with 
radiotherapy patients being significantly older (M = 59.2, SD = 8.9, range 38-78) than 
chemotherapy patients (M = 51.4, SD = 10.6, range 28-73) and healthy controls (M = 
51.6, SD = 10.7, range 29-78). There were also significant group differences in the 
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highest education attained, χ²(4, N = 173) = 27.33, p < .001, φ = .40, menopausal status, 
χ²(2, N = 174) = 14.81, p = .001, φ = .29, employment status before diagnosis, χ²(4, N = 
172) = 17.52, p = .002, φ = .32, and type of occupation for those in employment, χ²(2, N 
= 110) = 12.88, p = .002, φ = .35. No significant differences existed in terms of marital 
status, χ²(2, N = 174) = .58, p = .750, φ = .06, and ethnicity, χ²(2, N = 174) = .35, p = 
.839, φ = .05. 
 
Table 6.3 summarises the cancer-related characteristics for the chemotherapy group and 
radiotherapy group. The groups significantly differed in terms of the type of breast 
cancer that the patients had, χ²(5, N = 116) = 24.27, exact p < .001, φ = .46, the stage of 
breast cancer, χ²(3, N = 116) = 36.06, p < .001, φ = .56, the grade of breast cancer, χ²(3, 
N = 116) = 40.93, exact p < .001, φ = .59, the type of surgery, χ²(3, N = 116) = 32.90, 
exact p < .001, φ = .53, the administration of radiotherapy, χ²(2, N = 116) = 5.48, exact 
p = .040, φ = .22, and the type of biological therapy received, χ²(1, N = 116) = 9.11, 
exact p = .003, φ = .28. There were no group differences in terms of the type of 
hormone therapy received by both patient groups, χ²(3, N = 116) = 2.47, exact p = .474, 
φ = .15. 
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Table 6.2 
Demographic Characteristics for the Chemotherapy Group, Radiotherapy Group and Healthy Control Group 
Variable Chemotherapy (n = 60)
a
 Radiotherapy (n = 56)
b
 Healthy (n = 58) p 
Age (years), M (SD) 51.4 (10.6) 59.2 (8.9) 51.6 (10.7) <.001 
        
Marital status, n (%)       .750 
   Single/widowed 15 (25.0) 16 (28.6) 13 (22.4)  
   Married/cohabiting 45 (75.0) 40 (71.4) 45 (77.6)  
        
Ethnicity, n (%)       .839 
   White European 58 (96.7) 55 (98.2) 56 (96.6)  
   Other 2 (3.3) 1 (1.8) 2 (3.4)  
        
Education, n (%)       <.001 
   None 11 (18.3) 11 (20.0) 2 (3.4)  
   High School 30 (50.0) 25 (45.5) 13 (22.4)  
   University 19 (31.7) 19 (34.5) 43 (74.1)  
        
Menopausal status, n (%)       .001 
   Pre-menopausal 26 (43.3) 9 (16.1) 28 (48.3)  
   Post-menopausal 34 (56.7) 47 (83.9) 30 (51.7)  
        
Employment status (pre-diagnosis), n (%)       .002 
   Full-time (≥18.5 hrs) 33 (56.9) 19 (33.9) 39 (67.2)  
   Part-time (≤18.4 hrs) 8 (13.8) 5 (8.9) 6 (10.3)  
   Not working 17 (29.3) 32 (57.1) 13 (22.4)  
        
Occupation, n (%)       .002 
   Manual 18 (43.9) 7 (29.2) 4 (8.9)  
   Non-manual 23 (56.1) 17 (70.8) 41 (91.1)  
Note. M = mean; SD = standard deviation. 
a
Missing data for one participant for the variable menopausal status and for two participants for the variable 
employment status. 
b
Missing data for one participant for the variable education.
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Table 6.3 
Treatment Details for the Chemotherapy Group and Radiotherapy Group 
 
Variable 
Chemotherapy (n = 60) Radiotherapy (n = 56) 
p 
n (%) n (%) 
Type of breast cancer     <.001
a
 
   Invasive ductal 49 (81.7) 25 (44.6)  
   Invasive lobular 4 (6.7) 7 (12.5)  
   Tubular 0 (0.0) 10 (17.9)  
   Other 5 (8.3) 8 (14.3)  
   Unknown 2 (3.3) 6 (10.7)  
      
Stage of breast cancer     <.001 
   I 15 (25.0) 39 (69.6)  
   II 24 (40.0) 8 (14.3)  
   III 18 (30.0) 1 (1.8)  
   Unknown 3 (5.0) 8 (14.3)  
      
Grade of breast cancer     <.001
a
 
   I 0 (0.0) 23 (41.1)  
   II 25 (41.7) 17 (30.4)  
   III 33 (55.0) 9 (16.1)  
   Unknown 2 (3.3) 7 (12.5)  
      
Type of surgery     <.001
a
 
   None 1 (1.7) 1 (1.8)  
   Lumpectomy 29 (48.3) 52 (92.9)  
   Mastectomy 29 (48.3) 1 (1.8)  
   Unknown 1 (1.7) 2 (3.6)  
      
Type of chemotherapy      
   FEC 24 (40.0) n/a n/a  
   FEC-T 33 (55.0) n/a n/a  
   Other 2 (3.3) n/a n/a  
   Unknown 1 (1.7) n/a n/a  
      
Radiotherapy     .040
a
 
   Not received 9 (15.0) 2 (3.6)  
   Received 50 (83.3) 54 (96.4)  
   Unknown 1 (1.7) 0 (0.0)  
      
Type of hormone therapy     .474
a
 
   Tamoxifen 19 (31.7) 17 (30.4)  
   Arimidex 15 (25.0) 10 (17.9)  
   Letrozole 3 (5.0) 1 (1.8)  
   None 23 (38.3) 28 (50.0)  
      
Type of biological therapy     .003
a
 
   Herceptin 9 (15.0) 0 (0.0)  
   None 51 (85.0) 56 (100.0)  
Note. FEC (fluorouracil, epirubicin and cyclophosphamide); FEC-T (FEC followed by 
taxotere). 
a
Exact significance test due to the violation of the minimum expected cell frequency 
assumption.
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6.6 Preliminary Baseline Data Analysis 
As an initial step, preliminary analyses were conducted on the pre-treatment baseline 
data to identify any differences between participant groups on the following DVs: 
anxiety, depression, fatigue and cognitive function. Primarily, this served to identify 
any differences in scores on these measures that could potentially be attributed to the 
impact of breast cancer diagnosis and therefore controlled for in subsequent repeated 
measures analyses. It is important that differences at baseline were not incorrectly 
attributed to the onset of chemotherapy treatment. Furthermore, since the current 
psycho-oncology literature reports inconsistent findings, with some researchers 
suggesting that cognitive difficulties exist in breast cancer patients prior to the 
commencement of chemotherapy (e.g. Ahles et al., 2008; Bender et al., 2006; 
Hermelink et al., 2007; Hurria et al., 2006; Mar Fan et al., 2005; Paraska & Bender, 
2003; Quesnel, Savard, & Ivers, 2009), while others reporting typical levels of 
cognitive function (e.g. Jenkins et al., 2006; Schagen, Muller, Boogerd, Mellenbergh, & 
van Dam, 2006; Stewart, Collins, Mackenzie, Tomiak, Verma, & Bielajew, 2008), this 
preliminary baseline data analysis provided additional contribution to this debate. In 
keeping with previous literature, and due to significant differences in age and education 
between participant groups in the current study, the impact of these demographic 
variables on the DVs were considered using correlations (see Table 6.4).  
 
Table 6.4 
Correlations Between Demographic Variables, Psychosocial Variables and Cognitive Function 
in the Chemotherapy Group (n = 60), Radiotherapy Group (n = 56) and Healthy Control 
Group (n = 58) at Baseline 
Note. Pearson’s product moment correlation performed on age; Spearman’s rank order 
correlation performed on education. 
a
Data missing for one participant due to missing education data. 
*p < .05. ** p < .01. 
 
 Chemotherapy  Radiotherapy  Healthy 
Variable Age Education  Age Education
a
  Age Education 
Anxiety 0.04 -0.40**  -0.23 0.03  -0.17 0.07 
Depression 0.08 -0.27*  -0.23 0.04  0.03 0.08 
Fatigue -0.14 0.28*  0.11 -0.24  0.05 -0.14 
Cognitive function 0.02 -0.23  -0.25 -0.05  -0.24 0.03 
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As Table 6.4 shows, education significantly correlated with anxiety, depression and 
fatigue in the chemotherapy group. In the following sections, for each DV (anxiety, 
depression, fatigue and cognitive function), a one-way between-groups ANOVA was 
conducted, followed by a two-way between-groups ANOVA with education as an 
additional factor, where relevant. Table 6.5 presents the results of these ANOVAs. 
 
Anxiety 
The one-way ANOVA showed that the three participant groups differed significantly on 
levels of anxiety at baseline with a medium effect size, F(2, 171) = 5.13, p = .007, η2 = 
.06. Post-hoc comparisons using the Bonferroni correction revealed that breast cancer 
patients about to receive chemotherapy (M = 7.50, SD = 4.38) reported significantly 
higher levels of anxiety compared to breast cancer patients about to receive 
radiotherapy (M = 5.23, SD = 4.00). There was no significant difference in anxiety 
levels between these two patient groups and healthy controls (M = 5.91, SD = 3.32).  
 
The two-way ANOVA showed similar results. There was a statistically significant main 
effect for participant group, F(2, 164) = 4.61, p =.011, ηp
2
 = .05. Post-hoc comparisons 
using the Bonferroni correction indicated that breast cancer patients about to receive 
chemotherapy (M = 7.75, SE = 0.54) reported significantly higher levels of anxiety 
compared to those about to receive radiotherapy (M = 5.56, SE = 0.55). No significant 
differences were found in anxiety levels between the patient groups and healthy 
controls (M = 5.61, SE = 0.99). There was no main effect of education on anxiety 
levels, F(2, 164) = 0.61, p = .544, ηp
2
 = .01. The overall interaction between participant 
group and education was significant, F(4, 164) = 2.69, p = .033, ηp
2
 = .06.  
 
Depression 
The Levene’s F test revealed that the homogeneity of variance assumption was not met 
for the depression variable, therefore the Welch F-test was used. The one-way ANOVA 
showed that the three participant groups did not significantly differ on levels of 
depression at baseline, Welch’s F(2, 112.84) = 2.62, p = .077, η2 = .03. 
 
The two-way ANOVA showed similar results. There was no significant interaction 
between participant group and education, F(4, 164) = 1.943, p = .106, ηp
2
 = .05, no 
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main effect of participant group, F(2, 164) = 2.62, p = .076, ηp
2 
= .03, and no main 
effect of education on depression, F(2, 164) = 1.844, p = .161, ηp
2 
= .02. 
 
Fatigue 
The Levene’s F test revealed that the homogeneity of variance assumption was not met 
for the fatigue variable, therefore the Welch F-test was used. The one-way ANOVA 
showed that the three participant groups did not significantly differ on levels of fatigue 
at baseline, Welch’s F(2, 171) = 1.383, p = .254, η2 = .02. 
 
The Levene’s F test revealed that the homogeneity of variance assumption for the two-
way ANOVA was not met, therefore the more stringent significance level (p < .01) was 
set, as recommended by Pallant (2007). Similar results were found to the one-way 
ANOVA, with no main effect of participant group, F(2, 164) = 1.033, p = .354, ηp
2
 = 
.012, no main effect of education on fatigue, F(2, 164) = .744, p = .477, ηp
2
 = .01, and 
the interaction was not considered significant at the new significance level, F(4, 164) = 
2.840, p = .026, ηp
2
 = .07. 
 
Cognitive Function 
The one-way ANOVA showed that the three participant groups did not significantly 
differ on levels of cognitive function at baseline, F(2, 171) = 1.573, p = .210, η2 = .02. 
Since education was not correlated with cognitive function in any of the participant 
groups (see Table 6.4), a two-way between-groups ANOVA was not conducted. 
 
6.6.1 Section Summary 
In summary, breast cancer patients about to receive chemotherapy, breast cancer 
patients about to receive radiotherapy and healthy controls reported similar levels of 
depression, fatigue and subjective cognitive function at pre-treatment baseline. 
However, breast cancer patients about to receive chemotherapy experienced 
significantly higher levels of anxiety compared to breast cancer patients about to 
receive radiotherapy. This significant difference remained after adjusting for education 
level. However, there was no significant difference in anxiety scores between the 
chemotherapy group and healthy control group.
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Table 6.5 
One-Way and Two-Way ANOVA Results for the Chemotherapy Group (n = 60), Radiotherapy Group (n = 56) and Healthy Control Group (n = 58) at 
Baseline 
 
 One-way ANOVA  Two-way ANOVA  
 Chemotherapy Radiotherapy Healthy   Chemotherapy Radiotherapy
a
 Healthy  
Variable M (SD) M (SD) M (SD) p  M (SE) M (SE) M (SE) p 
Anxiety 7.50 (4.38) 5.23 (4.00) 5.91 (3.32) .007  7.75 (0.54) 5.56 (0.55) 5.61 (0.99) .011 
Depression 3.58 (3.37) 2.32 (2.56) 2.91 (2.44) .077
b
  3.70 (0.39) 2.44 (0.40) 3.40 (0.72) .076 
Fatigue 41.13 (9.06) 41.79 (9.46) 43.63 (6.53) .186
b
  40.65 (1.16) 41.74 (1.19) 44.12 (2.14) .358 
Cognitive  function 34.12 (13.44) 30.09 (13.65) 33.86 (13.66) .210  - - - - - - - 
Note. The p-value for the main effect of participant group is shown for the two-way ANOVA. 
a
Data missing for one participant due to missing education data. 
b
Welch F-ratio (assumption of homogeneity of variance violated). 
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6.7 Findings from Hypothesis I 
There will be differences in levels of anxiety, depression and fatigue between the 
chemotherapy group, radiotherapy group and healthy control group, and over time. 
 
To consider the impact of chemotherapy on psychosocial well-being over time, a series 
of 3 x 3 mixed ANOVAs were conducted with participant group (chemotherapy, 
radiotherapy, healthy control group) as the between-subjects factor and time (follow-up 
time 1, follow-up time 2, follow-up time 3) as the within-subjects factor for each DV 
(anxiety, depression, fatigue). Further analyses were conducted, with the baseline 
measure for the DV as a covariate, in a series of 3 x 3 mixed ANCOVAs. In addition, a 
series of 3 x 3 x 3 mixed ANCOVAs were performed with education (none, high 
school, university) as an additional between-subjects factor to filter out the effect of this 
variable. 
 
Anxiety 
A 3 x 3 mixed ANOVA was conducted to assess the impact of chemotherapy on breast 
cancer participants’ subjective levels of anxiety over time (see Table 6.6; higher scores 
indicate higher levels of anxiety). There was no main effect for time, F(2, 308) = 0.46, 
p = .633, ηp
2 
< .01, suggesting no significant temporal changes in anxiety scores during 
treatment. There was no significant interaction between time and participant group, F(4, 
308) = 1.14, p = .340, ηp
2 
= .02. The main effect for participant group was not 
significant, F(2, 154) = 2.84, p = .061, ηp
2 
= .04, suggesting similar levels of anxiety 
scores between participant groups. 
 
The analysis was re-run as a 3 x 3 mixed ANCOVA with baseline anxiety score as a 
covariate. Although controlling for baseline anxiety measure did not change the 
significance of these results, there were deviations in the adjusted mean anxiety scores 
(see Table 6.6). For example, the ANOVA showed that the chemotherapy group scored 
higher levels of anxiety compared to the radiotherapy and healthy control group, 
whereas the ANCOVA revealed that healthy controls scored the highest levels of 
anxiety across all follow-up time-points. There was no main effect for time, F(2, 306) = 
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2.79, p = .063, ηp
2 
= .02. There was no significant interaction between treatment group 
and time, F(4, 306) = 1.26, p = .287, ηp
2
 = .02. The main effect comparing the three 
participant groups was not significant, F(2, 153) = 0.87, p = .422, ηp
2
 = .01, suggesting 
no differences in anxiety amongst the three participant groups.  
 
Further adjustment for education was examined using a 3 x 3 x 3 mixed ANCOVA with 
education as an additional between-subjects factor. Similar to previous analyses, there 
was no main effect for time, F(2, 292) = 1.67, p = .190, ηp
2 
= .01, no main effect for 
participant group, F(2, 306) = 2.79, p = .063, ηp
2 
= .02, and no interaction between these 
variables, F(2, 146) = 0.60, p = .548, ηp
2 
= .01. Overall, this suggests that the three 
participant groups exhibited comparative levels of anxiety over time (see Figure 6.1). 
 
 
Figure 6.1. Adjusted mean anxiety scores (+ SE) for the chemotherapy, radiotherapy 
and healthy control groups at each follow-up time-point. 
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As shown in Figure 6.1 above, anxiety scores were similar between participant groups 
and over time. The healthy control group in particular showed stable levels of anxiety 
over time. In contrast, radiotherapy patients showed a slight reduction in anxiety score 
from follow-up time 1 to follow-up time 2, followed by a slight increase in anxiety from 
follow-up time 2 to follow-up time 3. Interestingly, the chemotherapy group showed the 
reverse pattern. However, these changes between group and over time did not reach 
statistical significance. Therefore, this finding does not support Hypothesis I.
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Table 6.6 
Mixed ANOVA and ANCOVA Results for Anxiety for the Chemotherapy Group (n = 53), Radiotherapy Group (n = 46) and Healthy Control Group (n = 58) 
 
Type of analysis Participant group 
Follow-up  
time 1 
 Follow-up  
time 2 
 Follow-up  
time 3 
 
Factor F p ηp
2
 
M SD/SE 
 
M SD/SE 
 
M SD/SE 
 
Two-way mixed 
ANOVA 
Chemotherapy 6.38 4.22 
 
6.93 4.80 
 
6.30 4.45 
 
Time 0.46 .633 <.01 
Radiotherapy 4.65 3.91 
 
4.50 3.81 
 
5.13 3.99 
 
Group 2.84 .061 .04 
Healthy 5.85 3.69 
 
6.07 4.06 
 
5.98 3.95 
 
Time x Group 1.14 .340 .02 
 
   
 
  
 
  
 
    
Two-way mixed 
ANCOVA 
Chemotherapy 5.35 0.33 
 
6.05 0.46 
 
5.41 0.43 
 
Time 2.79 .063 .02 
Radiotherapy 5.60 0.35  5.31 0.49  5.96 0.46  Group 0.87 .422 .01 
Healthy 6.04 0.31 
 
6.23 0.44 
 
6.15 0.41 
 
Time x Group 1.26 .287 .02 
 
   
 
  
 
  
 
    
Three-way mixed 
ANCOVA 
Chemotherapy 5.42 0.35 
 
6.20 0.50 
 
5.57 0.47 
 
Time 1.67 .190 .01 
Radiotherapy
a
 5.80 0.37 
 
5.39 0.53 
 
6.09 0.49 
 
Group 0.60 .548 .01 
Healthy 6.45 0.60 
 
6.54 0.86 
 
6.47 0.81 
 
Time x Group 1.27 .283 .02 
a
Radiotherapy group, n = 45, due to missing education data. 
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Depression 
A 3 x 3 mixed ANOVA was conducted to assess the impact of chemotherapy on breast 
cancer participants’ subjective levels of depression over time (see Table 6.7; higher 
scores indicate higher levels of depression). To correct for the violation of sphericity, 
values for the Greenhouse-Geisser Epsilon are reported. There was a significant 
interaction between time and participant group, F(3.82, 294.03) = 3.42, p = .011, ηp
2 
= 
.04. There was a main effect for time, F(1.91, 294.03) = 5.57, p = .005, ηp
2 
= .04. 
Depression levels in the radiotherapy and healthy control groups remained relatively 
stable over time; however, they decreased over time in the chemotherapy group. The 
main effect for participant group was significant, F(2, 154) =12.38, p < .001, ηp
2 
= .14, 
with the chemotherapy group reporting higher levels of depression compared to the 
radiotherapy and healthy control groups at each time-point. 
 
The analysis was re-run as a 3 x 3 mixed ANCOVA with baseline depression score as a 
covariate, and again values for the Greenhouse-Geisser Epsilon are reported. There was 
a significant interaction between time and participant group, F(3.82, 292.01) = 3.28, p = 
.013, ηp
2 
= .04. The main effect for time was not significant, F(1.91, 292.01) = 2.60, p = 
.076, ηp
2 
= .02. There was a significant main effect of participant group, F(2, 153) = 
11.89, p < .001, ηp
2 
= .14. Post-hoc comparisons showed a significant difference in 
depression score between the chemotherapy group and both the radiotherapy and 
healthy control groups (p < .001). 
 
Further adjustment for education was examined using a 3 x 3 x 3 mixed ANCOVA with 
education as an additional between-subjects factor. There was no main effect for time, 
F(1.91, 278.92) = 1.39, p = .250, ηp
2 
= .01. There was a main effect for participant 
group, F(2, 146) = 8.12, p < .001, ηp
2 
= .10. Post-hoc comparisons revealed that the 
chemotherapy group scored significantly higher on levels of depression compared to the 
radiotherapy group (p = .001) and the healthy control group (p = .018). There was an 
interaction between time and participant group, F(4, 278.92) = 2.80, p = .026, ηp
2 
= .04 
(see Figure 6.2).
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Table 6.7 
Mixed ANOVA and ANCOVA Results for Depression for the Chemotherapy Group (n = 53), Radiotherapy Group (n = 46) and Healthy Control Group (n = 
58) 
Note. Greenhouse-Geisser reported due to violation of sphericity. 
a
Radiotherapy group, n = 45, due to missing education data.
Type of analysis Participant group 
Follow-up  
time 1 
 Follow-up  
time 2 
 Follow-up  
time 3 
 
Factor F p ηp
2
 
M SD/SE 
 
M SD/SE 
 
M SD/SE 
 
Two-way mixed 
ANOVA 
Chemotherapy 6.28 4.41 
 
5.23 4.50 
 
4.42 4.61 
 
Time 5.57 .005 .04 
Radiotherapy 2.48 2.89 
 
2.37 3.09 
 
2.50 3.06 
 
Group 12.38 <.001 .14 
Healthy 3.96 2.74 
 
2.97 2.95 
 
2.62 2.91 
 
Time x Group 3.42 .011 .04 
 
   
 
  
 
  
 
    
Two-way mixed 
ANCOVA 
Chemotherapy 5.73 0.35 
 
4.70 0.39 
 
3.87 0.38 
 
Time 2.60 .079 .02 
Radiotherapy 3.06 0.37  2.93 0.42  3.08 0.41  Group 11.89 <.001 .14 
Healthy 3.04 0.33 
 
3.00 0.37 
 
2.66 0.36 
 
Time x Group 3.28 .013 .04 
 
   
 
  
 
  
 
    
Three-way mixed 
ANCOVA 
Chemotherapy 5.80 0.38 
 
4.76 0.42 
 
3.91 0.42 
 
Time 1.39 .250 .01 
Radiotherapy
a
 3.17 0.41  2.85 0.45  3.12 0.44  Group 8.12 <.001 .10 
Healthy 2.89 0.66 
 
3.29 0.74 
 
2.81 0.72 
 
Time x Group 2.80 .029 .04 
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Figure 6.2. Adjusted mean depression scores (+ SE) for the chemotherapy, radiotherapy 
and healthy control groups at each follow-up time-point. 
 
As shown in Figure 6.2 above, chemotherapy patients experienced relatively high levels 
of depression at follow-up time 1, which decreased at follow-up time 2. Depression 
scores continued to decrease at follow-up time 3 and reached more similar levels 
reported by the radiotherapy group and healthy control group. Radiotherapy patients 
and healthy controls experienced similar levels of depression and with minimal 
fluctuation over time. This finding supports Hypothesis I. 
 
Fatigue 
A 3 x 3 mixed ANOVA was conducted to assess the impact of chemotherapy on breast 
cancer participants’ subjective levels of fatigue over time (see Table 6.8; higher scores 
indicate better fatigue). To correct for the violation of sphericity, values for the 
Greenhouse-Geisser Epsilon are reported. For this measure the higher the score 
indicates less fatigue. There was a significant interaction between time and participant 
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group, F(3.83, 294.84) = 5.36, p < .001, ηp
2 
= .07. There was a main effect for time, 
F(1.92, 294.84) = 17.32, p < .001, ηp
2 
= .10. The level of fatigue in the radiotherapy and 
healthy control groups remained relatively stable over time; however, fatigue scores 
increased over time in the chemotherapy group indicating a reduction in fatigue over 
time. The main effect for participant group was significant, F(2, 154) =15.22, p < .001, 
ηp
2 
= .17, with the chemotherapy group reporting lower scores on this measure (higher 
levels of fatigue) compared to the radiotherapy and healthy control groups at each time-
point. 
 
The analysis was re-run as a 3 x 3 mixed ANCOVA with baseline fatigue score as a 
covariate, and again values for the Greenhouse-Geisser Epsilon are reported. There was 
a significant interaction between time and participant group, F(3.81, 291.28) = 5.31, p < 
.001, ηp
2 
= .07. The main effect for time was not significant, F(1.90, 291.28) = 2.00, p = 
.139, ηp
2 
= .01. However, post-hoc comparisons revealed a significant difference in 
fatigue scores between follow-up time 1 and follow-up time 2 (p < .001) and follow-up 
time 3 (p < .001). There was a significant main effect of participant group, F(2, 153) = 
17.44, p < .001, ηp
2 
= .19. Post-hoc comparisons showed a significant difference in 
fatigue scores between the chemotherapy group and both the radiotherapy group (p < 
.001) and healthy control group (p < .001), suggesting that the chemotherapy group 
experienced lower scores on this measure (higher levels of fatigue). 
 
Further adjustment for education was examined using a 3 x 3 x 3 mixed ANCOVA with 
education as an additional between-subjects factor. There was no main effect for time, 
F(1.90, 277.41) = 1.59, p = .208, ηp
2 
= .01. There was a main effect for participant 
group, F(2, 146) = 10.20, p < .001, ηp
2 
= .12. Post-hoc comparisons revealed that the 
chemotherapy group scored significantly lower on the FACIT-F, indicating higher 
fatigue, compared to the radiotherapy group (p < .001) and the healthy control group (p 
= .020) (see Figure 6.3). There was an interaction between time and participant group, 
F(3.8, 277.41) = 3.88, p = .005, ηp
2 
= .05. 
 
As shown in Figure 6.3 below, chemotherapy patients experienced higher levels of 
fatigue at follow-up time 1, which reduced at follow-up time 2. Levels of fatigue 
continued to reduce by follow-up time 3 to reach similar levels reported by the 
radiotherapy group and healthy control group. Radiotherapy patients and healthy 
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controls experienced similar levels of fatigue to each other and with relatively little 
change over time. This finding supports Hypothesis I. 
 
 
Figure 6.3. Adjusted mean fatigue scores (+ SE) for the chemotherapy, radiotherapy 
and healthy control groups at each follow-up time-point. 
 
6.7.1 Section Summary 
In summary, Hypothesis I was partially supported. All three participant groups 
experienced similar levels of anxiety, with minimal temporal changes over follow-up 
time-points. However, breast cancer patients in the chemotherapy group reported 
considerably higher levels of depression and fatigue compared to the radiotherapy 
group and the healthy control group at follow-up time 1. By follow-up time 2, levels of 
depression and fatigue reduced and by follow-up time 3 scores were similar to those 
reported in the radiotherapy group and healthy control group. 
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Table 6.8 
Mixed ANOVA and ANCOVA Results for Fatigue for the Chemotherapy Group (n = 53), Radiotherapy Group (n = 46) and Healthy Control Group (n = 58) 
 
Note. Greenhouse-Geisser reported due to violation of sphericity. 
a
Radiotherapy group, n = 45, due to missing education data.
Type of analysis Participant group 
Follow-up  
time 1 
 Follow-up  
time 2 
 Follow-up  
time 3 
 
Factor F p ηp
2
 
M SD/SE 
 
M SD/SE 
 
M SD/SE 
 
Two-way mixed 
ANOVA 
Chemotherapy 28.54 12.48 
 
35.07 13.34 
 
36.19 12.37 
 
Time 17.32 <.001 .10 
Radiotherapy 40.72 10.73 
 
42.56 10.88 
 
42.46 10.80 
 
Group 15.22 <.001 .17 
Healthy 41.43 8.19  43.01 7.84  42.62 8.98  Time x Group 5.36 <.001 .07 
 
   
 
  
 
  
 
    
Two-way mixed 
ANCOVA 
Chemotherapy 29.70 1.17 
 
36.40 1.13 
 
37.28 1.24 
 
Time 2.00 .137 .01 
Radiotherapy 40.41 1.25 
 
42.20 1.20 
 
42.16 1.33 
 
Group 17.44 <.001 .19 
Healthy 40.61 1.12 
 
42.08 1.07 
 
41.85 1.19 
 
Time x Group 5.31 <.001 .07 
 
   
 
  
 
  
 
    
Three-way mixed 
ANCOVA 
Chemotherapy 30.35 1.28  37.06 1.20  37.98 1.35  Time 1.59 .207 .01 
Radiotherapy
a
 40.28 1.35 
 
42.49 1.27 
 
42.33 1.42 
 
Group 10.20 <.001 .12 
Healthy 40.86 2.22 
 
41.20 2.08 
 
40.69 2.34 
 
Time x Group 4.42 <.001 .06 
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6.8 Findings from Hypothesis II 
There will be differences in subjective cognitive function scores between the 
chemotherapy group, radiotherapy group and healthy control group, and over time. 
 
The second hypothesis examined the impact of chemotherapy on subjective cognitive 
function. Correlations previously conducted between the study variables revealed no 
relationship between age and education with cognitive function in all participant groups 
(see Table 6.4), thus these demographic variables were not included as covariates. A 
number of studies have demonstrated that anxiety, depression and fatigue are associated 
with subjective cognitive function (e.g. Bender et al., 2008; Castellon et al., 2004). 
Therefore, baseline measures of these psychosocial variables were considered as 
potential covariates and Pearson’s product moment correlations were conducted with 
baseline cognitive function scores for each participant group. Table 6.9 shows that 
anxiety, depression and fatigue were significantly associated with cognitive function in 
all participant groups. Therefore, these psychosocial variables were included as 
covariates in a mixed ANCOVA in order to filter out their effect. 
 
Table 6.9 
Correlations Between Psychosocial Variables and Cognitive Function in the Chemotherapy 
Group (n = 60), Radiotherapy Group (n = 56) and Healthy Control Group (n = 58) at Baseline 
 
Variable 
Chemotherapy 
 
Radiotherapy 
 
Healthy 
Cognitive function 
 
Cognitive function 
 
Cognitive function 
Anxiety 
0.46*  0.46*  0.55* 
Depression 
0.51*  0.52*  0.37* 
Fatigue 
-0.45*  -0.43*  -0.38* 
* p < .01 (two-tailed). 
 
First, a 3 x 3 mixed ANOVA was conducted to assess the impact of chemotherapy on 
breast cancer participants’ subjective levels of cognitive function over time (see Table 
6.10; higher scores indicate higher frequency of cognitive failures). The interaction 
between time and participant group was not significant, F(4, 308) = 0.62, p = .650, ηp
2 
= 
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.01. There was no main effect for time, F(2, 308) = 0.77, p = .465, ηp
2 
= .01, suggesting 
that cognitive function scores remained relatively stable over time. The main effect for 
participant group was marginally significant, F(2, 154) =3.10, p < .05, ηp
2 
= .04, with 
the chemotherapy group reporting significantly more cognitive difficulties compared to 
the radiotherapy group. 
 
The analysis was re-run as a 3 x 3 mixed ANCOVA with baseline anxiety, depression, 
fatigue and cognitive function scores as covariates. There was no main effect for time, 
F(2, 300) = 0.12, p = .983, ηp
2 
< .01. There was no significant interaction between 
treatment group and time, F(4, 300) = 0.57, p = .683, ηp
2
 = .01. The main effect 
comparing the three participant groups was not significant, F(2, 150) = 1.91, p = .152, 
ηp
2
 = .03, suggesting no significant differences in cognitive function score across the 
three participant groups (see Figure 6.4). 
 
Figure 6.4. Adjusted mean cognitive function scores (+ SE) for the chemotherapy, 
radiotherapy and healthy control groups at each follow-up time-point. 
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Figure 6.4 above shows that chemotherapy patients experienced relatively high levels of 
cognitive impairment at follow-up time 1, which remained stable by follow-up time 2. 
However, by follow-up time 3, the frequency of cognitive failures declined. 
Radiotherapy patients and healthy controls exhibited similar levels of cognitive function 
to each, with minimal temporal fluctuation.  
 
6.8.1 Section summary 
In summary, Hypothesis II was not supported. Although there were subtle differences in 
cognitive function scores between the chemotherapy group and the two control groups, 
these did not reach statistical significance level.
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Table 6.10 
Mixed ANOVA and ANCOVA Results for Cognitive Function for the Chemotherapy Group (n = 53), Radiotherapy Group (n = 46) and Healthy Control 
Group (n = 58) 
Type of analysis Participant group 
Follow-up  
time 1 
 Follow-up  
time 2 
 Follow-up  
time 3 
 
Factor F p ηp
2
 
M SD/SE 
 
M SD/SE 
 
M SD/SE 
 
Two-way mixed 
ANOVA 
Chemotherapy 39.43 16.68 
 
39.62 16.57 
 
37.26 19.48 
 
Time 0.77 .465 <.01 
Radiotherapy 31.96 16.49 
 
30.76 16.95 
 
31.00 14.53 
 
Group 3.10 .048 .04 
Healthy 34.48 13.88 
 
35.14 15.73 
 
34.67 15.89 
 
Time x Group 0.62 .650 .01 
 
   
 
  
 
  
 
    
Two-way mixed 
ANCOVA 
Chemotherapy 37.98 1.57 
 
37.89 1.56 
 
35.60 1.58 
 
Time 0.02 .983 <.01 
Radiotherapy 34.83 1.69 
 
33.91 1.67 
 
34.16 1.70 
 
Group 1.91 .152 .03 
Healthy 33.53 1.49 
 
34.23 1.47 
 
33.69 1.50 
 
Time x Group 0.57 .683 <.01 
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6.9 Findings from Hypothesis III (a) 
Anxiety, depression and fatigue scores will be significantly associated with each other 
and with subjective cognitive function scores in the chemotherapy group at each 
time-point. 
 
Research has shown that anxiety, depression and fatigue are associated with subjective 
cognitive difficulties in breast cancer patients (e.g. Bender et al., 2008; Castellon, Ganz, 
Bower, Petersen, Abraham, & Greendale, 2004; van Dam et al., 1998). Hypothesis III 
(a) examines the associations between demographic variables (age and education), 
psychosocial variables (anxiety, depression and fatigue) and cognitive function at each 
time-point in the chemotherapy group. The purpose of this hypothesis is twofold: first, 
to consider potential changes in the relationship between these variables over time, 
which has received little attention in previous literature; and second, to identify 
significant correlations amongst variables to be included in regression analyses in 
Hypothesis III (b). Pearson’s product moment correlations (r) were conducted, except 
for correlations including education, where Spearman’s rank order correlations (rѕ) were 
performed. 
 
Correlations at Baseline 
Table 6.11 shows that psychosocial variables were significantly correlated with each 
other and with cognitive function in the chemotherapy group at pre-treatment baseline. 
Age and education were not significantly correlated with cognitive function.  
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Table 6.11  
Correlations Between Psychosocial Variables and Cognitive Function in the Chemotherapy 
Group at Baseline (n = 60) 
Variable Age Education Anxiety Depression Fatigue 
Anxiety 0.04 -0.40**    
Depression 0.08 -0.27* 0.78**   
Fatigue -0.14 0.28* -0.55** -0.71**  
Cognitive function 0.02 -0.23 0.46** 0.51** -0.45** 
Note. Spearman’s rank order correlation performed on education; Pearson’s product moment 
correlation performed on all other variables. 
*p < .05. ** p < .01. 
 
Correlations at Follow-Up Time 1 
Table 6.12 shows that psychosocial variables were significantly correlated with each 
other and with cognitive function in the chemotherapy group at follow-up time 1.  
Education was also significantly correlated with cognitive function. 
 
Table 6.12 
Correlations Between Psychosocial Variables and Cognitive Function in the Chemotherapy 
Group at Follow-Up Time 1 (n = 55) 
Variable Age Education Anxiety Depression Fatigue 
Anxiety -0.08 -0.45**    
Depression -0.11 -0.30* 0.58**   
Fatigue 0.05 0.22 -0.45** -0.73**  
Cognitive function -0.24 -0.29* 0.50** 0.43** -0.41** 
Note. Spearman’s rank order correlation performed on education; Pearson’s product moment 
correlation performed on all other variables. 
*p < .05. ** p < .01. 
 
Correlations at Follow-Up Time 2 
Table 6.13 shows that psychosocial variables were strongly correlated with each other 
and with cognitive function in the chemotherapy group at follow-up time 2. Age and 
education were also significantly correlated with cognitive function. 
 
 
 
 
 
 
Chapter Six  Quantitative Results: Objective One 
149 
Table 6.13 
Correlations Between Psychosocial Variables and Cognitive Function in the Chemotherapy 
Group at Follow-Up Time 2 (n = 59) 
Variable Age Education Anxiety Depression Fatigue 
Anxiety -0.16 -0.39**    
Depression -0.13 -0.33* 0.79**   
Fatigue 0.16 0.34** -0.73** -0.89**  
Cognitive function -0.34** -0.29* 0.72** 0.70** -0.63** 
Note. Spearman’s rank order correlation performed on education; Pearson’s product moment 
correlation performed on all other variables. 
*p < .05. ** p < .01. 
 
Correlations Follow-Up Time 3 
Table 6.14 shows that psychosocial variables were strongly correlated with each other 
and with cognitive function in the chemotherapy group at follow-up time 3. Age and 
education were not significantly correlated with cognitive function. 
 
Table 6.14 
Correlations Between Psychosocial Variables and Cognitive Function in the Chemotherapy 
Group at Follow-Up Time 3 (n = 57) 
Variable Age Education Anxiety Depression Fatigue 
Anxiety -0.15 -0.35**    
Depression -0.12 -0.31* 0.76**   
Fatigue 0.13 0.29* -0.65** -0.82**  
Cognitive function -0.12 -0.25 0.61** 0.74** -0.64** 
Note. Spearman’s rank order correlation performed on education; Pearson’s product moment 
correlation performed on all other variables. 
*p < .05. ** p < .01. 
 
6.9.1 Section Summary 
In summary, these findings support Hypothesis III (a). Psychosocial variables (anxiety, 
depression and fatigue) were found to be significantly correlated with each other and 
with cognitive function, suggesting that perceived poorer cognitive function was related 
to higher levels of anxiety, depression and fatigue at each time-point.  
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6.10 Findings from Hypothesis III (b) 
Anxiety, depression and fatigue scores will predict subjective cognitive function score 
in the chemotherapy group at each time-point. 
 
Standard multiple or hierarchical regression analyses were conducted at each time-point 
to identify predictors for cognitive function in the chemotherapy group. Standard 
multiple regressions were performed when age and education were not found to be 
significantly correlated with cognitive function in Hypothesis III (a). Where they were 
found to be significantly correlated, hierarchical multiple regressions were performed 
with age and/or education were entered as covariates in the first step, followed by 
anxiety, depression and fatigue in the second step. 
 
Regression at Baseline 
Standard multiple regression was used to assess the ability of anxiety, depression and 
fatigue to predict cognitive function (see Table 6.15). These predictors explained a 
significant proportion of the variance in cognitive function scores at baseline, adjusted 
R
2
 = .24, F (3, 56) = 7.35, p < .001. However, anxiety, depression and fatigue were not 
statistically significant unique predictors of cognitive function. This finding does not 
support Hypothesis III (b). 
 
Table 6.15 
Standard Multiple Regression Analysis for Anxiety, Depression and Fatigue Predicting 
Cognitive Function in the Chemotherapy Group at Baseline (n = 60) 
 
Variable B SE B Β 
Constant 37.38 11.83  
Anxiety 0.48 0.56 .16 
Depression 1.04 0.86 .26 
Fatigue -0.26 0.24 -.17 
Note. R
2 = .28, ∆R2 = .24 (p < .001). 
 
Regression at Follow-Up Time 1 
Hierarchical regression was used to assess the ability of anxiety, depression and fatigue 
to predict cognitive function after controlling for education (see Table 6.16). Education 
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was entered at Step 1 and explained 9% of the variance in cognitive function scores. 
Anxiety, depression and fatigue were entered at Step 2 and the total variance explained 
by the model as a whole was 25%, F (4, 50) = 5.46, p = .001. Anxiety, depression and 
fatigue explained an additional 22% of the variance in cognitive function, after 
controlling for education, R
2 
change = .22, F change (3, 50) = 5.17, p < .005. In the 
final model, anxiety (β = .36, t = 2.14, p < .05) was a statistically significant predictor 
of cognitive function. This finding partially supports Hypothesis III (b). 
 
Table 6.16 
Hierarchical Regression Analysis for Anxiety, Depression and Fatigue Predicting Cognitive 
Function in the Chemotherapy Group at Follow-Up Time 1 (n = 55) 
 
Variable B SE B Β 
Step 1    
   Constant 47.53 4.17  
   Education -7.09 3.14 -.30* 
Step 2    
   Constant 41.85 11.77  
   Education -1.94 3.20 -.08 
   Anxiety 1.37 0.64 .36* 
   Depression 0.02 0.77 <.01 
   Fatigue -0.32 0.23 -.24 
Note. R
2 
= .09 for Step 1 (p < .05)., ∆R2 = .25 for Step 2 (p = .001). 
*p < .05. 
 
Regression at Follow-Up Time 2 
Hierarchical regression was used to assess the ability of anxiety, depression and fatigue 
to predict quality of life after controlling for age and education (see Table 6.17). Age 
and education was entered at Step 1 and explained 22% of the variance in cognitive 
function. Anxiety, depression and fatigue were entered at Step 2 and the total variance 
explained by the model as a whole was 58%, F (5, 53) = 17.24, p < .001. Anxiety, 
depression and fatigue explained an additional 38% of the variance in cognitive 
function, after controlling for age and education, R
2 
change = .38, F change (3, 53) = 
17.50, p < .001. In the final model, age (β = -.25, t = -2.74, p < .01) and anxiety (β = 
.40, t = 2.77, p < .01) were statistically significant. This finding partially supports 
Hypothesis III (b). 
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Table 6.17 
Hierarchical Regression Analysis for Anxiety, Depression and Fatigue Predicting Cognitive 
Function in the Chemotherapy Group at Follow-Up Time 2 (n = 59) 
 
Variable B SE B Β 
Step 1    
   Constant 87.15 11.58  
   Age -0.69 0.20 -.42*** 
   Education -9.22 2.99 -.37** 
Step 2    
   Constant 43.94 15.02  
   Age -0.41 0.15 -.25* 
   Education -1.77 2.45 -.07 
   Anxiety 1.49 0.54 .40* 
   Depression 1.46 0.81 .37 
   Fatigue 0.06 0.25 .05 
Note. R
2 
= .24 for Step 1 (p < .001)., ∆R2 = .58 for Step 2 (p < .001). 
*p < .01. **p < .005. ***p = .001. 
 
Regression at Follow-Up Time 3 
Standard multiple regression was used to assess the ability of anxiety, depression and 
fatigue to predict cognitive function (see Table 6.18). These predictors explained a 
significant proportion of the variance in cognitive function scores at follow-up time 3, 
adjusted R
2
 = .56, F (3, 53) = 22.14, p < .001. Depression (β = .57, t = 3.03, p < .005) 
was a statistically significant predictor of cognitive function. This finding partially 
supports Hypothesis III (b). 
 
Table 6.18 
Standard Multiple Regression Analysis for Anxiety, Depression and Fatigue Predicting 
Cognitive Function at Follow-Up Time 3 (n = 57) 
 
Variable B SE B Β 
Constant 30.45 12.52  
Anxiety 0.51 0.66 .11 
Depression 2.54 0.84 .57* 
Fatigue -0.19 0.26 -.11 
Note. R
2 = .56, ∆R2 = .53 (p < .001). 
*p < .005. 
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6.10.1 Section Summary 
In summary, these findings partially support Hypothesis III (b). Only anxiety was found 
to predict cognitive function scores at follow-up time 1 and at follow-up time 2 (in 
addition to age). Only depression was found to significantly predict cognitive function 
at follow-up time 3. 
6.11 Chapter Summary 
This chapter presented the results of the first objective, which examined the impact of 
chemotherapy for breast cancer on levels of anxiety, depression, fatigue and cognitive 
function during and after treatment. Preliminary analyses showed no differences in 
these variables between groups at baseline except for anxiety. Breast cancer patients 
about to receive chemotherapy experienced significantly higher levels of anxiety 
compared to breast cancer patients about to receive radiotherapy, but they were of a 
similar level to those reported by the healthy control group. These findings could be 
taken to suggest that there are generally no pre-existing differences in levels of anxiety, 
depression, fatigue and cognitive function in breast cancer patients and healthy controls. 
In addition, these results suggest that there is a minimal impact of breast cancer 
diagnosis on levels of anxiety, depression, fatigue and cognitive function.  
 
Hypothesis I was partially supported. Although there were no significant differences in 
levels of anxiety between participant groups and over time, chemotherapy patients did 
report significantly higher levels of depression and fatigue compared to the two control 
groups at follow-up time 1. This suggests that the administration of chemotherapy may 
increase feelings of depression and fatigue, particularly at four months into the 
treatment. However, this effect is temporary, as depression and fatigue scores resumed 
to normal levels by follow-up time 3.  
 
Hypothesis II was not supported. There was no significant difference in cognitive 
function scores between participant groups or over time. This finding suggests that 
chemotherapy does not impact upon subjective cognitive function in breast cancer 
patients. 
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Hypothesis III (a) was supported. Results suggest that anxiety, depression, fatigue and 
cognitive function were highly correlated with each other. Hypothesis III (b) was 
partially supported. Anxiety was found to predict cognitive function at follow-up time 1 
and follow-up time 2, whereas depression was found to predict cognitive function at 
follow-up time 3. Fatigue was not found to significantly predict cognitive function. A 
comprehensive discussion of these results is presented in Chapter Ten. 
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Chapter Seven 
The Impact of Chemotherapy for Breast Cancer on Safety 
Outcomes in the Home and Workplace 
7.1 Chapter Introduction 
This chapter presents the results of the questionnaire data in relation to Objective Two. 
This considered the impact of chemotherapy for breast cancer on accident frequency in 
the home and workplace during and after treatment. Findings from Chapter Six 
suggested that the chemotherapy group experienced higher levels of depression and 
fatigue compared to the radiotherapy group and healthy control group. As discussed in 
Chapter Four, there is a wealth of literature from a number of research areas that has 
demonstrated an association between these variables and an increase in the frequency of 
accidents. To the researcher’s knowledge, the experience of accidents related to 
psychological predictors has not currently been examined in the breast cancer patient 
population. Therefore, to address this current research gap, the following hypotheses are 
examined in this chapter: 
 
Hypothesis IV: Breast cancer patients undergoing chemotherapy will report more 
incidences of accidents at all follow-up time-points compared to treatment and healthy 
controls.  
 
Hypothesis V (a): Demographic, psychosocial, and cognitive function variables will be 
significantly associated with accident frequency in the chemotherapy group at each 
time-point. 
 
Hypothesis V (b): Demographic, psychosocial, and cognitive function variables will 
predict accident frequency in the chemotherapy group at each time-point. 
7.2 Statistical Analyses 
This section briefly describes the statistical analyses employed in this chapter relevant 
to Objective Two. 
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Hypothesis IV 
For Hypothesis IV, Chi-square tests were conducted to compare the frequency of 
accidents between participant groups at each time-point. The distribution of accident 
frequency at each time-point is also presented in histograms. Accidents occurring in the 
home are examined first, followed by accidents in the workplace. 
 
Hypothesis V (a) and  (b) 
For Hypothesis V (a), Spearman’s rank order correlations were performed at each time-
point to examine which variables were associated with accidents in the chemotherapy 
group. For Hypothesis V (b), logistic regression analyses were conducted at each time-
point with variables found to be significantly correlated with accidents entered as 
predictors. 
 
Preliminary checks revealed that the assumptions underlying Chi-square, Spearman’s 
rank order correlations and logistic regression were met, unless otherwise stated. An 
alpha level of .05 was used for all analyses, unless otherwise stated. 
7.3 Findings from Hypothesis IV  
Breast cancer patients undergoing chemotherapy will report more incidences of 
accidents at all follow-up time-points compared to treatment and healthy controls. 
 
7.3.1 Frequency of Accidents in the Home 
This section presents the results of the frequency of accidents experienced by 
participants in the home over the study period. A 3 x 5 Chi-square test for independence 
was conducted at each time-point. The minimum expected cell frequency assumption 
was violated in each analysis, since less that 80% of cells had expected frequencies of 5 
or more; therefore, an exact significance test was selected for Pearson’s Chi-square 
(Brace et al., 2009). Figure 7.1 shows the frequency of accidents in the home for each 
participant group at baseline (A), follow-up time 1 (B), follow-up time 2 (C), and 
follow-up time 3 (D). 
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Baseline 
The chemotherapy group (n = 60), radiotherapy group (n = 56) and healthy control 
group (n = 58) did not significantly differ in terms of frequency of accidents at baseline, 
χ²(6, N = 174) = 5.66, exact p = .47. The majority of participants in each group reported 
experiencing no accidents in the home during the previous week: 42 (70.0%) breast 
cancer patients about to receive chemotherapy, 44 (78.6%) breast cancer patients about 
to receive radiotherapy, and 36 (62.1%) healthy controls (see Figure 7.1, A). Thirteen 
(21.7%) chemotherapy patients, 10 (17.9%) radiotherapy patients, and 16 (27.6%) 
healthy controls reported that they had rarely experienced accidents, while 5 (8.3%) 
chemotherapy patients, 2 (3.6%) radiotherapy patients, and 5 (8.6%) healthy controls 
reported that they had occasionally experienced accidents in the preceding week. Only 
1 (1.7%) participant in the healthy control group reported having experienced accidents 
often, and no participants reported having accidents all the time. 
 
Follow-Up Time 1 
The chemotherapy group (n = 55), radiotherapy group (n = 52) and healthy control 
group (n = 57) marginally differed in their experience of frequency of accidents, χ²(8, N 
= 164) = 14.57, exact p < .05. Similar to baseline accounts, the vast majority of 
participants in each group reported having experienced no accidents in the previous 
week (see Figure 7.1, B). However, it is important to also compare subtle temporal 
changes within participant groups, as well as between these groups. Compared to 
baseline accounts, fewer breast cancer patients (now generally four months into their 
chemotherapy treatment) reported having experienced no accidents: only 29 (52.7%) 
patients, compared to 70.0% chemotherapy patients at baseline. Also, fewer 
radiotherapy patients, 34 (65.4%) reporting having experienced no accidents, compared 
to 78.6% of radiotherapy patients at baseline. In the opposite trend, there was a slight 
increase in the reporting of no accidents by healthy controls compared to baseline 
reports: now 38 (66.7%) healthy controls reported having experienced no accidents, 
compared to 62.1% of healthy controls at baseline. A similar proportion of participants 
reported rarely experiencing accidents: 11 (20.0%) chemotherapy patients, 12 (23.1%) 
radiotherapy patients, and 14 (24.6%) healthy controls. There was an increase in the 
number of chemotherapy patients and radiotherapy patients reporting that they 
occasionally have accidents: 9 (16.4%) chemotherapy patients and 6 (11.5%) 
radiotherapy patients. The same number of healthy controls reported occasionally 
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having accidents as baseline: 5 (8.8%). No radiotherapy patients or healthy controls 
reported experiencing accidents often or all the time. However, 5 (9.1%) chemotherapy 
patients reported experiencing accidents often and 1 (1.8%) reported such incidences all 
the time. 
 
Follow-Up Time 2 
There was no significant difference between the chemotherapy group (n = 58), 
radiotherapy group (n = 52) and healthy control group (n = 58) in the frequency of 
accidents reported at follow-up time 2, χ²(6, N = 168) = 10.40, exact p = .11. For the 
chemotherapy group, the trend for the number of participants reporting no accidents 
continued to decrease: 24 (41.4%) participants (see Figure 7.1, C). Thirty-six (69.2%) 
radiotherapy patients and 32 (55.2%) healthy controls reported having experienced no 
accidents during the previous week. Twenty-one (36.2%) chemotherapy patients 
reported accidents occurring rarely, compared to 13 (25.0%) radiotherapy patients, and 
16 (27.6%) healthy controls. Ten (17.2%) chemotherapy patients occasionally 
experienced accidents, compared to only two (3.8%) radiotherapy patients and eight 
(13.8%) healthy controls. Three (5.2%) chemotherapy patients reported accidents often, 
so did one (1.9%) radiotherapy patient and two (3.4%) healthy controls. No participants 
reported experiencing accidents all the time. 
 
Follow-Up Time 3 
At follow-up time 3, there was a significant difference in frequency of accidents 
between the chemotherapy group (n = 56), radiotherapy group (n = 48) and healthy 
control group (n = 58), χ²(6, N = 163) = 14.58, exact p < .05. Compared to the previous 
time-point, similar numbers of radiotherapy patients and healthy controls reported never 
experiencing accidents: 36 (73.5%) and 31 (53.4%), respectively (see Figure 7.1, D). 
However, there was an increase in the number of chemotherapy patients reporting no 
accidents in the previous week: 28 (50.0%). Thirteen (23.2%) chemotherapy patients, 
10 (22.4%) radiotherapy patients and 19 (32.8%) healthy controls reported accidents 
occurring rarely. A relatively large proportion of chemotherapy patients reporting 
experiencing accidents occasionally: 14 (25.0%), compared to 1 (2.0%) radiotherapy 
patient and 7 (12.1%) healthy controls. One chemotherapy patient, one radiotherapy 
patient and one healthy control reported often experiencing accidents: 1.8%, 2.0% and 
1.7%, respectively. 
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Frequency of accidents 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1. Frequency of accidents in the home reported (A) in the CT group (n = 60), RT group (n = 56), and HC group (n = 58) at pre-treatment baseline; (B) in the CT 
group (n = 55), RT group (n = 52), and HC group (n = 57) at follow-up time 1; (C) in the CT group (n = 58), RT group (n = 52), and HC group (n = 58) at follow-up time 2, 
and (D) in the CT group (n = 56), RT group (n = 48), and HC group (n = 58) at follow-up time 3.
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7.3.2 Frequency of Accidents in the Workplace 
This section presents the results of the frequency of accidents experienced by participants in 
the workplace over the study period. A 3 x 5 Chi-square test for independence was conducted 
at each time-point. The minimum expected cell frequency assumption was violated in each 
analysis, since less that 80% of cells had expected frequencies of 5 or more; therefore, an 
exact significance test was selected for Pearson’s Chi-square. Figure 7.2 shows the frequency 
of accidents in the workplace for each participant group at baseline (A), follow-up time 1 (B), 
follow-up time 2 (C), and follow-up time 3 (D). 
 
Baseline 
The chemotherapy group (n = 14), radiotherapy group (n = 15) and healthy control group (n = 
44) did not differ in terms of frequency of accidents at baseline, χ²(4, N = 73) = 5.13, exact p 
= .25. The majority of participants in each group reported experiencing no accidents in the 
workplace during the previous week: 10 (71.4%) breast cancer patients about to receive 
chemotherapy, 15 (100.0%) breast cancer patients about to receive radiotherapy, and 38 
(86.4%) healthy controls (see Figure 7.2, A). Three (21.4%) chemotherapy patients and four 
(9.1%) healthy controls reported that they had rarely experienced accidents. One (7.1%) 
chemotherapy patients, two (4.5%) healthy controls reported that they had occasionally 
experienced accidents in the preceding week. There were no reports in any participant group 
of experiencing accidents often or all the time while at work. 
 
Follow-Up Time 1 
At follow-up time 1, the chemotherapy group (n = 12), radiotherapy group (n = 20) and 
healthy control group (n = 44) did not differ in frequency of accidents, χ²(4, N = 76) = 3.4, 
exact p = .52. Similar to baseline accounts, the vast majority of participants in each group 
reported having experienced no accidents in the previous week (see Figure 7.2, B). Nine 
(75.0%) breast cancer patients in the chemotherapy group reported (now four months into 
their chemotherapy treatment) reported no accidents, as did 19 (95.0%) radiotherapy patients 
and 37 (84.11%) healthy controls. Only three (25%) chemotherapy patients, one (5.0%) 
radiotherapy patient and six (13.6%) healthy controls reported having experienced accidents 
rarely in the workplace. None of the chemotherapy or radiotherapy patients and only one 
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(2.3%) healthy control reported accidents occasionally in the workplace. There were no 
reports of accidents occurring more frequently than this. 
 
Follow-Up Time 2 
There was no difference between the chemotherapy group (n = 29), radiotherapy group (n = 
17) and healthy control group (n = 44) in the reported frequency of accidents at follow-up 
time 2, χ²(4, N = 90) = 0.59, exact p = 1.00. In fact, the distribution of accidents across 
participant groups was remarkably similar. Twenty-two (75.9%) chemotherapy patients, 13 
(76.5%) radiotherapy patients and 35 (79.5%) healthy controls reported never having 
experienced accidents in the workplace during the previous week. There were six (20.7%) 
chemotherapy patients, three (17.6%) radiotherapy patients and eight (18.2%) healthy 
controls that reported rarely experiencing accidents rarely in the previous week. Finally, just 
one participant in each group (chemotherapy, 3.4%; radiotherapy, 5.9%; healthy control, 
2.3%) experienced accidents occasionally. Again, there were no accounts of experiencing 
accidents often or all the time in the workplace. 
 
Follow-Up Time 3 
At follow-up time 3, there was no significant difference in the frequency of accidents 
between the chemotherapy group (n = 34), radiotherapy group (n = 14) and healthy control 
group (n = 40), χ²(4, N = 88) = 5.00, exact p = .28. The majority of chemotherapy patients (n 
= 27; 79.4%), radiotherapy patients (n = 13; 92.9%), and healthy controls (n = 26; 65.0%) 
reported experiencing no accidents in the workplace during the previous week. Five (14.7%) 
chemotherapy patients, one (7.1%) radiotherapy patient and ten (25.0%) healthy controls 
reported experiencing accidents rarely. Only two (5.9%) chemotherapy patients and four 
(10.0%) healthy controls reported accidents occasionally in the workplace. Similar to 
previous time-points, there were no accounts of experiencing accidents often or all the time in 
the workplace.
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Figure 7.2. Frequency of accidents in the workplace reported (A) in the CT group (n = 14), RT group (n = 15), and HC group (n = 44) at pre-treatment baseline; (B) in the CT 
group (n = 12), RT group (n = 20), and HC group (n = 44) at follow-up time 1; (C) in the CT group (n = 29), RT group (n = 17), and HC group (n = 44) at follow-up time 2, 
and (D) in the CT group (n = 34), RT group (n = 14), and HC group (n = 40) at follow-up time 3.
C 
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7.3.3 Section Summary 
Hypothesis IV was partially supported. Findings suggested that at baseline, 
chemotherapy patients, radiotherapy patients and healthy controls reported similar 
levels of accidents in the home. However, at follow-up time 1, chemotherapy patients 
encountered accidents more frequently. At follow-up time 2, differences in accident 
frequency between the groups subsided, but at follow-up time 3, chemotherapy patients 
once again reported more accidents compared to the two control groups. In contrast, all 
participant groups reported similar levels of accidents in the workplace at each time-
point. 
7.4 Findings from Hypothesis V (a) 
Demographic, psychosocial, and cognitive function variables will be significantly 
associated with accident frequency in the chemotherapy group at each time-point. 
 
To identify the best predictors of accidents in the chemotherapy group, a series of 
correlational analyses and logistic regressions were conducted at each time-point. 
Chapter Four provided evidence for a number of variables shown to predict the risk of 
accidents, including age, anxiety, depression, fatigue and cognitive function. First, 
correlations were conducted at each time point to identify which of these variables were 
significantly associated with accident frequency. Only those significantly correlated 
were included in the regression models. As shown in Figure 7.1, the vast majority of 
participants experienced accidents rarely or never, and relatively few participants 
reporting accidents occasionally, often or all the time. Therefore, accident frequency 
was re-coded to binary format, so that never and rarely were grouped (recoded = 0) and 
occasionally, often and all the time were grouped (recoded = 1). Due to the small 
number of participants in the chemotherapy group at work (many took sickness 
absence), there were very few reports of accidents for these categories; therefore, 
regressions for predictors of accidents in the workplace were not conducted. 
 
Correlations with Accident Frequency at Baseline 
As Table 7.1 below shows, accident frequency scores were significantly correlated with 
depression (rѕ = 0.27, p < .05) and cognitive function (rѕ = 0.27, p < .05).  
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Table 7.1  
Correlations Between Demographic Variables, Psychosocial Variables, Cognitive Function 
and Accident Frequency in the Chemotherapy Group (n = 60) at Baseline  
 
Variable Age Education Anxiety Depression Fatigue 
Cognitive 
function 
Accident frequency -0.15 -0.14 0.06 0.27* -0.08 0.27* 
*p < .05. 
 
Correlations with Accident Frequency at Follow-Up Time 1 
As Table 7.2 below shows, accident frequency  scores were significantly correlated 
with fatigue (rѕ = -0.30, p < .05) and cognitive function (rѕ = 0.42, p < .01). 
 
Table 7.2 
Correlations Between Demographic Variables, Psychosocial Variables, Cognitive Function 
and Accident Frequency in the Chemotherapy Group (n = 55) at Follow-Up Time 1  
 
Variable Age Education Anxiety Depression Fatigue 
Cognitive 
function 
Accidents 0.06 -0.19 0.12 0.22 -0.30* 0.42** 
*p < .05. ** p < .01. 
 
Correlations with Accident Frequency at Follow-Up Time 2 
As Table 7.3 below shows, accident frequency scores were significantly correlated with 
anxiety (rѕ = 0.26, p < .05), depression (rѕ = 0.38, p < .01), fatigue (rѕ = -0.39, p < .01), 
and cognitive function (rѕ = 0.30, p < .05).  
 
Table 7.3 
Correlations Between Demographic Variables, Psychosocial Variables, Cognitive Function 
and Accident Frequency in the Chemotherapy Group (n = 58) at Follow-Up Time 2 
 
Variable Age Education Anxiety Depression Fatigue 
Cognitive 
function 
Accidents -0.03 -0.08 0.26* 0.38** -0.39** 0.30* 
*p < .05. ** p < .01. 
 
Correlations with Accident Frequency at Follow-Up Time 3 
As Table 7.4 below shows, accident frequency scores were significantly correlated with 
anxiety (rѕ = 0.32, p < .05) and cognitive function (rѕ = 0.41, p < .01). 
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Table 7.4 
Correlations Between Demographic Variables, Psychosocial Variables, Cognitive Function 
and Accident Frequency in the Chemotherapy Group (n = 56) at Follow-Up Time 3 
 
Variable Age Education Anxiety Depression Fatigue 
Cognitive 
function 
Accidents -0.20 -0.07 0.32* 0.24 -0.22 0.41** 
*p < .05. ** p < .01. 
 
7.4.1 Section Summary 
In summary, since not all variables were found to be significantly correlated with 
accident frequency, Hypothesis V (a) was partially supported. At baseline, increased 
levels of depression and cognitive difficulties were significantly associated with 
increased accident frequency. At follow-up time 1, increased levels of fatigue and 
cognitive difficulties were significantly correlated with increased accident frequency. 
At follow-up time 2, increased levels of anxiety, depression, fatigue and cognitive 
difficulties were related to increased accident frequency. At follow-up time 3, increased 
levels of anxiety and cognitive difficulties were correlated with increased accident 
frequency. 
7.5 Findings from Hypothesis V (b)  
Demographic, psychosocial, and cognitive function variables will predict accident 
frequency in the chemotherapy group at each time-point. 
 
Standard logistic regression analyses were conducted at each time-point to identify 
significant predictors for accident frequency in the home in the chemotherapy group. 
Variables found to be significantly correlated with accident frequency in Hypothesis V 
(a) were entered as predictor variables in the regression model. 
 
Predictors of Accidents at Baseline 
A logistic regression analysis was conducted with frequency of accidents as the DV and 
depression and cognitive function as predictor variables (see Table 7.5 below). The full 
model did not significantly predict accident frequency, χ²(2, N = 60) = 5.20, p = .07. 
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The model accounted for between 8.3% (Cox and Snell R square) and 19.0% 
(Nagelkerke R square) of the variance in accident frequency. Overall, the model 
accurately classified 91.7% of cases. As the table shows, neither depression nor 
cognitive function made a statistically significant contribution to the model. 
 
Table 7.5 
Logistic Regression Model Predicting Accident Frequency at Baseline (n = 60) 
 
Predictor B SE Odds Ratio (95% CI) 
Depression 0.08 0.15 1.09 (0.81, 1.46) 
Cognitive function 0.07 0.05 1.07 (0.98, 1.17) 
Constant -5.60 1.87 
 
 
Predictors of Accidents at Follow-Up Time 1 
Table 7.6 below shows the results from the logistic regression for the chemotherapy 
group follow-up time 1. The full model was statistically significantly at predicting 
accident frequency, χ²(2, N = 55) = 12.31, p = .002. The model accounted for between 
20.1% (Cox and Snell R square) and 29.1% (Nagelkerke R square) of the variance in 
accident frequency. Overall, the model accurately classified 81.8% of cases. Cognitive 
function made a statistically significant contribution to the model. 
 
Table 7.6 
Logistic Regression Model Predicting Accident Frequency at Follow-Up Time 1 (n = 55) 
 
Predictor B SE Odds Ratio (95% CI) 
Fatigue -0.03 0.03 0.97 (0.91, 1.03) 
Cognitive function 0.07 0.03 1.07 (1.01, 1.13) 
Constant -2.96 1.69  
 
Predictors of Accidents at Follow-Up Time 2 
Table 7.7 below shows the results from the logistic regression for the chemotherapy 
group follow-up time 2. The full model was statistically significantly at predicting 
accident frequency, χ²(4, N = 58) = 10.88, p = .028. The model accounted for between 
17.1% (Cox and Snell R square) and 26.1% (Nagelkerke R square) of the variance in 
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accident frequency. Overall, the model accurately classified 81.0% of cases. None of 
the selected predictors made a statistically significant contribution to the model. 
 
Table 7.7 
Logistic Regression Model Predicting Accident Frequency at Follow-Up Time 2 (n = 58) 
 
Predictor B SE Odds Ratio (95% CI) 
Anxiety -0.12 0.14 0.89 (0.68, 1.17) 
Depression 0.17 0.18 1.18 (0.83, 1.68) 
Fatigue -0.03 0.05 0.97 (0.88, 1.08) 
Cognitive function 0.03 0.03 1.04 (0.97, 1.10) 
Constant -2.03 2.73  
 
Predictors of Accidents at Follow-Up Time 3 
Table 7.8 below shows the results from the logistic regression for the radiotherapy 
group follow-up time 3. The full model was statistically significantly at predicting 
accident frequency, χ²(2, N = 56) = 9.59, p = .008. The model accounted for between 
15.7% (Cox and Snell R square) and 22.9% (Nagelkerke R square) of the variance in 
accident frequency. Overall, the model accurately classified 73.2% of cases. None of 
the selected predictors made a statistically significant contribution to the model. 
 
Table 7.8 
Logistic Regression Model Predicting Accident Frequency at Follow-Up Time 3 (n = 56) 
 
Predictor B SE Odds Ratio (95% CI) 
Anxiety 0.06 0.10 1.06 (0.88, 1.28) 
Cognitive function 0.04 0.02 1.04 (1.00, 1.09) 
Constant -3.15 0.88  
 
7.5.1 Section Summary 
In summary, only cognitive function was found to be a significant predictor of accident 
frequency at follow-up time 1. There were no other significant predictors of accident 
frequency at other time-points. Therefore, this finding partially supports Hypothesis V 
(b). 
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7.6 Chapter Summary 
This chapter presented the results of the second objective, which examined the impact 
of chemotherapy for breast cancer on accident frequency in the home and workplace 
during and shortly after treatment. The Chi-square tests relating to Hypothesis IV 
revealed significant differences in the distribution of accident frequency between 
participant groups at follow-up time 1 and follow-up time 3. The histograms suggested 
that the chemotherapy group experienced accidents more frequently compared to the 
radiotherapy group and healthy control group at these time-points. Findings from 
Hypothesis V (a) suggested that cognitive function was significantly and consistently 
correlated with accident frequency at each time-point. At baseline depression was also 
found to be significantly associated with accident frequency; at follow-up time 1 fatigue 
was also significantly associated with accident frequency; at follow-up time 2 anxiety, 
depression and fatigue were also significantly correlated with accident frequency, and at 
follow-up time 3 anxiety was also significantly associated with accident frequency. 
However, findings from Hypothesis V (b) suggested that despite these significant 
associations, only cognitive function was found to be a significant predictor of accident 
frequency and only at follow-up time 1. A discussion of these results is presented in 
Chapter Ten. 
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Chapter Eight 
The Impact of Chemotherapy for Breast Cancer on                  
Quality of Life and Work Ability 
8.1 Chapter Introduction 
This chapter presents the results of the questionnaire data in relation to Objective Three. 
This considered the impact of chemotherapy for breast cancer on quality of life and 
work ability during and shortly after treatment. Findings from the previous results 
chapters suggested that the chemotherapy group reported higher levels of depression 
and fatigue compared to the radiotherapy group and healthy control group (Chapter Six) 
and experienced a slightly higher frequency of accidents in the home compared to the 
radiotherapy group and healthy control group at follow-up time 1 and follow-up time 3 
(Chapter Seven). The psycho-oncology literature has found that although treatment side 
effects are generally subtle and improve following treatment cessation, they can still 
have a profound impact on quality of life and affect daily functioning in the home and 
workplace (Vardy, 2009). Therefore, the following hypotheses are examined in this 
chapter: 
 
Hypothesis VI: There will be significant differences in quality of life scores between 
the chemotherapy group, radiotherapy group and healthy control group, and over time. 
 
Hypothesis VII (a): Anxiety, depression, fatigue, cognitive function and frequency of 
accidents will be significantly associated with quality of life in the chemotherapy group 
at each time-point. 
 
Hypothesis VII (b): Anxiety, depression, fatigue, cognitive function and frequency of 
accidents will predict quality of life scores in the chemotherapy group at each time-
point. 
 
Hypothesis VIII: There will be significant differences in work ability scores between 
the chemotherapy group, radiotherapy group and healthy control group, and over time. 
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Hypothesis IX (a): Demographic, psychosocial, cognitive function and accident 
frequency variables will be significantly correlated with work ability scores in the 
chemotherapy group at each time-point. 
 
Hypothesis IX (b): Demographic, psychosocial, cognitive function and accident 
frequency variables will predict work ability scores in the chemotherapy group at each 
time-point. 
8.2 Statistical Analyses 
This section briefly describes the statistical analyses employed in this chapter relevant 
to Objective Three. 
 
Hypothesis VI 
For Hypothesis VI, a 3 x 3 mixed ANCOVA with participant group (chemotherapy, 
radiotherapy, healthy control group) as the between-subjects factor and time (follow-up 
time 1, follow-up time 2, follow-up time 3) as the within-subjects factor, with baseline 
quality of life measure as a covariate, was conducted. In addition, a 3 x 3 x 3 mixed 
ANCOVA with education (none, high school, university) as an additional between-
subjects factor was conducted. 
 
Hypothesis VII (a) and (b) 
For Hypothesis VII (a), associations between variables were calculated using Pearson’s 
product moment correlations at each time-point. For Hypothesis VII (b), standard 
multiple regressions were conducted to examine the ability of anxiety, depression, 
fatigue, cognitive function and accident frequency at home to predict quality of life. 
Where demographic variables were significantly correlated with quality of life, 
hierarchical multiple regressions were conducted with these covariates entered at Step 
1. 
 
Hypothesis VIII 
For Hypothesis VIII, a 3 x 3 mixed ANCOVA with participant group (chemotherapy, 
radiotherapy, healthy control group) as the between-subjects factor and time (follow-up 
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time 1, follow-up time 2, follow-up time 3) as the within-subjects factor, with baseline 
work ability measure as a covariate was conducted. Further adjustment was made to the 
model with age as an additional covariate. In order to compare the physical work ability 
and mental work ability scores between participant groups, a 2 x 3 Chi-square test for 
independence was conducted at each time-point. 
 
Hypothesis IX (a) and (b) 
For Hypothesis IX (a), associations between variables were calculated using Pearson’s 
product moment correlations at each time-point. For Hypothesis IX (b), standard 
multiple regressions were conducted to examine the ability of anxiety, depression, 
fatigue, cognitive function and accident frequency in the work place to predict work 
ability. Where demographic variables were significantly correlated with work ability, 
hierarchical multiple regressions were conducted with these covariates entered at Step 
1. 
 
Preliminary checks revealed that the assumptions underlying ANCOVA, Chi-square,  
Pearson’s product moment correlations and regressions were met, unless otherwise 
stated. An alpha level of .05 was used for all analyses, unless otherwise stated. 
8.3 Findings from Hypothesis VI 
There will be differences in quality of life between breast cancer patients undergoing 
chemotherapy and the treatment and healthy control groups over time. 
 
Hypothesis VI compared differences in quality of life scores over time and between 
participant groups. Since significant differences in age and education exist between the 
participant groups, correlations were conducted between these demographic variables 
and overall quality of life for each participant group (see Table 8.1 below). A 
significant correlation at p < .05 was taken to suggest that the demographic variable 
may have an effect on the DV and therefore should be addressed in further analyses. 
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Table 8.1 
Correlations Between Demographic Variables and Quality of Life in the Chemotherapy Group 
(n = 58), Radiotherapy Group (n = 56) and Healthy Control Group (n = 58) at Baseline 
Note. Pearson’s product moment correlation performed on age; Spearman’s rank order 
correlation performed on education. 
a
Radiotherapy group, n = 55, due to missing education data. 
*p < .01. 
 
Table 8.1 shows that age was not significantly correlated with the baseline measure of 
quality of life in any participant group and was therefore not included as a covariate in 
further analyses. Education was found to be significantly associated with quality of life 
in the chemotherapy group and was therefore controlled for in further analyses.  
 
Table 8.2 below presents the results of the 3 x 3 mixed ANCOVA with participant 
group (chemotherapy, radiotherapy, healthy control group) as the between-subjects 
factor and time (follow-up time 1, follow-up time 2, follow-up time 3) as the within-
subjects factor, with baseline quality of life measure as a covariate. Further analyses 
were conducted using a 3 x 3 x 3 mixed ANCOVA with education (none, high school, 
university) as an additional between-subjects factor to filter out its effect on the 
relationship between participant group and the DV. To correct for the violation of 
sphericity, values for the Greenhouse-Geisser Epsilon are reported for both the two-way 
and three-way ANCOVAs. 
 
The two-way mixed ANCOVA showed that there was a significant interaction between 
time and participant group, F(3.62, 262.63) = 3.55, p = .010, ηp
2 
= .05. The main effect 
for time was not significant, F(1.81, 262.63) = 0.51, p = .582, ηp
2 
< .01. The main effect 
for participant group was significant, F(2, 145) = 6.49, p = .002, ηp
2 
= .08. Post-hoc 
comparisons showed a significant difference in quality of life scores between the 
chemotherapy group and radiotherapy group (p = .001) and a near significant difference 
with the healthy control group (p = .065), suggesting that the chemotherapy group 
experienced poorer quality of life compared to these groups. There was no significant 
 Chemotherapy  Radiotherapy
a
  Healthy 
Variable Quality of life  Quality of life  Quality of life 
Age -0.01  0.14  -0.08 
Education 0.36*  -0.09  0.02 
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difference in quality of life scores between the radiotherapy group and healthy control 
group (p = .488). 
 
The three-way mixed ANCOVA, with additional adjustment for education, showed that 
there was a significant interaction between time and participant group, F(3.62, 249.83) 
= 2.52, p = .042, ηp
2 
= .04 (see Figure 8.1; higher scores indicate better quality of life). 
The main effect for time was not significant, F(1.81, 249.83) = 0.43, p = .631, ηp
2 
< .01. 
The main effect for participant group was significant, F(2, 138) = 5.98, p = .003, ηp
2 
= 
.08. Post-hoc comparisons showed a significant difference in quality of life scores 
between the chemotherapy group and radiotherapy group (p = .002). No significant 
differences were revealed between the chemotherapy group and healthy control group 
(p = .642), or between the radiotherapy group and healthy control group (p = .620). 
 
As shown in Figure 8.1 below, the chemotherapy group reported lower scores on the 
FACT-G, indicating poor quality of life scores compared to the radiotherapy group and 
healthy control group. At follow-up time 1, quality of life scores improved, and 
continued to increase at follow-up time 2. In the healthy control group, quality of life 
scores also increased between follow-up time 1 and follow-up time 2; however, they 
decreased at follow-up time 3. In contrast, quality of life scores remained relatively 
stable over time in the radiotherapy group. 
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Figure 8.1. Adjusted mean quality of life scores (+ SE) for the chemotherapy, 
radiotherapy and healthy control groups at each follow-up time-point. 
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Table 8.2 
Mixed ANOVA Results for Quality of Life for the Chemotherapy Group (n = 48), Radiotherapy Group (n = 46) and Healthy Control Group (n = 55) 
 
Type of analysis Participant group 
Follow-up  
Time 1 
 Follow-up  
Time 2 
 Follow-up  
Time 3 
 
Factor F p ηp
2
 
M SE 
 
M SE 
 
M SE 
 
Two-way mixed 
ANCOVA 
Chemotherapy 80.11 1.58 
 
84.66 1.70 
 
87.30 1.68 
 
Time 0.51 .582 <.01 
Radiotherapy 90.94 1.59 
 
90.19 1.71 
 
91.40 1.69 
 
Group 6.49 .002 .08 
Healthy 87.77 1.45 
 
89.58 1.57 
 
87.53 1.55 
 
Time x Group 3.55 .010 .05 
 
   
 
  
 
  
 
    
Three-way mixed 
ANCOVA 
Chemotherapy 80.08 1.67 
 
84.50 1.81 
 
87.28 1.80 
 
Time 0.43 .631 <.01 
Radiotherapy
a
 91.03 1.71 
 
90.39 1.85 
 
91.60 1.83 
 
Group 5.98 .003 .08 
Healthy 86.86 2.84 
 
89.37 3.07 
 
86.12 3.04 
 
Time x Group 2.52 .048 .04 
Note. Greenhouse-Geisser reported due to violation of sphericity. 
a
Data missing for one participant due to missing education data.  
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8.3.1 Section Summary 
In summary, Hypothesis VI was partially supported. The chemotherapy group reported 
poorer quality of life scores compared to the radiotherapy group, but scores were not 
significantly different to those reported in the healthy control group. At follow-up time 
1, quality of life scores in the chemotherapy were relatively poor but improved over 
time to scores more similar to those found in the radiotherapy group and healthy control 
group. 
 
8.4 Findings from Hypothesis VII (a) 
Anxiety, depression, fatigue, cognitive function and frequency of accidents will be 
significantly associated with quality of life in the chemotherapy group at each time-
point. 
 
A number of studies have found significant associations between psychosocial variables 
and self-perceived cognitive difficulties with quality of life (e.g. Mehnert et al., 2007). 
However, to date, the relationship between accident frequency and quality of life has 
not been considered in the breast cancer population. Therefore, correlations were 
conducted to examine the relationship between demographic, psychosocial, cognitive 
and accident variables with quality of life in the chemotherapy group at baseline, 
follow-up time 1, follow-up time 2 and follow-up time 3 (see Tables 8.3 to 8.6 below). 
 
Correlations with Quality of Life at Baseline 
As Table 8.3 below shows, quality of life scores in the chemotherapy group were 
significantly correlated with education, anxiety, depression, fatigue, cognitive function 
and accident frequency in the home at baseline.  
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Table 8.3 
Correlations Between Psychosocial Variables, Cognitive Function, Accident Frequency and 
Quality of Life in the Chemotherapy Group (n = 58) at Baseline  
 
Variable Quality of life 
Age -0.01 
Education 0.36** 
Anxiety -0.75** 
Depression -0.84** 
Fatigue 0.72** 
Cognitive function -0.39** 
Accidents (home) -0.50** 
*p < .05. ** p < .01. 
 
Correlations with Quality of Life at Follow-Up Time 1 
As Table 8.4 below shows, quality of life scores in the chemotherapy group were 
significantly correlated with anxiety, depression, fatigue, cognitive function and 
accident frequency in the home at follow-up time 1.  
 
Table 8.4 
Correlations Between Psychosocial Variables, Cognitive Function, Accident Frequency and 
Quality of Life in the Chemotherapy Group (n = 53) at Follow-Up Time 1  
 
Variable Quality of life 
Age 0.12 
Education 0.25 
Anxiety -0.67** 
Depression -0.71** 
Fatigue 0.67** 
Cognitive function -0.50** 
Accidents (home) -0.28* 
*p < .05. ** p < .01. 
 
Correlations with Quality of Life at Follow-Up Time 2 
As Table 8.5 below shows, quality of life scores in the chemotherapy group were 
significantly correlated with education, anxiety, depression, fatigue, cognitive function 
and accident frequency in the home at follow-up time 2. 
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Table 8.5 
Correlations Between Psychosocial Variables, Cognitive Function, Accident Frequency and 
Quality of Life in the Chemotherapy Group (n = 57) at Follow-Up Time 2 
 
Variable Quality of life 
Age 0.14 
Education 0.32* 
Anxiety -0.83** 
Depression -0.87** 
Fatigue 0.87** 
Cognitive function -0.71** 
Accidents (home)
a
 -0.45** 
a
Missing data for one participant. 
*p < .05. ** p < .01. 
 
Correlations with Quality of Life at Follow-Up Time 3 
As Table 8.6 below shows, quality of life scores in the chemotherapy group were 
significantly correlated with education, anxiety, depression, fatigue, cognitive function 
and accident frequency at follow-up time 3. 
 
Table 8.6 
Correlations Between Psychosocial Variables, Cognitive Function, Accident Frequency and 
Quality of Life in the Chemotherapy Group (n = 55) at Follow-Up Time 3 
 
Variable Quality of life 
Age 0.08 
Education 0.29* 
Anxiety -0.76** 
Depression -0.89** 
Fatigue 0.79** 
Cognitive function -0.67** 
Accidents (home)
a
 -0.37** 
a
Missing data for one participant. 
*p < .05. ** p < .01. 
 
8.4.1 Section Summary 
In summary, anxiety, depression, fatigue, cognitive function and accident frequency in 
the home were significantly correlated with quality of life in the chemotherapy group at 
each time-point. Increased levels of anxiety, depression, fatigue, cognitive difficulties 
and accident frequency were associated with poorer quality of life. Education was also 
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significantly associated with quality of life at baseline, follow-up time 2 and follow-up 
time 3. This finding supports Hypothesis VII (a). 
 
8.5 Findings from Hypothesis VII (b) 
Anxiety, depression, fatigue, cognitive function and frequency of accidents will 
predict quality of life scores in the chemotherapy group at each time-point. 
Regressions at Baseline 
Hierarchical regression was used to assess the ability of anxiety, depression, fatigue, 
cognitive function and accident frequency to predict quality of life after controlling for 
education (see Table 8.7). Education was entered at Step 1 and explained 8% of the 
variance in quality of life scores. Anxiety, depression, fatigue, cognitive function and 
accident frequency were entered at Step 2 and the total variance explained by the model 
as a whole was 75%, F (6, 51) = 29.39, p < .001. Anxiety, depression, fatigue, cognitive 
function and accident frequency explained an additional 69% of the variance in quality 
of life, after controlling for education, R
2 
change = .69, F change (5, 51) = 31.56, p < 
.001. In the final model, anxiety (β = -.29, t = -2.55, p < .05), depression (β = -.45, t = -
3.33, p < .005) and fatigue (β = .30, t = 3.02, p < .005) were statistically significant.  
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Table 8.7 
Hierarchical Regression Analysis for Anxiety, Depression, Fatigue, Cognitive Function and 
Accident Frequency Predicting Quality of Life in the Chemotherapy Group at Baseline (n = 58) 
 
Variable B SE B Β 
Step 1    
   Constant 77.39 3.91  
   Education 6.55 2.94 .29* 
Step 2    
   Constant 74.82 9.27  
   Education -0.56 1.68 -.03 
   Anxiety -1.07 0.42 -.29* 
   Depression -2.15 0.65 -.45** 
   Fatigue 0.53 0.18 .30** 
   Cognitive function 0.15 0.10 .13 
   Accident frequency -5.69 4.25 -.10 
Note. R
2 
= .08 for Step 1 (p < .05), ∆R2 = .75 for Step 2 (p < .001). 
*p < .05. **p < .005. 
 
Regressions at Follow-Up Time 1 
Standard multiple regression was used to assess the ability of anxiety, depression, 
fatigue, cognitive function and accident frequency to predict quality of life (see Table 
8.8 below). These predictors explained a significant proportion of the variance in 
quality of life scores at follow-up time 1, adjusted R
2
 = .60, F (5, 47) = 16.88, p < .001. 
Anxiety (β = -.33, t = -2.68, p = .01) and fatigue (β = .33, t = 2.54, p < .05) were 
statistically significant. 
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Table 8.8 
Standard Multiple Regression Analysis for Anxiety, Depression, Fatigue, Cognitive Function 
and Accident Frequency Predicting Quality of Life in the Chemotherapy Group at Follow-Up 
Time 1 (n = 53) 
 
Variable B SE B Β 
Constant 80.76 8.77  
Anxiety -1.28 0.48 -.33** 
Depression -0.79 0.58 -.21 
Fatigue 0.45 0.18 .33* 
Cognitive function -0.12 0.11 -.12 
Frequency of accidents 1.28 3.73 .03 
Note. R
2 = .64, ∆R2 = .60 (p < .001). 
*p < .05. ** p = .01. 
 
Regressions at Follow-Up Time 2 
Hierarchical regression was used to assess the ability of anxiety, depression, fatigue, 
cognitive function and accident frequency to predict quality of life after controlling for 
education (see Table 8.9 below). Education was entered at Step 1 and explained 11% of 
the variance in quality of life scores. Anxiety, depression, fatigue, cognitive function 
and accident frequency were entered at Step 2 and the total variance explained by the 
model as a whole was 83%, F (6, 49) = 46.20, p < .001. Anxiety, depression, fatigue, 
cognitive function and accident frequency explained an additional 74% of the variance 
in work ability, after controlling for age, R
2 
change = .74, F change (5, 49) = 48.55, p < 
.001. In the final model anxiety (β = -.30, t = -2.93, p = .005) and fatigue (β = .42, t = 
3.51, p = .001) were statistically significant. 
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Table 8.9 
Hierarchical Regression Analysis for Anxiety, Depression, Fatigue, Cognitive Function and 
Accident Frequency Predicting Quality of Life in the Chemotherapy Group at Follow-Up Time 
2 (n = 57) 
 
Variable B SE B Β 
Step 1    
   Constant 69.09 4.72  
   Education 8.97 3.55 .33* 
Step 2    
   Constant 75.02 9.43  
   Education -0.34 1.67 -.01 
   Anxiety -1.22 0.42 -.30** 
   Depression -0.82 0.60 -.19 
   Fatigue 0.63 0.18 .43*** 
   Cognitive function -0.10 0.09 -.09 
   Accident frequency -1.39 2.82 -.03 
Note. R
2 
= .11 for Step 1 (p < .05), ∆R2 = .83 for Step 2 (p < .001). 
*p < .05. **p = .005. ***p = .001. 
 
Regressions at Follow-Up Time 3 
Hierarchical regression was used to assess the ability of anxiety, depression, fatigue, 
cognitive function and accident frequency to predict quality of life after controlling for 
education (see Table 8.10 below). Education was entered at Step 1 and explained 5% of 
the variance in quality of life scores. Anxiety, depression, fatigue, cognitive function 
and accident frequency were entered at Step 2 and the total variance explained by the 
model as a whole was 80%, F (6, 27) = 22.78, p < .001. Anxiety, depression, fatigue, 
cognitive function and accident frequency explained an additional 76% of the variance 
in work ability, after controlling for age, R
2 
change = .76, F change (5, 27) = 24.77, p < 
.001. In the final model only depression (β = -.73, t = -3.97, p < .001) was statistically 
significant. 
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Table 8.10 
Hierarchical Regression Analysis for Anxiety, Depression, Fatigue, Cognitive Function and 
Accident Frequency Predicting Quality of Life in the Chemotherapy Group at Follow-Up Time 
3 (n = 54) 
 
Variable B SE B Β 
Step 1    
   Constant 73.74 6.31  
   Education 7.86 4.76 .28 
Step 2    
   Constant 94.73 11.71  
   Education -0.15 2.40 -.01 
   Anxiety -0.78 0.57 -.17 
   Depression -3.18 0.80 -.73* 
   Fatigue 0.17 0.22 .11 
   Cognitive function 0.07 0.12 .07 
   Accident frequency -4.22 2.99 -.12 
Note. R
2 
= .08 for Step 1 (p > .10), ∆R2 = .80 for Step 2 (p < .001). 
*p < .001. 
 
8.5.1 Section Summary 
In summary, Hypothesis VII (b) was partially supported. At baseline, anxiety, 
depression and fatigue were significant predictors of quality of life. At follow-up time 1 
and follow-up time 2, anxiety and fatigue significantly predicted quality of life. Finally, 
at follow-up time 3, only depression was found to significantly predict quality of life. 
 
8.6 Findings from Hypothesis VIII 
There will be significant differences in work ability scores between the chemotherapy 
group, radiotherapy group and healthy control group, and over time. 
 
Hypothesis VIII compared differences in work ability scores over time and between 
participant groups. First, responses to the overall current work ability question were 
considered (0 = cannot currently work at all; 10 = current work ability is at its best). 
Responses to current physical work ability and mental work ability were examined 
separately (Gudbergsson, Torp, Flotten, Fossa, Nielsen, & Dahl, 2011). Preliminary 
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analyses considered the effect of age and education on work ability (see Table 8.11 
below). A significant correlation at p < .05 was taken to suggest that the demographic 
variable may have an effect on the DV and therefore should be controlled for in further 
analyses. 
 
Table 8.11 
Correlations Between Demographic Variables and Work Ability in the Chemotherapy Group (n 
= 15), Radiotherapy Group (n = 15) and Healthy Control Group (n = 45) at Baseline 
Note. Pearson’s product moment correlation performed on age; Spearman’s rank order 
correlation performed on education. 
*p < .05. 
 
Table 8.11 shows that age was significantly correlated with work ability in the 
radiotherapy group. Table 8.12 below presents the results of the 3 x 3 mixed ANCOVA 
with participant group (chemotherapy, radiotherapy, healthy control group) as the 
between-subjects factor and time (follow-up time 1, follow-up time 2, follow-up time 3) 
as the within-subjects factor, with baseline work ability measure as a covariate. Further 
analyses were conducted with age as an additional covariate. To correct for the 
violation of sphericity, values for the Greenhouse-Geisser Epsilon are reported for both 
ANCOVAs. 
 
The two-way mixed ANCOVA showed that there was a significant interaction between 
time and participant group, F(3.51, 101.80) = 3.12, p = .023, ηp
2 
= .10. The main effect 
for time was not significant, F(1.76, 101.80) = 0.44, p = .618, ηp
2 
= .01. The main effect 
for participant group was not significant, F(2, 58) = 0.56, p = .577, ηp
2 
= .02. 
  
After additional adjustment for age, there was a significant interaction between time 
and participant group, F(3.52, 100.33) = 3.15, p = .022, ηp
2 
= .10 (see Figure 8.2 
below). The main effect for time was not significant, F(1.76, 100.33) = 0.79, p = .444, 
ηp
2 
< .01. The main effect for participant group was not significant, F(2, 57) = 0.47, p = 
.628, ηp
2 
= .02.  
 Chemotherapy  Radiotherapy  Healthy 
Variable Work ability  Work ability  Work ability 
Age 0.18  0.61*  0.16 
Education -0.38  0.13  -0.25 
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Figure 8.2. Adjusted mean work ability scores (+ SE) for the chemotherapy, 
radiotherapy and healthy control groups at each follow-up time-point. 
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Table 8.12 
Mixed ANOVA Results for Current Work Ability for the Chemotherapy Group (n = 10), Radiotherapy Group (n = 10) and Healthy Control Group (n = 42) 
 
Type of analysis Participant group 
Follow-up  
Time 1 
 Follow-up  
Time 2 
 Follow-up  
Time 3 
 
Factor F p ηp
2
 
M SE  M SE  M SE  
Two-way 
ANCOVA 
Chemotherapy 7.57 .44  9.01 .34  8.95 .38  Time 0.44 .643 .01 
Radiotherapy 8.96 .44  8.78 .34  9.05 .38  Group 0.56 .577 .02 
Healthy 8.66 .21  8.60 .16  8.67 .19  Time x Group 3.12 .023 .10 
               
Two-way 
ANCOVA
a
 
Chemotherapy 7.56 .44  9.00 .34  8.96 .39  Time 0.79 .444 .01 
Radiotherapy
b
 8.91 .44  8.74 .34  9.06 .39  Group 0.47 .628 .02 
Healthy 8.68 .22  8.61 .17  8.66 .19  Time x Group 3.15 .022 .10 
Note. Greenhouse-Geisser reported due to violation of sphericity. 
a
ANCOVA with age as additional covariate. 
b
Data missing for one participant due to missing education data.  
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The following section describes the proportion of participants working full-time, part-
time or on sick leave at each time-point in order to understand the impact of 
chemotherapy on work status. The remaining proportion (those retired, unemployed or 
who did not answer) is not presented. Current physical work ability and mental work 
ability were rated on 5-point Likert scales (1 = very poor; 5 = very good) and 
dichotomised to very good/rather good versus moderate/rather poor/very poor, an 
approach taken by previous researchers (e.g. Gudbergsson, Torp, Flotten, Fossa, 
Nielsen, & Dahl, 2011). Chi-square analyses were conducted to compare physical work 
ability and mental work ability scores between participant groups at each time-point 
(see Table 8.13 below). 
 
At baseline, 7 (11.67%) breast cancer patients about to undergo chemotherapy were 
working full-time, 8 (13.33%) were working part-time, and 21 (35.00%) were on sick 
leave. In the radiotherapy group, 6 (10.71%) were working full-time, 10 (17.86%) were 
working part-time and 5 (8.93%) were on sick leave. In the healthy control group, 31 
(53.45%) were working full-time, 14 (24.14%) were working part-time and there were 
no healthy controls on sick leave. As Table 8.13 below shows, of those working, there 
were no significant differences in physical work ability between participant groups at 
baseline, χ²(2, N = 75) = 4.45, exact p = .144. However, there was a significant 
difference in mental work ability, χ²(2, N = 75) = 8.85, exact p = .010. 
 
At follow-up time 1, 7 (12.73%) patients in the chemotherapy group were working full-
time, 5 (9.09%) were working part-time and 22 (40.00%) were on sick leave. In the 
radiotherapy group, 5 (9.62%) were working full-time, 16 (30.77%) were working part-
time and 1 (1.92%) patient was on sick leave. In the healthy control group, 31 (53.45%) 
participants were working full-time, 14 (24.14%) were working part-time and there 
were no healthy controls on sick leave. As Table 8.13 shows, of those working, there 
were significant differences in physical work ability between participant groups at 
follow-up time 1, χ²(2, N = 80) = 8.16, exact p = .016, and also in mental work ability, 
χ²(2, N = 80) = 10.58, exact p = .007. 
 
At follow-up time 2, 13 (22.03%) patients in the chemotherapy group were working 
full-time, 14 (23.73%) were working part-time, and 11 (18.64%) were on sick leave. In 
the radiotherapy group, 6 (11.54%) were working full-time, 13 (25.00%) were working 
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part-time, and no patients were on sick leave. In the healthy control group, 28 (48.28%) 
were working full-time, 17 (29.31%) were working part-time, and there were no 
controls on sick leave. As Table 8.13 shows, of those working, there was no significant 
difference in physical work ability between participant groups at follow-up time 2, χ²(2, 
N = 92) = 2.58, p = .275, but there was a significant difference in mental work ability, 
χ²(2, N = 93) = 11.64, p = .003. 
 
At follow up time 3, 12 (21.05%) patients in the chemotherapy group were working 
full-time, 21 (36.84%) were working part-time, and 5 (8.77%) were on sick leave. In 
the radiotherapy group, 7 (14.29%) patients were working full-time, 7 (14.29%) were 
working part-time, and there were no patients on sick leave. In the healthy control 
group, there were 24 (41.38%) working full-time, 19 (32.76%) working part-time, and 
again no cases of sick leave. As Table 8.13 shows, of those working, there was a 
significant difference in physical work ability between participant groups at follow-up 
time 2, χ²(2, N = 92) = 7.88, p = .019, and also in mental work ability, χ²(2, N = 93) = 
10.46, p = .005. 
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Table 8.13 
Physical Work Ability and Mental Work Ability 
 
Variable Chemotherapy Radiotherapy Healthy 
p 
 n % N % n % 
Baseline         
   Physical work ability       .144
a
 
      Very good/Rather good 11 73.3 10 66.7 40 88.9  
      Moderate/Rather poor/Very poor 4 26.7 5 33.3 5 11.1  
        
   Mental work ability       .010
 a
 
      Very good/Rather good 10 66.7 12 80.0 43 95.6  
      Moderate/Rather poor/Very poor 5 33.3 3 20.0 2 4.4  
        
Follow-up time 1         
   Physical work ability       .016
 a
 
      Very good/Rather good 8 61.5 15 68.2 41 91.1  
      Moderate/Rather poor/Very poor 5 38.5 7 31.8 4 8.9  
        
   Mental work ability       .007
a
 
      Very good/Rather good 8 61.5 17 77.3 43 95.6  
      Moderate/Rather poor/Very poor 5 38.5 5 22.7 2 4.4  
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Variable Chemotherapy Radiotherapy Healthy 
p 
 n % N % n % 
Follow-up time 2         
   Physical work ability       .275 
      Very good/Rather good 20 71.4 15 78.9 39 86.7  
      Moderate/Rather poor/Very poor 8 28.6 4 21.1 6 13.3  
        
   Mental work ability       .003 
      Very good/Rather good 18 62.1 16 84.2 42 93.3  
      Moderate/Rather poor/Very poor 11 37.9 3 15.8 3 6.7  
        
Follow-up time 3         
   Physical work ability       .019 
      Very good/Rather good 21 61.8 11 78.6 39 88.6  
      Moderate/Rather poor/Very poor 13 38.2 3 21.4 5 11.4  
        
   Mental work ability       .005 
      Very good/Rather good 19 54.3 11 78.6 38 86.4  
      Moderate/Rather poor/Very poor 16 45.7 3 21.4 6 13.6  
a
Exact significance test due to minimum expected cell frequency assumption violated
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8.6.1 Section Summary  
In summary, Hypothesis VIII was partially supported. At baseline, physical work ability 
scores were similar between participant groups. However, healthy controls rated their 
mental work better, whereas a relatively high proportion of chemotherapy patients rated 
their mental work ability as poor. 
 
At follow-up time 1, a higher proportion of chemotherapy patients rated their physical 
work ability and mental work ability as poor. This finding was reflected in ANOVA 
analysis comparing overall current work ability scores. 
 
At follow-up time 2, current work ability scores improved and reached a similar level 
found in the control groups. However, Chi-square analyses revealed significant 
differences for both physical work ability and mental work ability. As before, a high 
proportion of healthy controls rated their physical work ability and mental work ability 
as good, whereas chemotherapy patients were more likely to rate their work ability as 
poor. 
 
The level of current work ability remained consistent at follow-up time 3. However, 
significant differences in physical work ability and mental work ability were found. A 
higher proportion of chemotherapy patients rated their physical work ability and mental 
work ability as poor compared the radiotherapy group and healthy control group. 
 
8.7 Findings from Hypothesis IX (a) 
Demographic, psychosocial, cognitive function and accident frequency variables will 
be significantly correlated with work ability scores in the chemotherapy group at each 
time-point. 
 
Correlations were conducted to examine the relationship between demographic, 
psychosocial, cognitive and accident variables with work ability for each participant 
group at baseline (see Table 8.14), follow-up time 1 (see Table 8.15), follow-up time 2 
(see Table 8.16) and follow-up time 3 (see Table 8.17). 
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Correlations at Baseline 
Work ability scores at baseline were significantly correlated with employment (r = -
0.56, p < .05) in the chemotherapy group (see Table 8.14 below).  
 
Table 8.14 
Correlations Between Demographic Variables, Psychosocial Variables, Cognitive Function, 
Accident Frequency at Work and Work Ability in the Chemotherapy Group (n = 15) at Baseline  
 
Variable Work ability 
Age 0.18 
Education -0.38 
Employment pt/ft -0.56* 
Anxiety -0.51 
Depression -0.25 
Fatigue 0.02 
Cognitive function 0.26 
Accidents (work)
a
 0.01 
*p < .05. 
a
n = 12 
 
Correlations at Follow-Up Time 1 
Work ability scores at follow-up time 1 were not significantly correlated with any of the 
study variables in the chemotherapy group (see Table 8.15 below).  
 
Table 8.15 
Correlations Between Demographic Variables, Psychosocial Variables, Cognitive Function, 
Accident Frequency at Work and Work Ability in the Chemotherapy Group (n = 14) at Follow-
Up Time 1 
 
Variable Work ability 
Age 0.10 
Education 0.10 
Employment pt/ft 0.39 
Anxiety 0.02 
Depression 0.38 
Fatigue -0.13 
Cognitive function 0.15 
Accidents (work)
a
 0.00 
a
n = 12 
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Correlations at Follow-Up Time 2 
Work ability scores at follow-up time 2 were shown to have a medium, positive 
relationship between age and work ability (r = 0.40, p < .05) and a large, positive 
relationship between fatigue and work ability (r = 0.65, p < .01) in the chemotherapy 
group (see Table 8.16 below). There were also large, negative associations between 
work ability and anxiety (r = -0.66, p < .01), depression (r = -0.63, p < .01) and 
cognitive function (r = -0.61, p < .01) in this group.  
 
Table 8.16 
Correlations Between Demographic Variables, Psychosocial Variables, Cognitive Function, 
Accident Frequency at Work and Work Ability in the Chemotherapy Group (n = 29) at Follow-
Up Time 2  
 
Variable Work ability 
Age 0.40* 
Education 0.16 
Employment pt/ft 0.33 
Anxiety -0.66** 
Depression -0.63** 
Fatigue 0.65** 
Cognitive function -0.61** 
Accidents (work) -0.37 
*p < .05. ** p < .01. 
 
Correlations at Follow-Up Time 3 
Work ability scores at follow-up time 3 were shown to have a medium, positive 
relationship between work ability and fatigue (r = 0.43, p < .01) and a medium, negative 
relationship between work ability and depression (r = -0.36, p < .05) in the 
chemotherapy group (see Table 8.17 below).  
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Table 8.17 
Correlations Between Demographic Variables, Psychosocial Variables, Cognitive Function, 
Accident Frequency at Work and Work Ability in the Chemotherapy Group (n = 35) at Follow-
Up Time 3 
 
Variable Work ability 
Age 0.30 
Education 0.05 
Employment pt/ft 0.24 
Anxiety -0.31 
Depression -0.36* 
Fatigue 0.43** 
Cognitive function -0.21 
Accidents (work)
a
 -0.11 
*p < .05. ** p < .01. 
a
n = 34 
 
8.7.1 Section Summary 
In summary, Hypothesis VIII (a) was partially supported. The relationship between 
variables and work ability in the chemotherapy group varied at each time-point. This 
may reflect the fluctuation in sample size over time due to many breast cancer patients 
going on sick leave during chemotherapy treatment. Increased levels of anxiety, 
depression, fatigue and cognitive difficulties were associated with poorer work ability. 
 
8.8 Findings from Hypothesis IX (b) 
Demographic, psychosocial, cognitive function and accident frequency variables will 
predict work ability scores in the chemotherapy group at each time-point. 
 
Regressions were not conducted at baseline, follow-up time 1 or follow-up time 2. A 
regression analysis could not be run at baseline because the only variable significantly 
associated with work ability was dichotomous. At follow-up time 1, none of the 
variables were significantly correlated with work ability. At follow-up time 2, the 
sample size was too small considering the number of predictor variables. 
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Regression at Follow-Up Time 3 
Standard multiple regression was used to assess the ability of depression and fatigue to 
predict work ability (see Table 8.18 below). Depression and fatigue explained a 
significant proportion of the variance in work ability scores at follow-up time 3, 
adjusted R
2
 = .14, F (2, 32) = 3.65, p < .05. Depression and fatigue did not make a 
significant unique contribution to the model. This may result from overlap between 
depression and fatigue. Hypothesis IX (b) was not supported. 
 
Table 8.18 
Standard Multiple Regression Analysis for Depression and Fatigue Predicting Work Ability in 
the Chemotherapy Group (n = 35) at Follow-Up Time 3 
 
Variable B SE B Β 
Constant 5.64 1.75  
Depression -0.01 0.10 -.02 
Fatigue 0.06 0.04 .42 
Note. R
2 = .19, ∆R2 = .14 (p < .05). 
 
8.9 Chapter Summary 
This chapter presented the results of the third objective, which examined the impact of 
chemotherapy for breast cancer on quality of life and work ability during and shortly 
after treatment. Findings from Hypothesis VI suggested that at four months post-
diagnosis, breast cancer patients undergoing chemotherapy experience relatively poor 
levels of quality of life, compared to treatment and healthy controls. However, over 
time quality of life improved and by follow-up time 3, scores were comparable to those 
in the treatment and healthy control groups. This supports the existing literature. As 
expected, Hypothesis VII found that poorer anxiety, depression, fatigue and cognitive 
function were significantly correlated with poorer quality of life. Interestingly, 
frequency of accidents in the home was also related to quality of life, but only in the 
chemotherapy group. This may be explained by chemotherapy patients generally 
experiencing more accidents compared to radiotherapy and healthy controls, and this 
was found to be related to poorer quality of life. 
 
Findings from Hypothesis VIII suggested that breast cancer patients in the 
chemotherapy group reported impaired work ability scores at four months into 
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treatment; however, work ability scores increased to levels comparable to those 
demonstrated by the treatment and healthy control groups by follow-up time 2. Work 
ability scores remained consistent between follow-up time 2 and time 3, which suggests 
that chemotherapy does not appear to have a long-term impact on work ability. Work 
ability scores in the radiotherapy group and healthy control group remained relatively 
stable over time. In addition, significant differences were found in mental work ability 
between participant groups at baseline, follow-up time 1, follow-up time 2 and follow-
up time 3, with a higher proportion of chemotherapy patients generally reporting poorer 
work ability. In relation to physical work ability, significant differences were found 
between participant groups at follow-up time 1 and follow-up time 3. 
 
Finally, Hypothesis IX found that generally psychosocial variables were strongly 
associated with work ability in the chemotherapy group, but only in later follow-up 
time-points. This may be explained by those experiencing higher levels of psychosocial 
and cognitive impairment being on sick leave. 
 
See Table 8.19 below for a summary of the findings from the quantitative analyses of 
the questionnaire data. Although the quantitative results chapters (Chapters Six, Seven 
and Eight) have provided evidence for some impact of chemotherapy on daily 
functioning, some findings are inconsistent. However, in-depth findings from the 
qualitative analysis of the diary entries may further elucidate the impact of treatment of 
patients’ daily lives (see Chapter Nine). A comprehensive discussion of these results is 
presented in Chapter Ten.
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Table 8.19 
Summary of the Findings from the Quantitative Analyses of the Questionnaire Data
Objective One: Examine the impact of chemotherapy for breast cancer on psychosocial well-being and subjective cognitive function 
Hypothesis Summary of findings 
Preliminary analyses: Identify any differences between 
participant groups on anxiety, depression, fatigue and cognitive 
function scores at baseline. 
The chemotherapy group reported significantly higher levels of anxiety compared to the radiotherapy 
group, but not significantly different to the healthy control group at baseline. 
 
No significant differences between participant groups relating to depression, fatigue and cognitive 
function scores at baseline. 
Hypothesis I: There will be differences in levels of anxiety, 
depression and fatigue between the chemotherapy group, 
radiotherapy group and healthy control group, and over time 
(partially supported). 
Anxiety: no significant differences between groups or over time. 
 
Depression: significant main effect for group and time x group interaction. Chemotherapy group 
reported higher levels of depression compared to the radiotherapy group and the healthy control group. 
 
Fatigue: significant main effect for group and time x group interaction. Chemotherapy group reported 
higher levels of fatigue compared to the radiotherapy group and the healthy control group. 
Hypothesis II: There will be differences in subjective cognitive 
function scores between the chemotherapy group, radiotherapy 
group and healthy control group, and over time (not supported). 
Subtle differences in cognitive function scores between groups, but did not reach statistical significance 
level. 
Hypothesis III (a): Anxiety, depression and fatigue scores will 
be significantly associated with each other and with subjective 
cognitive function scores in the chemotherapy group at each 
time-point (supported). 
At each time-point, anxiety, depression and fatigue scores were significantly associated with each other 
and will cognitive function scores. 
Hypothesis III (b): Anxiety, depression and fatigue scores will 
predict subjective cognitive function scores in the chemotherapy 
group at each time-point (partially supported). 
Baseline: there were no significant predictors of cognitive function scores. 
Follow-up time 1: anxiety significantly predicted cognitive function scores. 
Follow-up time 2: age and anxiety significantly predicted cognitive function scores. 
Follow-up time 3: depression significantly predicted cognitive function scores. 
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Objective Two: Examine the impact of chemotherapy for breast cancer on safety outcomes in the home and workplace 
Hypothesis Summary of findings 
Hypothesis IV: Breast cancer patients undergoing 
chemotherapy will report more incidences of accidents 
at all follow-up time-points compared to treatment and 
healthy controls (partially supported). 
 
Home 
Baseline: no difference in accident frequency between groups. 
Follow-up time 1: marginal difference in accident frequency between groups. 
Follow-up time 2: no difference in accident frequency between groups. 
Follow-up time 3: significant difference in accident frequency between groups. 
 
Workplace 
Baseline: no significant difference in accident frequency between groups. 
Follow-up time 1: no significant difference in accident frequency between groups. 
Follow-up time 2: no significant difference in accident frequency between groups. 
Follow-up time 3: no significant difference in accident frequency between groups. 
Hypothesis V (a): Demographic, psychosocial, and 
cognitive function variables will be significantly 
associated with accident frequency in the 
chemotherapy group at each time-point (partially 
supported). 
Baseline: depression and cognitive function scores were significantly associated with accident frequency. 
Follow-up time 1: fatigue and cognitive function scores were significantly associated with accident frequency. 
Follow-up time 2 anxiety, depression, fatigue and cognitive function scores were significantly associated with 
accident frequency. 
Follow-up time 3: anxiety and cognitive function scores were significantly associated with accident frequency. 
Hypothesis V (b): Demographic, psychosocial, and 
cognitive function variables will predict accident 
frequency in the chemotherapy group at each time-
point (partially supported). 
Baseline: no variables significantly predicted accident frequency. 
Follow-up time 1: cognitive function scores predicted accident frequency. 
Follow-up time 2: no variables significantly predicted accident frequency. 
Follow-up time 3: no variables significantly predicted accident frequency. 
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Objective Three: Examine the impact of chemotherapy for breast cancer on quality of life and work ability 
Hypothesis Summary of findings 
Hypothesis VI: There will be 
significant differences in quality of 
life scores between the chemotherapy 
group, radiotherapy group and 
healthy control group, and over time 
(partially supported). 
Significant main effect for group and time x group interaction. The chemotherapy group reported significantly lower quality of life 
scores compared to the radiotherapy group, but scores were not significantly different to the healthy control group. 
 
Hypothesis VII (a): Anxiety, 
depression, fatigue, cognitive 
function and frequency of accidents 
will be significantly associated with 
quality of life in the chemotherapy 
group at each time-point (supported). 
Baseline: anxiety, depression, fatigue, cognitive function and accident frequency were significantly associated with quality of life 
scores. 
Follow-up time 1: anxiety, depression, fatigue, cognitive function and accident frequency were significantly associated with quality 
of life scores. 
Follow-up time 2: anxiety, depression, fatigue, cognitive function and accident frequency were significantly associated with quality 
of life scores. 
Follow-up time 3: anxiety, depression, fatigue, cognitive function and accident frequency were significantly associated with quality 
of life scores. 
Hypothesis VII (b): Anxiety, 
depression, fatigue, cognitive 
function and frequency of accidents 
will predict quality of life scores in 
the chemotherapy group at each 
time-point (partially supported). 
Baseline: anxiety, depression and fatigue scores predicted quality of life scores. 
Follow-up time 1: anxiety and fatigue scores predicted quality of life scores. 
Follow-up time 2: anxiety and fatigue scores predicted quality of life scores. 
Follow-up time 3: depression scores significant predicted quality of life scores. 
Hypothesis VIII: There will be 
significant differences in work ability 
scores between the chemotherapy 
group, radiotherapy group and 
healthy control group, and over time 
(partially supported). 
Significant time x group interaction. 
Baseline: significant differences in mental work ability. 
Follow-up time 1: significant differences in physical and mental work ability. 
Follow-up time 2: significant differences in mental work ability. 
Follow-up time 3: significant differences in physical and mental work ability. 
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Objective Three: Examine the impact of chemotherapy for breast cancer on quality of life and work ability 
Summary of findings 
Hypothesis IX (a): Demographic, 
psychosocial, cognitive function and 
accident frequency variables will be 
significantly correlated with work 
ability scores in the chemotherapy 
group at each time-point (partially 
supported). 
Baseline: employment was significantly correlated with workability. 
Follow-up time 1: no variables were significantly correlated with workability. 
Follow-up time 2: age, anxiety, depression, fatigue and cognitive function were significantly correlated with workability. 
Follow-up time 3: depression and fatigue were significantly correlated with workability.. 
Hypothesis IX (b): Demographic, 
psychosocial, cognitive function and 
accident frequency variables will 
predict work ability scores in the 
chemotherapy group at each time-
point (not supported). 
Baseline: n/a (dichotomous predictor variable). 
Follow-up time 1: n/a (no predictor variables). 
Follow-up time 2: n/a (insufficient sample size). 
Follow-up time 3: no significant predictors of work ability. 
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Chapter Nine 
The Impact of Chemotherapy for Breast Cancer on Patients’ 
Daily Lives During and Shortly Following Treatment 
9.1 Chapter Introduction 
To expand and develop the findings from the quantitative analyses in Chapters Six, 
Seven and Eight, a more in-depth account of the impact of chemotherapy on daily 
functioning was sought by asking participants to provide a narrative of their individual 
experiences. The objective of this study was to explore the impact of chemotherapy for 
breast cancer on patients’ daily life during and shortly following treatment. In 
particular, the aim was to: 
 
Describe the experience of cognitive failures, psychosocial difficulties and accidents 
in breast cancer patients undergoing chemotherapy in the home and workplace. 
 
The measures and procedures specific to the diary phase are presented in this chapter 
(see Chapter Five for information relating to the questionnaire phase). This is followed 
by the findings from the thematic analysis of the diary data and the open-ended 
questionnaire data. 
  
9.2 Method 
Qualitative methods of data collection, such as interviews, focus groups and dairies, can 
provide the means of capturing rich, in-depth data. Focus groups and interviews can be 
advantageous due to the presence of the researcher during data collection, which can 
enable participants’ responses to be probed in greater depth. However, these methods 
also require the participant(s) to be available at a pre-scheduled appointment. Following 
a review of the documented chemotherapy-related side effects in Chapter Two and 
Chapter Three, it was anticipated that participants receiving chemotherapy may not feel 
sufficiently well to be interviewed or to attend a focus group on several occasions 
throughout their treatment. Interviews conducted at participants’ homes may have been 
intrusive for participants at a particularly vulnerable time, while interviews and focus 
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groups at the University would impose travelling time and costs on participants. 
Therefore, diaries were considered to be most advantageous as they were not intrusive 
and there was some flexibility relating to when participants could record data (time- and 
event-based) should relevant incidences occur when they felt unwell or during an 
inopportune moment. Diaries are also a valuable research tool for capturing longitudinal 
insight into the lived experiences of participants (Broom & Tovey, 2008) and were 
therefore a useful tool to address Objective Four. They enable participants to provide 
frequent reports on events and experiences in their natural context, thereby offering an 
ecologically valid method of data collection (Bolger, Davis, & Rafaeli, 2003; Stone & 
Shiffman, 2004). Diaries have previously been used within psycho-oncology research to 
measure breast cancer patients’ experiences of their side effects following 
chemotherapy, particularly in relation to fatigue (Greene, Nail, Fieler, Dudgeon, & 
Jones 1994). They have been established as an effective tool for use in other patient 
populations, such as to evaluate insomnia and chronic pain (e.g. Jungquist et al., 2010). 
Participants in the current study were instructed to record entries in a structured diary as 
previous research has shown that a structured diary content, in comparison to free 
report, can enhance the accuracy and completeness of recorded data (Richardson & 
Ream, 1997). In addition, participants were asked to make entries either immediately 
following incidences (event-based design) or at the end of the day if more convenient 
(time-based design). The event-based design can reduce retrospection and recall bias 
(Reason, 1984); however, this can be intrusive if an event occurs during an inopportune 
moment (Bolger, Davis & Rafaeli, 2003), such as whilst driving during a long car 
journey. Combining time- and event-based scheduling for diary entry-making can 
strengthen the study design (Bolger, Davis, & Rafaeli, 2003; Mohr et al., 2001). 
 
The final section in the questionnaire survey invited participants to provide any 
additional comments they wished to share (see Appendix 12). This aimed to elicit 
meaningful data from participants that may not have been captured elsewhere by the 
study materials. Therefore, in addition to the diary data, some questionnaire data were 
analysed qualitatively, and the findings from both sources are presented in this chapter. 
It has been noted that using a combination of data sources enables the triangulation of 
findings (Denzin & Lincoln, 1994; Teddlie & Tashakkori, 2009), as this can help to 
improve the reliability of a study’s findings (Gifford, 1996). Furthermore, mutual 
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validation of the data was achieved by drawing together the findings from the 
qualitative data analysis and the quantitative data analysis (see Chapter Ten). 
 
9.3 Participants 
A subsample of participants from the questionnaire phase elected to keep personal 
solicited diaries. The initial sample comprised of 21 chemotherapy patients, 11 
radiotherapy patients, and 27 healthy controls. It was anticipated that time demands as 
well as the commitment involved in keeping the diary would result in a high attrition 
rate. Therefore, all participants who expressed an interest in keeping a diary were given 
the opportunity to do so, with the aim of collating as many completed diaries as 
possible. In total, 10 chemotherapy patients, 5 radiotherapy patients and 12 healthy 
controls withdrew from the diary phase. In the chemotherapy group, reasons for 
withdrawing included feeling too ill to continue (n = 3); experiencing cognitive 
difficulties resulting in forgetting to make entries or being unable to concentrate to 
make entries (n = 2), and no reason provided (n = 5). In the radiotherapy group, reasons 
for withdrawing included fatigue and not wanting to be reminded of the disease and its 
treatment (n = 1); lack of time (n =2), and no reason provided (n = 2). In the healthy 
control group, reasons for withdrawing included lack of interest in keeping the diary (n 
= 1) and no reason provided (n = 11). 
 
The final sample size included 11 breast cancer patients undergoing chemotherapy 
treatment, 6 breast cancer patients undergoing radiotherapy treatment, and 15 healthy 
controls. This sample size was considered sufficient for the qualitative phase of this 
study due to the rich data that can be obtained from qualitative methods (Castro et al., 
2010). Demographic details of the final sample are presented in Tables 9.1 to 9.3. 
Participants’ ages ranged from 28 to 65 years in the chemotherapy group, from 51 to 66 
years in the radiotherapy group, and from 29 to 70 years in the healthy control group.  
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Table 9.1 
Participant Characteristics for the Chemotherapy Group (n = 11) 
Participant 
identification 
Age Nationality Marital status 
Diary 
format 
Employment 
status prior to 
diagnosis 
Employment 
status during 
diary phase 
Diary data collection period 
Baseline 
to T1 
 
T1 to 
T2 
 
T2 to 
T3 
CT01 42 
White 
British 
Single Paper 
Occupational 
Therapist 
Full-time     • 
CT07 53 
White 
British 
Married/living with 
partner 
Audio 
Social Care 
Consultant 
Sick leave     • 
CT10 58 
White 
British 
Married/living with 
partner 
Audio Supply Teacher Not stated   •   
CT16 65 
White 
British 
Married/living with 
partner 
Paper Retired Retired     • 
CT18 28 
White 
British 
Married/living with 
partner 
Paper Unemployed Unemployed   •   
CT26 50 Indian 
Married/living with 
partner 
Audio 
Regional 
Development 
Officer 
Sick leave •     
CT34 42 
White 
British 
Married/living with 
partner 
Paper Teacher Sick leave   •   
CT54 60 
White 
British 
Married/living with 
partner 
Paper 
Learning 
Difficulties 
Support Officer 
 
Sick leave •     
CT55 58 White 
British 
Married/living with 
partner 
Paper Administrator Part-time •     
CT57 33 White 
British 
Separated/divorced Paper Admin Assistant Sick leave •     
CT60 51 White 
British 
Married/living with 
partner 
Paper Catering Manager Full-time •     
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Table 9.2 
Participant Characteristics for the Radiotherapy Group (n = 6) 
a
Self-employed. 
 
Participant 
identification 
Age Nationality Marital status 
Diary 
format 
Employment 
status prior to 
diagnosis 
Employment 
status during 
diary phase 
Diary data collection period 
Baseline 
to T1 
 
T1 to 
T2 
 
T2 to 
T3 
RT20 65 
White 
British 
Separated/divorced Paper Retired Retired     • 
RT25 51 
White 
British 
Married/living 
with partner 
Paper 
Pre-School 
Supervisor 
Part-time •     
RT33 54 
White 
British 
Separated/divorced Paper Promotions
a
 Not working •     
RT45 66 
White 
British 
Married/living 
with partner 
Paper Retired Retired •     
RT60 62 
White 
British 
Married/living 
with partner 
Paper Retired Retired •     
RT61 59 
White 
British 
Married/living 
with partner 
Paper Unemployed Unemployed •     
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Table 9.3 
Participant Characteristics for the Healthy Control Group (n = 15) 
 
Participant 
identification 
Age Nationality Marital status 
Diary 
format 
Employment at 
baseline 
Employment 
status during 
diary phase 
Diary data collection period 
Baseline 
to T1 
 
T1 to 
T2 
 
T2 to 
T3 
HC09 29 White British 
Married/living 
with partner 
Paper 
Psych. Well-
Being 
Practitioner
a
 
Part-time     • 
HC30 53 White British 
Married/living 
with partner 
Paper Administrator Full-time     • 
HC33 64 White British Single/windowed Paper Administrator Part-time     • 
HC60 50 White British 
Married/living 
with partner 
Paper Physiotherapist Part-time     • 
HC63 70 White British 
Married/living 
with partner 
Paper Retired Retired •     
HC67 33 White British 
Married/living 
with partner 
Paper Engineer Part-time     • 
HC68 37 American 
Married/living 
with partner 
Paper Administrator Full-time     • 
HC78 34 White British 
Married/living 
with partner 
Paper 
Research 
Associate 
Full-time   •   
HC80 58 White British 
Married/living 
with partner 
Paper Lab Technician Full-time   •   
HC88 47 White British Single Electronic Unemployed Unemployed •     
HC90 43 
English/South 
African 
Married/living 
with partner 
Paper 
Administrative 
Officer 
Full-time   •   
HC91 58 White British 
Married/living 
with partner 
Paper Translator
b
 Full-time   •  
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Participant 
identification 
Age Nationality Marital status 
Diary 
format 
Employment at 
baseline 
Employment 
status during 
diary phase 
Diary data collection period 
Baseline 
to T1 
 
T1 to 
T2 
 
T2 to 
T3 
HC92 45 White British 
Married/living 
with partner 
Paper PhD Student Full-time   •   
HC95 62 White British 
Married/living 
with partner 
Paper Supply Teacher Part-time   •   
HC104 57 White British 
Married/living 
with partner 
Paper Administrator Full-time •     
a
Trainee. 
b
Self-employed. 
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9.4 Measures 
Participants were invited to keep a four-month diary, available in paper, electronic or 
audio format (see Appendices 13 and 14). This variety in format ensured that the use of 
a diary was more accessible and appealing, with the overall aim of increasing 
participation. All diary formats were portable so that they could be carried with the 
participant while undertaking daily tasks with relative ease and unobtrusiveness. All 
three formats were employed by the subsample (see Table 9.4). 
 
Table 9.4 
Proportion of Participants Using Each Type of Diary Format 
 
Diary 
format 
Chemotherapy group 
(n = 11) 
 Radiotherapy group 
(n = 6) 
 Healthy control 
group (n = 15) 
n (%) n (%) n (%) 
Paper 
diary 
8 (72.73) 
 
6 (100.00) 
 
14 (93.33) 
Electronic 
diary 
0 - 
 
0 - 
 
1 (6.67) 
Audio 
diary 
3 (27.27) 
 
0 - 
 
0 - 
 
9.4.1 Paper and Electronic Diary 
A diary booklet was designed providing space for entries over a four-week period (see 
Appendix 14). A section at the end of each week allowed participants to reflect and 
comment on some of their entries in more detail. The diary booklet was posted or 
emailed to participants on four occasions in order to collate data over a four-month 
period in total. Although this was more costly and time-demanding compared to a 
single four-month diary booklet, four monthly booklets were considered advantageous 
for the following reasons. Firstly, a shorter monthly diary booklet was small enough to 
be portable whilst the participants carried out their daily tasks. Secondly, this booklet 
was considered to motivate participants and to optimise participation as completing and 
returning a monthly diary booklet may have provided a sense of achievement, which 
may have helped to sustain participant compliance.  
 
The paper and pencil diary format was considered to resemble a standard off-the-shelf 
diary and due to its familiar layout it was a relatively simple design for participants to 
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record their entries (Bolger, Davis & Rafaeli, 2003). Alternatively, an electronic version 
of the diary booklet that could be emailed to participants was available. The electronic 
format remained the same as the paper diary; however, as it was emailed to participants 
it required them to download the electronic diary as a Microsoft Word document and to 
type in entries using a computer. This was deemed a feasible method as approximately 
19 million households in the UK have an internet connection  and there is an annual 
trend of increasing usage (Office for National Statistics, 2011b). However, although this 
method can be time-saving for the participant it does rely on the accessibility of 
technology.  
 
9.4.2 Audio diary 
For the audio diary, participants recorded entries using a battery-operated Sony ICD-
MX20 digital recorder. Participants were asked to make entries by following an 
instruction guideline sheet (shown in Appendix 13). This format required knowledge of 
operating the digital recorder correctly, but was considered to be less time-demanding 
compared to the booklet formats (since speaking is generally faster than writing), thus 
making it a suitable option for those who were experiencing physical difficulties (e.g. 
lymphoedema) and/or psychosocial difficulties (e.g. fatigue). 
 
9.5 Procedure 
Informed consent to participate in the diary phase was obtained at the point of 
recruitment to the questionnaire phase. Participants were informed of the research aims 
and were provided with an information sheet (see Appendix 5). The researcher 
contacted participants after approximately seven days and participants were given the 
opportunity to ask any questions. Participants were asked to sign and return the Consent 
Form and initial the appropriate box indicating their consent to participant in the diary 
phase and then asked to choose a preferred diary format. For those participants who 
wished to make entries in a diary booklet, either an electronic copy was sent by email or 
a paper copy was sent by post, depending upon their preference. The researcher 
contacted these participants approximately seven days later to check they had received 
the diary booklet. This contact allowed the researcher to develop rapport with 
participants as well as confirm that they understood what was required of them. 
Participants were asked to inform the researcher of the date of the first diary entry. This 
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was recorded into a Microsoft Excel spreadsheet to aid the scheduling of distributing 
subsequent diary booklets. 
 
For those participants who wished to keep an audio diary, a meeting was arranged at a 
convenient time and location where the researcher explained how to operate the digital 
recorder and outlined the instructions for making entries. This meeting ensured that 
participants were given the opportunity to ask any questions and to practice making 
entries. The researcher contacted participants seven days later to check the progress of 
recording entries and to answer any further questions. Participants were contacted every 
couple of weeks to maintain rapport. At the end of the four-month period, the researcher 
met with each participant to collect the digital recorder. At the end of the research, all 
participants were thanked for their time and sent a summary of the research findings. 
 
9.6 Data Compilation and Analysis 
All entries from the diaries were converted to electronic form in a Microsoft Excel 
spreadsheet: written entries from the paper diaries were typed into the spreadsheet; 
typed entries from the electronic diaries were downloaded, copied and pasted to the 
spreadsheet, and audio entries on the digital recorders were transcribed verbatim and 
typed into the spreadsheet. All diary data and additional questionnaire data were 
analysed using thematic analysis, following a six-step process described by Braun and 
Clarke (2006). Thematic analysis has been employed by other researchers examining 
the impact of chemotherapy-related cognitive impairment on breast cancer patients’ 
daily functioning (e.g. Cheung, Shwe, Tan, Fan, Ng, & Chan, 2012). The participant 
group (chemotherapy, radiotherapy or healthy control) and time-point (baseline, follow-
up time 1, follow-up time 2 or follow-up time 3) were taken into account so that 
comparisons between participant group and temporal fluctuations could be explored. In 
this chapter, differences in the identified subthemes between participant group and 
changes over time are described, where relevant, and it is noted where there are no 
apparent differences. These qualitative findings are discussed alongside the quantitative 
findings in Chapter Ten. 
 
Thematic analysis is considered “a flexible and useful research tool that can potentially 
provide a rich and detailed, yet complex, account of data” (Braun & Clarke, 2006, p. 
Chapter Nine                Qualitative Results: Objective Four 
211 
78). The first step during analysis involved familiarisation with the data. This was 
achieved by transcribing audio diaries and typing up paper diary entries, re-reading the 
data and noting initial ideas. The second step involved systematically organising the 
entire data set into meaningful groups and developing initial codes. Next, broader 
themes were developed by collating similar codes together. Examination of the 
relationships between the codes led to the identification of overarching patterns and the 
development of a codebook. A second researcher, experienced in qualitative data 
analysis, independently analysed a subsample (25%) of the data in order to validate the 
coding. The researchers compared the labelling of themes and differences in opinion 
were resolved through discussion. The codebook was then further developed. The 
fourth step of the analysis involved reviewing and refining the themes. Finally, clear 
definitions of the themes were generated. The following section presents verbatim 
extracts from the diary data to illustrate the themes and subthemes. This method acts as 
a reliability check to demonstrate how the data fits the analysis (Smith, 1996; Elliot, 
Fischer & Rennie, 1999). The section also presents key verbatim extracts from the data 
in the questionnaire surveys that support or oppose findings from the diary analysis.  
 
9.7 Findings from Objective Four 
Following the thematic analysis of the data, four core themes were identified and are 
presented (with their subthemes) in Table 9.5. Three of the core themes were associated 
with difficulties experienced in the home and were labelled as follows: ‘managing 
cognitive function at home’, ‘managing psychosocial well-being at home’, and 
‘managing physical ability at home’. A fourth core theme was associated with 
difficulties experienced in the workplace and was labelled ‘managing working life’. The 
labelling of these core themes identifies the context of difficulties faced by participants. 
Since three of these core themes represent experiences in the home, this may reflect the 
fact that many breast cancer patients were on sick leave in the chemotherapy group and 
a number of participants in the radiotherapy group were retired. The context and 
temporal fluctuations within each theme and subtheme are discussed below. As this 
thesis is concerned with the impact of chemotherapy treatment on breast cancer 
patients’ daily functioning, the results focus on the experiences of participants in the 
chemotherapy group with comparisons made between the radiotherapy group and 
healthy control group. 
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Table 9.5 
Themes and Subthemes
Theme Subtheme 
  
Managing psychosocial well-being at home 
Anxiety and depression 
Fatigue 
Quality of life 
  
Managing cognitive function at home 
Memory difficulties 
Concentration difficulties 
Psychomotor difficulties 
Difficulty in decision making 
Language difficulties 
  
Managing physical ability at home 
Pain 
Numbness 
  
Managing working life 
The impact of treatment, cognitive, psychosocial, and physical difficulties on RTW intentions 
The impact of treatment, cognitive, psychosocial, and  physical difficulties on WA and adjustments 
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Managing cognitive difficulties at home 
The first key theme ‘managing cognitive difficulties at home’ relates to participants’ 
experiences of cognitive difficulties whilst carrying out daily tasks in the home, as 
described by a 58-year-old chemotherapy patient three months after starting 
chemotherapy treatment: 
“I can't seem to hold a thought. I think something like I'll go and take this upstairs, turn 
round and have instantly forgotten my thought. I have let things boil over when cooking 
nearly every day as I can't remember to turn them down to a simmer. I open 3 days 
(whoops 'doors') (I do that a lot too) to find a cup or cereal” (Participant CT55, 
baseline, week 12).  
This quote illustrates the range of cognitive difficulties reported by the majority of 
chemotherapy patients. These included memory difficulties, concentration difficulties, 
language difficulties, as well as psychomotor difficulties and difficulty in decision 
making. These types of cognitive impairment were identified as subthemes and were 
also evident in the diary entries made by participants in the radiotherapy group and 
healthy control group. However, despite a commonality and normalcy relating to these 
types of cognitive difficulties, key differences across groups were identified regarding 
the frequency, temporal changes and perceived potential cause(s) of impairment, as 
well as the emotional response, as described below. 
 
Memory difficulties 
The subtheme ‘memory difficulties’ refers to the problems that participants experienced 
with remembering, particularly relating to intentions and past events. The majority of 
participants experienced memory difficulties during chemotherapy treatment (see Table 
9.6 for typical examples). The vast majority of memory difficulties occurred in the 
home, although some memory lapses also occurred whilst driving. Similar findings 
were present in the radiotherapy group and healthy control group. 
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Table 9.6 
Typical Examples of Memory Difficulties Reported in the Chemotherapy Group 
Types of memory difficulties Diary extract 
Going from one room to another and 
forgetting why 
“I just forget everything like going upstairs and can't 
remember why etc. v annoying” (Participant CT60, 
baseline, week 3) 
 
Forgetting to complete tasks 
 
“Came upstairs to get laundry, came down without 
it” (Participant CT34, follow-up time 1, week 16) 
 
Forgetting past events 
“Mislaid glasses, found them on my head” 
(Participant CT54, baseline, week 1) 
 
Memory difficulties whilst driving 
“Returned from a few days with our in-laws today. 
Umm just took the complete wrong turning at a 
roundabout a journey I’ve done countless times and 
ended up umm coming off the A1 umm went back 
onto it and was heading south before my husband 
had to find a umm a sort of journey around, which we 
did, we got back, took us another extra 25 minutes on 
the journey. Something I’d never done before” 
(Participant CT10, aged 58 years, follow-up time 1 to 
follow-up time 2). 
 
 
The vast majority of memory complaints reported by participants across all groups were 
non-hazardous. However, in some contexts, memory difficulties were associated with 
potentially harmful consequences, particularly for chemotherapy patients in the kitchen. 
For example, a 60-year-old chemotherapy patient who “Forgot to switch electric ring off 
after making breakfast” and “also switched the wrong one [electric ring] off at dinner time so 
veg weren't cooked” (Participant CT54, baseline, week 6). This chemotherapy patient also 
reported “Double checking cooker all the time” and “Stuck note on fridge to remind me to 
switch ring OFF!” due to her persistent forgetfulness. In contrast, healthy controls tended 
to report isolated incidences. 
 
A small number of participants from each group reported forgetting to take medication. 
This incident had an emotional impact for one chemotherapy patient: 
“Does everyone take these Tamoxifen? Can they remember to take them every day I 
have to write on the packet days of the week. Things like this make me worried that I 
might be losing my marbles. The constant ‘insane’ feeling is playing heavily on my 
mind…I worry about concentrating on not losing it all round” (Participant CT05, 
questionnaire at follow-up time 2). 
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A 34-year-old healthy control participant commented that she forgot to take her 
medication, however she attributed this occurrence to being distracted and not due to 
difficulties in remembering the task that she had to undertake: “Forgot to put on 
deodorant and take medication. Had to wash hair so got distracted” (Participant HC78, follow-
up time 1, week 11). Memory difficulties impacted upon other aspects of treatment, as 
one 65-year-old chemotherapy patient commented that she “Forgot to ask consultant 
doctor a couple of questions at hospital” (Participant CT16, follow-up time 2, week 2). 
 
In contrast, a handful of chemotherapy patients shared positive reports relating to their 
cognitive function, as a 58-year-old chemotherapy patient stated: “Brain fairly OK” 
(Participant CT55, baseline, week 10). However, it is important to consider the contextual 
information surrounding this absence of impairment, as she added “ but not needing to 
think or do much”. This suggests that cognitive difficulties may arise if task demands 
were greater. 
  
Chemotherapy patients documented temporal changes to memory ability following the 
completion of chemotherapy treatment. In particular, at follow-up time 2, soon after 
completing chemotherapy treatment, several patients reflected on how their memory 
ability had deteriorated while undergoing chemotherapy treatment, and although they 
had experienced improvements since treatment completion, their memory ability had 
not fully resumed to pre-diagnosis levels:  
“Memory and concentration issues have been much reduced since chemo finished: I do 
sometimes find I forget things at work or confuse when things might be happening at 
home e.g. I think something is on Saturday when it’s Sunday. This tends to happen if I 
don’t get time to make a note in my notebook – where I write my ‘To do list’ – or if I’m 
told something while concentrating on another thing. This is slightly more frequent 
than before chemo – and I need the calendar more than before too. Emotionally I am 
fine. I get a little worried when I get breast pain – this can also affect my concentration 
as I become preoccupied by it” (Participant CT32, questionnaire at follow-up time 2). 
Another chemotherapy patient commented that “Forgetting why/what am doing is a daily 
occurrence ‘the norm’ for now” (Participant CT01, follow-up time 2, week 3). This shows a 
change in perception and acceptance of this side effect. In contrast, another 
chemotherapy patient longed for her pre-treatment level of functioning as she struggles 
to cope with her memory difficulties: “I just want to be ‘the old me’” (Participant CT35, 
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questionnaire at follow-up time 2). However, for some chemotherapy patients, a feeling of 
being “back to normal” several months following the completion of treatment was noted: 
“Since finishing treatment my memory has got a lot better” (Participant CT58, questionnaire at 
follow-up time 3). This suggests that chemotherapy may have a subtle enduring impact 
on memory ability as resumption to normality in memory ability was not acknowledged 
until follow-up time 3. Several radiotherapy patients also described changes over time, 
but healthy controls did not. This suggests that a diagnosis of breast cancer and/or its 
treatment may have had an impact on patients’ memory ability. 
 
Participants described a number of factors that they believed to have contributed to their 
change in memory ability (see Table 9.7). Several chemotherapy patients acknowledged 
that they had experienced memory difficulties prior to the commencement of treatment 
and were age-related. However, many also commented on an association between 
chemotherapy and memory difficulties. There was little consensus within the 
chemotherapy group and so the main cause of cognitive difficulties in this group was 
inconclusive. Age and fatigue were identified as potential factors across all participant 
groups, suggesting some normalcy. 
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Table 9.7 
Factors Participants Perceived to be the Potential Causes of Memory Difficulties 
Potential causes of memory 
difficulties 
Chemotherapy group Radiotherapy group Healthy control group 
Age “Some of the memory things e.g. not 
seeing things in the supermarket, 
forgetting someone’s name after being 
introduced, forgetting what I’ve gone to 
fetch in the house etc., I feel are not to 
do with my illness as I did these things 
before – I feel it is old age and 
sometimes just not concentrating on 
what you are doing!!” (Participant CT2, 
questionnaire at follow-up time 1) 
“Some of these things I would attribute to my 
age as much as or more than my operation 
and radiotherapy treatment” (Participant 
RT10, questionnaire at follow-up time 3) 
 
“My memory is getting worse as I 
get older; I also don't concentrate 
as much as I should, and therefore 
forget some things – e.g. something 
someone has mentioned” 
(Participant HC33, questionnaire at 
follow-up time 1) 
    
Fatigue “Just one instance to record today, 
although I have been dozing on and off 
all day very tired due to endo mastrics 
chemo. Umm half past six when I was 
serving up dinner umm went back into 
the kitchen to switch off the oven which 
I’d already done”  (CT10, audio diary, 
follow-up time 1 to follow-up time 2) 
“I am really struggling with my short term 
memory - not sure if it is linked to the very 
great fatigue I am suffering with at the 
present - I am sincerely hoping this will all 
pass soon” (Participant RT45, baseline, week 
15) 
 
“Feeling tired today and forgot a 
number of things when food 
shopping” (Participant HC30, 
follow-up time 2, week 6) 
    
Treatment-related “…a bit absent minded due to 
everything happening so fast and chemo 
starting, side effects that I will have 
from chemo” (Participant CT42, 
questionnaire at baseline) 
“Most of my problems have been connected 
to memory and organisation which are 
usually very good. I think whilst the 
treatment is happening, the problems arise 
from lack of time going to the hospital every 
day, and being out of routine” (Participant 
RT60, questionnaire at follow-up time 1) 
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In order to help manage memory difficulties, a number of compensatory strategies were 
employed by participants (see Table 9.8). It is interesting to note that while 
chemotherapy patients used a wider range of memory aids compared to the radiotherapy 
group and healthy control group, chemotherapy patients also reported experiencing 
more pronounced cognitive difficulties. This is illustrated by a 42-year-old 
chemotherapy patient who commented that writing to do lists made her feel “relieved 
and more relaxed”, however she went on to state that she would “Still keep forgetting why 
I have gone to a cupboard. Keep saying to myself ‘what am I doing’” (Participant CT01, 
follow-up time 2, week 15). This suggests that memory aids were not always effective for 
those in the chemotherapy group. Indeed, despite efforts to use compensatory strategies, 
the inherent nature of memory difficulties meant that efforts were not always rewarded, 
as a 60-year-old chemotherapy patient noted: “Made shopping list then left it at home” 
(Participant CT54, baseline, week 2). Another 42-year-old chemotherapy patient showed 
her reliance on using compensatory aids and without them she would forget to complete 
daily tasks: “Forgot to go to friend's house for coffee in afternoon because I hadn't written it 
on the calendar” (Participant CT34, follow-up time 1, week 8). In contrast, a 58-year-old 
healthy control commented that although sometimes forgetting to take her shopping list 
with her, this did not have a significant impact on her memory ability as she could 
“usually remember 8 or 9 things out of 10” (Participant HC80, follow-up time 1, week 3). 
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Table 9.8 
Types of Memory Aids used in the Home by the Chemotherapy Group, Radiotherapy 
Group and Healthy Control Group 
Type of memory aid 
Participant group 
Chemotherapy 
group 
 
Radiotherapy group 
 
Healthy control group 
Writing lists (e.g. ‘to 
do’ list, shopping list) •  •  • 
Diary •  •  • 
Calendar (paper and 
electronic) •  •  • 
Visual reminder (e.g. 
putting medication in a 
visually prominent 
location) 
•    • 
Reminders in phone 
and Outlook •    • 
Mental rehearsal •    • 
Timer •     
Complete one task at a 
time •     
Family organiser •     
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Concentration difficulties 
The subtheme ‘concentration difficulties’ refers to the problems that participants 
experienced with focussing on managing and completing their daily tasks. There were 
more accounts of concentration difficulties reported by the chemotherapy group than by 
the radiotherapy group and healthy control group. Typically, chemotherapy patients  
reported that an “Idea comes into my head, then I lost it!” (Participant CT55, baseline, week 
4). 
 
Chemotherapy patients often found it difficult to complete relatively simple everyday 
tasks during the first few weeks of their chemotherapy treatment, such as being “Unable 
to watch television for long periods of time and to read. Can concentrate in small batches” 
(Participant CT60, baseline, week 9). The impact of these difficulties was noted by family 
members, as a 58-year-old chemotherapy patient describes: “Actually difficulty single 
tasking. For first time in 35 years my husband had to wait for me instead of the other way 
round. He said ‘you're not your usual efficient self’” (Participant CT55, baseline, week 2). 
There was no marked difference in the reporting of concentration difficulties over time in the 
radiotherapy group and healthy control group. 
 
Several participants across all groups discussed what they perceived to be the causes of 
their concentration difficulties. Table 9.10 summarises the range of causes documented 
in the diary extracts and questionnaire responses. Chemotherapy patients described a 
variety of methods to manage concentration difficulties, such as technology, as a 51-
year-old chemotherapy patient commented: “Using Kindle…has eased the problem” and 
also that she “Can't deal with a lot of noise and need some peace and quiet. Difficult with a 
busy family” (Participant CT60, baseline, week 4). Other breast cancer patients described 
adapting their daily routine: “If I adapt e.g. slower pace, regular rest or sleep in daytime I do 
better” (Participant CT28, questionnaire at follow-up time 3). Radiotherapy patients also 
described “Seem to be only able to concentrate on one thing at a time. If I'm doing more than 
one thing I forget” (Participant RT60, baseline, week 1). 
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Table 9.9 
Factors Participants Perceived to be the Potential Causes of Concentration Difficulties 
 
Causes of concentration 
difficulties 
Chemotherapy group Radiotherapy group Healthy control group 
 
Looking after others 
 
“I have 3 young children and our house 
is very noisy, so concentration is a 
problem, because there are so many 
distractions” (Participant CT40, 
questionnaire at follow-up time 2) 
  
“Currently rather distracted because I 
have been caring for my daughter and 
her new born baby. Baby fine, but 
daughter had some complications, so I 
have been worried about her” 
(Participant HC118, questionnaire at 
baseline) 
 
Illness (non-cancer-related)  “stressful incidents that have occurred 
over this month that may have affected 
my concentration etc., rather than the 
radiotherapy…I developed a very nasty 
cold virus which has pretty much 
knocked the wind out of me and I am 
still fighting to be rid of it, 10 days later 
and no sign of getting better” 
(Participant RT33, baseline, week 8) 
 
 
Age “Some concentration/memory problems 
existed before treatment, probably age-
related (60)” (Participant CT28, 
questionnaire at follow-up time 3) 
“I am not sure if my memory los[s] is 
natural and lack of concentration is due 
to the radiotherapy or not” (Participant 
RT20, questionnaire at baseline) 
“My memory is getting worse as I get 
older; I also don't concentrate as much 
as I should, and therefore forget some 
things” (HC33, questionnaire at follow-
up time 1) 
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Causes of concentration 
difficulties 
Chemotherapy group Radiotherapy group Healthy control group 
Anxiety “Can only think about treatment 
tomorrow” (Participant CT60, baseline, 
week 3) 
“Currently the lost concentration I 
believe is all down to my anxiety 
concerning the treatment. It is not 
caused by the actual treatment” 
(Participant RT3, baseline, week 1) 
 
“Currently rather distracted because I 
have been caring for my daughter and 
her new born baby. Baby fine, but 
daughter had some complications, so I 
have been worried about her” 
(Participant HC118, questionnaire at 
baseline) 
 
Fatigue  “Had great difficulty concentrating on 
sorting and writing Christmas card. 
Felt myself getting very uptight - very 
tired” (Participant RT45, baseline, 
week 7) 
 
“Struggling to concentrate as quite 
tired today” (Participant HC30, follow-
up time 2, week 12) 
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Psychomotor difficulties 
The subtheme ‘psychomotor difficulties’ relates to participants’ experiences of 
problems with movement and co-ordination. Chemotherapy patients, radiotherapy 
patients and healthy controls all reported psychomotor difficulties. In particular, reports 
of being clumsy were reported by chemotherapy patients over several weeks, such as 
"dropping things quite a lot" (Participant CT16, follow-up time 2, week 9), as well as in the 
radiotherapy group, as described by a 66-year-old radiotherapy patient: “seem to miss 
things or just catch the edge of things and then knock them off a top of over onto the floor” 
(Participant RT45, baseline, week 5).  
 
The impact of psychomotor difficulties sometimes resulted in injury, for example a 60-
year-old chemotherapy patient commented: “Bruised leg after hitting it on kitchen table” 
(Participant CT54, baseline, week 4), while in other accounts no injury was sustained, as 
illustrated by a 53-year-old chemotherapy patient’s first entry in her audio diary: 
“…this is Day One the 24th of May. And I can’t believe it I’ve already had my first 
incident. Umm this morning about 11:30 between 11:30 and 12 noon I was reversing 
out of a car park space and I managed to reverse into a tree. So that’s a pretty 
dramatic start isn’t it. Thankfully the car isn’t too damaged and I wasn’t damaged at 
all. Umm just to my umm my umm I guess feeling a bit stupid about doing it really. 
Anyway that’s incident one. Hope there not too many more like that” (Participant 
CT07, audio diary, follow-up time 2 to time 3).  
In addition to “stupid”,  the words “daft” and “silly” were used in the chemotherapy 
group to describe how their cognitive difficulties made them feel. 
 
One chemotherapy patient commented in the questionnaire survey that she had noticed 
a change in her clumsiness over time: “…during treatment I found I became clumsy 
(dropping things) – now I have finished treatment they do seem to have become much, much, 
better and I feel I’m virtually back to normal” (Participant CT24, questionnaire at follow-up 
time 2). In contrast, no temporal pattern emerged within this subtheme for the radiotherapy 
group or healthy control group. A number of causes of psychomotor impairment were 
suggested by participants (see Table 9.11 below). For example, healthy controls 
reported environmental influences as a contributory factor, whereas chemotherapy 
patients often suggested cognitive and psychosocial causes. In an attempt to manage 
psychomotor difficulties, a 51-year-old chemotherapy patient described: “Wobbly legs 
when out of bed so don't attempt anything” (Participant CT60, baseline, week 7). 
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Table 9.10 
Factors Participants Perceived to be the Causes of Psychomotor Difficulties
Potential causes of 
psychomotor difficulties 
Chemotherapy group Radiotherapy group Healthy control group 
Unfavourable 
environmental  condition 
  “Tripped slightly when walking on 
rough ground” (Participant HC3, 
follow-up time 2, week 5) 
 
Cognitive domain 
Lack of spatial awareness 
“Cut right thumb whilst in kitchen. 
Can't judge distances i.e. knife to 
thumb” (Participant CT60, baseline, 
week 7) 
 
“Burnt elbow twice because not aware 
of pan on stove when standing next to it 
- changed kitchen layout to move me 
away from heat” (Participant CT60, 
baseline, week 10) 
 
  
Loss of balance “Lost balance getting out of shower 
(didn't fall, just stumbled)” (Participant 
CT34, follow-up time 1 to time 2, week 
3) 
 
  
Psychosocial domain 
Fatigue 
“Felt very tired this week and a bit 
clumsy with it” (Participant CT01, 
follow-up time 1, week 14) 
“very tired and keep tripping over 
nothing in particular” (Participant 
RT45, baseline, week 6) 
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Difficulty in decision making 
The subtheme ‘difficulty in decision making’ refers to the problems participants had 
with making choices. Healthy controls reported far more accounts of experiencing 
difficulty in this cognitive domain than the chemotherapy patients and radiotherapy 
patients. Examples of the types of decision making difficulties are illustrated in Table 
9.11 below. 
 
Table 9.11 
Typical Examples of Difficulties in Decision Making Reported in the Chemotherapy 
Group, Radiotherapy Group and Healthy Control Group 
 
Chemotherapy group Radiotherapy group Healthy control group 
“Overall - have had an ISA 
bond matured - just can't 
decide what to do with it” 
(Participant CT55, baseline, 
week 8) 
“Usually decide what to wear 
in the morning at night but 
struggle to decide” 
(Participant RT45, baseline, 
week 3) 
“Hosted a dinner party and 
spent lots of time in 
indecision over what to make 
and how much would be 
required so everyone had 
enough” (Participant HC09, 
follow-up time 2, week 2) 
 
 
Two chemotherapy patients described difficulties making decisions during certain parts 
of the week, related to chemotherapy treatment. A 58-year-old chemotherapy patient 
described: “Too much to fit into the good week. Too hard to decide rest of time. Part of the 
problem is lack of visual focus for close work in early days after chemo, but main problem is 
inability to concentrate” (Participant CT55, baseline, week 8), while a 51-year-old 
chemotherapy patient revealed that she “Only make decisions on good days” (Participant 
CT60, baseline, week 10). A 62-year-old radiotherapy patient revealed that she was “All 
day very weepy, unable to concentrate or make decisions” (Participant RT60, baseline, week 
1). In contrast, there was no temporal pattern in the reports of this subtheme in the healthy 
control group, which suggests that cancer treatment may have an impact on decision-making 
ability in breast cancer patients. 
 
Language difficulties 
The subtheme ‘language difficulties’ relates to the problems participants had with 
communicating, in particular mixing up words, word finding ability, spelling, 
comprehension and conversation, which were evident across all participant groups. 
However, there were no temporal changes apparent for this subtheme in each 
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participant group. In particular, in the audio diary of a 58-year-old chemotherapy 
patient, there were frequent reports of mixing up words, particularly in the kitchen, for 
example:  
“Wednesday 3rd March. I was preparing lunch talking to my husband I used the word 
oven when I meant fridge when I was telling him where where something was. And then 
likewise tonight when when doing dinner I confused the word freezer instead of oven 
umm again telling him something was in the freezer when it was already in the oven. 
And the third thing was talking with my daughter today had been sorting umm some 
clothes out ready to give to charity shops and I asked her to check some jackets she’d 
got in the and my mind just went blank and it took a good 30 40 seconds to think of the 
word cupboard under the stairs” (Participant CT10, audio diary, follow-up time 1 to 
time 2). 
 
Chemotherapy patients often documented persistent difficulties regarding language 
ability and the emotional impact this had, as evident by the diary extract from a 51-
year-old breast cancer patient (Participant CT60): 
“Start a sentence and forget what I was saying…Inability to judge conversation, 
misjudged body language and social conversation leading to upset family and tears” 
(baseline, week 1) 
 
“Keep saying the same thing over again” (baseline, week 2) 
 
“Just keep asking the same question over and over again…Terrible time when talking 
to people - forget train of thought” (baseline, week 4) 
 
“Constantly repeating self” (baseline, week 7) 
 
“Terrible memory loss. Keep repeating things to people I have already told. Can be v 
boring…Think of things to say to people and then forget then by the time I have gone to 
see the person. Makes me look like an idiot and is frustrating for others” (baseline, 
week 8) 
 
“Say what is on my mind regardless of the recipient which can be very embarrassing - 
especially when it is a personal statement” (baseline, week 9) 
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There were different reactions to the experience of language difficulties, which may 
reflect the length of time living with the impairment. For example, a 58-year-old 
chemotherapy patient recorded the following entry in her audio diary, shortly following 
the end of her chemotherapy treatment: 
“Monday 31st May. Nothing really to report. Just, you know, just seems to be general 
sometimes umm not being able to think immediately the word I wanted to say umm but 
it comes within a few seconds and that seems to happen I suppose most days I don’t 
really tend to think about it, you know” (Participant CT10, audio diary, follow-up time 
1 to time 2). 
In contrast, a 50-year-old chemotherapy patient described the lack of confidence she 
felt after experiencing difficulties with her language ability at the start of her 
chemotherapy treatment: 
“15th of April at 1 o’clock. Just been out for a meal with my sister and brother-in-law 
from London umm and tried to recall some words that were appropriate in sentences 
that I hadn’t been using over the last few weeks and struggled really to find the umm 
right word a couple of times for the sentence. Umm appropriate words. So umm feeling 
a little bit less confident. I don’t know whether that’s because I’ve not used umm that 
the type of vocabulary that I’d be using in those sentences umm in that type of 
conversation or whether it’s that I can’t recall them, but once umm the word was 
pointed out to me what it was I sorted of remembered that again. Umm and used that 
again in the same conversation” (Participant CT26, audio diary, baseline to follow-up 
time 1). 
Participants across all groups discussed the potential causes of their language 
difficulties (see Table 9.12 below). These included psychosocial influences relating to 
anxiety and depression. 
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Table 9.12 
Factors Participants Perceived to be the Causes of Language Difficulties
Causes of language 
difficulties 
Chemotherapy group Radiotherapy group Healthy control group 
Anxiety “There have been several times today 
when I’ve actually got words sort of 
mixed up or umm sometimes sort of 
started with one word and finished with 
another. Umm I’m putting it down to the 
fact that my daughter has actually gone 
off in holiday at the minute in Morocco 
and due back on Wednesday. And umm 
cos I’m worried about how she’ll get 
home” (Participant CT10, audio diary, 
follow-up time 1 to time 2) 
 
“Talking to my daughter in law early 
evening my concentration lapses on 
what she was saying as my mind was 
anxious relating to my future treatment” 
(Participant RT33, baseline, week 1) 
“I work as a translator, sometimes with 
very tight deadlines and multiple jobs 
which causes stress. I find myself using 
the dictionary to check spellings more 
and more - memory getting worse with 
age. When speaking, I have a big 
problem with not finishing my sentences 
- the last word or two just won't come 
out of my mouth” (Participant HC91, 
questionnaire at baseline) 
Fatigue “Have felt tired this week and can't be 
bothered to think or talk to people - not 
like me” (Participant CT01, follow-up 
time 2, week 16) 
“Since having the two operations for 
lumpectomy I have noticed I am tired 
and sometimes struggle finding the 
correct word” (Participant RT45, 
questionnaire at baseline) 
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Managing psychosocial well-being at home 
The second key theme ‘managing psychosocial well-being at home’ relates to 
participants’ experiences of psychosocial difficulties whilst carrying out daily tasks. In 
particular, participants recorded accounts of anxiety, depression and fatigue. Anxiety 
and depression were considered together as one subtheme due to participants’ 
interchangeable descriptions of both. 
 
Anxiety and depression 
A number of chemotherapy patients reported feeling overwhelmed over nothing in 
particular, for example: “Feel low, muddled up, everything seems a big deal” (Participant 
CT54, baseline, week 2) and “Getting up tight/upset about small things which are easily 
solved” (Participant CT60, baseline, week 2). In comparison, one healthy control 
participant’s anxiety was caused by a relatively significant event, such as selling and 
buying a house, while another’s emanated from “caring for my 91 year old father, juggling 
daily routine and lack of 'me' time causes stress” (Participant HC77, questionnaire at baseline). 
Other participants attributed their feelings of anxiety and depression to the 
commencement of treatment. However, opinions varied regarding which treatment 
contributed to these psychosocial side effects. One chemotherapy patient attributed her 
anxiety to chemotherapy treatment, although this was short-lived, whereas another 
participant attributed her feelings of depression to lymphoedema and surgery. 
Depression was also experienced in the radiotherapy group. 
 
Several participants commented on the relationship between anxiety and memory 
difficulties. For example, anxiety was also triggered by the consequences of memory 
difficulties, as one chemotherapy patient described that she felt “In a flap over losing 
tablets - rang sister to ask what to do” (Participant CT54, baseline, week 2). Furthermore, a 
53-year-old chemotherapy patient verbally recorded in her audio diary: 
“26th of August. Umm had lots of things on today which feels quite daunting compared 
to my relaxed lifestyle. Didn’t exactly forget about anything but I don’t know if this 
counts but I worry about forgetting stuff especially when I’ve got a lot on. In the event 
managed to do four different things today without getting anything wrong which felt 
quite an achievement” (Participant CT07, audio diary, follow-up time 2 to time 3). 
 
Chapter Nine           Qualitative Results: Objective Four 
230 
Both chemotherapy and radiotherapy patients reported an association between anxiety 
and fatigue, as illustrated by the following two extracts: 
“Temp v low so was in bed all weekend, therefore didn't have to worry about making 
decisions etc. Doing too much caused this fatigue. My husband was concerned because 
although physically fit my "behaviour" was not normal. So could class this as all the 
questions rolled into one i.e. clumsy, mixing words up etc. I put it down to being 
stressed because my hair was falling out so I shaved my head” (Participant CT60, 
baseline, week 3). 
 
“The most significant experience since receiving treatment has been odd days of 
chronic fatigue/exhaustion. These appear to be getting fewer but any extra ‘stress’ 
appears to re-activate the exhaustion very quickly” (Participant RT19, questionnaire at 
follow-up time 1). 
 
Chemotherapy patients described a number of strategies they used to minimise anxiety, 
such writing things down: “Too many things to think of - relief when I write them down” 
(Participant CT01, follow-up time 2), pacing oneself: “I’m back to normal fitness wise but feel 
anxious if I try to do as much in a day as I used to, so I’m having to pace myself a bit (others 
say that makes me more normal!)” (Participant CT55, questionnaire at follow-up time 2), and 
going on sick leave: “I have felt more relaxed and less stressed since my diagnosis because I 
have not had to think about work (teaching) and all the many stresses which go with it. I have 
had lots more time to enjoy leisure activities such as walking and spending time with family, 
despite the obvious worry of the illness and surgery etc.” (Participant CT34, questionnaire at 
baseline). 
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Table 9.13 
Factors Participants Perceived to be the Causes of Anxiety and Depression 
Causes of anxiety and 
depression 
Chemotherapy group Radiotherapy group Healthy control group 
Multi-tasking “I’m back to normal fitness wise but 
feel anxious if I try to do as much in a 
day as I used to” (Participant CT55, 
questionnaire at follow-up time 2) 
“I found getting ready to go away, 
packing etc. very stressful. I am usually 
very organised. The same happened 
when I returned with unpacking, 
washing etc. Was away 19-23rd felt 
much more relaxed, no real problems” 
(Participant RT60, baseline, week 6) 
“I work as a translator, sometimes 
with very tight deadlines and multiple 
jobs which causes stress” (Participant 
HC91, questionnaire at baseline) 
Caring for others “Overall I’ve found I coped fairly well 
through chemo and very well through 
radio but I’m feeling a bit down at times 
now – not helped by living with my 
severely depressed son” (Participant 
CT55, questionnaire at follow-up time 
2) 
 “I have had a very stressful two weeks 
dealing with my daughter who lost her 
partner, job and home all at once. She 
has had to come back to live with us 
whilst trying to rebuild her life and 
career” (Participant HC61, 
questionnaire at follow-up time 2) 
Memory difficulties “In a flap over losing tablets - rang 
sister to ask what to do” (Participant 
CT54, baseline, week 2) 
 
“I worry about forgetting stuff 
especially when I’ve got a lot on. In the 
event managed to do four different 
things today without getting anything 
wrong which felt quite an achievement” 
(Participant CT07, audio diary, follow-
up time 2 to time 3) 
“Also feeling a little down - feeling old - 
I am never normally like this” 
(Participant RT45, baseline, week 7) 
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Causes of anxiety and 
depression 
Chemotherapy group Radiotherapy group Healthy control group 
Lymphoedema “I am experiencing depression due to 
the possible effects of lymphoedema and 
after surgery but I don't believe this has 
anything to do with the effects of 
chemotherapy” (Participant CT49, 
questionnaire at follow-up tie 3) 
 
  
Chemotherapy/radiotherapy “Starting chemotherapy first session I 
was rather anxious, but this soon 
diminished further into the treatment” 
(Participant CT29, questionnaire at 
follow-up time 1) 
 
“During the past few months I have 
been experiencing bad side effects from 
the medication I have been taking for 
the cancer…I had to have a brain scan 
and had the stress of waiting for the 
results, all of which were thankfully 
OK”  (Participant CT58, questionnaire 
at follow-up time 2) 
“My stress levels were worse during the 
time I was first diagnosed until after I’d 
had an MRI scan to confirm the size of 
the cancer…After the news that the 
cancer was small enough for 
‘lumpectomy’, and after the surgery, 
finding that the cancer had not spread, 
has been a huge relief” (Participant 
RT57, questionnaire at baseline) 
 
“Thought I had coped very well. But 
during February had a bit of a wobble 
got it into my head it was back touching 
and feeling myself all the time thought 
found swellings. Went to the doctor on 
two occasions was nothing to worry 
about, but needed peace of mind, lost a 
bit of confidence, but OK now. Just a bit 
of a dark phase. That [h]as now 
passed” (Participant RT23, 
questionnaire at follow-up time 2) 
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Fatigue 
The subtheme ‘fatigue’ relates to the problems that participants experienced with 
regards to feelings of tiredness. There were numerous accounts of feeling fatigued and 
this having an impact on everyday tasks, such as reading a book and watching the 
television, across all participant groups. Although fatigue was common across all 
participant groups, the impact seemed to be more severe in the chemotherapy group as 
several breast cancer patients reported wanting to “sleep all day if I could” (Participant 
CT57, baseline, week 4). In addition, participants in the chemotherapy group and 
radiotherapy group commented on a link between fatigue and potentially hazardous 
events. For example, a chemotherapy patient commented that she “Carried on going 
when tired and should have stopped. Got wobbly on feet” (Participant CT60, baseline, week 2). 
A radiotherapy patient commented: “I am feeling much tireder. Do not seem to have any 
energy. I am so very frustrated with my memory - it's really driving me mad - my short term 
memory is non-existent! Started to trip over things or bump into things and think it's because I 
feel so tired” (Participant RT45, baseline, week 6).  
 
Table 9.14 
Typical Examples of Fatigue Reported in the Chemotherapy Group, Radiotherapy 
Group and Healthy Control Group 
 
Chemotherapy group Radiotherapy group Healthy control group 
“Have felt tired this week and 
can't be bothered to think or 
talk to people - not like me” 
(CT01, follow-up time 2, 
week 16) 
 
“My day was normal until the 
chemotherapy - this wiped me 
out and I was unable to do 
anything including filling 
diary in” (Participant CT55, 
baseline, week 1) 
“Difficulty doing household 
chores mainly because I'm 
very tired” (Participant RT60, 
baseline, week 3) 
 
“During all of these weeks I 
have not felt able to do my 
card making it just feels too 
much bother - which is not 
like me at all. I also enjoy 
reading but just do not seem 
to be able to settle down - 
most unusual of me. Not 
sleeping well - apart from 
having very hot flushes also 
have been having bad 
dreams” (Participant RT45, 
baseline, week 4) 
“Really tired. Struggling to 
do anything at all” 
(Participant HC30, follow-up 
time 2, week 8) 
 
 
Between baseline and follow-up time 2, a cyclical experience linking fatigue and 
treatment administration was documented in the chemotherapy group: “At the moment it 
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is less than one week since my 5
th
 chemo session which accounts for my extreme tiredness and 
lack of energy. Within the next week I anticipate feeling somewhat more energetic and should 
begin to sleep better at night” (Participant CT10, questionnaire at follow-up time 2). This was 
echoed by another participant who described: “Tiredness came after say 5-7 days after 
treatment but I soon felt back to normal after 3-4 days. The last treatment proved more tiring 
directly after the treatment lasting about 10 days but again I was then able to resume normal 
duties” (Participant CT29, questionnaire at follow-up time 1). “During treatment I have 1 week 
off work following each session. Mum came to stay for 5 days each time. She did all cooking 
and cleaning in that time. At least a couple of days where I do little but sleep. Normally OK 
again after a week” (Participant CT66, questionnaire at follow-up time 1). Radiotherapy 
patients most frequently reported fatigue between baseline and follow-up time 1, which 
coincided with receiving radiotherapy treatment. 
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Table 9.15 
Factors Participants Perceived to be the Causes of Fatigue  
 
Causes of anxiety Chemotherapy group Radiotherapy group Healthy control group 
Age-related  “I do get tired more but think this is 
probably due to getting older and 
working still. I never seem to stop and 
when I do feel very tired. Do think it is 
old age!!!” (Participant RT55, 
questionnaire at follow-up time 2) 
 
 
Anxiety   “Haven't slept well last couple of days 
- I'm sure it's simple stress - have sold 
[house] and nowhere to go” 
(Participant HC104, baseline, week 
12) 
Treatment-related “Thursday 18th March. Umm just I 
noticed on a few occasions today 
when I was reading I was having to 
re-read a few lines or you know a 
short paragraph to take in what was 
happening in my book. I took that 
down to the fact that I had my final 
chemo at the end of last week and I 
am still incredibly tired because of 
that” (Participant CT10, audio diary, 
follow-up time 1 to time 2) 
“Do not sleep well but this is mostly 
due to the very hot flushes which are 
the side effects of the Amidrex tablets 
I am taking” (Participant RT45, 
baseline, week 2) 
 
“Developed tiredness mid-week, 
concentration not affected but feel a 
little forgetful. I am informed that 
tiredness is related to my body healing 
itself after the radiotherapy” 
(Participant RT33, baseline, week 5) 
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Causes of anxiety Chemotherapy group Radiotherapy group Healthy control group 
Pain “My main problem has been 
lymphoedema which started after 
finishing chemo. This has been very 
painful particularly at night time, 
hence lack of sleep” (Participant 
CT16, questionnaire at follow-up time 
3) 
“I get tired because of arthritis. 
Because of the pain in my hands, knee 
joints and feet it can be very tiring. It 
is not the cancer and the treatment I 
have been given that makes me tired, 
thought I should explain” (Participant 
RT01, questionnaire at follow-up time 
1) 
 
 
Looking after others   “I have a busy lifestyle, which I find 
very fulfilling but the present illness of 
my 86yrs blind mother- who is now 
living with me- is causing strain on 
the time I am able to give to the rest of 
my family. This is causing emotional 
tensions all round and leaves me 
physically tired with no spare time for 
myself” (Participant HC95, 
questionnaire at follow-up time 1) 
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Participants across all groups reported feeling fatigued and took naps to compensate. 
However, several chemotherapy patients acknowledged that “normally this is something I 
would never do” (Participant CT16, questionnaire at follow-up time 2). In order to cope with 
the fatigue, chemotherapy patients reduced the number of daily tasks to complete: “I 
was able to pace myself during the day, especially after I was advised to perhaps complete one 
task per day rather than say three” (Participant CT29, questionnaire at baseline). Another 
breast cancer patient described a number of methods she used to help cope with fatigue: 
“When I get tired I go home and get in bed. This is the only way I can overcome the 
fog. Kept a routine. Make sure others keep to it too. Make lists - do jobs as soon as you 
think of them. Recognise the symptoms of tiredness and listen to them. Ask for help. 
Accept help is given” (Participant CT60, baseline, week 2). 
 
Quality of life 
The subtheme ‘quality of life’ relates to participants’ experiences of their psychological 
well-being and outlook on life. A number of chemotherapy patients reported 
experiencing a negative impact on quality of life associated with chemotherapy, as 
described by the following 33-year-old breast cancer patient: 
“Day 2: Fell really ill, lost my anti-sickness pills, not sleeping 4 hours at the most at 
night. It's really getting to me now. I don't want to go back for more treatment. Went to 
the Doctor because I have been feeling very down, tired and in pain (my arm hurts, the 
vein that they use all the time is very sore all the time). Less chest pains now I'm not 
taking anti-sickness pills. Went to the consultant and I had to wait 2 hours, when I 
explained it really wasn't good enough he told me I should be grateful he had turned 
up” (Participant CT57, baseline, week 2). 
 
Another chemotherapy participant described her difficulty in remembering to take her 
Tamoxifen tablets and questioned if others experienced similar, suggested reassurance 
that this was a normal experience, because she was worried “that I might be losing my 
marbles” and described a “constant “insane” feeling is playing heavily on my mind…. These 
hot flushes that these pills cause make me have sleepless nights my work ‘mates’ have fun at my 
expense and after they leave me drained. Doctors say I have to put up with it’ (5 years I have to 
take these) yes I worry about concentrating on not losing it all round” (Participant CT05, 
questionnaire at follow-up time 2). This extract also shows that colleagues could be more 
understanding and supportive. 
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Similarly, another chemotherapy patient discussed the negative impact of Herceptin 
treatment on her quality of life: 
“I was told that Herceptin was a breeze. I am allergic to it and it has caused no end of 
physical problems i.e. consistent pain, muscle fatigue etc. I have been positive and 
happy until about 4 weeks ago when I no longer wanted to carry on with treatment or 
life. I had a word with myself and I have now adjusted to the misery. I have now started 
back at Guides and the girls love my new hair. I do not rest because life is too short and 
I am constantly restless which increases the fatigue. However I am working full time, 
making wedding cakes, doing guides, helping my daughter set up home, helping other 
daughter pass her A Levels, look after my granddaughter and I am lucky that I am still 
alive to do all this” (Participant CT60, questionnaire at follow-up time 2). 
Negative reports were also evident in the radiotherapy group: 
“I have a general feeling that my daily activities are meaningless and that my life is ‘on 
hold’ until the treatment I need is completed. The main effect on my activities is that I 
feel less confident and physically my hands shake and the more I try to prevent it 
happening the worse it gets” (Participant RT10, questionnaire at baseline). 
 
In contrast, some reports were more positive. For example at the start of chemotherapy 
treatment, a 65-year-old chemotherapy patient commented (Participant CT16, 
questionnaire at baseline): “At this moment I remain cheerful and positive about things, 
enjoying my life, and I am determined to remain this way, come what may”. Similarly, the 
following chemotherapy patient described an optimistic approach to her management of 
daily tasks:  
“Just doing what I can and trying not to worry about what I can’t. Rather independent 
and find it hard to accept I need help and most of all ask, even though I know my 
friends and family want to help me. I know I have to get over this!” (Participant CT62, 
questionnaire at baseline). 
 
Another chemotherapy patient described that she was “physically in pain in every joint all 
the time and do not sleep”, however she did not let this impact her working life, as she 
would “manage 160 staff and a £2.5 million budget to the best of my ability”. She described 
her coping mechanisms being “a no cry policy and never cry about cancer. I do struggle 
making difficult decisions but never pull the cancer card. I have discussed this strategy with my 
consultant and he says my mental health is more important than my physical health so do what 
I can. I will not let cancer spoil my life” (Participant CT60, questionnaire at follow-up time 3). 
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Other reports from the final follow-up time-point described being back to a pre-
diagnosis level of functioning: “My life is 100% back to normal now and I’m looking 
forward to going on holiday in the Summer with my hubby! By Jan next year I’m hoping to have 
my reconstruction completed! All good! :)” (Participant CT33, questionnaire at follow-up time 
3). Other accounts suggested that normality was approaching: “Having cancer and the on-
going treatment is hard going but I know that there is light at the end of the tunnel and I will get 
there. I won’t get to 100% but this year I am a lot better than I was in May 2010 when I first 
found out I had cancer. I am also going for extra tests to see if my cancer is genetic” 
(Participant CT36, questionnaire at follow-up time 3). 
 
In contrast, accounts from radiotherapy patients suggested a quicker resumption to 
normality: “My health and my life seem to have returned very quickly to how things were 
before I was diagnosed with breast cancer. I am very actively involved on a number of 
committees and I feel my life is most interesting. My family also is most important and brings 
me a great deal of pleasure and happiness” (Participant RT39, questionnaire at follow-up time 
2).  
 
Managing physical ability at home 
The third key theme ‘managing physical ability at home’ refers to participants’ 
experiences of physical difficulties whilst carrying out daily tasks. In particular, 
participants commented on pain and numbness, which are presented as separate 
subthemes below.  
 
Pain 
A number of participants reported experiencing pain during their daily life, which had a 
significant impact upon their ability to manage their everyday tasks. Therefore, ‘pain’ 
was identified as a subtheme and was particularly evident in the chemotherapy group. 
Due to the cytotoxic and systemic nature of chemotherapy, fast-dividing cells 
throughout the body are targeted, such as those located in the nail. Consequently, this 
can create pain and looseness of the nail (as described in Chapter Two). This can impact 
upon the ability to perform daily tasks, as documented by the following chemotherapy 
patient: 
“Practical things (like pain in nails or nails falling off!) means you have to compensate 
when doing everyday “stuff” e.g. pulling up a zip, cutting veggies, changing gears, 
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opening ring pulls (on cans etc.) gets difficult and causes frustration!” (Participant 
CT19, questionnaire at follow-up time 1). 
Another chemotherapy patient commented: “I have had difficulty walking in the 2nd half of 
my treatment the bottom of my feet got sore and my skin came off also lost most of my finger 
nails” (Participant CT22, questionnaire at follow-up time 1). In addition, several 
chemotherapy patients expressed similar accounts as the following 65-year-old 
chemotherapy patient: “Main problem is still the lymphoedema which is still very painful” 
(Participant CT16,  follow-up time 2, week 3). In contrast, there was no reference to pain in 
the diary extracts from the radiotherapy group or healthy control group. 
  
The following extract comes from diary and questionnaire extracts from a 65-year-old 
chemotherapy patient (Participant CT16), which documents the temporal changes 
relating to her management of pain: 
“I had mastectomy on the 29/1/2010 and arrived home on 1/1/2010. I was pleased that 
I could cope with my normal routine almost straight away, although the drain that was 
still attached to me slowed me down a bit. Oh! what a relief to get rid of it. Going out in 
the car was a bit more painful at first, as I was aware of vibrations on my chest wounds 
as we went over bumps and hollows on the roads, but after the first week or so this soon 
settled down. I am doing my arm exercises every day. I still can’t get my arm up as high 
as my good left arm but I am working hard on this and it is starting to feel easier and 
not so numb…The main problem though this week has been my lymphoedema, although 
the compression sleeve and mitten have reduced the swelling in the hand and lower 
arm, the top arm and shoulder still swollen and very painful at times. This is another 
factor in being a bit clumsy” (questionnaire at baseline). 
 
“Main problem is still the lymphoedema which is still very painful. Loros lymphoedema 
clinic provided me with a compression sleeve and glove and this has helped to take the 
swelling down. The glove worked well and in just two days wearing, my swelling in my 
hand went right down to normal again, so was able to leave glove off and so far have 
not had to put it on again” (follow-up time 2, week 3). 
 
“Nothing really to report this week. Fourth week is usually a good week, when I feel 
more my normal self. Hair still growing back and finger nails looking much 
better…Lymphoedema still painful and arm still. Saw physiotherapist at Loros, who 
was very helpful and gave me some good advice on how to manage exercises. The staff 
at the Loros Lymphoedema Clinic are excellent and seem to take the subject very 
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seriously. I am lucky to live in Leicester and have such a good clinic available to me to 
help with this painful and sometimes disabilitating problem” (follow-up time 2, week 
4). 
 
“Lymphoedema getting a bit painful again and hard to do arm exercises. I saw my 
lovely sister [name removed] at Loros on Monday and she is sending away for a 
different compression sleeve for me to try to see if this helps the arm. Head wound from 
last month’s fall is still sore, though it is healing, but frustrating slow…I feel a wreck 
and I don't like these hormone tablets that have put on, I get hot sweats two or three 
times a day. I’m too old to have the menopause all over again and now I'm turning into 
a moaning old woman. Oh dear! Oh dear! Oh dear!” (follow-up time 2, week 10). 
 
“Arm still painful and underarm and right side of chest gets quite painful too. Energy 
levels not too bad even though I'm not sleeping well at the moment” (follow-up time 2, 
week 11). 
 
“Nothing really to significant happened this week. Lymphoedema still a problem 
though, very painful, and have had to have my compression sleeve altered to another 
one again. Not sleeping very well because of the pain. Feet still very numb and can’t 
get them warm at night in bed. Have started to wear bed socks, now I feel like a real 
granny” (follow-up time 2, week 13). 
 
“Lymphoedema still painful. Compression sleeve fitting better now and I'm hoping this 
will help the arm. Energy levels back to normal now which is quite surprising 
considering lack of sleep. I am over half way through my Herceptin now and seem to be 
keeping OK with this treatment. My head wound has started to get a bit painful in the 
last couple of days” (follow-up time 2, week 14). 
 
“Lymphoedema no better at the moment, getting twinges of pain in my elbow and 
sometimes get a real good stab of pain if I put any kind of pressure on the arm. Keep 
taking Paracetamol to kill pain in arm. Apart from pain I'm keeping well and very busy 
getting ready for Christmas” (follow-up time 2, week 15). 
 
“…lymphoedema still painful, but it's not all bad news as finger nails are back to 
normal…and I’ve managed to get all my Christmas decoration up, and Christmas 
shopping done. Not bad eh for a one-armed, one breasted, wounded headed, suffering 
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lack of sleep woman. I'm not complaining, could be up there with the angels playing on 
a harp” (follow-up time 2, week 16). 
 
“… having a stiff arm and shoulder has made mobility a bit more awkward, but I am 
learning to manage it and live with the pain” (questionnaire at follow-up time 3). 
 
In addition, breast cancer patients undergoing chemotherapy reported a number of 
physical side effects associated with chemotherapy treatment. Temporal changes linked 
to the onset of different chemotherapeutic agents were noted: “With the first three 
chemotherapy I coped really well (FEC) but the last two sessions of chemotherapy the (T) has 
made me feel ill about three days later (I just ache and feel weak) it only last about four days 
then I feel fine again” (Participant CT65, questionnaire at follow-up time 1). 
  
Another chemotherapy patient aged 33 years described pain relating to blood tests she 
underwent as part of her chemotherapy treatment: “They couldn't find a vein. My arm was 
hurting quite a bit. I feel sick, tired and I really don't want to go back, and I have chest pains 
they started within an hour of treatment” (Participant CT57, baseline, week 1) and the 
following week she commented: “Fell really ill, lost my anti-sickness pills, not sleeping 4 
hours at the most at night. It's really getting to me now. I don't want to go back for more 
treatment. Went to the Doctor because I have been feeling very down, tired and in pain (my arm 
hurts, the vein that they use all the time is very sore all the time). Less chest pains now I'm not 
taking anti-sickness pills” (Participant CT57, baseline, week 2). 
 
Numbness 
The subtheme ‘numbness’ relates to participants’ experiences of lack of feeling in their 
hands and feet (neuropathy), which impacted on their ability to complete daily tasks at 
home, and at times resulted in “clumsiness” and  hazardous events. Neuropathy is a 
known side effect of chemotherapy (as described in Chapter Two) and was present in 
the chemotherapy group only. Chemotherapy patients associated increased clumsiness 
with treatment, as described by one participant: “during treatment I found I became clumsy 
(dropping things) – now I have finished treatment they do seem to have become much, much, 
better and I feel I’m virtually back to normal” (Participant CT24, questionnaire at follow-up 
time 2). The following extract comes from a 65-year-old chemotherapy patient 
(Participant CT16), towards the end of her chemotherapy treatment and describes how 
numbness in her fingers impacted her confidence: 
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“Numbness in fingers has caused minor problems this week, more frustrating when you 
are trying to get jobs around the house done quickly…Things like putting on socks or 
tights is a bit of a struggle and takes me longer because of stiff arm and numb fingers” 
(follow-up time 2 to time 3, week 1). 
 
“Still got numb fingers so am a bit clumsy. It was amazing how heavy things seem now 
I have lymphoedema, simple things like lifting saucepans, kettles, pails of water have 
become more difficult and I have to remember to try things with my other good arm” 
(follow-up time 2 to time 3, week 2). 
 
“Fourth week is usually a good week, when I feel more my normal self. Still have a 
little numbness in tips of fingers but getting much better so it's easier to do more fiddly 
jobs. Feet however are still very numb and big toe nails are black and blue” (follow-up 
time 2 to time 3, week 4). 
 
“Had a really nasty fall on the 25th. Tripped over the edge of mat in conservatory. Hit 
my head on the edge of a concrete step. My head had a nasty gash on it and it poured 
with blood. Luckily I keep a well-stocked first aid box so managed to pad and dress 
wound..Finger tips still improving only one of them a bit numb now” (follow-up time 2, 
week 5). 
 
“Head still sore after last week's accident but it is healing up nicely now. Think I was 
very lucky not to have done more damage. Took a little while to get my confidence back 
though and I moving around a lot more slowly and carefully…Feet still very numb and 
toes nails still black” (follow-up time 2, week 6). 
 
“Although numbness in fingers is much improved, still dropping things a lot. My feet 
are still completely numb. I am getting energy levels back now and although head is 
still a bit painful I am feeling more like my old self” (follow-up time 2, week 7). 
 
 “Still feeling all fingers and thumbs. Feet very numb still” (follow-up time 2, week 
10). 
 
 “Have new compression sleeve fitted on. Arm feels a little more comfortable, hope it 
lasts. Numbness continuing so I'm still a bit clumsy, however feeling a lot stronger in 
myself this week” (follow-up time 2, week 12). 
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In order to cope with numbness in the hands, Participant CT16 described using a 
compensatory aids to help manage her daily tasks, such as “used magnet to pick pin up off 
floor…use gaject [gadget] to pull ring on cans, as cannot pull with fingers” (Participant CT16, 
follow-up time 2, week 1). 
 
Managing working life 
The fourth key theme ‘managing working life’ refers to participants’ experiences of the 
impact of cognitive, psychosocial and physical difficulties in the workplace, particularly 
relating to returning to work and whilst at work. Subsequently, two subthemes emerged, 
reflecting these aspects. 
 
The impact of treatment, cognitive, psychosocial, and physical difficulties on RTW 
intentions 
The subtheme ‘the impact of treatment, cognitive, psychosocial, and physical 
difficulties on RTW intentions’ refers to problems that participants’ experienced while 
resuming employment, for example following sick leave. This subtheme was only 
present in the chemotherapy group. This reflects the severity of the invasive nature of 
chemotherapy treatment, resulting in many breast cancer patients taking sick leave 
whilst undergoing treatment. Some chemotherapy patients also commented on taking 
time off work following surgery. Since radiotherapy is a type of local therapy and 
therefore associated with fewer side effects, this may have impacted to a lesser extent 
upon daily functioning. In addition, it is important to note that radiotherapy patients 
tend to be older, and in the current sample, the majority of radiotherapy patients were 
retired, which may account for the lack of data from this sample linked to this 
subtheme. Finally, as shown in Chapter Eight, section 8.5, there were no accounts of 
sick leave in the healthy control group, which explains the lack of data associated with 
the current subtheme in this participant group. Despite the presence of this subtheme 
being prevalent in only the chemotherapy group, it was deemed important because of 
the impact that this experience had on the daily lives of several breast cancer patients. 
 
As previously stated, the majority of chemotherapy patients were on sick leave during 
their treatment. One chemotherapy patient reported taking sick leave because of 
anticipated cognitive difficulties: “I have stopped working as there is no way I would be able 
to juggle work demands. I need to be able to think on my feet when teaching and manage a lot 
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of paper work. I am sure I would rate far worse if I were doing this. My employer has cleared 
my teaching commitments and has been very supportive” (Participant CT25, questionnaire at 
baseline). 
 
On the other hand, the following extract from a 42-year-old chemotherapy patient 
(Participant CT34) reveals the emotional stress related to returning to work and after an 
unsuccessful attempt at returning to work she extended her sick leave: 
 
“Emotional week - went to work to talk about return to work but had panic attack and 
got very tearful (Wed). Then had 'interview' with lovely ladies at Ingeus (D.W.P.) and 
there were lots more tears (Fri). Mon - went to see GP and got signed off work for bit 
longer” (follow-up time 1, week 15). 
 
“Since last questionnaire I have had some meetings with health counsellor and 
employment adviser to help me prepare for return to work. Had some emotional issues 
when contemplating return to workplace and experienced first ever “panic attack” 
style symptoms in meeting with line manager. Have since made full use of Breast Care 
Nurse, GP, Health Counsellor etc. to talk through all concerns and fears and it has 
helped hugely. Also helped my concentration because anxiety about work was 
beginning to dominate thoughts when pre-occupied. Talking to people other than family 
and friends has improved all aspects of my mental health which, in turn, has helped 
with coping with everyday tasks” (questionnaire at follow-up time 2). 
 
“I have had a phased return over 6 weeks, gradually increasing hours and teaching 
load until reached 4 full days/week (pre-diagnosis level). Finding it physically and 
mentally exhausting but confidence has improved noticeably since starting return. Find 
I can learn pupil names with some effort. One side effect I still struggle to deal with is 
having a hot flush and palpitations when feeling stressed or unexpected event occurs 
(often!) Workload has been reduced slightly as I don’t have to do break 
duty/reports/parents evenings for this term” (questionnaire at follow-up time 3). 
 
In contrast, another chemotherapy patient commented that returning to work helped her 
cognitive function and she seemed to enjoy resuming her working life: “Once returned to 
work my mind was much better. However this is the first time that I did not want to carry on 
with the chemo because I have been so disassociated from real life” (Participant CT60, 
baseline, week 9). 
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The impact of treatment, cognitive, psychosocial, and physical difficulties on work 
ability and adjustments 
The subtheme ‘the impact of treatment, cognitive, psychosocial, and physical 
difficulties on WA and adjustments’ refers to the problems participants’ experienced 
relating to managing and completing tasks at work. There were far more accounts of 
difficulties with work ability in the healthy control group than in the chemotherapy 
group and radiotherapy group. An interesting difference was that the duration of poor 
work ability in the healthy control group was often minimal, as illustrated by the 
following diary extract: “At work, in the middle of a job on pc - and just lost my place 
completely - for several seconds” (Participant HC104, baseline, week10). In contrast, a 51-
year-old chemotherapy patient commented that: “Late afternoon meeting last 1/2 hours 
was a waste of time because couldn't concentrate” (Participant CT60, baseline, w eek 3). The 
types of work ability issues experienced across participant groups are summarised in 
Table 9.16 below. Although the consequences of psychosocial and cognitive 
impairments were minor,  they impacted upon work ability.
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Table 9.16 
Typical Examples of Poor Work Ability Reported in the Chemotherapy Group, Radiotherapy Group and Healthy Control Group 
Types of poor work ability Chemotherapy group Radiotherapy group Healthy control group 
Memory difficulties “Couldn't remember details at work 
of something 2 weeks ago” 
(Participant CT01, follow-up time 2) 
 “Got to door of office having 
forgotten what I was going to do” 
(Participant HC30, follow-up time 
2, week 3) 
 
Concentration difficulties “Late afternoon meeting last 1/2 
hours was a waste of time because 
couldn't concentrate” (Participant 
CT60, baseline, week 3) 
“Went to a meeting first time since I 
have been ill. After an hour I 
couldn't keep my concentration” 
(Participant RT45, baseline, week 
13) 
“Doing a repetitive job - boring and 
no brain power required. My mind 
starts to wander and then I forgot 
where I'm up to/how many I've 
done!”(Participant HC104, baseline, 
week 6) 
 
Multi-tasking difficulties “Work - couldn't multi-task - only 
one thing at a time” (Participant 
CT01, follow-up time 2) 
 “Large workload. Kept starting one 
task and getting side tracked by 
another task” (Participant HC90, 
follow-up time 1, week 12) 
 
Language difficulties   “Made a few errors in note writing 
at work” (Participant HC60, follow-
up time 2, week 5) 
 
Psychomotor difficulties “Felt clumsy using computer system 
at work” (Participant CT01, follow-
up time 2) 
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Temporal changes regarding work ability were documented by chemotherapy patients, 
as illustrated by the following extract:  
“Memory and concentration issues have been much reduced since chemo finished: I do 
sometimes find I forget things at work…This tends to happen if I don’t get time to make 
a note in my notebook – where I write my ‘To do list’ – or if I’m told something while 
concentrating on another thing. This is slightly more frequent than before chemo – and 
I need the calendar more than before too. Emotionally I am fine. I get a little worried 
when I get breast pain – this can also affect my concentration as I become preoccupied 
by it” (Participant CT32, questionnaire at follow-up time 2). 
One chemotherapy patient described how she struggled to complete a poem as part of 
her work and shared her poem: 
“I edit a monthly newsletter for the care agency I work for and this has to be produced 
to a deadline. I’ve had moderate difficulty finding a topic for the main article 
(“editorial”) and great difficulty producing an amusing poem – which I normally write 
with ease. Last month, with the printing date approaching I had to resort to one entitled 
“I haven’t got a poem” (3 verses instead of the usual 5+), the first verse which went as 
follows:  
I’ve got to write a poem – but where’s my inspiration? 
I need to write a poem – it’s causing consternation! 
I want to write a poem – no-one could be keener 
But chemo takes your brain and in its place leaves semolina!”  
(Participant CT28, questionnaire at follow-up time 1). 
 
Chemotherapy patients frequently reported chemotherapy treatment affecting their work 
ability. There were also reports of anxiety impacting work ability. This was also evident 
in the healthy control group, however the prevalence was minimal, “Felt stressed this 
morning - sudden burst of tasks and completely forgot what I was doing - honestly, seconds 
long!” (Participant HC104, baseline, week 12). Fatigue was cited as having an impact on 
work ability in the radiotherapy group: “The main thing which affects me generally and my 
work performance is fatigue, Whether getting good quality sleep/rest is affected by emotional or 
physical conditions I’m unsure? My feeling is it could well be” (Participant RT19, questionnaire 
at follow-up time 2). In contrast, there were several reports in the healthy control group of 
unfavourable environmental conditions as the cause of their poor work ability: 
“Struggling to get on at work - weather at office warm/stuffy which doesn't help” (Participant 
HC30, follow-up time 2, week 10).  
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A 42-year-old chemotherapy patient explained that she coped with her forgetfulness at 
work by applying greater cognitive effort when completing her work tasks: “Day 2 of 
this week felt more ‘with it’ than I have in ages and less tired despite getting up at 5:30 coz of 
hot flushes! Forgetting why/what I am doing is a daily occurrence ‘the norm’ for now. I really 
have to concentrate on what I am doing especially at work and I find myself constantly checking 
that I have done it right” (Participant CT01, follow-up time 2, week 3). However, a 51-year-
old chemotherapy patient reported that memory difficulties persisted despite using a 
memory aid: “Missed the VC lunch - just forgot even though had a reminder” (Participant 
CT60, baseline, week 3). Another chemotherapy patient commented how she maintained 
good work ability by changing her home life: 
“I do 100% at work but go to bed at 4pm as soon as I get home. Not being told about 
treatment and hospital appointments at difficult time I find more stressful than the 
treatment. I cannot now write so secretary does most of hard writing for me” 
(Participant CT60, questionnaire follow-up time 1). 
 
Some chemotherapy patients managed their chemotherapy side effects and work by 
taking time off when they felt poorly: “Alterations to work helpful. Took off one day per 
treatment cycle when felt unfit to work re side effects” (Participant CT31, questionnaire at 
follow-up time 1). Similarly, the following radiotherapy reported taking sick leave due to 
treatment. Due to the physical impact of treatment, one radiotherapy patient 
commented: “Have cut my working week from 28 hours to 18 as I feel I can no longer do the 
lifting” (Participant RT03, questionnaire at follow-up time 1). 
 
Table 9.17 summarises the aids and compensatory strategies reported by each 
participant group to facilitate good work ability. However, such strategies were not 
always effective in the chemotherapy group, as described by a 42-year-old occupational 
therapist: “Boss pointed out made a mistake on a weekly absence form - even though I thought 
I'd checked it twice” (Participant CT01, follow-up time 1). 
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Table 9.17 
Strategies and Adjustments Employed to Enable Good Work Ability 
 
Chemotherapy group Radiotherapy group Healthy control group 
Lists (e.g. to do list) None Lists (e.g. to do list) 
Change home life  Tidy desk 
Cut work hours  Diary 
Double checking tasks  Calendar 
  Prioritise tasks 
 
Chemotherapy patients expressed more of an emotional reaction relating to work tasks, 
as illustrated by the following diary extracts from Participant CT60: 
“At work when lots of people talking at once. Had to leave the situation. As a manager 
this was very stressful” (baseline, week 2). 
 
“Friday was a terrible day. I had deadlines to meet and a lot of pressure. I just went 
home in the end. By profession I am a cater so having a panic attack over a simple 
lunch was uncharacteristic and unfounded. Feeling guilty all the time is a negative 
emotion which needs dealing with as it is making me stressful and irritable” (baseline, 
week 2). 
 
“Recalled info from a meeting on Friday which I couldn't recall earlier in the week so 
really pleased with myself” (baseline, week 3). 
 
“Went back to work and did difficult sums!” (baseline, week 4). 
 
Further positive accounts of work ability are shown by the following extract: 
“I started back work after Easter while I was having radiotherapy. I feel better being at 
work with staff and children. My boss at playgroup said they all thought I would get 
tired but it is as though I have never been away. Working in the kitchen at weekends I 
sometimes feel tired but I am usually working 7pm until 1am. The boss there said she 
has not noticed any difference in how fast I work” (Participant CT65, questionnaire at 
follow-up time 2). 
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9.8 Chapter Summary 
The diaries provided detailed descriptions of the experiences of chemotherapy patients 
undergoing chemotherapy. After comparing the diary entries from these participants 
with radiotherapy patients and healthy controls, it is clear that cognitive difficulties are 
ubiquitous and typically inconsequential. However, an interesting finding was that 
although chemotherapy patients reported using a greater number of compensatory 
strategies to manage cognitive difficulties, they did in fact experience more memory 
difficulties and the impact on daily life seemed more profound. In general, 
chemotherapy patients reported memory difficulties more frequently compared to 
radiotherapy patients and healthy controls, and also for an extended period of time. 
Cognitive difficulties in the chemotherapy group also fluctuated over time, which 
reflected the trajectory of their treatment. The difficulties reported by radiotherapy 
patients were often short-lived and coincided with the diagnosis of breast cancer, but 
improved following the commencement of radiotherapy treatment. Furthermore, the 
types of memory difficulties experienced by chemotherapy patients were more often 
linked to accidents and injuries. Healthy controls reported far more accounts of 
experiencing difficulty in making decisions. However, it is unclear whether this is 
because healthy controls experienced greater impairment in this cognitive function or 
because they were exposed to greater opportunities or contexts that required decisions 
to be made. The contextual information from one chemotherapy patient who revealed 
that she experienced difficulties with making decisions and so would do these on their 
“good days”. In addition, healthy controls struggled to make decisions regarding what to 
do with their free time. However, it may be that chemotherapy patients focus on only 
one task or thought at a time and therefore this excludes the need to making decisions in 
some contexts. This is an important finding and neuropsychological measures might not 
reflect this temporal change. Despite having experienced a number of adverse physical 
and psychological side effects associated with chemotherapy, a number of participants 
valued the benefits of this treatment and looked to the future. Chemotherapy patients 
expressed a number of psychosocial and cognitive difficulties in the workplace. 
Although these were frequently subtle changes, they still impacted upon their work 
ability.  
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It is important to consider how reliable it is to use a tool such as a diary to record 
cognitive failures, particularly memory difficulties. One chemotherapy participant 
wrote in her diary: “To be honest I have completely forgot to do this diary for the last few 
weeks. So will start again on the new one this week” (Participant CT18, follow-up time 1, week 
5). Healthy control participants also reported forgetting to write in the diary. This 
highlights the limitation of using this type of measure. However, considering the vast 
amount of data generated from the diaries, it is clear that this tool is able to provide 
detailed accounts of participants’ lived experiences. 
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Chapter Ten 
Discussion 
10.1 Chapter Introduction 
This thesis examined the impact of chemotherapy for breast cancer on patient’s ability 
to manage their daily tasks. In particular, cognitive, psychosocial and safety-related 
outcomes in the home and workplace were considered using a longitudinal, mixed-
methods design. The experiences of breast cancer patients undergoing chemotherapy 
were compared with a treatment control group and healthy control group. Data were 
collected using questionnaires and diaries. This chapter begins by integrating the 
quantitative and qualitative findings in relation to each objective, as outlined in Chapter 
Four (section 4.7). The strengths and limitations of the current research are then 
discussed. This is followed by a discussion of the implications of the findings and 
finally the chapter concludes with recommendations for future work. 
 
10.2 Summary of Key Findings 
In this section, the findings from the questionnaire phase and the diary phase are 
integrated and discussed in relation to the impact of chemotherapy for breast cancer on 
the following outcomes: psychosocial well-being, subjective cognitive function, safety-
related incidences, quality of life, and work ability. 
 
Pre-chemotherapy psychosocial well-being and cognitive function 
Inconsistent findings in the psycho-oncology literature concerning chemotherapy-
related cognitive impairment may relate to methodological limitations of previous 
research. For example, cross-sectional studies tend to report higher levels of cognitive 
impairment due to the lack of a pre-treatment measure that can be used to control for 
differences between participant groups. In this study, preliminary analyses of baseline 
data revealed no significant differences in subjective cognitive function between the 
chemotherapy group, radiotherapy group and healthy control group, which is in line 
with previous findings (e.g. Jenkins et al., 2006; Schagen, Muller, Boogerd, 
Mellenbergh, & van Dam, 2006; Stewart, Collins, Mackenzie, Tomiak, Verma, & 
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Bielajew, 2008). However, these findings are incongruent to other studies (e.g. Bender 
et al., 2006; Hermelink et al., 2007; Hurria et al., 2006; Ahles et al., 2008; Mar Fan et 
al., 2005; Paraska & Bender, 2003; Quesnel, Savard, & Ivers, 2009), and so this finding 
adds to the debate surrounding pre-chemotherapy cognitive function in the breast 
cancer population. In addition, there were no significant differences between any 
groups in baseline measures of depression and fatigue. In contrast, breast cancer 
patients about to undergo chemotherapy experienced significantly higher levels of 
anxiety compared to radiotherapy patients and healthy controls. Interestingly, breast 
cancer patients about to receive radiotherapy experienced the lowest levels of anxiety. 
There are several potential reasons that may explain this difference in levels of anxiety. 
Breast cancer patients in the chemotherapy group were more likely to be diagnosed 
with a more advanced stage of breast cancer, which could pose a greater risk to 
survival, and subsequently a more rigorous form of treatment was required (i.e. 
chemotherapy). Higher levels of anxiety in the chemotherapy group may have resulted 
from the impact of the diagnosis itself and/or the knowledge of the oncoming 
chemotherapy treatment and its associated (many) side effects. Alternatively, there may 
have been variation in the demographic characteristics of the samples. Healthy controls 
tended to be in full-time employment and so may have experienced relatively high 
levels of anxiety due to demanding workloads, whereas the radiotherapy group tended 
to be in retirement, which may give rise to a more sedentary lifestyle, as identified in 
Chapter Nine. In addition, older individuals may have greater exposure to, and 
experience of, breast cancer (since the incidence of breast cancer increases with age), 
such as attending mammogram screenings. Subsequently, the diagnosis and impending 
treatment may have had a reduced psychological impact in the radiotherapy group 
compared to those in the chemotherapy group who were generally younger and were 
more likely to be in full-time employment. However, it is important to note that there 
was no significant difference in levels of anxiety between the chemotherapy group and 
healthy control.  
 
These findings highlight the importance of including a pre-treatment baseline measure 
so that between-groups differences can be controlled for in repeated measures analyses. 
In doing so, any temporal fluctuations can be accurately attributed to the onset of 
treatment instead of pre-existing differences between participant groups. This is 
highlighted by the diary findings, and also reported elsewhere (e.g. Cheung, Shwe, Tan, 
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Fan, Ng & Chan, 2012;  Hurria et al., 2006), where participants acknowledged that they 
experienced cognitive difficulties prior to the commencement of treatment. 
 
The impact of chemotherapy for breast cancer on psychosocial well-being 
The quantitative findings suggest that chemotherapy may adversely impact upon 
depression and fatigue, although not anxiety, particularly at mid-chemotherapy (follow-
up time 1). Chemotherapy patients self-reported significantly higher levels of 
depression and fatigue compared to radiotherapy patients and healthy controls at 
follow-up time 1. However, by follow-up time 2 (towards the end of chemotherapy 
treatment) both depression and fatigue scores reached similar levels to those reported by 
the radiotherapy group and healthy control group. The radiotherapy group and healthy 
control group exhibited similar levels of fatigue with minimal fluctuation over time 
This finding suggests that chemotherapy treatment may have an acute impact on the 
depression and fatigue, which alleviate as the administration of chemotherapy treated 
reduces.  
 
The qualitative findings supported the quantitative findings. In relation to depression, 
the diaries revealed that chemotherapy patients became emotionally upset by relatively 
“small things which are easily solved” (Participant CT60), particularly earlier on in the 
treatment course. Some chemotherapy patients experienced lymphoedema, which 
persisted up to follow-up time 3, and often resulted in feeling depressed. In relation to 
fatigue, there were many more reports of feeling fatigued in the chemotherapy group 
than in the control groups and chemotherapy patients described a more severe type of 
fatigue. Participants from all groups commented on napping to help resolve feeling 
fatigued; however, for several chemotherapy patients, they had to take time off work  
and “do little but sleep” (Participant CT29). The qualitative findings also provided a more 
in-depth account of the subtle temporal fluctuations of participants’ experiences. For 
example, a number of chemotherapy patients reported a cyclical experience of feeling 
fatigued that coincided with each administration of chemotherapy, as illustrated by the 
following extract: “Tiredness came after say 5-7 days after treatment but I soon felt back to 
normal after 3-4 days” (Participant CT29). Taken together, the findings from the 
questionnaires and diaries suggest that chemotherapy treatment can have a profound 
impact on breast cancer patients’ daily lives, in particular resulting from fatigue. This 
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side effect inhibits patients from carrying out simple daily tasks and leaves patients 
needing to sleep excessively so that they are able to regain their energy. 
 
Quantitative findings from the questionnaire survey demonstrated no impact of 
chemotherapy on anxiety, as participants in the chemotherapy group, radiotherapy 
group, and healthy control group reported relatively similar levels of anxiety across all 
follow-up time-points. Although chemotherapy patients experienced higher levels of 
anxiety at baseline, the qualitative findings also revealed that feelings of anxiety 
subsided over time, “Starting chemotherapy first session I was rather anxious, but this soon 
diminished further into the treatment” (Participant CT29). Furthermore, diary extracts 
showed that some chemotherapy patients used strategies to help them manage anxious 
feelings (related to cognitive difficulties), such as writing things down, pacing 
themselves, and taking sickness absence from work. It may be that anxiety is easier to 
manage than depression and fatigue. For example, cancer-related fatigue is thought to 
be severe in cancer patients and cannot always be alleviated by rest (Cella, Lai, Chang, 
Peterman, & Slavin, 2002). Alternatively, although anxiety levels were particularly high 
in the chemotherapy group at pre-treatment baseline, it may be that this was due to the 
thought of the oncoming course of chemotherapy and its associated, well-documented 
numerous side effects. Anxiety levels may then lessened due to familiarity with the 
treatment, as suggested by the excerpt above. Jacobsen, Bovbjerg and Redd (1993) 
described this as anticipatory anxiety reducing over time. Furthermore, breast cancer 
patients may have received further information from healthcare professionals about 
their prognosis and obtained support from cancer support groups and other patients, 
which again may have helped to alleviate anxiety. 
 
The impact of chemotherapy for breast cancer on cognitive functioning 
The psycho-oncology literature provides evidence of subtle cognitive difficulties in 
breast cancer patients undergoing chemotherapy. Unexpectedly, the quantitative 
findings from the questionnaire phase revealed subtle but non-significant differences in 
subjective cognitive function scores between the chemotherapy group, radiotherapy 
group and healthy group, and over time. This contradicts the findings from a number of 
previous longitudinal studies (e.g. Bender et al., 2006; Hermelink et al., 2007; Jansen, 
Dodd, Miaskowski, Dowling, & Kramer, 2008). In the current study, significant 
between-groups difference were no longer significant after controlling for baseline 
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anxiety, depression and fatigue, which illustrates the importance of accounting for 
confounding variables.  
 
Mean CFQ scores in the chemotherapy group were 37.98, 37.89 and 35.60 at follow-up 
time 1, time 2 and time 3, respectively. Wagle, Berrios, and Ho (1999) suggested that 
typical CFQ scores range from 25 to 35 in the general population, which was true for 
the mean score found in the radiotherapy group and healthy control group, and so 
suggests that chemotherapy patients may have experienced subtle cognitive impairment. 
Although this is a reassuring finding for breast cancer patients undergoing 
chemotherapy, it is important to recognise that even subtle cognitive changes can have a 
detrimental impact on daily functioning and quality of life (Meyers & Perry, 2008; 
Vardy & Tannock, 2007), as evidenced by the qualitative findings. Findings from the 
diary phase and responses to the open-ended questionnaire items revealed that all 
participant groups experienced cognitive difficulties, in particular memory difficulties, 
concentration difficulties, language difficulties, and psychomotor difficulties. However, 
excerpts revealed that chemotherapy patients experienced these cognitive difficulties 
more frequently, and most notably between baseline and follow-up time 2. Similar 
findings have been reported in previous qualitative work (e.g. Cheung, Shwe, Tan, Fan, 
Ng, & Chan, 2012; Downie, Mar Fan, Houede-Tchen, Yi, & Tannock, 2006; Munir, 
Burrows, Yarker, Kalawsky, & Bains, 2010; Myers, 2010). Furthermore, the impact of 
these cognitive difficulties on daily functioning included difficulty driving and 
returning to the workplace, which corroborates findings reported by Myers (2010) and 
Thielen (2008). Chemotherapy patients in the current study described difficulty reading 
a book and word finding ability, as well as using more compensatory strategies (e.g. ‘to 
do’ list, diary, calendar) than normal, which is congruent with findings by Boykoff, 
Moieni, and Subramanian (2009) and Cheung et al. (2012). The diary findings also 
suggested that family members were used as a source of support, particularly following 
the administration of each chemotherapy cycle when side effects were more acute, 
which has also been documented by other researchers (e.g. Mulrooney, 2007; Myers, 
2010). In support of the quantitative findings, the qualitative findings also illustrated 
that cognitive function improved by follow-up time 3, as documented by one 
chemotherapy patient, “Memory and concentration issues have been much reduced since 
chemo finished” (Participant CT32), while others reported feeling “back to normal”.  
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As reported above, several chemotherapy patients noticed a decline in cognitive 
function while receiving chemotherapy, which is reflected by the CFQ scores reported 
above. The diary findings captured more subtle temporal fluctuations, revealing a 
cyclical pattern of cognitive impairment linked to the cycles of chemotherapy 
administration. Improvements in cognitive function were described by a number of 
breast cancer patients by follow-up time 2, although resumption to normality was not 
expressed by some patients until follow-up time 3. These findings suggest that 
chemotherapy can have an enduring impact on cognitive function in some individuals. 
This pattern is somewhat reflected in the questionnaire data, as shown in Figure 6.4 (see 
Chapter Six), which shows a subtle decrease in the number of cognitive failures 
experienced at follow-up time 1 to follow-up time 3.  
 
The qualitative findings provide insightful contextual information relating to potential 
reasons why cognitive function improved over time. It may be that chemotherapy 
patients develop compensatory strategies to manage their cognitive difficulties (Calvio, 
Peugeot, Bruns, Todd, & Feuerstein, 2010). The qualitative findings suggested that 
chemotherapy patients used a greater range of memory aids compared to radiotherapy 
patients and healthy controls (see Chapter Nine, Table 9.8). Alternatively, the lack of a 
significant difference between the cognitive function scores in the chemotherapy group, 
radiotherapy group and healthy control group could be the result of participants in the 
radiotherapy group experiencing ‘cognitive frailty’ due to their older age (Hurria et al., 
2006) and healthy controls experiencing higher cognitive loads (due to their full-time 
jobs), leading to both control groups experiencing relatively high levels of cognitive 
difficulties than would typically be reported in the general population. The radiotherapy 
group scored 34.83, 33.91, 34.16, and the healthy control group scored 33.53, 34.23, 
33.69, at follow-up time 1, time 2 and time 3, respectively, which are on the upper end 
of Wagle’s (1999) range for the general population. 
 
Recently, Schagen, Das and van Dam (2009) demonstrated that priming or pre-existing 
knowledge regarding the concept of chemotherapy-related cognitive impairment 
significantly increases the reporting of cognitive complaints. However, for ethical 
reasons, it was necessary to inform participants of the purpose of research and so the 
association between chemotherapy and possible cognitive difficulties is evident in 
Information Sheets. In addition, breast cancer patients may have knowledge about 
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chemotherapy-related cognitive impairment through the media or cancer support groups 
(Schagen, Das, & van Dam, 2009). However, findings from the diaries suggested that 
this may not be an issue in this work because although some chemotherapy patients 
reported that they believed chemotherapy to be the cause of their cognitive difficulties, 
others dismissed this idea and described that these difficulties existed prior to 
chemotherapy and instead were age-related (see Chapter Nine, Tables 9.7 & 9.10). 
 
Consistent with other longitudinal studies, subjective cognitive function was 
significantly related to anxiety and depression (Hermelink et al., 2007; Schagen, van 
Dam, Muller, Boogerd, Lindeboom, & Bruning, 1999) as well as fatigue. This suggests 
that as impairment in one of these variables increases, so does impairment in the others. 
It was anticipated that anxiety, depression and fatigue scores would predict subjective 
cognitive functioning scores. However, significant predictors of cognitive function in 
the chemotherapy included anxiety at follow-up time 1, age and anxiety at follow-up 
time 2, and depression at follow-up time 3. Based on these findings, it could be 
suggested that reducing levels of anxiety and depression may reduce the frequency of 
perceived cognitive difficulties. 
 
The impact of chemotherapy for breast cancer on safety outcomes 
The findings from both the quantitative and qualitative data analyses have been 
integrated and incorporated into Figure 10.1 (see below). This figure demonstrates how 
the risk factors for safety-related outcomes change over time. Note that significant 
predictors identified following regression analyses are in bold. At baseline, findings 
from the questionnaire data analysis showed no difference in the distribution of 
accidents reported between participant groups in the home. Depression and cognitive 
difficulties were associated with safety-related outcomes, but neither were significant 
predictors. Findings from the thematic analysis support the link between cognitive 
difficulties and unsafe behaviour, as one chemotherapy patient frequently reported 
forgetting to turn off her cooker at baseline. The qualitative findings also provided a 
more in-depth understanding of the factors impacting upon safety between baseline and 
follow-up time 1. For example, detailed accounts provided by participants describing 
the context of accidents identified the specific types of cognitive difficulties that were 
involved, such as spatial awareness difficulties, “Cut right thumb whilst in kitchen. Can’t 
judge distances i.e. knife to thumb…Burnt elbow twice because not aware of pan on stove when 
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standing next to it” (Participant CT60, baseline). Furthermore, the chemotherapy group 
commented on several factors that they thought were associated were hazardous events, 
including fatigue, neuropathy, weakness in legs, and lymphoedema. These findings 
suggest that there are both psychological and physical risk factors that contribute to 
potentially unsafe outcomes in the breast cancer population. 
 
At follow-up time 1, the quantitative findings showed that chemotherapy patients 
encountered accidents more frequently compared to the two treatment groups. Fatigue 
and cognitive difficulties were associated with safety-related outcomes and results from 
the regression analyses revealed that cognitive function significantly predicted accident 
frequency. This could be explained by the previous finding that chemotherapy patients 
reported slightly more cognitive difficulties compared to the control groups, particularly 
at follow-up time 1. This association between cognitive difficulties and accidents has 
been reported in the safety literature (e.g. Larson, Alderton, Neideffer, & Underhill, 
1997; Larson & Merritt, 1991). Findings from the qualitative data analysis revealed that 
chemotherapy patients identified fatigue, loss of balance and neuropathy as being 
associated with unsafe behaviour between follow-up time 1 and follow-up time 2. 
Similar physical treatment-related side effects have also been linked to accident 
proneness previous research (e.g. Myers, 2010). Chemotherapy patients reported 
difficulty performing daily tasks, such as putting on socks, dropping objects, and 
tripping over things due to numbness in the extremities. 
  
Towards the end of chemotherapy treatment, chemotherapy patients reported fewer 
accidents and the quantitative findings demonstrated that there were no differences in 
the frequency of accidents reported between participant groups at follow-up time 2. 
Although fatigue, depression and cognitive difficulties were found to be significantly 
correlated with accidents, none of these variable significantly predicted accidents. 
However, this may have been due to collinearity amongst the predictor variables. 
Findings from the qualitative data analyses revealed that only fatigue and neuropathy 
were thought to have an impact on safety-related outcomes between follow-up time 2 
and follow-up time 3. This may reflect enduring treatment-related side effects, and so it 
is important that patients are aware of these. One chemotherapy patient frequently 
described the impact of the neuropathy she experienced, including “a really nasty 
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fall…Tripped over the edge of a mat in the conservatory. Hit my head on the edge of a concrete 
step…Feet very numb…Numbness continuing so I’m still a bit clumsy” (Participant CT16). 
 
At follow-up time 3, quantitative findings revealed that chemotherapy patients once 
again reported more accidents compared to the two controls groups. The significant 
difference in accident frequency between participant groups at follow-up time 3 may 
result from chemotherapy patients returning to employment or other activities (as 
suggested by the diary excerpts, “My life is 100% back to normal now” (Participant CT33), 
and therefore increasing the number of potentially hazardous events encountered.  
 
With regards to accidents in the workplace, all participant groups reported similar levels 
of accidents in the workplace as measured by the questionnaire survey at each time-
point. Since Salminen and Heiskanen (1997) found high correlations between accidents 
at work, traffic accidents and accidents during leisure activities, it was surprising to find 
no difference in the distribution of accidents in the workplace at each follow-up time-
point in the current study. However, it is important to note that the sample size of the 
chemotherapy group in particular fluctuated for this analysis: 40.00%, 18.64%, and 
8.77% of chemotherapy patients took sickness absence at follow-up time 1, follow-up 
time 2 and follow-up time 3, respectively. Therefore, it may be that those chemotherapy 
patients who were experiencing an increased number of accidents took sickness absence 
to avoid injury in the workplace. Some chemotherapy patients described using cognitive 
aids, such as a calendar, more frequently since undergoing chemotherapy. Since 
cognitive difficulty has been shown to predict accidents, the increased use of cognitive 
aids could reduce this risk. Furthermore, one chemotherapy patient described a change 
to her daily routine, which may reduce the impact of treatment-related side effects at 
work: “I do 100% at work but go to bed at 4pm as soon as I get home”.
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Figure 10.1. Accident theory model illustrating risk factors as reported by breast cancer patients undergoing chemotherapy (Lawrence Model 2) 
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The impact of chemotherapy for breast cancer on quality of life 
The chemotherapy group reported significantly lower quality of life scores at follow-up 
time 1 compared to the control groups, however scores reached levels in line with the 
control groups by later time-points. As expected, anxiety, depression, fatigue, cognitive 
function, and accident frequency in the home were all significantly correlated with 
quality of life in the chemotherapy group. Ignoring accident frequency (as this has not 
previously been considered in the breast cancer population), this supports previous 
findings (Schagen, van Dam, Muller, Boogerd, Lindeboom, & Bruning, 1999). This 
relationship could explain the temporal fluctuation in quality of life scores as these 
factors were most prevalent at follow-up time 1. Furthermore, it was gleaned from the 
diary entries that chemotherapy patients implemented more compensatory strategies to 
help alleviate the negative effects of treatment on daily life, which may have improved 
quality of life over time.  
 
In addition to practical changes, chemotherapy patients also underwent psychological 
changes over time, in the sense of an outlook on life. Between baseline and follow-up 
time 2, many diary extracts revealed accounts of poor quality of life; however, by 
follow-up time 3, reports on quality of life were more positive. For example, one 
woman undergoing chemotherapy reported feeling “back to normal” by follow-up time 3 
and had a holiday and breast reconstruction to look forward to, whereas another woman 
described there being “a light at the end of the tunnel” to reflect her change to a more 
optimistic perspective regarding the cancer experience. While radiotherapy patients also 
underwent treatment, the experience was typically short-lived as radiotherapy lasts 
several weeks as opposed to months and has fewer associated physical and 
psychological side effects than chemotherapy. Similar to Mulrooney (2007), cognitive 
impairment affected self-esteem as participants described feeling “stupid”, “silly” and 
“daft”. 
 
The impact of chemotherapy for breast cancer on work ability 
Questionnaire data revealed temporal differences in work ability. Interestingly, at 
baseline, chemotherapy patients rated their mental work ability as being significantly 
poorer than healthy controls. This may reflect pre-occupation and high levels of anxiety 
following a recent diagnosis. At follow-up time 1, overall work ability was significantly 
poorer in the chemotherapy group compared to the control groups. This was expected 
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since, as previously stated, psychosocial and cognitive side effects were more 
pronounced at this time. Somewhat surprisingly, few variables were significantly 
related with work ability. However, this may reflect the fluctuation in sample size at 
each time-point due to chemotherapy patients taking sickness absence. 
 
A number of chemotherapy patients involved in the diary phase described concentration 
difficulties impacting upon work ability. This finding is consisted with other research 
(Munir, Burrows, Yarker, Kalawsky, & Bains, 2010; Myers, 2010). While the majority 
of chemotherapy patients took sickness absence due to the inability to cope with work 
tasks related to cognitive difficulties, for one chemotherapy patient, returning to work 
was physically and mentally challenging, however it did improve her confidence. 
 
Contribution to current knowledge 
Findings from this research contribute to several literatures. Firstly, further evidence is 
offered to the psycho-oncology literature regarding the impact of chemotherapy for 
breast cancer on patients’ daily functioning. Secondly, findings broaden the current 
accident literature to include evidence on prevalence and severity of accident risk in 
breast cancer patients undergoing chemotherapy, as well as the predictors of accidents 
within this population.  
 
This thesis could help (a) health professionals to provide clear information to breast 
cancer patients about potential treatment side effects; (b) enable breast cancer patients 
to make informed treatment decisions and evaluate the risk-benefit factors of treatment; 
(c) inform employers of potential treatment-related side effects that breast cancer 
survivors may experience in the workplace and identify what adjustments may be 
necessary to improve the successful transition of cancer survivors back into the 
workplace, and (d) identify appropriate interventions to support breast cancer patients to 
effectively manage their daily tasks. This research also exemplifies the value of 
employing a mixed-methods approach, which is currently under-utilised within psycho-
oncology research, to provide a holistic understanding of treatment-related side effects 
among breast cancer patients that could be recommended for future research. 
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10.3 Methodological Considerations 
As outlined in Chapter One, there have been recent recommendations in the psycho-
oncology literature for research to adopt longitudinal designs (including pre-treatment 
baseline) with treatment and healthy control groups to address the limitations associated 
with previous work (Vardy et al., 2008). This study addressed these recommendations 
and as a result it was able to control the effect of covariates to allow for a realistic 
assessment of the impact of chemotherapy on important outcomes (Jenkins et al., 2006). 
Furthermore, the mixed-methods approach proved valuable. For example, several breast 
cancer patients noted a cyclical nature to their side effects, such as feeling particularly 
tired for several days following chemotherapy administration. However, the 
questionnaire survey did not capture these subtle temporal fluctuations due to the four 
months between questionnaires. This is important to recognise when interpreting 
findings from longitudinal research. In particular, this could have important 
implications for where interventions would be most effective and useful for the 
individual. 
 
There are issues regarding the generalisability of the findings to the wider breast cancer 
population in the UK for several reasons. Firstly, male breast cancer patients were 
excluded from the current study since notable differences in the experiences of breast 
cancer in males and females have been documented (Ravandi-Kashani & Hayes, 1998). 
Unfortunately, due to the limited timeframe and resources inherent in a PhD project, it 
would not have been feasible to recruit a sufficient cohort of male breast cancer patients 
in order to provide generalisable findings to this subpopulation. Therefore, this thesis 
reviewed and documented the experiences of female breast cancer patients only. It is 
acknowledged that future studies with sufficient resources should consider the 
experiences of this subpopulation. 
 
As outlined in Chapter Five, in addition to on-site recruitment at five NHS cancer 
clinics, efforts were made to recruit breast cancer patients from across the UK via 
support groups. Despite a number of advertisements displayed at support groups centres 
and on online forums, only three breast cancer patients expressed an interest in the 
study, and only one patient remained in the study. Potential reasons for this low 
recruitment rate may be the lack of direct researcher presence, meaning that participants 
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are required to be proactive and contact the researcher themselves, and it may be that 
few breast cancer patients access support groups prior to the commencement of their 
treatment. Whilst the recruitment from two NHS hospitals from different counties has 
its advantages, further multi-centre research spanning larger geographic areas is 
necessary in order to recruit larger samples and broaden the generalisability of the 
findings to the UK breast cancer population. 
 
In addition, this study was limited by its relatively small sample size, which is a 
common limitation in psycho-oncology research (e.g. Jansen, Dodd, Miaskowski, 
Dowling, & Kramer, 2008). Although the sample sizes are higher compared to recent 
longitudinal studies examining cognitive difficulties in breast cancer patients (Bender et 
al., 2006; Collins, Mackenzie, Stewart, Bielajew, & Verma, 2009; Hurria et al., 2006; 
Quesnel, Savard, & Ivers, 2009), findings from the power calculations (see Chapter 
Five) suggest that larger samples sizes than obtained would have been able to detect a 
medium effect size for all analyses conducted. Therefore, the findings from the 
questionnaire phase should be interpreted with caution. However, a strength of this 
study is its relatively low attrition rate compared to other studies. This may reflect the 
less burdensome nature (e.g. time demands) of the questionnaire design compared to 
neuropsychological testing. With regards to the diary phase, the sample size was 
comparable to other qualitative work by Mulrooney (2007) (n = 10), Munir, Burrows, 
Yarker, Kalawsky, & Bains (2010) (n = 13), and Thielen (2008) (n = 13).  
 
Another shortcoming is the use of convenience samples. Although a highly popular 
recruitment strategy (e.g. Jansen, Dodd, Miaskowski, Dowling, & Kramer, 2008), 
convenience samples may not always result in a representative sample and findings 
must therefore be interpreted with caution. In the current study, age, family and work 
pressures may have confounded results. Although the sample characteristics of the 
chemotherapy group were similar in age as previous studies (e.g. Jansen et al., 2008), 
and the chemotherapy group were closely matched on age with the healthy control 
group in the current study, the radiotherapy patients were significantly older. This may 
reflect the fact that older patients tend to be offered non-invasive treatment (such as 
radiotherapy), and so recruiting an age-matched sample of radiotherapy patients may 
have been out of the researcher’s control. However, it is important to consider the 
impact of this potentially confounding factor. In particular, the literature reviewed in 
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Chapter Three suggested that older people are more likely to experience memory 
difficulties and in Chapter Four it was shown that older people tend to experience more 
accidents. Therefore, these age-related differences may mask any treatment-related 
differences when comparing the experiences of patients who have received radiotherapy 
treatment and those who received chemotherapy treatment. Subsequently, it was 
important to statistically control for age in the quantitative analyses when necessary. 
 
Furthermore, the healthy control group had a disproportionately higher level of 
education compared to the chemotherapy group and radiotherapy group, which may 
reflect the interest of academics in the study following the University press release. In 
addition, participants in the radiotherapy group were more likely to be retired, whereas 
healthy control participants were more likely to be in full-time education. 
Consequently, the healthy control group may have experienced greater family and work 
pressures. Again, these differences may have masked any impact that chemotherapy 
may have had in the chemotherapy patient group. Although there were no significant 
differences in marital status between the participant groups, results from the diaries 
analyses showed that some participants were caring for young families or older 
relatives. These family pressures may have had an impact on the outcomes examined in 
the current study. 
 
Finally, response bias may have been present in the diary study. All participants 
consenting to the questionnaire phase were invited to take part in the diary phase. The 
purpose of the diary study was briefly explained: to obtain a better understanding of the 
context surrounding any incidences of cognitive failures, near-misses and unintentional 
injuries participants may experience. Those participants believing to experience 
relatively few such incidences may have opted out of the study considering their 
experiences irrelevant to the study. Indeed, several participants decided to withdraw 
from the diary study after several weeks of keeping the diary as they found they had 
little incidences to report. Despite reassurances from the researcher that blank diaries 
were useful as it demonstrates they were experiencing fewer incidences, participants 
maintained their desire to withdraw from the study. Therefore, the diaries may be 
biased to those experiencing higher incidences of psychosocial difficulties, cognitive 
impairment and accidents. Participants may have thought they were wasting their own 
time by not having much to write about. Perhaps future diary studies could include a 
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tick box indicating that no or fewer difficulties were experienced so that participants 
still feel that they are contributing something to the study. In addition, some breast 
cancer patients withdrew from the study due to treatment-related side effects, such as 
feeling ill, tiredness and cognitive difficulties resulting in forgetting to make entries or 
being able to concentrate on making entries. This is linked to the Metamemory Paradox, 
which proposes that individuals experiencing cognitive impairment inherently have 
difficulty in remembering these incidences. 
 
Some participants who kept a diary commented that they forgot what incident they 
wished to write about. Shilling and Jenkins (2007) found that when breast cancer 
patients were interviewed regarding their cognitive difficulties and asked to provide 
multiple examples of difficulties encountered, many were unable to do so. They 
concluded that this was because these accounts were not meaningful to the participants. 
However, an alternative interpretation is that subtle memory difficulties are frequent 
and as the diaries reveal can have an emotional impact, affect confidence and quality of 
life. Furthermore, several chemotherapy patients withdrew from the study or failed to 
return some questionnaire survey due to feeling unwell. 
 
10.4 Implications of Findings 
There are approximately 46,100 diagnoses of breast cancer in women annually in the 
UK (Office for National Statistics, 2011a). The survival rate is increasing and so 
women look to maintain a normal life during and beyond treatment. Due to the 
extension of working life in the UK, it is anticipated that there will be more cases of 
breast cancer in the workplace in the near future. Findings from this research suggest 
that chemotherapy treatment can have important implications for daily functioning in 
the home and workplace. 
 
Implications of findings for health professionals 
This thesis has expanded the current knowledge of psychosocial and cognitive side 
effects associated with chemotherapy for breast cancer as well as providing novel 
information regarding the link between these psychological side effects and accident 
risk. Recent research has documented that health professional’s lack information on 
chemotherapy-related cognitive impairment (Cheung, Shwe, Tan, Fan, Ng, & Chan, 
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2012; Munir, Kalawsky, Lawrence, Yarker, Haslam, & Ahmed, 2011; Myers & Teel, 
2008). It is important that information regarding the potential safety implications of 
chemotherapy-related cognitive impairment is disseminated to health professionals so 
that future breast cancer patients can be educated and awareness is increased. 
Subsequently, this could improve informed consent for treatment options. However, 
since the aetiology of chemotherapy-related cognitive impairment is currently unclear, 
it is important that breast cancer patients are informed that psychosocial factors and 
other treatments for breast cancer may also contribute to cognitive changes. By 
providing this information, at an early stage, it could help to improve patients’ 
management of these side effects. For example, they could implement coping strategies 
(Bender et al., 2008). Indeed, awareness alone could help to diffuse patient concern 
regarding whether these side effects are “normal” or whether they were “losing [their] 
marbles”. It is important that further qualitative work is conducted on the lived 
experiences of breast cancer patients so that healthcare professionals can provide 
information on a profile of normal side effects following chemotherapy. Skalla, Bakitas, 
Furstenberg, Ahles, and Henderson (2004) found that cancer patients want information 
about specific side effects of treatment as well as the impact of treatment on their lives. 
Future work should consider which chemotherapeutic agents are associated with side 
effects so that healthcare professionals are better informed of the risks associated with 
chemotherapy regimens. 
 
Implications of findings for patients and relatives 
The finding that cognitive function did not significantly differ from control groups or 
over time is a reassuring finding for prospective chemotherapy patients, although 
qualitative findings suggested more subtle temporal changes can have a detrimental 
impact upon daily functioning. Recent qualitative research identified that breast cancer 
patients value receiving information regarding chemotherapy-related side effects, such 
as cognitive difficulties (Myers, 2010), and so it is likely that the potential impact of 
these side effects on safety outcomes would also be valued. It is vital that breast cancer 
patients are provided with comprehensive information regarding the potential side 
effects associated with their treatment options. A lack of awareness promotes issues 
relating to a lack of informed consent (Myers, 2010). Myers reported that 33% of 
participants were informed about chemotherapy-related cognitive changes and some 
wished to be involved in intervention to improve their cognitive function. This shows 
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that breast cancer patients want to reduce the impact of treatment-related side effects 
and manage their daily tasks effectively. The findings from the current study also 
highlight that it is important that breast cancer patients are able to perform their daily 
tasks safely. 
 
An interesting finding from the diary phase was that despite employing cognitive aids, 
chemotherapy patients experienced more cognitive difficulties compared to the other 
two groups. It may also be that these types of aids are not effective in this group or that 
they are not being used to their best advantage. It may be that breast cancer patients 
need assistance and information regarding the most appropriate tools to help manage 
the impact of cognitive impairment on daily tasks. 
 
Implications of findings for employers 
It is important that employers recognise that chemotherapy-related side effects can 
impact upon work ability. Since many chemotherapy patients took sickness absence 
during treatment, little information was gleaned regarding the impact of treatment-
related side effects on safety in the workplace. Work adjustments may be necessary for 
breast cancer patients undergoing chemotherapy and employers may need tailored 
evidence-based guidance on how best to minimise potential safety risks so that 
employees undergoing treatment for breast cancer can successfully manage their return 
to work and work ability within a safe and supportive environment. 
 
Future research directions 
These findings highlight the need for future research to consider both the physical and 
psychological side effects of chemotherapy for breast cancer in order to fully 
understand the impact of treatment on safety-related outcomes. Firstly, it is important 
that the findings from the current study are validated, which could be done through 
further triangulation of the study results by follow-up interviews with the current 
participants in order to provide an additional source of data collection to support the 
current findings. In addition, the findings could be presented at breast cancer survivor 
groups and the feedback from these individuals could be analysed to examine whether 
their experiences are congruent with those who took part in the current study. Further 
longitudinal work is also required to map temporal changes in different types of 
accidents during and following chemotherapy so that interventions can be applied at 
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their most effective stage. Assessment time-points should be relatively close together 
during chemotherapy to coincide with the cycles of administration when side effects are 
at their most profound, as identified by the qualitative findings. The more long-term 
side effects and their impact should also be a focus for future work, especially as subtle 
cognitive difficulties may become more pronounced once patients resume functional 
ability, such as social and work activities (Ferguson, McDonald, Saykin, & Ahles, 
2007; Meyers & Perry, 2008; Vardy & Tannock, 2007).  
 
Furthermore, more work is required to explore return to work and safety issues as there 
may be scope for utilising work as a form of rehabilitation. Evidence for this comes 
from findings reported in the diaries, as one chemotherapy patient described how 
returning to work improved her cognitive function and she seemed to enjoy resuming 
her working life: “Once returning to work my mind was much better” (Participant CT60). 
Another chemotherapy patient reported how returning to work improved her 
confidence: “I have had a phased return over 6 weeks, gradually increasing hours and 
teaching load until reached 4 full days/week (pre-diagnosis level). Finding it physically and 
mentally exhausting but confidence has improved noticeably since starting return” (Participant 
CT34). However, it is important to consider that there may be more opportunities for 
accidents to occur in the workplace as individuals may be potentially exposed to a 
greater number of hazards. Further intervention studies are required to help manage the 
impact of cognitive and psychosocial difficulties on safety outcomes. Although several 
interventions currently under investigation in the literature include exercise and 
cognitive retraining, more specialised approaches may be required to minimise 
accidents and injuries in the breast cancer population. A number of intervention studies 
to improve quality of life in cancer patients have been conducted. However, relatively 
few studies have specifically addressed cognitive side effects in cancer patients. Indeed, 
many studies exclude cancer patients with cognitive difficulties (Locke, Cerhan & 
Malec, 2008). In contrast, cognitive rehabilitation interventions are widely applied in 
patients with acquired brain injury (Locke, Cerhan, & Malec, 2008). As previously 
stated, since the cognitive side effects of cancer and its treatment tend to be subtle, 
compensatory strategies could be applied by the patients themselves, such as using 
memory aids (e.g. cue cards). 
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These findings may also facilitate the development of self-reports tools to quantify 
chemotherapy-related side effects. As recently acknowledged by Myers (2010), self-
report measures of cognitive function designed for cancer patients, such as the 
Functional Assessment for Cancer Therapy-Cognition (FACT-COG), do not include 
items related to driving or reading ability. This suggests that further qualitative studies 
are required to develop a comprehensive in-depth understanding of the range of side 
effects associated with chemotherapy (including psychosocial, cognitive and physical). 
As found in the current study, diaries can be a valuable tool for capturing in-depth data, 
and findings could be used to develop standardised measures, such as questionnaires 
and neuropsychological tests. This will help to ensure that the complete experience of 
breast cancer patients undergoing chemotherapy is understood and examined 
accurately. Since many side effects are interactive, it is important to address as many as 
possible for intervention to reduce the impact of chemotherapy on daily functioning. 
This provides support for adopting a holistic approach to disease and healthcare, as 
suggested by the biopsychosocial model. This is in line with the national service 
frameworks (NSFs), previously discussed in Chapter One. Qualitative work can provide 
the opportunity to record the lived experiences from the ‘expert patient’ so that a 
comprehensive understanding of treatment on daily can inform interventions in a 
patient-focussed manner (Department of Health, 2009). There needs to be a balance 
between comprehensive measures that capture the range of side effects, but not 
excessively time-demanding as this may induce fatigue, which could invalidate results.  
 
As previously discussed in Chapter Three, researchers examining chemotherapy-related 
cognitive impairment have employed a diverse range of methodological designs (Vardy 
et al., 2008). Subsequently, this can make it difficult to compare findings across studies. 
Despite the growing literature on the cognitive impact of chemotherapy in the breast 
cancer population, there is a need for greater collaborative efforts involving multi-
centre recruitment sites to undertake large-scale standardised research (Hurria, Somlo, 
& Ahles, 2007). Future research needs to investigate these important outcomes in a 
larger and more representative sample to validate the current findings. In particular, 
further longitudinal studies are required to determine the nature of cognitive impairment 
in breast cancer patients undergoing chemotherapy (e.g. prevalence, onset, duration) as 
well as the implications on daily life. There is an obvious need for further work to 
consider the safety outcomes associated with chemotherapy treatment in the breast 
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cancer population. In turn, intervention strategies could be developed to facilitate 
effective management of daily tasks in the breast cancer population. Furthermore, 
although the majority of research examining the impact of chemotherapy-related side 
effects is conducted in breast cancer patients due to the relatively large incidence and 
high survival rate of this disease, it is important that further work is conducted in other 
cancer populations. 
 
10.5 Conclusion 
To summarise, the findings from the quantitative analysis of the questionnaire data and 
the qualitative analysis of the diary data provided a valuable insight into the impact of 
chemotherapy on psychosocial well-being, cognitive function, and safety outcomes. In 
particular, the diaries provided rich data on the lived experiences of breast cancer 
patient’s management of their daily tasks during chemotherapy. This offered valuable 
supplementary data to the quantitative analyses. Breast cancer patients undergoing 
chemotherapy report some temporal changes to their psychosocial well-being, cognitive 
function, physical function, and experience of accidents, which reflect the course of 
their treatment. However, the aetiology of these experiences is unclear and further 
research is required to establish the exact causes. Meanwhile, the identification of safety 
outcomes related to cognitive, psychosocial and physical side effects needs to be taken 
seriously by health professionals, as clearly they can have a detrimental impact on 
patients’ daily lives. In particular, as the survival rate of breast cancer is increasing and 
prognosis improves, many patients are now looking to resume pre-diagnosis levels of 
daily functioning following treatment or continuing typical activities throughout 
treatment. Therefore, it is important that they are aware of potential safety-related side 
effects so that they can minimise potential hazards. 
                References 
274 
References 
Aapro, M., & Cull, A. (1999). Depression in breast cancer patients: The need for treatment. 
Annals of Oncology, 10(6), 627-636. 
Abraham, J., Haut, M. W., Moran, M. T., Filburn, S., Lemiuex, S., & Kuwabara, H. (2008). 
Adjuvant chemotherapy for breast cancer: Effects on cerebral white matter seen in 
diffusion tensor imaging. Clinical Breast Cancer, 8(1), 88-91. 
Adler, N., & Page, A. (2008). Cancer care for the whole patient: meeting psychosocial 
health needs. Washington, DC: Institute of Medicine: The National Academies Press. 
Ahles, T. A., Saykin, A. J., Furstenberg, C. T., Cole, B., Mott, L. A., Titus-Ernstoff, L., et 
al. (2005). Quality of life of long-term survivors of breast cancer and lymphoma 
treated with standard-dose chemotherapy or local therapy. Journal of Clinical 
Oncology, 23(19), 4399-4405. 
Ahles, T. A., & Saykin, A. J. (2001). Cognitive effects of standard-dose chemotherapy in 
patients with cancer. Cancer Investigation, 19(8), 812-820. 
Ahles, T. A., & Saykin, A. J. (2002a). Breast cancer chemotherapy-related cognitive 
dysfunction. Clinical Breast Cancer, 3(Suppl. 3), 84-90. 
Ahles, T. A., & Saykin, A. (2002b). Cognitive effects of standard-dose chemotherapy in 
patients with breast cancer. Cancer Investigation, 19(8), 812-820. 
Ahles, T. A., Saykin, A. J., Furstenberg, C. T., Cole, B., Mott, L. A., Skalla, K., et al. 
(2002c). Neuropsychologic impact of standard-dose systemic chemotherapy in long-
term survivors of breast cancer and lymphoma. Journal of Clinical Oncology, 20(2), 
485-493. 
Ahles, T. A., & Saykin, A. J. (2007). Candidate mechanisms for chemotherapy-induced 
cognitive changes. Nature Reviews Cancer, 7, 192-201. 
Ahles, T. A., Saykin, A. J., Noll, W. W., Furstenberg, C. T., Guerin, S., Cole, B., et al. 
(2003). The relationship of APOE genotype to neuropsychological performance in 
long-term cancer survivors treated with standard dose chemotherapy. Psycho-
Oncology, 12(6), 612-619. 
Ahles, T. A., Saykin, A. J., McDonald, B. C., Furstenberg, C. T., Cole, B. F., Hanscom, B. 
S., et al. (2008). Cognitive function in breast cancer patients prior to adjuvant 
treatment. Breast Cancer Research and Treatment, 110(1), 143-152. 
Ahles, T. A., Saykin, A. J., McDonald, B. C., Li, Y., Furstenberg, C. T., Hanscom, B. S., et 
al. (2010). Longitudinal assessment of cognitive changes associated with adjuvant 
treatment for breast cancer: Impact of age and cognitive reserve. Journal of Clinical 
Oncology, 28(29), 4434-4440. 
                References 
275 
Ahlstrom, L., Grimby-Ekman, A., Hagberg, M., & Dellve, L. (2010). The work ability 
index and single-item question: associations with sick leave, symptoms, and health—
a prospective study of women on long-term sick leave. Scandinavian Journal of 
Work, Environment and Health, 36(5), 404-412. 
Åkerstedt, T, Fredlund, P., Gillberg, M., & Jansson, B. (2002). A prospective study of fatal 
occupational accidents – relationship to sleeping difficulties and occupational factors. 
Journal of Sleep Research, 11(1), 69-71. 
Alcee, D. (2000). The experience of a community hospital in quantifying and reducing 
patient falls. Journal of Nursing Care Quality, 14(3), 45-53. 
Amir, Z., Neary, D., & Luker, K. (2008). Cancer survivors’ views of work 3 years post 
diagnosis: A UK perspective. European Journal of Oncology Nursing, 12(3), 190-
197. 
Anderson-Hanley, C., Sherman, M. L., Riggs, R., Agocha, V. B., & Compas, B. E. (2003). 
Neuropsychological effects of treatments for adults with cancer: A meta-analysis and 
review of the literature. Journal of the International Neuropsychological Society, 
9(7), 967-982. 
Artherholt, S. B., & Fann, J. R. (2012). Psychosocial care in cancer. Current Psychiatry 
Reports, 14(1), 23-29. 
Asato, R., Akiyama, Y., Ito, M., Kubota, M., Okumura, R., Miki, Y., et al. (1992). Nuclear 
magnetic resonance abnormalities of the cerebral white matter in children with acute 
lymphoblastic leukemia and malignant lymphoma during and after central nervous 
system prophylactic treatment with intrathecal methotrexate. Cancer, 70(7), 1997-
2004. 
Badger, T. A., Braden, C. J., Mishel, M. H., & Longman, A. (2004). Depression burden, 
psychological adjustment, and quality of life in women with breast cancer: patterns 
over time. Research in Nursing Health, 27(1), 19–28 
Bains, M., Munir, F., Yarker, J., Thomas, A., Armitage, N., & Steward, W. (2012). The 
impact of colorectal cancer and self-efficacy beliefs on work ability and employment 
status: A longitudinal study. European Journal of Cancer Care, 21(5), 634-641. 
Bakitas, M., Lyons, K. D., Hegel, M. T., & Ahles, T. (2012). Oncologists’ perspectives on 
concurrent palliative care in a National Institute-designated comprehensive cancer 
center [published online ahead of print]. Palliative and Supportive Care. 
Bender, C. M., Paraska, K. K., Sereika, S. M., Ryan, C. M., & Berga, S. L. (2001). 
Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: 
A critical review. Journal of Pain and Symptom Management, 21(5), 407-424. 
                References 
276 
Bender, C. M., Sereika, S. M., Berga, S. L., Vogel, V. G., Brufsky, A. M., & Paraska, K. 
K., et al. (2006). Cognitive impairment associated with adjuvant therapy in breast 
cancer. Psycho-Oncology, 15(5), 422-430. 
Bender, C. M., Pacella, M. L., Sereika, S. M., Brufsky, A. M., Vogel, V. G., Rastogi, P., et 
al. (2008). What do perceived cognitive problems reflect? The Journal of Supportive 
Oncology, 6(5), 238-242. 
Bhattacherjee, A., Chau, N., Otero Sierra, C., Lergas, B., Benamghar, L., Michaely, J.-P., 
Ghosh, A. K., Guillemin, F., et al. (2003). Relationships of job and some individual 
characteristics to occupational injuries in employed people: A community-based 
study. Journal of Occupational Health, 45, 382-391. 
Blows, W. T. (2005). The biological basis of nursing: Cancer care. Abingdon, Oxfordshire: 
Routledge. 
Boehmke, M. M., & Dickerson, S. S. (2005). Symptom, symptom experiences, and 
symptom distress encountered by women with breast cancer undergoing current 
treatment modalities. Cancer Nursing, 28(5), 382-389. 
Boles, M., Pelletier, B., & Lynch, W. (2004). The relationship between health risks and 
work productivity. Journal of Occupational and Environmental Medicine, 46(7), 
737-745.  
Bolger, N., Davis, A., & Rafaeli, E. (2003). Diary methods: Capturing life as it is lived. 
Annual Review of Psychology, 54(1), 579-616. 
Bower, J. E., Ganz, P. A., Desmond, K. A., Bernaards, C., Rowland, J. H., Meyerowitz, B. 
E., et al. (2006). Fatigue in long-term breast carcinoma survivors. Cancer, 106(4), 
751-758. 
Bower, J. E. (2008). Behavioral symptoms in patients with breast cancer and survivors. 
Journal of Clinical Oncology, 26(5), 768-777. 
Bowling, A. (1997). Research methods in health: Investigating health and health services. 
Buckingham: Open University Press. 
Bowling, A. (2005). Just one question: If one question works, why ask several? Journal of 
Epidemiology and Community Health, 59(5):342–345.  
Boykoff, N., Moieni, M., & Subramanian, S. K. (2009). Confronting chemobrain: an in-
depth look at survivors’ reports of impact on work, social networks, and health care 
response. Journal of Cancer Survivorship, 3(4), 223-232. 
Bradley, C. J., Neumark, D., Luo, Z., & Schenk, M. (2007). Employment and cancer: 
Findings from a longitudinal study of breast and prostate cancer survivors. Cancer 
Investigation, 25(1), 47-54. 
Braun, V., & Clarke, V. (2006). Using thematic analysis in psychology. Qualitative 
Research in Psychology, 3(2), 77-101. 
                References 
277 
Brennan, J. (2001). Adjustment to cancer - coping or personal transition? Psycho-Oncology 
10(1), 1–18. 
Brezden, C. B., Phillips, K.-A., Abdolell, M., Bunston, T., & Tannock, I. F. (2000). 
Cognitive function in breast cancer patients receiving adjuvant chemotherapy. 
Journal of Clinical Oncology, 18(14), 2695-2701. 
British Medical Association. (1993). Complementary medicine: new approaches to good 
practice. Oxford: Oxford University Press. 
Broadbent, D. E., Cooper, P. F., FitzGerald, P., & Parkes, K. R. (1982). The Cognitive 
Failures Questionnaire (CFQ) and its correlates. British Journal of Clinical 
Psychology, 21(1), 1-16. 
Broom, T., & Tovey, P. (2008). Exploring the temporal dimension in cancer patients’ 
experiences of nonbiomedical therapeutics. Qualitative Health Research, 18(12), 
1650-1661. 
Brown, M. S., Stemmer, S. M., Simon, J. H., Stears, J. C., Jones, R. B., Cagnoni, P. J., et al. 
(1998). White matter disease induced by high-dose chemotherapy: Longitudinal 
study with MR imaging and proton spectroscopy. American Journal of 
Neuroradiology, 19, 217-221. 
Buccheri, G. (1998). Depressive reactions to lung cancer are common and often followed 
by a poor outcome. European Respiratory Journal, 11(1), 173-178. 
Budischewski, K., Fuschbeck, S., & Mose, S. (2008). Quality of life of breast cancer 
patients in the course of adjuvant chemotherapy. Support Care Cancer, 16, 299-304. 
Bulmash, E. L., Moller, H. J., Kayumov, L., Shen, J., Wang, X., & Shapiro, C. M. (2006). 
Psychomotor disturbance in depression: Assessment using a driving simulator 
paradigm. Journal of Affective Disorders, 93(1-3), 213-218. 
Burgess, C., Cornelius, V., Love, S., Graham, J., Richards, M., & Ramirez, A. (2005). 
Depression and anxiety in women with early stage breast cancer: Five year 
observational cohort study. British Medical Journal, 330(7493), 702-705. 
Bylow, K., Dale, W., Mustian, K., Stadler, W. M., Rodin, M., Hall, W., Lachs, M., & 
Mohile, S. G. (2008). Falls and physical performance deficits in older patients with 
prostate cancer undergoing androgen deprivation therapy. Urology, 72(2), 422-427. 
Bylow, K., Hemmerich, J., Mohile, S. G., Stadler, W. M., Sajid, S., & Dale, W. (2011). 
Obese frailty, physical performance deficits, and falls in older men with biochemical 
recurrence of prostate cancer on androgen deprivation therapy: a case-control study. 
Urology, 77(4), 934-910. 
Calvio, L., Peugeot, M., Bruns, G. L., Todd, B. L., & Feuerstein, M. (2010). Measures of 
cognitive function and work in occupationally active breast cancer survivors. 
American College of Occupational and Environmental Medicine, 52, 219-227. 
                References 
278 
Cancer Research UK. (2011). Breast cancer incidence statistics. Retrieved September 12, 
2012, from http://www.cancerresearchuk.org/cancer-info/cancerstats/types/breast/ 
incidence/#age 
Cancer Research UK. (2009). Breast cancer section overview. Retrieved August 10, 2009, 
from http://www.cancerhelp.org.uk/help/default.asp?page=3270 
Capone, L. J., Albert, N. M., Bena, J. F., & Morrison, S. M. (2010). Characteristics of 
hospitalized cancer patients who fall. Journal of Nursing Care Quality, 25(3), 216-
223. 
Capone, L. J., Albert, N. M., Bena, J. F., & Tang, A. S. (2013). Serious fall injuries in 
hospitalized patients with and without cancer. Journal of Nursing Care Quality, 
28(1), 52-59. 
Capuron, L., Welberg, L., Heim, C., Wagner, D., Solomon, L., Papanicolaou, D. A., et al. 
(2006).Cognitive dysfunction relates to subjective report of mental fatigue in patients 
with chronic fatigue syndrome. Neuropsychopharmacology, 31, 1777–1784. 
Casebeer, A. L., & Verhoef, M. J. (1997). Combining qualitative and quantitative research 
methods: Considering the possibilities for enhancing the study of chronic diseases. 
Chronic Disease in Canada, 18(3), 130-135. 
Castellon, S. A., Ganz, P. A., Bower, J. E., Petersen, L., Abraham, L., & Greendale, G. A. 
(2004). Neurocognitive performance in breast cancer survivors exposed to adjuvant 
chemotherapy and tamoxifen. Journal of Clinical and Experimental 
Neuropsychology, 26(7), 955-969. 
Castaneda, A. E., Suvisaari, J., Marttunen, M., Perala, J., Saarni, S. I., Aalto-Setala, T., 
Koskinen, S., Lonnqvist, J., et al. (2008). Cognitive functioning in a population-
based sample of young adults with a history of non-psychotic unipolar depressive 
disorders without psychiatric comorbidity. Journal of Affective Disorders, 110(1), 
36-45. 
Castro, F. G., Kellison, J. G., Boyd, S. J., & Kopak, A. (2010). A methodology for 
conducting integrative mixed methods research and data analyses. Journal of Mixed 
Methods Research, 4(4), 342-360. 
Cella, D., Lai, J.-S., Chang, C.-H., Peterman, A., & Slavin, M. (2002). Fatigue in cancer 
patients compared with fatigue in the general United States population. Cancer, 
94(2), 528-538. 
Cella, D., Peterman, A., Passik, S., Jacobsen, P., & Breitbart, W.  (1998). Progress toward 
guidelines for the management of fatigue. Oncology, 12(11A), 369-377. 
Charlton, R. A., Barrick, T. R., McIntyre, D. J., Shen, Y., O’Sullivan, M., Howe, F. A., et 
al. (2006). White matter damage on diffusion tensor imaging correlates with age-
related cognitive decline. Neurology, 66(2), 217-222. 
                References 
279 
Chaytor, N., & Schmitter-Edgecombe, M. (2003). The ecological validity of 
neuropsychological tests: A review of the literature on everyday cognitive skills. 
Neuropsychology Review, 13(4), 181-197. 
Chen, Y., Jungsuwadee, P., Vore, M., Butterfield, D. A., & St. Claire, D. K. (2007). 
Collateral damage in cancer chemotherapy: Oxidative stress in nontargeted tissues. 
Molecular Interventions, 7(3), 147-155. 
Chen, Z., Maricic, M., Aragaki, A. K., Mouton, C., Arendell, L., Lopez, A. M., Bassford, 
T., & Chlebowski, R. T. (2009). Fracture risk increases after diagnosis of breast or 
other cancers in postmenopausal women – Results from the Women’s Health 
Initiative. Osteoporosis International, 20(4), 527-536. 
Chen, Z., Maricic, M., Bassford, T. L., Pettinger, M., Ritenbaugh, C., Lopez, A. M., et al. 
(2005). Fracture risk among breast cancer survivors: Results from the women’s 
health initiative observational study. Archives of Internal Medicine, 165(5), 552-558. 
Cheung, S., Greenway, N., Lagord, C., Williams, L., Kearins, O., & Lawrence, G. (2009). 
All breast cancer report: A UK analysis of all symptomatic and screen-detected 
breast cancers diagnosed in 2006. NHS Cancer Screening Programme. 
Cheung, Y. T., Shwe, M., Tan, Y. P., Fan, G., Ng, R, & Chan, A. (2012). Cognitive 
changes in multiethnic Asian breast cancer patients: a focus group study. Annals of 
Oncology, 23(10), 2547-2552. 
Cimprich, B., So, H., Ronis, D. L., & Trask, C. (2005). Pre-treatment factors related to 
cognitive functioning in women newly diagnosed with breast cancer. Psycho-
Oncology, 14(1), 70-78. 
Clarke, S. (2012). Accident Proneness: Back in Vogue? In Occupational Health and Safety. 
R. J. Burke, S. Clarke, C. L. Cooper. Gower Publishing Limited: Surrey.  
Cohen, J. (1992). A power primer. Psychological Bulletin, 112(1), 155-159. 
Collins, B., Mackenzie, J., Stewart, A., Bielajew, C., & Verma, S. (2009). Cognitive effects 
of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. 
Psycho-Oncology, 18(2), 134-143. 
Colman, A. M. (2009). A dictionary of psychology (3rd ed.). Oxford: Oxford University 
Press. 
Crawford, J. R., Henry, J. D., Crombie, C., & Taylor, E. P. (2001). Brief report: Normative 
data for the HADS from a large non-clinical sample. British Journal of Clinical 
Psychology, 40(4), 429-434. 
Creswell, J. W., Clark, V. L. P., Gutmann, M. L., & Hanson, W. E. (2003). Advanced 
mixed methods research designs. In A. Tashakkori & C. B. Teddlie (Eds.), Handbook 
of mixed methods in social and behavioural research (pp. 209-240). Thousand Oaks, 
CA: Sage.  
                References 
280 
Cull, A., Hay, C., Love, S. B., Mackie, M., Smets, E., & Stewart, M. (1996). What do 
cancer patients mean when they complain of concentration and memory problems? 
British Journal of Cancer, 74(10), 1674-1679. 
Curt, G. A. (2001). Fatigue in cancer; like pain, this is a symptom that physicians can and 
should manage. British Medical Journal, 322, 1560. 
Curt, G. A., Breitbart, W., Cella, D., Groopman, J. E., Horning, S. J., Itri, L. M., et al. 
(2000). Impact of cancer-related fatigue on the lives of patients: New findings from 
the fatigue coalition. The Oncologist, 5(5), 353-360. 
Day, A. J., Brasher, K., & Bridger, R. S. (2012). Accident proneness revisited The role of 
psychological stress and cognitive failure. Accident Analysis and Prevention, 49, 
532-535. 
de Boer, A. G. E. M., Verbeek, J. H. A. M., Spelten, E. R., Uitterhoeve, A. L. J., Ansink, A. 
C., de Reijke, T. M., et al. (2008). Work ability and return-to-work in cancer patients. 
British Journal of Cancer, 98(8), 1342-1347. 
Debess, J., Riis, J. O., Engebjerg, M. C., & Ewertz, M. (2010). Cognitive function after 
adjuvant treatment for early breast cancer: a population-based longitudinal study. 
Breast Cancer Research and Treatment, 121(1), 91–100. 
Dekker, S. (2002). The Field Guide to Human Error Investigations. Aldershot: Ashgate 
Publishing Ltd.. 
Denzin, N. K., & Lincoln, Y. S. (1994). Handbook of qualitative research. London: Sage 
Publications. 
Department of Health. (2009). The expert patient: A new approach to chronic disease 
management for the 21
st
 Century. Retrieved March 12, 2011, from 
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ 
PublicationsPolicyAndGuidance/DH_4006801 
Department for Work and Pensions. (2006). Security in retirement: Towards a new 
pensions system. Cm 6841. The Stationery Office: London. Retrieved June 20, 2009, 
from http://www.dwp.gov.uk/policy/pensions-reform/security-in-retirement/white-
paper/ 
Deshields, T., Tibbs, T., Fan, M. Y., & Taylor, M. (2006). Differences in patterns of 
depression after treatment for breast cancer. Psycho-Oncology 15(5), 398–406 
Dimeo, F., Schwartz, S., Wesel, N., Voigt, A., & Thiel, E. (2008). Effects of an endurance 
and resistance exercise program on persistent cancer-related fatigue after treatment. 
Annals of Oncology, 19(8), 1495-1499. 
Directgov. (2012). Calculating your State Pension age. Retrieved September 12, 2012, 
from http://www.direct.gov.uk/en/Pensionsandretirementplanning/StatePension/ 
DG_4017919 
                References 
281 
Dolbeault, S., Cayrou, S., Bredart, A., Viala, A. L., Desclaux, B., Saltel, P., et al. (2009). 
The effectiveness of a psycho-educational group after early-stage breast cancer 
treatment: Results of a randomized French study. Psycho-Oncology, 18(6), 647-656. 
Donovan, K. A., Small, B. J., Andrykowski, M. A., Schmitt, F. A., Munster, P., & 
Jacobsen, P. B. (2005). Cognitive functioning after adjuvant chemotherapy and/or 
radiotherapy for early-stage breast carcinoma. Cancer, 104(11), 2499-2507. 
Downer, S. M., Cody, M. M., McCluskey, P., Wilson, P. D., Arnott, S. J., Lister, T. A., et 
al. (1994). Pursuit and practice of complementary therapies by cancer patients 
receiving conventional treatment. British Medical Journal, 309, 86-89. 
Downie, F. P., Mar Fan, H. G., Houede-Tchen, N., Yi, Q.-L., & Tannock, I. F. (2006). 
Cognitive function, fatigue, and menopausal symptoms in breast cancer patients 
receiving adjuvant chemotherapy: Evaluation with patient interview after formal 
assessment. Psycho-Oncology, 15(10), 921-930. 
Elliott, R., Fischer, C. T., & Rennie, D. L. (1999). Evolving guidelines for publication of 
qualitative research studies in psychology and related fields. British Journal of 
Clinical Psychology, 38(3), 215-229. 
Engel, G. L. (1977). The need for a new medical model: A challenge for biomedicine. 
Science, 196(4286), 129-136. 
Escorpizo, R., Bombardier, C., Boonen, A., Hazes, J. M., Lacaille, D., Strand, V., et al. 
(2007). Worker productivity outcome measures in arthritis. The Journal of 
Rheumatology, 34(6), 1372-1380. 
Faul, F., Erdfelder, E., Lang., A.-G., & Buchner, A. (2007). G*Power 3: A flexible 
statistical power analysis program for the social, behavioural, and biomedical 
sciences. Behavior Research Methods, 39(2), 175-191. 
Ferguson, R. J., & Ahles, T. A. (2003). Low neuropsychologic performance among adult 
cancer survivors treated with chemotherapy. Current Neurology and Neuroscience 
Reports, 3(3), 215-222. 
Ferguson, R. J., McDonald, B. C., Saykin, A. J., & Ahles, T. A. (2007). Brain structure and 
function differences in monozygotic twins: Possible effects of breast cancer 
chemotherapy. Journal of Clinical Oncology, 25(25), 3866-3870. 
Field, A. (2009). Discovering statistics in SPSS. London: SAGE Publications Ltd. 
Fischer, I. D., Krauss, M. J., Dunagan, W. C., Birge, S., Hitcho, E., Johnson, S., 
Costantinou, E., & Fraser, V. J. (2005). Patterns and predictors of inpatient falls and 
fall-related injuries in a large academic hospital. Infection Control and Hospital 
Epidemiology, 26(10), 822-827. 
                References 
282 
Forouzanfar, M. H., Foreman, K. J., Delossantos, A. M., Lozano, R., Lopez, A. D., Murray, 
C. J. L., et al. (2011). Breast and cervical cancer in 187 countries between 1980 and 
2010: A systematic analysis. The Lancet, 378(9801), 1461-1484. 
Freeman, J. R., & Broshek, D. K. (2002) Assessing cognitive dysfunction in breast cancer: 
What are the tools? Clinical Breast Cancer, 3(Suppl. 3), 91-99. 
Gaston-Johansson, F., Fall-Dickson, J. M., Bakos, A. B., & Kennedy, J. (1999). Fatigue, 
pain and depression in pre-autotransplant breast cancer patients. Cancer Practice, 
7(5), 240-247. 
Genazzani, A. R., Pluchino, N., Luisi, S., & Luisi, M. (2007). Estrogen, cognition and 
female ageing. Human Reproduction Update, 13(2), 175-187. 
Gifford, S. (1996) Qualitative research: the soft option? Health Promotion Journal of 
Australia, 6, 58–61. 
Green, J. (1991). Accident proneness. Journal of the Royal Society of Medicine, 84(8), 510-
510. 
Greene, D., Nail, L. M., Fieler, V. K., Dudgeon, D., & Jones, L. S. (1994). A comparison of 
patient-reported side effects among three chemotherapy regimens for breast cancer. 
Cancer Practice, 2(1), 57-62. 
Greenwood, M., & Woods, H. (1919). The incidence of industrial accidents upon 
individuals with special reference to multiple accidents. Tech. rep., Industrial Fatigue 
Research Board, London. 
Gudbergsson, S. B., Fossa, S. D., Borgeraas, E., & Dahl, A. A. (2006). A comparative study 
of living conditions in cancer patients who have returned to work after curative 
treatment. Support Care Cancer, 14(10), 1020-1029. 
Gudbergsson, S.B., Torp, S., Flotten, T., Fossa, S. D., Nielsen, R., & Dahl, A. A. (2011). A 
comparative study of cancer patients with short and long sick-leave after primary 
treatment. Acta Oncologica, 50, 381-389. 
Guill, B., & Raynor, R. H. (2008). Support services. In C. A. Meyers & J. R. Perry (Eds). 
Cognition and cancer (pp. 295-311). Cambridge: Cambridge University Press.  
HSC. (2004). A strategy for workplace health and safety in Great Britain to 2010 and 
beyond. Retrieved May 8, 2010, from http://www.hse.gov.uk/consult/condocs/ 
strategycd.pdf 
Halbreich, U., Rojansky, N., Palter, S., Tworek, H., Hissin, P., & Wang, K. (1995). 
Estrogen augments serotonergic activity in postmenopausal women. Biological 
Psychiatry, 37(7), 434-441.  
Haslam, C., Atkinson, S., Brown, S. S., & Haslam, R. A. (2005). Anxiety and depression in 
the workplace: Effects on the individual and organisation (a focus group 
intervention). Journal of Affective Disorders, 88(2), 209-215. 
                References 
283 
Hayes, N. (1997). Doing qualitative analysis in psychology. Hove: The Psychology Press. 
Health and Safety Executive. (n.d.). Annual statistics report. Retrieved September 18, 2012, 
from http://www.hse.gov.uk/statistics/index.htm 
Health and Safety Executive. (2009). The hand safety of Great Britain: Be part of the 
solution. Retrieved July 18, 2012, from 
http://www.hse.gov.uk/strategy/document.htm 
Hendrich, A., Nyhuis, A., Kippenbrock, T., & Soja, M. E. (1995). Hospital falls: 
Development of a predictive model for clinical practice. Applied Nursing Research, 
8(3), 129-139. 
Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. 
(2010). Two different sides of ‘chemobrain’: determinants and nondeterminants of 
self‐perceived cognitive dysfunction in a prospective, randomized, multicenter study. 
Psycho-Oncology, 19(12), 1321-1328. 
Hermelink, K., Untch, M., Lux, M. P., Kreienberg, R., Beck, T., Bauerfeind, I., et al. 
(2007). Cognitive function during neoadjuvant chemotherapy for breast cancer: 
Results of a prospective, multicenter, longitudinal study. Cancer, 109(9), 1905-1913. 
Hesketh, P. J. (2009). Penny wise, dollar foolish approach to antiemetic use may 
compromise patient care. Journal of Oncology Practice, 5(5), 221-222. 
Hess, L. M., & Insel, K. C. (2007). Chemotherapy-related change in cognitive function: A 
conceptual model. Oncology Nursing Society, 34(5), 981-994. 
Higginson, I. J., & Carr, A. J. (2001). Measuring quality of life: Using quality of life 
measures in the clinical setting. British Medical Journal, 322(7297), 1297-1300. 
Hitcho, E. B., Krauss, M. J., Birge, S., Dunagan, W. C., Fischer, I., Johnson, S., Nast, P. A., 
Costantinou, E., & Fraser, V. J. (2004). Characteristics and circumstances of falls in a 
hospital setting: A prospective analysis. Journal of General Internal Medicine, 19(7), 
732-739. 
Hjermstad, M. J., Fayers, P. M., Bjordal, K., & Kaasa, S. (1998). Health-related quality of 
life in the general Norwegian population assessed by European Organization for 
Research and Treatment of Cancer Core Quality-of-Life Questionnaire: the 
QLQ=C30 (+3). Journal of Clinical Oncology, 16(3), 1188–1196. 
Holland, J., Watson, M., & Dunn, J. (2011). The IPOS New International Standard of 
Quality Cancer Care: Integrating the psychosocial domain into routine care. Psycho-
Oncology, 20(7), 677–80. 
Horne, J.A., & Reyner, L.A. (1995). Sleep related vehicle accidents. British Medical 
Journal, 310(6979), 565–567. 
Hunter-Zaworski, K. (1990). T-intersection simulator performance of drivers with physical 
limitations. Transportation Research Record, 1281, 11–15. 
                References 
284 
Hurria, A., Goldfarb, S., Rosen, C., Holland, J., Zuckerman, E., Lachs, M. S., et al. (2006). 
Effect of adjuvant breast cancer chemotherapy on cognitive function from the older 
patient’s perspective. Breast Cancer Research and Treatment, 98(3), 343-348. 
Hurria, A., Somlo, G., & Ahles, T. (2007). Renaming “Chemobrain”. Cancer Investigation, 
25(6), 373-377. 
Hussain, S., Breunis, H., Timilshina, N., & Alibhai, S. M. H. (2010). Falls in men on 
androgen deprivation therapy for prostate cancer. Journal of Geriatric Oncology, 
1(1), 32-39. 
Hutchinson, A.D., Hosking, J. R., Kichenadasse, G., Mattiske, J. K., & Wilson, C. (2012). 
Objective and subjective cognitive impairment following chemotherapy for cancer: A 
systematic review. Cancer Treatment Reviews, 38(7), 926-934. 
Iconomou, G., Mega, V., Koutras, A., Iconomou, A. V., & Kalofonos, H. P. (2004). 
Prospective assessment of emotional distress, cognitive function, and quality of life 
in patients with cancer treated with chemotherapy. Cancer, 101(2), 404-411. 
Ilmarinen, J., Tuomi, K., & Seitsamo, J. (2005). New dimensions of work ability. 
International Congress Series, 1280, 3-7. 
Inagaki, M., Yoshikawa, E., Matsuoka, Y., Sugawara, Y., Nakano, T., Akechi, T., et al. 
(2007). Smaller regional volumes of brain gray and white matter demonstrated in 
breast cancer survivors exposed to adjuvant chemotherapy. Cancer, 109(1), 146-156.  
Iop, A., Manfredi, A. M., & Bonura, A. (2004). Fatigue in cancer patients receiving 
chemotherapy: An analysis of published studies. Annals of Oncology, 15(5), 712-720. 
Issever, H., Ozdilli, K., Onen, L., Tan, O., Disci, R., & Yardimci, O. (2008). Examination 
of personal factors in work accidents. Indoor and Built Environment, 17(6). 562-566. 
Jacobsen, P. B., Bovbjerg, D. H., & Redd, W. H. (1993). Anticipatory anxiety in women 
receiving chemotherapy for breast cancer. Health Psychology, 12, 469-475. 
Jacobsen, P. B., Hann, D. M., Azzarello, L. M., Horton, J., Balducci, L., & Hyman, G. H. 
(1999). Fatigue in women receiving adjuvant chemotherapy for breast cancer: 
Characteristics, course, and correlates. Journal of Pain and Symptom Management, 
18(4), 233–242. 
Janesick, V. J. (1994). The dance of qualitative research design: Metaphor, methodolatry, 
and meaning. In N. K. Denzin & Y. S. Lincoln (Eds.), Handbook of qualitative 
research (pp. 209-235). Thousand Oaks, CA: Sage.  
Jansen, C. E., Dodd, M. J., Miaskowski, C. A., Dowling, G. A., & Kramer, J. (2008). 
Preliminary results of a longitudinal study of changes in cognitive function in breast 
cancer patients undergoing chemotherapy with doxorubicin and cyclophosphamide. 
Psycho-Oncology, 17(12), 1189-1195. 
                References 
285 
Jansen, C. E., Miaskowski, C., Dodd, M., Dowling, G., & Kramer, J. (2005). A 
metaanalysis of studies of the effects of cancer chemotherapy on various domains of 
cognitive function. Cancer, 104(10), 2222-2233.  
Jenkins, V., Shilling, V., Deutsch, G., Bloomfield, D., Morris, R., Allan, S., et al. (2006). A 
3-year prospective study of the effects of adjuvant treatments on cognition in women 
with early stage breast cancer. British Journal of Cancer, 94(6), 828-834. 
Jenkins, V., Shilling, V., Fallowfield, L., Howell, A., & Hutton, S. (2004). Does hormone 
therapy for the treatment of breast cancer have a detrimental effect on memory and 
cognition? A pilot study. Psycho-Oncology, 13(1), 61-66. 
Jungquist, C. R., O’Brien, C., Matteson-Rusby, S., Smith, M. T., Pigeon, W. R., Xia, Y., et 
al. (2010). The efficacy of cognitive-behavioral therapy for insomnia in patients with 
chronic pain. Sleep Medicine, 11, 302-309. 
Kayl, A. E., Wefel, J. S., & Meyers, C. A. (2006). Chemotherapy and cognition: Effects, 
potential mechanisms, and management. American Journal of Therapeutics, 13(4), 
362-369. 
Kehlet, H., & Wilmore, D. W. (2002). Multimodal strategies to improve surgical outcome. 
The American Journal of Surgery, 183(6), 630–641.  
Kesler, S. R., Bennett, F. C., Mahaffey, M. L., & Spiegel, D. (2009). Regional brain 
activation during verbal declarative memory in metastatic breast cancer. Clinical 
Cancer Research, 15(21), 6665-6673. 
Khanzode, V. V., Maiti, J., & Ray, P. K. (2012). Occupational injury and accident research. 
Safety Science, 50(5), 1355-1367. 
Kidman, A. D., & Edelman, S. (1997). Developments in psycho-oncology and cognitive 
behavior therapy in cancer. Journal of Cognitive Psychotherapy, 11(1), 45-62. 
Kim, H. C., Park, S.G., Min, K. B., & Yoon, K. J. (2009). Depressive symptoms and self-
reported occupational injury in small and medium-sized companies. International 
Archives of Occupational and Environmental Health, 82(610, 715-721. 
Klepstad, P., Hilton, P., Moen, J., Fougner, B., Borchgrevink, P. C., & Kaasa, S. (2002). 
Self-reports are not related to objective assessments of cognitive function and 
sedation in patients with cancer pain admitted to a palliative care unit. Palliative 
Medicine, 16(6), 513–519. 
Lach, H. W., & Chang, Y.-P. (2007). Caregiver perspectives on safety in home dementia 
care. Western Journal of Nursing Research, 29(8), 993-1014. 
Lai, J.-S., Cella, D., Chang, C.-H., Bode, R. K., & Heinemann, A. W. (2003). Item banking 
to improve, shorten and computerize self-reported fatigue: An illustration of steps to 
create a core item bank from the FACIT-Fatigue Scale. Quality of Life Research 
12(5), 485–501. 
                References 
286 
Lakatos, B. E., Capasso, V., Mitchell, M. T., Kilroy, S. M., Lussier-Cushing, M., Sumner, 
L., Repper-Delisi, J., Kelleher, E. P., Delisle, L. A., Cruz, C., & Stern, T. A. (2009). 
Falls in the general hospital: Association with delirium, advanced age, and specific 
surgical procedures. Psychosomatics, 50(3), 218-226. 
Larson, G. E., & Merritt, C. R. (1991). Can accidents be predicted? An empirical test of the 
Cognitive Failures Questionnaire. Applied Psychology: An International Review, 
40(1), 37-45. 
Larson, G. E., Alderton, D. L., Neideffer, M., & Underhill, E. (1997). Further evidence on 
dimensionality and correlates of the Cognitive Failures Questionnaire. British 
Journal of Psychology, 88(1), 29-38. 
Locke, D. E. C., Cerhan, J. H., & Malec, J. F. (2008). Behavioral strategies and 
rehabilitation. In C. A. Meyers & J. R. Perry (Eds.), Cognition and cancer (pp. 281-
294). Cambridge: Cambridge University Press.  
Loewenthal, K. M. (2001). An Introduction to Psychological Tests and Scales 2nd edition. 
Hove Psychology Press.  
McPherson, K., Steel, C. M., & Dixon, J. M. (2000). Breast cancer – epidemiology, risk 
factors, and genetics. British Medical Journal, 321(7261), 624-628. 
Maly, R. C., Umezawa, Y., Leake, B., & Silliman, R. A. (2005). Mental health outcomes in 
older women with breast cancer: impact of perceived family support and adjustment. 
Psycho-Oncology, 14(7), 535-545. 
Mancuso, A., Migliorino, M., De Santis, S., Saponiero, A., & De Marinis, F. (2006). 
Correlation between anemia and functional/cognitive capacity in elderly lung cancer 
patients treated with chemotherapy, Annals of Oncology, 17(1), 146-150. 
Mar Fan, H. G., Houede-Tchen, N., Yi, Q.-L., Chemerynsky, I., Downie, F. P., Sabate, K., 
et al. (2005). Fatigue, menopausal symptoms, and cognitive function in women after 
adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective 
controlled study. Journal of Clinical Oncology, 23(31), 8025-8032. 
Matotek, K., Saling, M. M., Gates, P., & Sedal, L. (2001). Subjective complaints, verbal 
fluency, and working memory in mild multiple sclerosis. Applied Neuropsychology: 
Adult, 8(4), 204–210. 
Maunsell, E., Drolet, M., Brisson, J., Brisson, C., Masse, B., et al. (2004). Work situation 
after breast cancer: Results from a population-based study. Journal of the National 
Cancer Institute, 96(24), 1813-1822. 
Mehlsen, M., Pedersen, A. D., Jensen, A. B., & Zachariae, R. (2009). No indications of 
cognitive side-effects in a prospective study of breast cancer patients receiving 
adjuvant chemotherapy. Psycho-Oncology, 18(3), 248-257. 
                References 
287 
Mehnert, A., Scherwath, A., Schirmer, L., Schleimer, B., Petersen, C., Schulz-Kindermann, 
F., et al. (2007). The association between neuropsychological impairment, self-
perceived cognitive deficits, fatigue and health related quality of life in breast cancer 
patients following standard adjuvant versus high-dose chemotherapy. Patient 
Education and Counselling, 66(1), 108-118. 
Melamed, S., & Oksenberg, A. (2002). Excessive daytime sleepiness and risk of 
occupational injuries in non-shift daytime workers. Sleep, 25, 315–322 
Meyers, C. A., Geara, F., Wong, P.-F., & Morrison, W. H. (2000). Neurocognitive effects 
of therapeutic irradiation for base of skull tumors. International Journal of Radiation 
Oncology, Biology, Physics, 46(1), 51–55. 
Meyers, C. A., & Perry, J. R. (2008). Cognition and cancer. Cambridge: Cambridge 
University Press.  
Mincey, B. A., Moraghan, T. J., & Perez, E. A. (2000). Prevention and treatment of 
osteoporosis in women with breast cancer. Mayo Clinic Proceedings, 75(8), 821-829.  
Minisini, A., Atalay, G., Bottomley, A., Piccart, M., & Biganzoli, L. (2004). The Lancet 
Oncology, 5(5), 273-282. 
Minton, O., & Stone, P. (2008). How common is fatigue in disease-free breast cancer 
survivors? A systematic review of the literature. Breast Cancer Research and 
Treatment, 112(1), 5-13.  
Mohr, C. D., Armeli, S., Tennen, H., Carney, M. A., Affleck, G., et al. (2001). Daily 
interpersonal experiences, context, and alcohol consumption: Crying in your beer and 
toasting good times. Journal of Personality and Social Psychology, 80(3), 489-500. 
Molassiotis, A., Fernadez-Ortega, P., Pud, D., Ozden, G., Scott, J. A., Panteli, V., et al. 
(2005). Use of complementary and alternative medicine in cancer patients: A 
European survey. Annals of Oncology, 16(4), 655-663. 
Molina, J. R., Barton, D. L., & Loprinzi, C. L. (2005). Chemotherapy-induced ovarian 
failure: Manifestations and management. Drug Safety, 28(5), 401-416. 
Montazeri, A. (2008). Health-related quality of life in breast cancer patients: A 
bibliographic review of the literature from 1974 to 2007. Journal of Experimental 
and Clinical Cancer Research, 27(32). 
Moorey, S., Greer, S., Watson, M., Gorman, C., Rowden, L., et al. (1991). The factor 
structure and factor stability of the hospital anxiety and depression scale in patients 
with cancer. the British Journal of Psychiatry, 158, 255-259. 
Morrell, J., & Pryce, J. (2005). Work and cancer: How cancer affects working lives. 
CancerBACUP: Ashford Colour Press. Retrieved August 9, 2009, from 
http://www.cancerbackup.org.uk/News/Mediacentre/Pressreleasesstatements/2005/45
691514/WorkandCancer.pdf 
                References 
288 
Mulrooney, T. (2007). The lived experience of cognitive impairment in women treated with 
chemotherapy for breast cancer. Unpublished doctoral dissertation, University of 
Utah, Salt Lake City.  
Munir, F., Burrows, J., Yarker, J., Kalawsky, K., & Bains, M. (2010). Women’s perceptions 
of chemotherapy-induced cognitive side effects on work ability: A focus group study. 
Journal of Clinical Nursing, 19(9-10) 1362-1370. 
Munir, F., Kalawksy, K., Lawrence, C., Yarker, J., Haslam, C., & Ahmed, S. (2011). 
Cognitive intervention for breast cancer patients undergoing adjuvant chemotherapy. 
Cancer Nursing, 34(5), 385-392. 
Murata, K., Kawakami, N., & Amari, N. (2000). Does job stress affect injury due to labor 
accident in Japanese male and female blue-collar workers? Industrial Health, 38, 
246-251. 
Murphy,  F. C., Sahakian, B. J., & O’Carroll, R.E. (1998). Cognitive impairment in 
depression: Psychological models and clinical issues. In D. Ebert & Ebmeier, K. P. 
(Eds.), New models for depression. Karger: Basel. 
Murray, A. J. (2010). The genetics of breast cancer. Surgery (Oxford), 28(3), 103-106. 
Myers, J. S. (2010). Chemotherapy-related cognitive impairment: The breast cancer 
experience. Unpublished PhD thesis, University of Kansas. 
Myers, J. S., & Teel, C. (2008). Oncology nurses’ awareness of cognitive impairment 
secondary to chemotherapy. Clinical Journal of Oncology Nursing, 12, 725-729. 
Newman, S., Stygall, J., Hirani, S., Shaefi, S., & Maze, M. (2007). Postoperative cognitive 
dysfunction after noncardiac surgery: A systemic review. Anesthesiology, 106(3), 
572-590.  
National Statistics (2010). Unintentional injuries. Retrieved September 8, 2012, from 
http://www.isdscotlandarchive. scot.nhs.uk/isd/6509.html 
Neumann, M., Kreps, G., & Visser, A. (2011). Methodological pluralism in health 
communication research. Patient Education and Counseling, 82(3), 281-284. 
Nordstrom, D. L., Zwerling, C., Stromquist, A. M., Burmeister, L. F., & Merchant, J. A. 
(2001). Epidemiology of unintentional adult injury in a rural population. Journal of 
Trauma-Injury Infection and Critical Care, 51(4), 758-766. 
O’Connell, B., Baker, L., Gaskin, C. J., & Hawkins, M. T. (2007). Risk items associated 
with patient falls in oncology and medical settings. Journal of Nursing Care Quality, 
22(2), 130-137. 
O’Neill, D., Neubauer, K., Boyle, M., Gerrard, J., Surmon, D., et al. (1992). Dementia and 
driving. Journal of the Royal Society of Medicine, 85(4), 199-202. 
O’Shaughnessy, J. A. (2003). Chemotherapy-induced cognitive dysfunction: A clearer 
picture. Clinical Breast Cancer, 4(Suppl. 2), 89-94. 
                References 
289 
Office for National Statistics. (2012). Cancer incidence and mortality in the UK, 2007 – 
2009. Retrieved September 8, 2012, from http://www.ons.gov.uk/ons/dcp171778 
_259504.pdf 
Office for National Statistics. (2011a). Cancer Survival in England - Patients diagnosed 
2005-2009 and followed up to 2010. Retrieved September 8, 2012, from 
http://www.ons.gov.uk/ons/publications/re-reference-
tables.html?edition=tcm%3A77-239726 
Office for National Statistics. (2011b). Household Internet Access, Retrieved January 9, 
2012, from http://www.ons.gov.uk/ons/dcp171778_227158.pdf 
Overcash, J. A. & Beckstead, J. (2008). Predicting falls in older patients using components 
of a comprehensive geriatric assessment. Clinical Journal of Oncology Nursing, 
12(6), 941-949. 
Overcash, J. A., Rivera Jr., H. R., & Van Schaik, J. (2010). An analysis of falls experienced 
by older adult patients diagnosed with cancer. Oncology Nursing Forum, 37(5), 573-
580. 
Pallant, J. (2007). SPSS survival manual (3rd ed.). New York: Open University Press. 
Paraska, K. K., & Bender, C. M. (2003). Cognitive dysfunction following adjuvant 
chemotherapy for breast cancer: Two case studies. Oncology Nursing Society, 30(3), 
473-478. 
Pelengaris, S., & Khan, M. (2006). Introduction. In S. Pelengaris, M. Khan (Eds.), The 
molecular biology of cancer (pp. 1-34).  Malden: Blackwell Publishing. 
Peteet, J. (2000). Cancer and the meaning of work. General Hospital Psychiatry, 22(3), 
200-205. 
Phillips, L. H., Saldias, A., McCarrey, A., Henry, J. D., Scott, C., et al. (2009). Attentional 
lapses, emotional regulation and quality of life in multiple sclerosis. British Journal 
of Clinical Psychology, 48(1), 101-106. 
Portenoy, R.K., & Itri, L. M.  (1999). Cancer-related fatigue: Guidelines for evaluation and 
management. The Oncologist, 4(1), 1-10. 
Prokasheva, S., Faran, Y., Cwikel, J., & Geffen, D. B. (2011). Analysis of memory deficits 
following chemotherapy in breast cancer survivors: Evidence from the Doors People 
Test. Journal of Psychosocial Oncology, 29(5), 499-514. 
Pullens, M. J. J., De Vries, J., & Roukema, J. A. (2010). Subjective cognitive dysfunction in 
breast cancer patients: A systematic review. Psycho-Oncology, 19, 1127-1138. 
Puts, M. T. E., Monette, J., Girre, V., Wolfson, C., Monette, M., Batist, G., & Bergman, H. 
(2013). The fall rate of older community-dwelling cancer patients. Support Care 
Cancer, 21(3), 775-783. 
                References 
290 
Quesnel, C., Savard, J., & Ivers, H. (2009). Cognitive impairments associated with breast 
cancer treatments: results from a longitudinal study. Breast Cancer Research and 
Treatment, 116(1), 113-123. 
Rabbitt, P., Maylor, E., McInnes, L., Bent, N., & Moore, B. (1995). What goods can self-
assessment questionnaires deliver for cognitive gerentology? Applied Cognitive 
Psychology, 9(7), 127-152. 
Radkiewicz, P., & Widerszal-Bazyl, M. (2005). Psychometric properties of Work Ability 
Index in the light of comparative survey study. International Congress Series, 1280, 
304-309. 
Raffa, R. B., & Tallarida, R. J. (2010). Effects on the visual system might contribute to 
some of the cognitive deficits of cancer chemotherapy-induced ‘chemo-fog’. Journal 
of Clinical Pharmacy and Therapeutics, 35(3), 249-255. 
Rasmussen, J. (1983). Skills, rules, and knowledge; signals, signs, and symbols, and other 
distinctions in human performance models. IEEE Transactions on Systems, Man and 
Cybernetics, 13, 257-266. 
Ravandi-Kashani, F. & Hayes, T. G. (1998). Male breast cancer: A review of the literature. 
European Journal of Cancer, 34(9), 1341-1347. 
Reason, J. (1984). Lapses of attention in everyday life. In R. Parasuraman & D. R. Davies 
(Eds.), Varieties of attention (pp. 515-549). London: Academic Press, Inc. 
Reason, J. (1990). Human Error. New York: Cambridge University Press. 
Reason, J. (1997). Managing the risks of organisational accidents. Aldershot: Ashgate 
Publishing Ltd. 
Rees, R. W., Feigel, I., Vickers, A., Zollman, C., McGurk, R., & Smith, C. (2000). 
Prevalence of complementary therapy use by women with breast cancer: A 
population-based surgery. European Journal of Cancer, 36(11), 1359-1364. 
Reid-Arndt, S.A., Hsieh, C., & Perry, M. C. (2010). Neuropsychological functioning and 
quality of life during the first year after completing chemotherapy for breast cancer. 
Psycho-Oncology, 19(5), 535-544.  
Respini, D., Jacobsen, P. B., Thors, C., Tralongo, P., & Balducci, L. (2003). The prevalence 
and correlates of fatigue in older cancer patients. Critical Reviews in 
Oncology/Hematology, 47(3), 273-279. 
Rey, D., Bouhnik, A.-D., Mancini, J., Bendiane, M.-K., Seror, V., & Viens, P. (2012). Self-
reported cognitive impairment after breast cancer treatment in young women from 
the ELIPPSE40 cohort: The long-term impact of chemotherapy. The Breast Journal, 
5, 406-414. 
                References 
291 
Rich, J. B., & Troyer, A. K. (2008). Clinical neuropsychology. In C. A. Meyers & J. R. 
Perry (Eds). Cognition and cancer (pp. 6-18). Cambridge: Cambridge University 
Press. 
Richardson, A., & Ream, E. (1996) Research and development: fatigue in patients receiving 
chemotherapy for advanced cancer. International Journal of Palliative Nursing, 2, 
199–204.  
Robb, C., Haley, W.E., Balducci, L., Extermann, M., Perkins, E.A., et al. (2007). Impact of 
breast cancer survivorship on quality of life in older women. Critical Reviews in 
Oncology/Hematology, 62(1), 84-91. 
Robertson, I. H. (2003). The absent mind attention and error. The Psychologist, 16(9), 476-
479. 
Rowland, J. H., Aziz, N., Tesauro, G., & Feuer. (2001). The changing face of cancer 
survivorship. Seminars in Oncology Nursing, 17(4), 236-240. 
Rubin, G. J., & Hotopf, M. (2002). Systematic review and meta-analysis of interventions 
for postoperative fatigue. British Journal of Surgery, 89(8), 971–984. 
Rugo, H. S., & Ahles, T. (2003). The impact of adjuvant therapy for breast cancer on 
cognitive function: Current evidence and directions for research. Seminars in 
Oncology, 30(6), 749-762. 
Sale, J. E. M., Lohfeld, L. H., & Brazil, K. (2002). Revisiting the quantitative-qualitative 
debate: Implications for mixed-methods research. Quality & Quantity, 36(1), 43-53. 
Salminen, S., & Heiskanen, M. (1997). Correlations between traffic, occupational, sports, 
and home accidents. Accident, Analysis and Prevention, 29(1), 33-36.  
Saykin, A. J., Ahles, T. A., & McDonald, B. C. (2003). Mechanisms of chemotherapy-
induced cognitive disorders: Neuropsychological, pathophysiological, and 
neuroimaging perspectives. Seminars in Clinical Neuropsychiatry, 8(4), 201-216. 
Schagen, S. B., Das, E., & van Dam, F. S. (2009). The influence of priming and pre-
existing knowledge of chemotherapy-associated cognitive complaints on the 
reporting of such complaints in breast cancer patients. Psycho-Oncology, 18, 674-
678. 
Schagen, S. B., Muller, M. J., Boogerd, W., & van Dam, F. S. (2002a). Cognitive 
dysfunction and chemotherapy: Neuropsychological findings in perspective. Clinical 
Breast Cancer, 3(Suppl 3), 100-108. 
Schagen, S. B., Muller, M. J., Boogerd, W., Rosenbrand, R. M., van Rhijn, D., Rodenhuis, 
S., et al. (2002b). Late effects of adjuvant high-dose chemotherapy on cognitive 
function: A follow-up study in breast cancer patients. Annals of Oncology, 13(9), 
1387-1397. 
                References 
292 
Schagen, S. B., Hamburger, H. L., Muller, M. J., Boogerd, W., & van Dam, F. S. A. M. 
(2001). Neuropsychologic evaluation of late effects of adjuvant high-dose 
chemotherapy on cognitive function. Journal of Neuro-Oncology, 51(2), 159-165. 
Schagen, S. B., Muller, M. J., Boogerd, W., Mellenbergh, G. J., & van Dam, F. S. A. M. 
(2006). Change in cognitive function after chemotherapy: A prospective longitudinal 
study in breast cancer patients. Journal of the National Cancer Institute, 98(23), 
1742-1745. 
Schagen, S. B., van Dam, F. S. A. M., Muller, M. J., Boogerd, W., Lindeboom, J., & 
Bruning, P. F. (1999). Cognitive deficits after postoperative adjuvant chemotherapy 
for breast carcinoma. Cancer, 85(3), 640-650. 
Scherwath, A., Mehnert, A., Schleimer, B., Schirmer, L., Fehlauer, F., Kreienberg, R., et al. 
(2006). Neuropsychological function in high-risk breast cancer survivors after stem-
cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of 
long-term treatment effects. Annals of Oncology, 17(3), 415–423. 
Schilder, C. M., Eggens, P. C., Seynaeve, C., Linn, S. C., Boogerd, W., Gundy, C. M., et al. 
(2009). Neuropsychological functioning in postmenopausal breast cancer patients 
treated with tamoxifen or exemestane after AC-chemotherapy: Cross-sectional 
findings from the neuropsychological TEAM-side study. Acta Oncologica, 48(1), 76-
85. 
Schilder, C., Schagen, S., & van Dam, F. (2008). Effect of hormones and hormonal 
treatment on cognition. In C. A. Meyers & J. R. Perry (Eds)., Cognition and cancer 
(pp. 115-141). Cambridge: Cambridge University Press.  
Schilder, C. M. T., Seynaeve, C., Linn, S. C., Booger, W., Beex, L. V. A. M., Gundy, C. 
M., et al. (2012). Self-reported cognitive functioning in postmenopausal breast cancer 
patients before and during endocrine treatment: findings from the neuropsychological 
TEAM side-study. Psycho-Oncology, 21(5), 479-487. 
Schreier, A. M., & Williams, S. A. (2007). Anxiety and quality of life of women who 
receive radiation or chemotherapy for breast cancer. Oncology Nursing Society, 
31(1), 127-130. 
Servaes, P., Verhagen, C., & Bleijenberg, G. (2002a). Determinants of chronic fatigue in 
disease-free breast cancer patients. Annals of Oncology, 13(4), 589-598. 
Servaes, P., Verhagen, C., & Bleijenberg, G. (2002b). Fatigue in cancer patients during and 
after treatment: Prevalence, correlates and interventions. European Journal of 
Cancer, 38(1), 27-43. 
Shallice, T., Burgess, P. W., Schon, F., & Baxter, D. M. (1989). The origins of utilization 
behavior. Oxford: Oxford University Press.  
                References 
293 
Shappell, D. A., & Wiegmann, S. A. (2000). The Human Factors Analysis and 
Classification System. Aldershot: Ashgate Publishing Ltd. 
Shilling, V., & Jenkins, V. (2007). Self-reported cognitive problems in women receiving 
adjuvant therapy for breast cancer. European Journal of Oncology Nursing, 11(1), 6-
15. 
Shilling, V., Jenkins, V., Morris, R., Deutsch, G., & Bloomfield, D. (2005). The effects of 
adjuvant chemotherapy on cognition in women with breast cancer – preliminary 
results of an observational longitudinal study. The Breast, 14(2), 142-150. 
Shilling, V., Jenkins, V., & Trapala, I. S. (2006). The (mis)classification of chemo-fog – 
methodological inconsistencies in the investigation of cognitive impairment after 
chemotherapy. Breast Cancer Research and Treatment, 95(2), 125-129. 
Silverman, D. H., Dy, C. J., Castellon, S. A. Lai, J., Pio, B. S., Abraham, L., et al. (2007). 
Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-related breast 
cancer survivors 5-10 years after chemotherapy. Breast Cancer Research and 
Treatment, 103(3), 303-311. 
Simpson, S. A., Wadsworth, E. J. K., Moss, S. C., & Smith, A. P. (2005). Minor injuries, 
cognitive failures and accidents at work: Incidence and associated features. 
Occupational Medicine, 55(2), 99-108. 
Skalla, K. A., Bakitas, M., Furstenberg, C. T., Ahles, T., & Henderson, J. V. (2004). 
Patients’ need for information about cancer therapy. Oncology Nursing Forum, 
31(2), 313-319. 
Skeel, R. T. (2003). Handbook of cancer chemotherapy (7
th
 ed). Philadelphia: Lippincott 
Williams & Wilkins. 
Smith, J. A., & Wefel, J. S. (2008). Neurocognitive testing in clinical trials. In C. A. Meyers 
& J. R. Perry (Eds.), Cognition and cancer (320-328). Cambridge: Cambridge 
University Press.  
Smith, J. A. (1996). Evolving Issues In Qualitative Psychology, in J. T. E. Richardson (Ed). 
Handbook Of Qualitative Research Methods For Psychology And The Social 
Sciences. British Psychological Society: Leicester. 
Spelten, E. R., Sprangers, M. A. G., & Verbeek, J. H. A. M. (2002). Factors reported to 
influence the return to work of cancer survivors: A literature review. Psycho-
Oncology, 11(2), 124-131. 
Spelten, E. R., Verbeek, J. H. A. M., Uitterhoeve, A. L. J., Ansink, A. C., van der Lelie, J., 
de Reijke, T. M., et al. (2003). Cancer, fatigue and the return of patients to work – a 
prospective cohort study. European Journal of Cancer, 39(11), 1562-1567. 
Spiegel, D. (1997). Psychosocial aspects of breast cancer treatment. Seminars in Oncology, 
1(Suppl. 1), 36–47. 
                References 
294 
Spoelstra, S., Given, B., von Eye, A., & Given, C. (2010). Falls in the community-dwelling 
elderly with a history of cancer. Cancer Nursing, 33(2), 149-155. 
Stanton, A. L., Ganz, P. A., Kwan, L., Meyerowitz, B. E., Bower, J. E., Krupnick, J. L., et 
al. (2005). Outcomes from the moving beyond cancer psychoeducational, 
randomized, controlled trial with breast cancer patients. Journal of Clinical 
Oncology, 23(25), 6009-6018. 
Steiner, J. F., Cavender, T. A., Main, D. S., & Bradley, C. J. (2004). Assessing the impact 
of cancer on work outcomes: What are the research needs? Cancer, 101(8), 1703-
1711. 
Steward, W., & Thomas, A. (2006). The burden of cancer. In S. Pelengaris & Khan, M. 
(Eds.), The molecular biology of cancer. Oxford: Blackwell Publishing. 
Stewart, A., Collins, B., Mackenzie, J., Tomiak, E., Verma, S., & Bielajew, C. (2008). The 
cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective 
study. Psycho-Oncology, 17(2), 122-130. 
Stewart, W. F., Ricci, J. A., & Leotta, C. (2004). Health-related lost productivity tie (LPT): 
Recall interval and bias in LPT estimates. Journal of Occupational and 
Environmental Medicine, 46, S12-S22. 
Stone, C., Lawlor, P. G., Nolan, B., & Kenny, R. A. (2011). A prospective study of the 
incidence of falls in patients with advanced cancer. Journal of Pain and Symptom 
Management, 42(4), 535-540. 
Stone, A. A., & Shiffman, S. (2004). Capturing momentary, self-report data: A proposal for 
reporting guidelines. Annals of Behavioral Medicine, 24(3), 236-243. 
Stuss, D. T., Wincour, G., & Robertson, I. H. (1999). Cognitive neurorehabilitation. 
Cambridge University Press. 
Tabachnick, B. G., & Fidell, L. S. (2007). Using multivariate statistics (5th ed.). Boston: 
Pearson Education. 
Tager, F. A., McKinley, P. A., Schnabel, F. R., El-Tamer, M., Cheung, Y. K. K., Fang, Y., 
et al. (2010). The cognitive effects of chemotherapy in postmenopausal breast cancer 
patients: A controlled longitudinal study. Breast Cancer Research and Treatment, 
123(1), 25-34. 
Taillibert, S., Voillery, D., & Bernard-Marty, C. (2008). Chemobrain: Is systemic 
chemotherapy neurotoxic? Current Opinion in Oncology, 19(6), 623-627.  
Tannock, I. F., Ahles, T. A., Ganz, P. A., & van Dam, F. S. (2004). Cognitive impairment 
associated with chemotherapy for cancer: A report of a workshop. Journal of Clinical 
Oncology, 22(11), 2233-2239. 
Taskila, T., & Lindbohm, M. L. (2007). Factors affecting cancer survivors’ employment 
and work ability. Acta Oncologica, 46(4), 446-451. 
                References 
295 
Taskila, T., Martikainen, R., Hietanen, P., & Lindbohm, M.-L. (2007). Comparative study 
of work ability between cancer survivors and their referents. European Journal of 
Cancer, 43(5), 914-920. 
Tchen, N., Juffs., H. G., Downie, F. P., Qi-Long, Y., Hu, H., Chemerynsky, I., et al. (2003). 
Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant 
chemotherapy for breast cancer. Journal of Clinical Oncology, 21(2), 4175-4183. 
Teddlie, C. B., & Tashakkori, A. (2009). Foundations of mixed methods research: 
Integrating quantitative and qualitative approaches in the social and behavioral 
sciences. Los Angeles: Sage 
Thomas-MacLean, R., Towers, A., Quinlan, E., Hack, T. F., Kwan, W., Miedema, B., et al. 
(2009). “This is a kind of betrayal”: A qualitative study of disability after breast 
cancer. Rehabilitation and Survivorship, 16(3), 26-32.  
Thielen, J. (2008). The experience of neurocognitive changes in women undergoing 
chemotherapy for breast cancer. PhD thesis, University of Connecticut. 
http://digitalcommons.uconn.edu/dissertations/AAI3308251 
Tofthagen, C., Overcash, J., & Kip, K. (2012). Falls in persons with chemotherapy-induced 
peripheral neuropathy. Support Cancer Care, 20(3), 585-589. 
Troy, L., McFarland, K., Littman-Power, S., Kelly, B. J., Walpole, E. T., Wyld, D., et al. 
(2000). Cisplatin-based therapy: A neurological and neuropsychological review. 
Psycho-Oncology, 9(1), 29-39.  
Tsai, R. J., Dennis, L. K., Lynch, C. F., Snetselaar, L. G., Zamba, G. K .D., & Scott-
Conner, C. (2009). The risk of developing arm lymphedema among breast cancer 
survivors: A meta-analysis of treatment factors. Annals of Surgical Oncology, 16(7), 
1959-1972. 
Tuomi, K., Ilmarinen, J., Jahkola, A., Katajarinne, L., & Tulki, A. (1998). Work Ability 
Index (2nd ed.), Occupational Health Care 19. Helsinki: Finnish Institute of 
Occupational Health.  
van Dam, F. S. A. M., Schagen, S. B., Muller, M. J., Boogerd, W., Wall, E. v. d., Fortuyn, 
M. E. D., et al. (1998). Impairment of cognitive function in women receiving 
adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose 
chemotherapy. Journal of the National Cancer Institute, 90(3), 210-218. 
van Dyck, C., Frese, M., Baer, M., & Sonnentag, S. (2005). Organizational error 
management culture and its impact on performance: A two-study replication. Journal 
of Applied Psychology, 90(6), 1228-1240. 
Vardy, J. (2009). Cognitive function in survivors of cancer. American Society of Clinical 
Oncology Educational Book 2009, 570. 
                References 
296 
Vardy, J., & Tannock, I. (2007). Cognitive function after chemotherapy in adults with solid 
tumours. Critical Reviews in Oncology/Hematology, 63(3), 183-202. 
Vardy, J., Wong, K., Yi, Q.-L., Park, A., Maruff, P., Wagner, L., et al. (2006). Assessing 
cognitive function in cancer patients. Supportive Care in Cancer, 14(11), 1111-1118. 
Vardy, J. L., Xu, W., Booth, C. M., Park, A., Dodd, A., Rourke, S., et al. (2008). Relation 
between perceived cognitive function and neuropsychological performance in 
survivors of breast and colorectal cancer. American Society of Clinical Oncology,  
Meeting Abstracts, 26(15), 9520. 
Verstappen, C. C. P., Heimans, J. J., Hoekman, K., & Postma, T. J. (2003). Neurotoxic 
complications of chemotherapy in patients with cancer: Clinical signs and optional 
management. Drugs, 63(15), 1549–1563.  
Vihinen, P. P., Katka, K. M., Johansson, R. K., Vihinen, T. A., & Salminen, E. K. (2003). 
Acute reversible encephalopathy after repeated low-dose cisplatin infusions and 
concomitant radiotherapy for cancer of the tongue. Acta Oncologica, 42(3), 237–239. 
Visser, E., Pijl, Y. J., Stolk, R. P., Neeleman, J., & Rosmalen, J. G. M. (2007). Accident 
proneness, does it exist A review and meta-analysis. Accident Analysis & Prevention, 
39(3), 556-564. 
Vogelzang, N. J., Breitbart, W., Cella, D., Curt, G. A., Groopman, J. E., Horning, S., et al. 
(1997). Patient, caregiver, and oncologist perceptions of cancer-related fatigue: 
Results of a tripart assessment survey. Seminars in Hematology, 34(3 Suppl. 2), 4-12. 
Von Ah, D., Harvison, K. W., Monahan, P. O., Moser, L. R., Zhao, Q., Carpenter, J. S., et 
al. (2009). Cognitive function in breast cancer survivors compared to healthy age- 
and education-matched women. The Clinical Neuropsychologist, 23(4), 661-674. 
Waddell, G., & Burton, A. K. (2006). Is work good for your health and well-being? The 
Stationary Office, London. 
Wadsworth, E. J. K., Simpson, S. A., Moss, S. C., & Smith, A. P. (2003). The Bristol Stress 
and Health Study: Accidents, minor injuries and cognitive failures at work. 
Occupational Medicine, 53, 392-393. 
Wagle, A.C., Berrios, G.E., & Ho, L. (1999). The cognitive failures questionnaire in 
psychiatry. Comprehensive Psychiatry, 40(6), 478-484. 
Wagner, L. I., Sweet, J., Butt, Z., Lai, J.-S., & Cella, D. (2009). Measuring patient self-
reported cognitive function: Development of the Functional Assessment of Cancer 
Therapy–Cognitive Function instrument. Journal of Support Oncology, 76(6), W23-
W39. 
Wallace, J. C., Kass, S. J., & Stanny, C. J. (2002). The cognitive failures questionnaire 
revisited: Dimensions and correlates. The Journal of General Psychology, 129(3), 
238-256. 
                References 
297 
Wallace, J. C., & Vadanovich, S. J. (2003). Workplace safety performance: 
Conscientiousness, cognitive failure and their interaction. Journal of Occupational 
Health Psychology, 8(4) 316-327. 
Wefel, J. S., Lenzi, R., Theriault, R., Buzdar, A. U., Cruickshank, S., & Meyers, C. A. 
(2004a). “Chemobrain” in breast carcinoma? A prologue. Cancer, 101(3), 466-475. 
Wefel, J. S., Lenzi, R., Theriault, R. L., Davis, R. N., & Meyers, C. A. (2004b). The 
cognitive sequelae of standard dose adjuvant chemotherapy in women with breast 
cancer: results of a prospective, randomized, longitudinal trial. Cancer, 100(11), 
2292-2299. 
Weis, J., Poppelreuter, M., & Bartsch, H. H. (2009). Cognitive deficits as long-term side-
effects of adjuvant therapy in breast cancer patients: ‘Subjective’ complaints and 
‘objective’ neuropsychological test results. Psycho-Oncology, 18(7), 775-782. 
Whittingham, R. B. (2003). The blame machine: Why human error causes accidents. 
Oxford: Elsevier Butterworth-Heinemann. 
Wieneke, M. H., & Dienst, E. R. (1995). Neuropsychological assessment of cognitive 
functioning following chemotherapy for breast cancer. Psycho-Oncology, 4(1), 61-
66. 
White, C. A. (2000). Body image dimensions and cancer: A heuristic cognitive behavioural 
mode. Psycho-Oncology, 19(3), 183-192. 
WHO. (2000). Injury: A leading cause of the global burden of disease. Retrieved 
September 8, 2012, from http://whqlibdoc.who.int/publications/2002/9241562323. 
pdf 
Wilkins, K., & Mackenzie, S. G. (2007). Work injuries. Health Reports, 18(3), 25-42. 
Winters-Stone, K. M., Nail, L., Bennett, J. A., Schwartz, A. (2009). Bone health and falls: 
Fracture risk in breast cancer survivors with chemotherapy-induced amenorrhea. 
Oncology Nursing Forum, 36(3), 315-325. 
Winters-Stone, K. M., Horak, F., Eisner, A., Leo, M. C., Chui, S., & Luoh, S.-W. (2011). 
Identifying factors associated with falls in postmenopausal breast cancer survivors: A 
multi-disciplinary approach. Archives of Physical Medicine and Rehabilitation, 
92(4), 646-652. 
Yellen, S. B., Cella, D. F., Webster, K., Blenowski, C., & Kaplan, E. (1997). Measuring 
fatigue and other anemia-related symptoms with the Functional Assessment of 
Cancer Therapy (FACT) measuring system. Journal of Pain and Symptom 
Management, 13(2), 63-74. 
Yuen, H. K., Gillespie, M. B., Day, T. A., Morgan, L., & Burik, J. K. (2007). Driving 
behaviors in patients with head and neck cancer during and after cancer treatment: A 
preliminary report. Head and Neck, 29(7), 675-681. 
                References 
298 
Yuen, H. K., Gillespie, M. B., Barkley, R. A., Day, T. A., Bandyopadhyay, D., & Sharma, 
A. K. (2007). Driving performance in patients with cancer in the head and neck 
region. Archives of Otolaryngology – Head and Neck Surgery, 133(9), 904-909. 
Yuen, H. K., Logan, W. C., Boyd, M. G., Day, T. A., & Brooks, J. O. (2009). Negative 
psychosocial consequence of self-restricted driving among cancer survivors in the 
head and neck region. Clinical Otolaryngology, 34(4), 395-396. 
Zigmond, A. S., & Snaith, R. P. (1983). The Hospital Anxiety and Depression Scale. Acta 
Psychiatrica Scandinavica, 67(6), 361-370. 
 
Appendices 
 
299 
Appendices 
 
 
 
Appendix 1           Loughborough University Ethical Advisory Committee Approval Letter 
300 
Ref No: R09-P99 
 
 
LOUGHBOROUGH UNIVERSITY 
ETHICAL ADVISORY COMMITTEE 
 
 
RESEARCH PROPOSAL 
INVOLVING HUMAN PARTICIPANTS 
_______________________________________________________________
Shower 
Bio oil legs 
 
 
Title: 
 
The effect of chemotherapy for breast cancer on 
managing daily tasks 
Applicant: 
 
Dr H McDermott, Dr F Munir, C Lawrence 
Department:
  
 
Human Sciences 
Date of 
clearance: 
 
17 June 2009 
 
Comments of the Sub-Committee: 
The Sub-Committee agreed to issue clearance to proceed. 
 
 
 
 
Appendix 2                                                 NHS Research Ethics Committee Approval Letter 
301 
 
Appendix 2                                                 NHS Research Ethics Committee Approval Letter 
302 
 
Appendix 2                                                 NHS Research Ethics Committee Approval Letter 
303 
Appendix 3  Study Advertisement Poster - Support Groups 
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If you would like to help with our research or have any questions then please contact us
Catherine Lawrence (Ph.D. student) Tel: 01509 228151 Email: C.L.Lawrence@lboro.ac.uk
Loughborough University research
• We are looking at how treatment for breast cancer affects thinking, 
memory and attention. This may have an influence on how breast cancer 
patients carry out their daily tasks.
• We are looking for adult women (of any age) to take part in our study. 
This involves answering a postal questionnaire on 4 occasions and also 
keeping a diary if you wish.
Are you interested in taking part in our cancer research project?
WE ARE RECRUITING BREAST CANCER PATIENTS ABOUT TO UNDERGO 
CHEMOTHERAPY OR RADIOTHERAPY TREATMENT
• We hope to increase knowledge on what is an important issue as 
more women are surviving breast cancer and continue their everyday 
activities during and after treatment.
27/05/2009; Version 1
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If you would like to help with our research or have any questions then please contact us
Catherine Lawrence (Ph.D. student) Tel: 01509 228151 Email: C.L.Lawrence@lboro.ac.uk
Loughborough University research
• We are looking at how chemotherapy treatment for breast cancer 
affects thinking, memory and attention. This may have an influence on 
how breast cancer patients carry out their daily tasks.
• We are looking for healthy adult women (of any age) to take part in 
our study. This involves answering a questionnaire (postal or online) on 4 
occasions.
Are you interested in taking part in our cancer research project?
WE ARE RECRUITING HEALTHY WOMEN TO JOIN OUR STUDY 
TO BE INVOLVED IN A COMPARISON GROUP
You need to be at least 18 years old and had no diagnosis of cancer
• We hope to increase knowledge on what is an important issue as 
more women are surviving breast cancer and continue their daily 
activities. By comparing information from breast cancer patients and 
healthy women we can identify any changes over time more clearly.
27/05/2009; Version 1
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THE EFFECT OF CHEMOTHERAPY FOR BREAST CANCER ON 
MANAGING DAILY TASKS 
 
PARTICIPANT INFORMATION SHEET 
 
We would like to invite you to take part in our research project. The research team is 
based at Loughborough University. 
 
Please read this information sheet carefully. It is important that you understand why the 
research is being done and what is involved should you wish to take part. If you have 
any questions or comments please contact the researcher – contact details are at the end 
of this sheet. You may also wish to talk to a member of the breast cancer team at the 
hospital, a family member or a friend about the study. Please take time to consider 
whether or not you wish to take part. If you do not wish to take part then please note 
that this decision has no impact whatsoever on your treatment or the standard of care 
you receive at the hospital. 
 
 What is the purpose of the study? 
We are interested in looking at the effect of chemotherapy and radiotherapy treatment 
on breast cancer patients’ ability to think, concentrate and remember. Problems with 
these abilities may have an influence on oversights, lapses and absent-mindedness 
experienced during daily activities. This might include looking for your glasses then 
realising you’re already wearing them, or injuring yourself during a fall. ‘Human error’ 
as a result of treatment may have an impact on typical activities at home, during leisure 
activities or at work. For some patients, maintaining or returning to their typical daily 
activities during and after treatment is an important step on the road to recovery. As 
more women are surviving cancer, understanding the impact of treatment is an 
important issue not only for patients, but also for healthcare professionals, employers, 
friends and family members who can offer support and guidance during and after 
treatment. 
 
This study, which is part of a Ph.D. research project, will give the opportunity for breast 
cancer patients to provide valuable insight into the effects of cancer treatment. This 
information will be used to inform others so that the experiences of breast cancer 
patients are better understood. In time, we hope this will lead to intervention and 
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rehabilitation programmes that support cancer patients coping with the side effects of 
cancer and treatment. Improved guidance for employers could also be developed. 
 
There are 2 parts to this study. Firstly, we would like to invite you to answer a 
questionnaire which will be posted to you. This will happen on 4 occasions throughout 
a 12-month period. Secondly, there is also the option to keep a diary during a period of 
your treatment. More information about each part follows. 
 
 Why have I been invited? 
You have been invited to take part in this study because you will be receiving breast 
cancer treatment at Leicester Royal Infirmary. We are interested in recruiting women 
who: have been diagnosed with breast cancer and will receive chemotherapy or 
radiotherapy treatment; have breast cancer as their primary cancer diagnosis; are able 
to read and write standard English. 
 
 Do I have to take part? 
It is your decision to volunteer to participate in the study. If you do not wish to take part 
then please note that this decision has no impact on the standard of care you receive. If 
you are interested and sign the Consent Form, you can still withdraw from the study at 
any time up to the point of publication. No reason is necessary. 
 
 What will happen to me if I take part? 
If you decide to take part then you will first need to contact the researcher to express 
your interest in the study – contact details are at the end of this sheet. Please take time 
to come to a decision and ask the researcher any questions you have. You will be asked 
to answer a brief recruitment questionnaire either by telephone or at the clinic with the 
researcher to make sure that you meet the criteria to take part. You will then be asked to 
sign the Consent Form if you are happy to do so. Three copies of the signed Consent 
Form will be made: one for you, one for the researcher and one for your medical 
records. 
 
If you are happy to take part, then with your permission, the researcher will ask your 
breast cancer nurse or consultant about the type of cancer you have and your treatment. 
Please note that this information will be kept strictly confidential. 
 
Questionnaire 
The study involves answering a questionnaire which will be posted to your home 
address on four occasions (Time 1: before you start treatment; Time 2: four months 
later; Time 3: eight months later, and Time 4: twelve months later). The questionnaire 
asks about your general feelings, memory and concentration. It will take about 30 
minutes to complete and you can return it in the pre-paid envelope within a week of 
receiving the questionnaire. 
 
Diary 
There is a second part to the study. It is up to you if you wish to keep a diary as well as 
answering the questionnaire. You will be asked to keep a diary for 4 months during 
your treatment and to record any incidences when you notice that you experience 
absent-mindedness. This might include forgetting to buy something from the 
supermarket, sending an email to the wrong person or a physical fall. Each entry need 
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only be a couple of minutes. We are interested in what errors you might make during 
typical activities, no matter how big or small.  
 
 What are the possible disadvantages and risks of taking part? 
The questionnaire should not cause you any discomfort or distress. You should only 
participate if you feel comfortable doing so. The researcher will meet with you at the 
start to outline the project and answer any questions you have. We will schedule 
meeting with you when you are attending the clinic to reduce any inconvenience to you. 
However, the researcher could visit you in your home if you prefer, or you could visit 
Loughborough University. Please note that we cannot reimburse travelling expenses. 
 
Please be aware that the researcher is not a clinician or a breast cancer nurse. We advise 
that you contact your GP, a member of the cancer team at the hospital, or your local 
support groups should you feel distressed, for whatever reason, at any point.  
  
 What are the possible benefits of taking part? 
There will be no direct immediate benefit to you. Your participation will give an insight 
into the effects of cancer treatment which will provide valuable information about the 
experiences of breast cancer patients. This will enable better information to be available 
to cancer patients, healthcare professionals, employers and the general public. In time, 
we hope that intervention and rehabilitation programmes will be designed to support 
cancer patients coping with treatment side effects. Guidance could also be developed 
for employers and others. You will receive a summary of our findings, which will be 
available approximately one year after the end of the study.  
 
 Will my taking part in the study be kept confidential? 
If you decide to take part in the study then the researcher will require information about 
the type of cancer you have and your treatment. This information will be provided by a 
member of the breast cancer team by a questionnaire. Your identity will be protected by 
allocating a number to this information and your completed questionnaires. This will be 
stored with your contact details in a locked filing cabinet at Loughborough University. 
All information you provide will be kept strictly confidential and will only be 
accessible by the research team.  
 
Electronic data will be stored securely on a computer at Loughborough University. This 
information will only be accessible by a password known only to the research team. 
The procedure for handling, processing, storage and destruction of your data will be 
compliant with the Data Protection Act 1998. 
  
All reported data, that is anything written up about the study, will be made anonymous 
so that you cannot be identified. If you decide to take part in keeping an audio-diary, 
then your entries will be typed up and stored securely on a computer at Loughborough 
University. Again, your allocated number, instead of your name, will be used. Extracts 
from diary entries may be reported in publications, but all quotations will be made 
anonymous so that you cannot be identified. 
 
 What happens if I don’t want to carry on with the study? 
You can withdraw from the study at any time and you don’t need to give a reason for 
doing so. Once you have withdrawn you will not be asked to answer any more 
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questionnaires. If you are keeping an audio-diary then we will ask you to return the 
tape-recorder to a member of the breast cancer team or the researcher can collect it.  
 
Withdrawing from the study does not affect your treatment or standard of care received. 
If you wish to withdraw you will be asked if you want any completed questionnaires or 
audio-diary entries to be discarded from the study. Previous information, although 
unfinished, may still benefit our research. We will shred questionnaires you have 
returned and delete any audio-tape recordings if you wish. 
 
 What if there is a problem? 
If you have any concerns about any aspect of the study then please contact the 
researcher. If you remain unhappy and wish to complain formally then please contact 
the Patient Advice and Liaison Service (PALS) at the hospital. You can contact PALS 
if you need advice or have concerns. Contact details are at the end of the sheet. 
 
In the event that something goes wrong and you are harmed during the research and this 
is due to someone’s negligence then you may have grounds for a legal action for 
compensation against Loughborough University. You may have to pay your legal costs. 
The Patient Advice and Liaison Service will be able to provide information. 
 
 What will happen to the results of the research study? 
This research is part of a Ph.D. project. We will summarise the data and anonymous 
data will be reported in academic journals and at conferences. This enables the sharing 
of information between researchers, filling the gap of knowledge and allows others to 
learn from the data. We will send you details of publications if you wish. You will be 
sent a summary of the findings once all results have been analysed.  
 
 Who has reviewed the study? 
This research has been reviewed by an independent group of people called the NHS 
Research Ethics Committee. They have given the research ethical approval to take place 
at Leicester Royal Infirmary. Loughborough University’s Ethical Advisory Committee 
has also approved the study. 
 
 What if I have any questions or concerns? 
If you have any questions or comments, or wish to express your interest in taking part, 
please contact the researcher: 
 
Miss Catherine Lawrence, B.Sc. M.Sc. 
School of Sport, Exercise and Health Sciences 
Wavy Top Building 
Loughborough University 
Loughborough 
Leicestershire 
LE11 3TU 
Tel: 01509 228151 
Email: C.L.Lawrence@lboro.ac.uk 
 
Other points of contact include your breast cancer team or the Patient Advice and 
Liaison Service (PALS) at Leicester Royal Infirmary. Please use this source if you need 
advice or have concerns: 
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PALS Office 
Glenfield Hospital 
Groby Road 
Leicester, LE3 9QP 
Tel: 0116 258 3100 
 
Thank you for taking the time to read this information sheet and for considering 
taking part in the study. Please retain this information sheet for future reference.   
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THE EFFECT OF CHEMOTHERAPY FOR BREAST CANCER ON 
MANAGING DAILY TASKS 
 
 
CONSENT FORM 
 
    Please initial box 
 
 
 I have read the Participant Information Sheet dated 13/08/2009 
(Version 3) and have had the opportunity to consider the information. 
Any questions I had have been answered satisfactorily. 
 
 I understand that my participation is voluntary and that I am free to 
withdraw from the study at any time and do not need to give a reason, 
without my medical care or legal rights being affected. 
 
 I understand that a member of the breast care team will be asked 
questions relating to my cancer and treatment regime. If my treatment 
changes I understand that the researcher will ask a breast cancer nurse 
or consultant for an update of my treatment details. 
 
 I agree to my GP being informed of my participation in the study. 
 
 I agree to being contacted by the researcher if necessary. 
 
 I understand that the researcher may contact a breast cancer nurse or 
consultant if she becomes concerned about my well-being. 
 
 I understand that relevant sections of my medical notes and data 
collected during the study may be looked at by individuals from 
regulatory authorities or from the NHS Trust where it is relevant to 
my taking part in this research. I give permission for these individuals 
to have access to my records. 
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 I understand that the information I provide will be kept strictly 
confidential to the research team at Loughborough University, in 
accordance with the Data Protection Act. 
 
 I understand that only anonymous data may be published. 
 
 
 
 I agree to take part in the questionnaire study. 
 
 
 Do you wish to keep a diary? YES 
NO 
  
 
If YES, I understand that anonymous quotations may be published. 
 
 
 
 
Name of patient      Date      Signature 
 
 
 
Name of researcher      Date      Signature 
 
 
When completed 1 copy for patient, 1 original for researcher site file & 1 copy kept in 
medical notes 
 
 
 
 
Appendix 7  Consent Form – Healthy Controls 
313 
27/05/2009; Version: 1 
 
 
 
 
 
THE EFFECT OF CHEMOTHERAPY FOR BREAST CANCER ON 
MANAGING DAILY TASKS  
 
HEALTHY PARTICIPANTS / NON-CANCER GROUP 
 
CONSENT FORM 
 
    Please initial box 
 
 I have read the Participant Information Sheet dated 27/05/2009 (Version 1) 
and have had the opportunity to consider the information. Any questions I 
had have been answered satisfactorily. 
 
 
 I understand that my participation is voluntary and that I am free to 
withdraw from the study at any time and do not need to give a reason. 
 
 
 I agree to being contacted by the researcher if necessary. 
 
 
 I understand that the information I provide will be kept strictly confidential 
to the research team at Loughborough University, in accordance with the 
Data Protection Act. 
 
 
 I understand that only anonymous data may be published. 
 
 
 
 I agree to take part in the questionnaire study. 
 
 
 Do you wish to keep a diary? YES 
NO 
  
 
If YES, I understand that anonymous quotations may be published. 
 
 
 
Name of participant      Date      Signature 
 
 
 
Name of researcher      Date      Signature 
When completed 1 copy for participant & 1 original for researcher site file  
Appendix 8  Recruitment Questionnaire - NHS patients 
314 
Date: 11/05/2009; Version: 2; Reference Number: 09/H0408/62 
 
 
THE EFFECT OF CHEMOTHERAPY FOR BREAST CANCER 
ON MANAGING DAILY TASKS 
 
RECRUITMENT QUESTIONNAIRE 
 
 
Participant Number: ______________________ Date: ______________________ 
 
Please answer all questions. The information you provide will be kept strictly 
confidential. The questionnaire will take approximately 10 minutes to complete. 
 
PART A: Questions about you 
 
1. What is your date of birth? (dd/mm/yy) ____/____/____    
 
2. What is your ethnic background? 
 
White British
White Irish
Other White (please state) __________________________________
Black African
Black Caribbean
Other Black (please state) __________________________________
Bangladeshi
Indian
Pakistani
Chinese
Other Asian (please state) __________________________________
Mixed ethnic origin (please state) __________________________________
Other ethnic group (please state) __________________________________
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3. What is your marital status? 
 
Single Married/living with partner
Separated/divorced Widowed
Other (please specify) ___________________
 
4. Is English your first language? 
 
Yes No (please specify)_______
 
5. Can you read and write standard English?    
 
Yes No  
 
6. What is the highest academic qualification you have obtained? 
 
None GSCE (or equivalent)
A Level (or equivalent) Degree (e.g. BSc, BA)
Higher Degree (e.g. MSc, MA, PhD) Other academic qualification
(please state) _____________
 
7. Please select the most appropriate menopausal stage you are at: 
 
Pre-menopausal Post-menopausal
(Not had menopausal symptoms) (Have menopausal symptoms)
 
 
 
PART B: Questions about your employment status just before the time 
of diagnosis 
 
8. How would you describe your employment status just before diagnosis? 
 
Working full-time Working part-time
On sick leave Unemployed
Retired Other (please specify) ______
_______________________
 
If you were not working just before you were diagnosed, go to PART C 
 
9. What was your occupation? 
_______________________________________________________________ 
 
10. On average, how many hours did you work per week?______ hours / week  
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PART C: Questions about cancer 
 
11. When were you diagnosed with breast cancer?  ___/___/___  (dd/mm/yy) 
 
12. What treatment will you receive (e.g. surgery, chemotherapy, 
radiotherapy, hormone therapy)? 
__________________________________________________________________
__________________________________________________________________ 
 
13. When is your first treatment appointment? ___/___/___  (dd/mm/yy) 
 
 
 
Thank you for taking the time to complete this questionnaire 
 
If you have any problems or require further information, please contact the 
researcher Catherine Lawrence  
Email: C.L.Lawrence@lboro.ac.uk Tel: 01509 228151 
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THE EFFECT OF CHEMOTHERAPY FOR BREAST CANCER 
ON MANAGING DAILY TASKS 
 
RECRUITMENT & TREATMENT QUESTIONNAIRE 
 
 
Participant Number: ______________________ Date: ______________________ 
 
Please answer all questions. The information you provide will be kept strictly 
confidential. The questionnaire will take approximately 10 minutes to complete. 
 
PART A: Questions about you 
 
1. What is your date of birth? (dd/mm/yy) ____/____/____    
 
2. What is your ethnic background? 
 
White British
White Irish
Other White (please state) __________________________________
Black African
Black Caribbean
Other Black (please state) __________________________________
Bangladeshi
Indian
Pakistani
Chinese
Other Asian (please state) __________________________________
Mixed ethnic origin (please state) __________________________________
Other ethnic group (please state) __________________________________
 
3. What is your marital status? 
 
Single Married/living with partner
Separated/divorced Widowed
Other (please specify) ___________________
 
4. Is English your first language? 
 
Yes No (please specify)_______
 
5. Can you read and write standard English?    
 
Yes No   
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6. What is the highest academic qualification you have obtained? 
 
None GSCE (or equivalent)
A Level (or equivalent) Degree (e.g. BSc, BA)
Higher Degree (e.g. MSc, MA, PhD) Other academic qualification
(please state) _____________
 
7. Please select the most appropriate menopausal stage you are at: 
 
Pre-menopausal Post-menopausal
(Not had menopausal symptoms) (Have menopausal symptoms)
 
 
 
PART B: Questions about your employment status just before the time 
of diagnosis 
 
8. How would you describe your employment status just before diagnosis? 
 
Working full-time Working part-time
On sick leave Unemployed
Retired Other (please specify) ______
_______________________
 
If you were not working just before you were diagnosed, go to PART C 
 
9. What was your occupation? 
_______________________________________________________________ 
 
10. On average, how many hours did you work per week?______ hours / week 
 
 
 
PART C: Questions about cancer 
 
11. When were you diagnosed with breast cancer?  ___/___/___  (dd/mm/yy) 
 
12. What type of breast cancer do you have?  
 
 
13. What is the stage of the breast cancer? Stage ____________________ 
 
Ductal carcinoma in situ (DCIS)
Lobular carcinoma in situ (LCIS)
Invasive ductal breast cancer
Invasive lobular breast cancer
Inflammatory breast cancer
Other (please specify) _______________________________________
Appendix 9                             Recruitment and Treatment Questionnaire - Support Groups 
319 
14. What is the grade of the breast cancer? Grade ___________________ 
 
15. Do you have any other type of cancer? 
 
Yes (please specify) ______________ No 
 
 
 
PART D: Questions about chemotherapy or radiotherapy treatment 
 
16. Please outline the type of cancer treatment (e.g. chemotherapy, 
radiotherapy, hormone therapy) you will receive  
Try to include as much information as you can – please put don’t know for any 
sections you cannot complete 
 
Treatment  Name of drugs Dose  Start date End date 
……………………………………………………………………………………… 
……………………………………………………………………………………… 
……………………………………………………………………………………… 
……………………………………………………………………………………… 
……………………………………………………………………………………… 
……………………………………………………………………………………… 
 
17. When is your first treatment appointment?  
 
Chemotherapy ___/___/___  (dd/mm/yy) I’m not having chemotherapy 
 
Radiotherapy ___/___/___  (dd/mm/yy) I’m not having radiotherapy 
 
   
18. Are you currently receiving any treatment(s) for another condition? 
 
Yes (please specify) _________________ No 
 
 
 
PART E: Questions about surgery 
 
19. Have you received surgery for breast cancer? 
 
Yes No  
If you have ticked NO, please go to Question 27 
 
 
20. Please state the type of surgery received and the date it was performed 
 
_______________________________________________  Date: ____/____/____ 
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23. Will you receive surgery in the future? 
 
Yes No  
 
24. Please state the type of surgery and the date it will be performed 
 
_______________________________________________  Date: ____/____/____ 
 
 
 
 
 
 
 
 
Thank you for taking the time to complete this questionnaire 
 
If you have any problems or require further information, please contact the 
researcher Catherine Lawrence  
Email: C.L.Lawrence@lboro.ac.uk Tel: 01509 228151 
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THE EFFECT OF CHEMOTHERAPY FOR BREAST CANCER 
ON MANAGING DAILY TASKS 
 
HEALTHY SAMPLE / NON-CANCER GROUP 
 
RECRUITMENT QUESTIONNAIRE 
 
 
Participant Number: ______________________ Date: ______________________ 
 
Please answer all questions. The information you provide will be kept strictly 
confidential. The questionnaire will take approximately 10 minutes to complete. 
 
PART A: Questions about you 
 
1. What is your date of birth? (dd/mm/yy) ____/____/____    
 
2. What is your ethnic background? 
 
White British
White Irish
Other White (please state) __________________________________
Black African
Black Caribbean
Other Black (please state) __________________________________
Bangladeshi
Indian
Pakistani
Chinese
Other Asian (please state) __________________________________
Mixed ethnic origin (please state) __________________________________
Other ethnic group (please state) __________________________________
 
3. What is your marital status? 
 
Single Married/living with partner
Separated/divorced Widowed
Other (please specify) ___________________
 
4. Is English your first language? 
 
Yes No (please specify)_______
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5. Can you read and write standard English?    
 
Yes No  
 
6. What is the highest academic qualification you have obtained? 
 
None GSCE (or equivalent)
A Level (or equivalent) Degree (e.g. BSc, BA)
Higher Degree (e.g. MSc, MA, PhD) Other academic qualification
(please state) _____________
 
7. Please select the most appropriate menopausal stage you are at: 
 
Pre-menopausal Post-menopausal
(Not had menopausal symptoms) (Have menopausal symptoms)
 
 
PART B: Questions about your current employment status 
 
8. How would you describe your current employment status? 
 
Working full-time Working part-time
On sick leave Unemployed
Retired Other (please specify) ______
_______________________
If you are not working, please go to PART C 
 
9. What is your occupation? 
_______________________________________________________________ 
 
10. On average, how many hours do you work per week?______ hours / week 
 
 
PART C: Questions about your health 
 
11. Do you have any chronic illnesses? 
 
Yes (please specify) ______________ No 
   
12. Are you currently receiving any treatment(s) for a condition? 
 
Yes (please specify) _________________ No 
 
 Thank you for taking the time to complete this questionnaire 
 
If you have any problems or require further information, please contact the 
researcher Catherine Lawrence  
Email: C.L.Lawrence@lboro.ac.uk Tel: 01509 228151 
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Date: 13/08/2009; Version: 2; Referenc  Number: 09/H0408/62 
 
 
THE EFFECT OF CHEMOTHERAPY FOR BREAST CANCER 
ON MANAGING DAILY TASKS 
 
TREATMENT QUESTIONNAIRE 
 
Participant Number: ____________________  Date: ____________________ 
 
Please answer the following questions about the patient named on the attached 
sheet, who has provided consent for this questionnaire to be completed by a breast 
cancer nurse or consultant. All information will be kept strictly confidential. The 
questionnaire will take approximately 10 minutes to complete. Please return the 
questionnaire to the researcher in the pre-paid envelope provided. 
 
 
PART A: Questions about the cancer diagnosis 
 
1. When was the patient diagnosed with breast cancer? _____/_____/_____    
 
2. What type of breast cancer does the patient have?  
 
 
3. At what stage is the patient’s breast cancer? Stage ____________________ 
 
4. At what grade is the patient’s breast cancer? Grade ___________________ 
 
5. Is breast cancer the patient’s primary cancer diagnosis? 
 
Yes No  
  
 
 
Invasive ductal breast cancer
Invasive lobular breast cancer
Inflammatory breast cancer
Other (please specify) _______________________________________
Appendix 11  Treatment Questionnaire - NHS Patients 
324 
Date: 13/08/2009; Version: 2; Referenc  Number: 09/H0408/62 
PART B: Questions about surgery 
 
6. Has the patient received surgery for her breast cancer? 
 
Yes No  
If you have ticked NO, please go to Question 8 
 
 
7. Please state the type of surgery received and the date it was performed 
_______________________________________________  Date: ____/____/____ 
Please go to PART C 
 
 
8. Will the patient receive surgery in the future? 
 
Yes No  
 
9. Please state the type of surgery and the date it will be performed 
_______________________________________________  Date: ____/____/____ 
 
 
PART C: Questions about cancer treatment 
 
10. Please outline the type of cancer treatment (e.g. chemotherapy, 
radiotherapy, hormone therapy, biological therapy) the patient 
will receive 
 
Treatment  Name of drugs Dose  Start date End date 
……………………………………………………………………………………… 
……………………………………………………………………………………… 
……………………………………………………………………………………… 
……………………………………………………………………………………… 
……………………………………………………………………………………… 
……………………………………………………………………………………… 
……………………………………………………………………………………… 
……………………………………………………………………………………… 
……………………………………………………………………………………… 
 
12. Has the patient experienced chemotherapy-induced menopause? 
  
Yes No
Not sure  
 
 
 
Thank you for taking the time to complete the questionnaire 
If you have any questions please contact the researcher Catherine Lawrence  
Email: C.L.Lawrence@lboro.ac.uk Tel: 01509 228151 
  
Appendix 12                                      Questionnaire Booklet – NHS Patients/Support Groups 
325 
 
Date: 22/06/2010; Version: 2; Reference Number: 09/H0408/62 
 
 
 
THE EFFECTS OF CHEMOTHERAPY FOR BREAST CANCER 
ON MANAGING DAILY TASKS 
 
QUESTIONNAIRE: ASSESSMENT 1 
 
 
Participant Number: ____________________ Date: ____________________ 
 
 
 
This questionnaire should take approximately 30 minutes to complete. 
 
Please answer the questionnaire as honestly and accurately as possible. All responses 
will be kept strictly confidential and anonymous. There is a blank page at the end of the 
questionnaire should you wish to add anything about your experiences of managing 
daily activities. 
 
Please complete and return the questionnaire in the pre-paid envelope within 1 week. 
 
 
 
 
If you have questions or comments please contact the researcher  
Catherine Lawrence at Loughborough University 
Tel: 01509 228151 or Email: C.L.Lawrence@lboro.ac.uk 
 
 
Thank you for taking the time to complete the questionnaire 
We value your thoughts and experiences 
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PART A: Questions about your general feelings 
 
The following statements are concerned with general feelings about yourself. Please 
don’t take too long to think about your replies; your immediate reaction to each item 
will probably be more accurate than a long thought-out response. Please circle the 
appropriate rating for each statement which best reflects how you have felt during the 
past week. 
 
1) I feel tense or 'wound up' 
Most of the 
time 
A lot of the 
time 
From time 
to time, 
occasionally 
Not at all 
2) 
I still enjoy the things I 
used to enjoy 
Definitely 
as much 
Not quite so 
much 
Only a little Hardly at all 
3) 
I get a sort of frightened 
feeling as if something 
awful is about to happen 
Very 
definitely 
and quite 
badly 
Yes, but not 
too badly 
A little, but 
it doesn't 
worry me 
Not at all 
4) 
I can laugh and see the 
funny side of things 
As much as 
I always 
could 
Not quite so 
much now 
Definitely 
not so much 
now 
Not at all 
5) 
Worrying thoughts go 
through my mind 
A great deal 
of the time 
A lot of the 
time 
From time 
to time but 
not too 
often 
Only 
occasionally 
6) I feel cheerful Not at all Not often Sometimes 
Most of the 
time 
7) 
I can sit at ease and feel 
relaxed 
Definitely Usually Not often Not at all 
8) 
I feel as if I am slowed 
down 
Nearly all 
the time 
Very often Sometimes Not at all 
9) 
I get a sort of frightened 
feeling like 'butterflies' 
in the stomach 
Not at all Occasionally Quite often Very often 
10) 
I have lost interest in my 
appearance 
Definitely 
I don't take 
as much care 
as I should 
I may not 
take quite as 
much care 
I take just as 
much care 
as ever 
11) 
I feel restless as if I have 
to be on the move 
Very much 
indeed 
Quite a lot 
Not very 
much 
Not at all 
12) 
I look forward with 
enjoyment to things 
As much as 
I ever did 
Rather less 
than I used 
to 
Definitely 
less than I 
used to 
Hardly at all 
13) 
I get sudden feelings of 
panic 
Very often 
indeed 
Quite often 
Not very 
often 
Not at all 
14) 
I can enjoy a good book 
or radio or TV 
programme 
Often Sometimes Not often 
Very 
seldom 
 
 
PART B: Questions about your energy levels 
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Not at 
all 
A little 
bit 
Somewhat 
Quite a 
bit 
Very 
much 
1) I feel fatigued □ □ □ □ □ 
2) I feel weak all over □ □ □ □ □ 
3) I feel listless ("washed out") □ □ □ □ □ 
4) I feel tired □ □ □ □ □ 
5) 
I have trouble starting things 
because I am tired 
□ □ □ □ □ 
6) 
I have trouble finishing things 
because I am tired 
□ □ □ □ □ 
7) I have energy □ □ □ □ □ 
8) I am able to do my usual activities □ □ □ □ □ 
9) I need to sleep during the day □ □ □ □ □ 
10) I am too tired to eat □ □ □ □ □ 
11) 
I need help doing my usual 
activities 
□ □ □ □ □ 
12) 
I am frustrated by being too tired 
to do the things I want to do 
□ □ □ □ □ 
13) 
I have to limit my social activity 
because I am tired 
□ □ □ □ □ 
 
 
PART C: Questions about your general well-being 
 
Below is a list of statements that other people with your illness have said are important.  
By ticking the most appropriate box per line, please indicate how true each statement has 
been for you during the past week. 
 
  Not at all 
A little 
bit 
Some-
what 
Quite a 
bit 
Very 
much 
1) I have a lack of energy □ □ □ □ □ 
2) I have nausea □ □ □ □ □ 
3) 
Because of my physical 
condition, I have trouble 
meeting the needs of my family 
□ □ □ □ □ 
4) I have pain □ □ □ □ □ 
5) 
I am bothered by the side effects 
of treatment 
□ □ □ □ □ 
6) I feel ill □ □ □ □ □ 
7) I am forced to spend time in bed □ □ □ □ □ 
8) I feel close to my friends □ □ □ □ □ 
9) 
I get emotional support from 
my family 
□ □ □ □ □ 
10) I get support from my friends □ □ □ □ □ 
11) 
My family has accepted my 
illness 
□ □ □ □ □ 
12) 
I am satisfied with family 
communication about my illness 
□ □ □ □ □ 
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  Not at all 
A little 
bit 
Some-
what 
Quite a 
bit 
Very 
much 
13) 
I feel close to my partner (or the 
person who is my main support) 
□ □ □ □ □ 
14) 
Regardless of your current level 
of sexual activity, please answer 
the following question. If you 
prefer not to answer it, please 
check this box  
□ and go on to the next item.                                                           
I am satisfied with my sex life 
□ □ □ □ □ 
15) I feel sad   □ □ □ □ □ 
16) 
I am satisfied with how I am 
coping with my illness   
□ □ □ □ □ 
17) 
I am losing hope in the fight 
against my illness   
□ □ □ □ □ 
18) I feel nervous   □ □ □ □ □ 
19) I worry about dying   □ □ □ □ □ 
20) 
I worry that my condition will 
get worse   
□ □ □ □ □ 
21) 
I am able to work (include work 
at home)   
□ □ □ □ □ 
22) 
My work (include work at 
home) is fulfilling   
□ □ □ □ □ 
23) I am able to enjoy life   □ □ □ □ □ 
24) I have accepted my illness   □ □ □ □ □ 
25) I am sleeping well   □ □ □ □ □ 
26) 
I am enjoying the things I 
usually do for fun   
□ □ □ □ □ 
27) 
I am content with the quality of 
my life right now   
□ □ □ □ □ 
28) I have been short of breath   □ □ □ □ □ 
29) 
I am self-conscious about the 
way I dress   
□ □ □ □ □ 
30) 
One or both of my arms are 
swollen or tender   
□ □ □ □ □ 
31) I feel sexually attractive   □ □ □ □ □ 
32) I am bothered by hair loss   □ □ □ □ □ 
33) 
I worry that other members of 
my family might someday get 
the same illness I have   
□ □ □ □ □ 
34) 
I worry about the effect of stress 
on my illness   
□ □ □ □ □ 
35) 
I am bothered by a change in 
weight   
□ □ □ □ □ 
36) I am able to feel like a woman   □ □ □ □ □ 
37) 
I have certain parts of my body 
where I experience significant 
pain   
□ □ □ □ □ 
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PART D: Questions about making mistakes 
 
The following questions are about minor mistakes which everyone makes from time to time, but 
some of which happen more often than others. We want to know how often these things have 
happened to you in the past week.  Please tick the most appropriate box for each question. 
  
Very 
Often 
Quite 
Often 
Occasionally 
Very 
Rarely 
Never 
1) 
Do you read something and 
find you haven’t been 
thinking about it and must 
read it again? 
□ □ □ □ □ 
2) 
Do you find you forget why 
you went from one part of the 
house to the other? 
□ □ □ □ □ 
3) 
Do you fail to notice signposts 
on the road? 
□ □ □ □ □ 
4) 
Do you find you confuse right 
and left when giving 
directions? 
□ □ □ □ □ 
5) Do you bump into people? □ □ □ □ □ 
6) 
Do you find you forget 
whether you’ve turned off a 
light or a fire or locked the 
door? 
□ □ □ □ □ 
7) 
Do you fail to listen to 
people’s names when you are 
meeting them? 
□ □ □ □ □ 
8) 
Do you say something and 
realise afterwards that it 
might be taken as insulting? 
□ □ □ □ □ 
9) 
Do you fail to hear people 
speaking to you when you are 
doing something else? 
□ □ □ □ □ 
10) 
Do you lose your temper and 
regret it? 
□ □ □ □ □ 
11) 
Do you leave important 
letters unanswered for days? 
□ □ □ □ □ 
12) 
Do you find you forget which 
way to turn on a road you 
know well but rarely use? 
□ □ □ □ □ 
13) 
Do you fail to see what you 
want in a supermarket 
(although it’s there)? 
□ □ □ □ □ 
14) 
Do you find yourself suddenly 
wondering whether you’ve 
used a word correctly? 
□ □ □ □ □ 
15) 
Do you have trouble making 
up your mind? 
□ □ □ □ □ 
16) 
Do you find you forget 
appointments? 
□ □ □ □ □ 
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Very 
Often 
Quite 
Often 
Occasionally 
Very 
Rarely 
Never 
17) 
Do you forget where you put 
something like a newspaper 
or a book? 
□ □ □ □ □ 
18) 
Do you find you accidentally 
throw away the thing you 
want and keep what you 
meant to throw away - as in 
the example of throwing 
away the matchbox and 
putting the used match in 
your pocket? 
□ □ □ □ □ 
19) 
Do you daydream when you 
ought to be listening to 
something? 
□ □ □ □ □ 
20) 
Do you find you forget 
people’s names? 
□ □ □ □ □ 
21) 
Do you start doing one thing 
at home and get distracted 
into doing something else 
(unintentionally)? 
□ □ □ □ □ 
22) 
Do you find you can’t quite 
remember something 
although it’s “on the tip of 
your tongue”? 
□ □ □ □ □ 
23) 
Do you find you forget what 
you came to the shops to buy? 
□ □ □ □ □ 
24) Do you drop things? □ □ □ □ □ 
25) 
Do you find you can’t think 
of anything to say? 
□ □ □ □ □ 
 
 
PART E: Questions about your experiences while at home and in the 
workplace 
 
 
1. How often have accidents occurred, while you were at home, during the past 
week? (E.g. dropped something; fallen over; injured yourself) 
 
All the time Often Occasionally Rarely Never
 
2. Please list the types of accidents that have occurred during the past week (if 
any) 
______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________ 
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AT WORK 
If you are not currently working, please go to PART F - Question 1 
 
 
3. How often have accidents occurred, while at work, during the past week? (E.g. 
dropped something; fallen over; injured yourself) 
 
All the time Often Occasionally Rarely Never
 
4. Please list the types of accidents that have occurred during the past week (if 
any) 
______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________ 
  
 
 
PART F: Questions about your current employment status 
 
Please answer the following questions in relation to your current employment status 
 
1. How would you describe your current employment status? 
 
Working full-time Working part-time
On sick leave Unemployed
Retired Other (please specify) ______
 
 
 
* If you are not currently working, please go PART H * 
 
 
 
What is your current occupation? 
___________________________________________________________________ 
 
2. On average, how many hours do you currently work per week?______ hours / 
week 
 
3. Have you experienced any changes, e.g. adjustments, in your work since you 
were diagnosed?  
 
Yes No  
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If yes, please tick the changes that have been made: 
 
Yes No 
Change 
currently in 
place 
Offered support services (e.g. counselling) □ □ □ 
Working fewer hours □ □ □ 
Flexible working hours □ □ □ 
Frequent breaks □ □ □ 
Slower work pace □ □ □ 
Shared responsibility for tasks □ □ □ 
Reduced physical demands (e.g. lifting) □ □ □ 
Reduced mental demands (e.g. work-load) □ □ □ 
Allocated space to rest / lie down □ □ □ 
Other (please specify) ____________________ □ □ □ 
Other (please specify) ____________________ □ □ □ 
Other (please specify) ____________________ □ □ □ 
 
 
 
1. Are the demands of your work primarily: 
 
Mental Physical Both mental and physical
 
 
2. Assume that your work ability at its best has a value of 10 points. How many 
points would you give your current work ability? Please circle the most 
appropriate number (0 = cannot currently work at all; 10 = current work 
ability is at its best). 
 
Completely unable 
to work
0 1 2 3 4 5 6 7 8 9 10
Work ability at 
its best
 
3. How do you rate your current work ability with respect to the physical 
demands of your work? 
 
Very good Rather good Moderate Rather poor Very poor
 
 
4. How do you rate your current work ability with respect to the mental 
demands of your work? 
 
Very good Rather good Moderate Rather poor Very poor
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PART G – Questions about the questionnaire 
 
1. Have you experienced any problems completing this questionnaire? 
 
Yes (please explain) No  
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________ 
 
 
2. Have you experienced any problems remembering things which the questions 
ask about? 
 
Yes (please explain) No  
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thank you for taking the time to complete the questionnaire. 
 
 
Please use the blank page on the next page if you would like to share 
anything else about your experiences of managing your daily activities. 
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______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________     
______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________ 
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Instructions for making diary entries 
 
Thank you for agreeing to take part in this research project. We are 
interested in hearing about your experiences of managing daily activities 
while undergoing cancer treatment.  
 
Cassette recorder 
The researcher has given you a compact digital recorder and spare 
batteries. Your diary will be recorded onto the digital recorder. If you are 
not sure how to use the recorder, please ask the researcher. If you need 
more batteries, or have a problem making a recording, please contact the 
researcher.  
 
When should I make an entry? 
Please try to make an entry in the diary every day, no matter how long or 
short. You do not have to make an entry in one sitting – you can make 
several entries per day if you wish.  
 
Please do not rewind the tape. You can record entries one after another. 
You will be given a start date and an end date indicating the period you 
should keep the diary. We ask that you keep the diary for 4 months. 
 
Making an entry 
Whenever you make an entry in the diary, please first state the date and 
time. You can then use your own words to describe any problems you have 
experienced during your daily activities, e.g. incidences of absent-
mindedness. These may be while you were at home, at work or during 
leisure activities. Please be as open as possible and remember that the 
information you provide will be kept strictly confidential and anonymous. 
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Here are some examples of the types of things we are interested in 
hearing about: 
 
 Difficulty in remembering how to do something 
 Difficulty in remembering what you have already done 
 Difficulty in remembering people’s names 
 Difficulty in remembering a particular word that is on the ‘tip of 
your tongue’ 
 Forgetting what you had intended to do (e.g. forgetting to post a 
letter; going shopping for milk but come home with items other than 
milk; going into a room and forgetting why) 
 Any mistakes you have made in carrying out a task 
 Any accidents or injuries (e.g. dropping a cup; falling over) 
 
We are interested in types of absent-mindedness, errors and accidents 
you may experience while at home (e.g. during household chores or chatting 
to a friend on the phone), at work (e.g. in a meeting or at your desk) or 
during leisure activities (e.g. during a hobby or socialising). The above are 
just a few examples. We would like to hear about all the incidences you 
encounter during the day so that we can better understand your 
experiences. 
 
We understand that some consequences of absent-mindedness may be 
upsetting or embarrassing. We encourage you to be as open about your 
experiences as possible, as this will provide a more complete and accurate 
picture of living with the effects of cancer treatment and managing daily 
activities. However, we do not want you to feel uncomfortable or 
distressed while keeping the diary, so please only record entries when you 
feel happy to do so. 
 
 
If you have any questions or require further information, please do not 
hesitate to contact the researcher, Catherine Lawrence  
Tel: 01509 22 8151     Email: C.L.Lawrence@lboro.ac.uk 
 
Thank you for your time! 
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Checklist for every diary entry: 
 
 Date (e.g. Monday 22nd March). 
 
 Time (e.g. 2:30pm).  
 
 Where the incident occurred (e.g. kitchen, office, shopping centre, 
driving my car, at the gym). 
 
 What happened (e.g. I was at home looking for my reading glasses in 
the living room, but forgot that they were around my neck; I was 
washing up but then dropped the plate). 
 
 You could make an entry as soon as you realise that you have 
experienced absent-mindedness and make several short entries that 
day; or you could split up the day and list the incidences that have 
happened during that morning and then again later that evening; or 
some days you may find that it is better for you to list the 
incidences that have occurred earlier that day. 
 
 Please try to make at least one diary entry per day. 
 
 Please keep the diary for 4 months: 
 
 
 
START DATE: ___________   END DATE: ___________ 
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The effects of chemotherapy for breast cancer on managing daily tasks 
 
DAILY DIARY (paper only) 
 
Thank you for agreeing to take part in the diary aspect of the research project. We are interested in hearing about your experiences of managing 
daily activities while undergoing cancer treatment. The information you provide in the diary, along with the questionnaire, will give us a clearer and 
more complete picture of your experiences. 
 
What do I need to do? 
When you turn over the page you will see 4 sets of tables – each double page represents a week. As soon as you receive this booklet please write 
the date at the top of the first table – your diary will start on this day. At the end of each day for the next 4 weeks, please jot down brief notes 
to each question. The diary should take about 10 minutes to complete each day. At the end of the 4 weeks, please return the booklet in the pre-
paid envelope provided.   
 
The researcher will send you another booklet for the next month just before you finish this one. We ask that you keep the diary for 4 months in 
total. We understand that this is quite a long time but the more information we can collect the better we can understand your experiences during 
this time. You may also find it useful and interesting to complete the diary and reflect upon your own experiences.  
 
Use the spaces to make your own notes about any problems you have experienced during your daily activities. We are interested in types of 
absent-mindedness, mistakes and accidents you may experience while at home (e.g. during household chores or chatting to family), at work (e.g. in a 
meeting or at your desk), or during leisure activities (e.g. during a hobby or socialising). 
 
You may withdraw from the study at any time with no reason necessary by contacting the researcher. Your responses will be kept strictly 
confidential to the research team. We will ensure that any reported information is anonymous so that your identity will not be known. 
 
 
If you have any questions or require further information, please contact the researcher Catherine Lawrence 
Tel: 01509 22 8151  Email: C.L.Lawrence@lboro.ac.uk  
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Week 13: Start date 
_____/_____/_____ 
Day 1 Day 2 Day 3 Day 4 
Difficulty in multi-tasking – 
when and what happened? 
    
Difficulty in making decisions – 
when and what happened? 
    
Made a mistake – when and 
what happened? 
    
Lost concentration – when and 
what happened? 
    
Forgot to do something or any 
memory problems – when and 
what happened? 
    
Did something but you intended 
to/meant to do something else 
– when and what happened? 
    
Felt clumsy – when and what 
happened? 
    
Had an accident or injured 
yourself – when and what 
happened? 
    
Used any aids/strategies to 
help manage your tasks, e.g. a 
calendar, shopping list? Please 
list. 
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Week 13 Day 5 Day 6 
 
Day 7 
Difficulty in multi-tasking – when and 
what happened? 
   
Difficulty in making decisions – when 
and what happened? 
   
Made a mistake – when and what 
happened? 
   
Lost concentration – when and what 
happened? 
   
Forgot to do something or any memory 
problems – when and what happened? 
   
Did something but you intended 
to/meant to do something else – when 
and what happened? 
   
Felt clumsy – when and what 
happened? 
   
Had an accident or injured yourself – 
when and what happened? 
   
Used any aids/strategies to help 
manage your tasks, e.g. a calendar, 
shopping list? Please list. 
 
   
 
Please use this space to write 
about some of your entries 
from the week in more detail: 
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________ 
________________________
________________________
________________________
________________________
________________________
________________________ 
________________________
________________________
________________________
________________________
________________________
________________________ 
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
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Week 14: Start date 
_____/_____/_____ 
Day 1 Day 2 Day 3 Day 4 
Difficulty in multi-tasking – 
when and what happened? 
    
Difficulty in making decisions – 
when and what happened? 
    
Made a mistake – when and 
what happened? 
    
Lost concentration – when and 
what happened? 
    
Forgot to do something or any 
memory problems – when and 
what happened? 
    
Did something but you intended 
to/meant to do something else 
– when and what happened? 
    
Felt clumsy – when and what 
happened? 
    
Had an accident or injured 
yourself – when and what 
happened? 
    
Used any aids/strategies to 
help manage your tasks, e.g. a 
calendar, shopping list? Please 
list. 
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Week 14 Day 5 Day 6 
 
Day 7 
Difficulty in multi-tasking – when and 
what happened? 
   
Difficulty in making decisions – when 
and what happened? 
   
Made a mistake – when and what 
happened? 
   
Lost concentration – when and what 
happened? 
   
Forgot to do something or any memory 
problems – when and what happened? 
   
Did something but you intended 
to/meant to do something else – when 
and what happened? 
   
Felt clumsy – when and what 
happened? 
   
Had an accident or injured yourself – 
when and what happened? 
   
Used any aids/strategies to help 
manage your tasks, e.g. a calendar, 
shopping list? Please list. 
 
   
 
Please use this space to write 
about some of your entries 
from the week in more detail: 
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________ 
________________________
________________________
________________________
________________________
________________________
________________________ 
________________________
________________________
________________________
________________________
________________________
________________________ 
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
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Week 15: Start date 
_____/_____/_____ 
Day 1 Day 2 Day 3 Day 4 
Difficulty in multi-tasking – 
when and what happened? 
    
Difficulty in making decisions – 
when and what happened? 
    
Made a mistake – when and 
what happened? 
    
Lost concentration – when and 
what happened? 
    
Forgot to do something or any 
memory problems – when and 
what happened? 
    
Did something but you intended 
to/meant to do something else 
– when and what happened? 
    
Felt clumsy – when and what 
happened? 
    
Had an accident or injured 
yourself – when and what 
happened? 
    
Used any aids/strategies to 
help manage your tasks, e.g. a 
calendar, shopping list? Please 
list. 
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Week 15 Day 5 Day 6 
 
Day 7 
Difficulty in multi-tasking – when and 
what happened? 
   
Difficulty in making decisions – when 
and what happened? 
   
Made a mistake – when and what 
happened? 
   
Lost concentration – when and what 
happened? 
   
Forgot to do something or any memory 
problems – when and what happened? 
   
Did something but you intended 
to/meant to do something else – when 
and what happened? 
   
Felt clumsy – when and what 
happened? 
   
Had an accident or injured yourself – 
when and what happened? 
   
Used any aids/strategies to help 
manage your tasks, e.g. a calendar, 
shopping list? Please list. 
 
   
 
Please use this space to write 
about some of your entries 
from the week in more detail: 
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________ 
________________________
________________________
________________________
________________________
________________________
________________________ 
________________________
________________________
________________________
________________________
________________________
________________________ 
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
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Week 16: Start date 
_____/_____/_____ 
Day 1 Day 2 Day 3 Day 4 
Difficulty in multi-tasking – 
when and what happened? 
    
Difficulty in making decisions – 
when and what happened? 
    
Made a mistake – when and 
what happened? 
    
Lost concentration – when and 
what happened? 
    
Forgot to do something or any 
memory problems – when and 
what happened? 
    
Did something but you intended 
to/meant to do something else 
– when and what happened? 
    
Felt clumsy – when and what 
happened? 
    
Had an accident or injured 
yourself – when and what 
happened? 
    
Used any aids/strategies to 
help manage your tasks, e.g. a 
calendar, shopping list? Please 
list. 
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Week 16 Day 5 Day 6 
 
Day 7 
Difficulty in multi-tasking – when and 
what happened? 
   
Difficulty in making decisions – when 
and what happened? 
   
Made a mistake – when and what 
happened? 
   
Lost concentration – when and what 
happened? 
   
Forgot to do something or any memory 
problems – when and what happened? 
   
Did something but you intended 
to/meant to do something else – when 
and what happened? 
   
Felt clumsy – when and what 
happened? 
   
Had an accident or injured yourself – 
when and what happened? 
   
Used any aids/strategies to help 
manage your tasks, e.g. a calendar, 
shopping list? Please list. 
 
   
 
Please use this space to write 
about some of your entries 
from the week in more detail: 
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________ 
________________________
________________________
________________________
________________________
________________________
________________________ 
________________________
________________________
________________________
________________________
________________________
________________________ 
________________________
________________________
________________________
________________________
________________________
________________________
________________________
________________________
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